Rancho Sort	GARD Disease Title	GARD Disease ID	Rancho Disease Comment	Rancho Disease Status	oopd Vlookup	Metamap Text1	Metamap Term1	Metamap Name1	Metamap Type1	Designation	Neo4j Resolve1	Neo4j Resolve2	Neo4j Resolve3	Generic Name	Trade Name	Designation Date	Designation	Orphan Drug Status	FDA Approval Status	Approved Indication	Marketing Approval Date	Exclusivity End Date	Contact Company	Contact Address 1	Contact Address 2	Contact City	Contact State	Contact Zip	Contact Country	CF Grid Key
1194	Acquired amegakaryocytic thrombocytopenia	9596	done		4482	of severe chemotherapy-induced thrombocytopenia.	C0040034	Thrombocytopenia	fndg	Prevention of severe chemotherapy-induced thrombocytopenia.	Acquired amegakaryocytic thrombocytopenia|GARD:0009596|OPRELVEKIN|NEUMEGA|GARD:0009596	VON WILLEBRAND DISEASE|VWD		Oprelvekin	Neumega	35416	Prevention of severe chemotherapy-induced thrombocytopenia.	Designated/Approved	Approved for Orphan Indication		Ê11/25/1997Ê	Ê11/25/2004	"Genetics Institute, Inc."	87 Cambridge Park Drive		Cambridge	Massachusetts	2140	USA	96796
506	Acquired hemophilia A	6405	approximate	aquired hemophilia B	3890	Factor IX	C0015491	factor IX	aapp	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Acquired hemophilia A|GARD:0006405|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0006405	Hemophilia B|GARD:0008732|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0008732	HEMOPHILIA B|CHRISTMAS DISEASE|FACTOR IX DEFICIENCY|ROYAL DISEASE	Coagulation factor VIIa (recombinant)	Novoseven	38189	Prevention of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia	Ê10/13/2006Ê	Ê10/13/2013	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA	190104
973	Acromegaly	5725	done		4222					Treatment for acromegly	Acromegaly|GARD:0005725|LANREOTIDE|SOMATULINE DEPOT|GARD:0005725			Lanreotide	Somatuline Depot	36780	Treatment for acromegly	Designated/Approved	Approved for Orphan Indication	Long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy	Ê08/30/2007Ê	Ê08/30/2014	"IPSEN, Inc."	27 Maple Street		Milford	Massachusetts	1757	USA	136300
3609	Acromegaly	5725			3150	of acromegaly	C0001206	Acromegaly	dsyn	Treatment of acromegaly	Acromegaly|GARD:0005725|VAPREOTIDE|SANVAR|GARD:0005725	Acromegaly|GARD:0005725|ATL-1103|2'-O-(2-METHOXYETHYL)PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE|GARD:0005725	Acromegaly|GARD:0005725|OCTREOTIDE (ORAL)|OCTREOLIN(TM)|GARD:0005725	pasireotide	n/a	40050	Treatment of acromegaly	Designated/Approved	Approved for Orphan Indication	Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option	Ê12/15/2014Ê	Ê12/15/2021	Novartis Pharmaceuticals Corporation	One Health Plaza	"Bldg 104, 3K28"	East Hanover	New Jersey	7936	USA	288609
3614	Acromegaly	5725			4382	of acromegaly.	C0001206	Acromegaly	dsyn	Treatment of acromegaly.	Acromegaly|GARD:0005725|VAPREOTIDE|SANVAR|GARD:0005725	Acromegaly|GARD:0005725|ATL-1103|2'-O-(2-METHOXYETHYL)PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE|GARD:0005725	Acromegaly|GARD:0005725|OCTREOTIDE (ORAL)|OCTREOLIN(TM)|GARD:0005725	Octreotide	Sandostatin Lar	36031	Treatment of acromegaly.	Designated/Approved	Approved for Orphan Indication	Reduction of growth hormone and IGF-1 (somatomedin C) in acromegaly.	Ê11/25/1998Ê	Ê11/25/2005	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA	114598
3613	Acromegaly	5725			4456	of acromegaly.	C0001206	Acromegaly	dsyn	Treatment of acromegaly.	Acromegaly|GARD:0005725|VAPREOTIDE|SANVAR|GARD:0005725	Acromegaly|GARD:0005725|ATL-1103|2'-O-(2-METHOXYETHYL)PHOSPHOROTHIOATE ANTISENSE OLIGONUCLEOTIDE|GARD:0005725	Acromegaly|GARD:0005725|OCTREOTIDE (ORAL)|OCTREOLIN(TM)|GARD:0005725	Pegvisomant	Somavert	35605	Treatment of acromegaly.	Designated/Approved	Approved for Orphan Indication	"Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate"	Ê03/25/2003Ê	Ê03/25/2010	Sensus Corporation	"Suite 430,"	98 San Jacinto Boulevard	Austin	Texas	78701	USA	105097
783	Acute intermittent porphyria	5732	done		5256	of recurrent attacks of acute intermittent porphyria	C0162565	Acute intermittent porphyria	dsyn	"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria."	Acute intermittent porphyria|GARD:0005732|HEMIN|PANHEMATIN|GARD:0005732	Acute intermittent porphyria|GARD:0005732|HEMIN|PANHEMATIN|GARD:0005732	Hereditary coproporphyria|GARD:0006619|HEMIN|PANHEMATIN|GARD:0006619	Hemin	Panhematin	30757	"Amelioration of recurrent attacks of acute intermittent porphyria (AIP) temporarily related to the menstrual cycle in susceptible women and similar symptoms which occur in other patients with AIP, porphyria variegata and hereditary coproporphyria."	Designated/Approved	Approved for Orphan Indication		Ê07/20/1983Ê	Ê07/20/1990	Abbott Laboratories	Diagnostics Division		Abbott Park	Illinois	60064	USA	683
3165	Acute lymphoblastic leukemia	522			2172	of Acute Lymphoblastic Leukemia	C0023449	Acute lymphocytic leukemia	neop	For the treatment of Acute Lymphoblastic Leukemia	ACUTE LYMPHOBLASTIC LEUKEMIA|DOID:9952|MESH:D054198	CHILDHOOD T ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|T ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|CL520601|NCIT:C131876|NCI:C131876	REFRACTORY CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)|NCIT:C122624|NCI:C122624|UMLS:C4054085	(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19	Kymriah (Tisagenlecleucel)	41670	For the treatment of Acute Lymphoblastic Leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse	Ê08/30/2017Ê	Ê08/30/2024	Novartis Pharmaceuticals Corporation	"One Health Plaza,"	Bldg 315 - Room 3650B	East Hanover	New Jersey	7936	USA	415113
3158	Acute lymphoblastic leukemia	522			3539	of acute lymphoblastic leukemia	C0023449	Acute lymphocytic leukemia	neop	Treatment of acute lymphoblastic leukemia	ACUTE LYMPHOBLASTIC LEUKEMIA|DOID:9952|MESH:D054198	CHILDHOOD T ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|T ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|CL520601|NCIT:C131876|NCI:C131876	REFRACTORY CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)|NCIT:C122624|NCI:C122624|UMLS:C4054085	vinCRIStine sulfate LIPOSOME injection	Marqibo	39090	Treatment of acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies.	Ê08/09/2012Ê	Ê08/09/2019	Acrotech Biopharma LLC	279 Princeton Hightstown Road		East Windsor	New Jersey	8520	USA	234406
3144	Acute lymphoblastic leukemia	522			4118	of acute lymphoblastic leukemia	C0023449	Acute lymphocytic leukemia	neop	Treatment of acute lymphoblastic leukemia	ACUTE LYMPHOBLASTIC LEUKEMIA|DOID:9952|MESH:D054198	CHILDHOOD T ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|T ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|CL520601|NCIT:C131876|NCI:C131876	REFRACTORY CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)|NCIT:C122624|NCI:C122624|UMLS:C4054085	clofarabine	Clolar	37294	Treatment of acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens	Ê12/28/2004Ê	Ê12/28/2011	Genzyme Corporation	4545 Horizon Hill Blvd.		San Antonio	Texas	78229	USA	153201
369	Acute lymphoblastic leukemia	522	approximate		4621	lymphocytic lymphoma	C0023434	Chronic Lymphocytic Leukemia	neop	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma	Acute lymphoblastic leukemia|GARD:0000522|BUFFERED INTRATHECAL ELECTROLYTE/DEXTROSE INJECTION|ELLIOTTS BÂ® SOLUTION|ELLIOTTS B SOLUTION|GARD:0000522			Buffered intrathecal electrolyte/dextrose injection	Elliotts B Solution	34570	For use as a diluent in the intrathecal administration of methotrexate and cytarabine for the prevention or treatment meningeal leukemia and lymphocytic lymphoma	Designated/Approved	Approved for Orphan Indication	For the intrathecal administration of methotrexate and cytarabine for the prevention or treatment of meningeal leukemia and lymphocytic lymphoma.	Ê09/27/1996Ê	Ê09/27/2003	"Lukare Medical, LLC"	4 Julia Court	P. O. Box 782	Scotch Plains	New Jersey	7076	USA	83994
3151	Acute lymphoblastic leukemia	522			2547	of acute lymphoblastic leukemia	C0023449	Acute lymphocytic leukemia	neop	Treatment of acute lymphoblastic leukemia in pediatric patients	Acute lymphoblastic leukemia|GARD:0000522|IDARUBICIN HCL FOR INJECTION|IDAMYCIN|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|METHOTREXATE ORAL LIQUID FORMULATION|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|METHOTREXATE ORAL SOLUTION|GARD:0000522	mercaptopurine oral solution	Purixan	41141	Treatment of acute lymphoblastic leukemia in pediatric patients	Designated/Approved	Approved for Orphan Indication	Treatment of patients with acute lymphoblastic leukemia as part of a combination regimen.	Ê04/28/2014Ê	Ê04/28/2021	Nova Laboratories Limited	Martin House	"Wigston, Leicester LE18 4YL"	England			United Kingdom	373512
3163	Acute lymphoblastic leukemia	522			1715	of acute lymphoblastic leukemia	C0023449	Acute lymphocytic leukemia	neop	Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age)	Acute lymphoblastic leukemia|GARD:0000522|METHOTREXATE ORAL SOLUTION|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|METHOTREXATE ORAL LIQUID FORMULATION|GARD:0000522		methotrexate oral solution	Xatmep	42152	Treatment of acute lymphoblastic leukemia in pediatric patients (0 through 16 years of age)	Designated/Approved	Approved for Orphan Indication	Treatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimen	Ê04/25/2017Ê	Ê04/25/2024	"Silvergate Pharmaceuticals, Inc."	6251 Greenwood Plaza Blvd.	Suite 101	Greenwood Village	Colorado	80111	USA	479615
3154	Acute lymphoblastic leukemia	522			2411	of B-cell acute lymphoblastic leukemia	C0006413	Burkitt Lymphoma	neop	Treatment of B-cell acute lymphoblastic leukemia	Acute lymphoblastic leukemia|GARD:0000522|NELARABINE|ARRANON|GARD:0000522	REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA|NCIT:C142812|NCI:C142812	Acute lymphoblastic leukemia|GARD:0000522|INOTUZUMAB OZOGAMICIN|GARD:0000522	inotuzumab ozogamicin	n/a	41358	Treatment of B-cell acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)	Ê08/17/2017Ê	Ê08/17/2024	"Pfizer, Inc."	10646 Science Center Drive		San Diego	California	92121	USA	391413
3141	Acute lymphoblastic leukemia	522			3885	lymphoblastic lymphoma	C0079748	Precursor cell lymphoblastic lymphoma	neop	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	Acute lymphoblastic leukemia|GARD:0000522|NELARABINE|ARRANON|GARD:0000522	Lymphoblastic lymphoma|GARD:0003329|NELARABINE|ARRANON|GARD:0003329	PRECURSOR LYMPHOBLASTIC LYMPHOMA/LEUKEMIA|PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA|RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA|DOID:5600|MESH:D054198	nelarabine	Arranon	38209	Treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens	Ê10/28/2005Ê	Ê10/28/2012	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA	184404
3156	Acute lymphoblastic leukemia	522			3713	of Philadelphia-positive acute lymphoblastic leukemia	C1709527	B Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1	neop	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Acute lymphoblastic leukemia|GARD:0000522|PONATINIB|ICLUSIG|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	Dasatinib	Sprycel	38674	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy	Ê06/28/2006Ê	Ê06/28/2013	Bristol-Myers Squibb Company	P. O Box 5326	Mailstop C 4065	Princeton	New Jersey	8542	USA	214605
3156	Acute lymphoblastic leukemia	522			3713	of Philadelphia-positive acute lymphoblastic leukemia	C1709527	B Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1	neop	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Acute lymphoblastic leukemia|GARD:0000522|PONATINIB|ICLUSIG|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	Dasatinib	Sprycel	38674	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	SPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in combination with chemotherapy.	Ê12/21/2018Ê	Ê12/21/2025	Bristol-Myers Squibb Company	P. O Box 5326	Mailstop C 4065	Princeton	New Jersey	8542	USA	214605
3148	Acute lymphoblastic leukemia	522			3725	of Philadelphia-positive acute lymphoblastic leukemia	C1709527	B Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1	neop	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Acute lymphoblastic leukemia|GARD:0000522|PONATINIB|ICLUSIG|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	imatinib	Gleevec	38636	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL)	Ê10/19/2006Ê	Ê10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA	208905
3148	Acute lymphoblastic leukemia	522			3725	of Philadelphia-positive acute lymphoblastic leukemia	C1709527	B Acute Lymphoblastic Leukemia with t(9;22)(q34;q11.2); BCR-ABL1	neop	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Acute lymphoblastic leukemia|GARD:0000522|PONATINIB|ICLUSIG|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	imatinib	Gleevec	38636	Treatment of Philadelphia-positive acute lymphoblastic leukemia	Designated/Approved	Approved for Orphan Indication	Pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy	Ê01/25/2013Ê	Ê01/25/2020	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA	208905
3139	Acute lymphoblastic leukemia	522			3095	of Philadelphia chromosome-positive acute lymphoblastic leukemia	C1960397	Philadelphia chromosome-positive acute lymphoblastic leukemia	neop	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	Acute lymphoblastic leukemia|GARD:0000522|PONATINIB|ICLUSIG|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	Acute lymphoblastic leukemia|GARD:0000522|IMATINIB|GLEEVEC|GARD:0000522	ponatinib	Iclusig	40137	Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL)	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy.	Ê12/14/2012Ê	Ê12/14/2019	ARIAD Pharmaceuticals Inc.	26 Landsdowne Street		Cambridge	Massachusetts	2139	USA	294809
1945	Acute lymphoblastic leukemia	522	done		3353	of acute lymphocytic leukemia	C0023449	Acute lymphocytic leukemia	neop	Treatment of acute lymphocytic leukemia	"NON-LYMPHOCYTIC LEUKEMIA|NONLYMPHOCYTIC LEUKEMIA, ACUTE|ACUTE NON-LYMPHOCYTIC LEUKEMIA|DOID:8692|MESH:D015470"	CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|CHILDHOOD PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ALL IN REMISSION|PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOID LEUKEMIA IN REMISSION|CHILDHOOD ALL IN REMISSION|CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOID LEUKEMIA IN REMISSION|NCI:C7938|UMLS:C0279097	ACUTE LYMPHOID LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA (IN REMISSION)|ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ALL IN REMISSION|NCI:C3586|UMLS:C0153876|SNOMEDCT_US:91856007	blinatumomab	Blincyto	39584	Treatment of acute lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).	Ê12/03/2014Ê	Ê12/03/2021	"Amgen, Inc."	One Amgen Center Dr.	Mail Stop 17-2-A	Thousand Oaks	California	91320	USA	255707
1945	Acute lymphoblastic leukemia	522	done		3353	of acute lymphocytic leukemia	C0023449	Acute lymphocytic leukemia	neop	Treatment of acute lymphocytic leukemia	"NON-LYMPHOCYTIC LEUKEMIA|NONLYMPHOCYTIC LEUKEMIA, ACUTE|ACUTE NON-LYMPHOCYTIC LEUKEMIA|DOID:8692|MESH:D015470"	CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|CHILDHOOD PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ALL IN REMISSION|PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOID LEUKEMIA IN REMISSION|CHILDHOOD ALL IN REMISSION|CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOID LEUKEMIA IN REMISSION|NCI:C7938|UMLS:C0279097	ACUTE LYMPHOID LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA (IN REMISSION)|ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ALL IN REMISSION|NCI:C3586|UMLS:C0153876|SNOMEDCT_US:91856007	blinatumomab	Blincyto	39584	Treatment of acute lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	BLINCYTO is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children.	Ê03/29/2018Ê	Ê03/29/2025	"Amgen, Inc."	One Amgen Center Dr.	Mail Stop 17-2-A	Thousand Oaks	California	91320	USA	255707
1263	Acute lymphoblastic leukemia	522	done		4972	of acute lymphocytic leukemia.	C0023449	Acute lymphocytic leukemia	neop	Treatment of acute lymphocytic leukemia.	"NON-LYMPHOCYTIC LEUKEMIA|NONLYMPHOCYTIC LEUKEMIA, ACUTE|ACUTE NON-LYMPHOCYTIC LEUKEMIA|DOID:8692|MESH:D015470"	CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|CHILDHOOD PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ALL IN REMISSION|PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOID LEUKEMIA IN REMISSION|CHILDHOOD ALL IN REMISSION|CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOID LEUKEMIA IN REMISSION|NCI:C7938|UMLS:C0279097	ACUTE LYMPHOID LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA (IN REMISSION)|ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ALL IN REMISSION|NCI:C3586|UMLS:C0153876|SNOMEDCT_US:91856007	Pegaspargase	Oncaspar; Asparlas	32801	Treatment of acute lymphocytic leukemia.	Designated/Approved	Approved for Orphan Indication	ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.	Ê12/20/2018Ê	ÊN/A	Servier Pharmaceuticals LLC	200 Pier Four Blvd		Boston	Massachusetts	2210	USA	39589
1263	Acute lymphoblastic leukemia	522	done		4972	of acute lymphocytic leukemia.	C0023449	Acute lymphocytic leukemia	neop	Treatment of acute lymphocytic leukemia.	"NON-LYMPHOCYTIC LEUKEMIA|NONLYMPHOCYTIC LEUKEMIA, ACUTE|ACUTE NON-LYMPHOCYTIC LEUKEMIA|DOID:8692|MESH:D015470"	CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|CHILDHOOD PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ALL IN REMISSION|PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOID LEUKEMIA IN REMISSION|CHILDHOOD ALL IN REMISSION|CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOID LEUKEMIA IN REMISSION|NCI:C7938|UMLS:C0279097	ACUTE LYMPHOID LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA (IN REMISSION)|ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ALL IN REMISSION|NCI:C3586|UMLS:C0153876|SNOMEDCT_US:91856007	Pegaspargase	Oncaspar; Asparlas	32801	Treatment of acute lymphocytic leukemia.	Designated/Approved	Approved for Orphan Indication	Combination chemotherapy for the treatment of patients with acute lymphoblastic leukemia who are hypersensitive to native forms of L-asparaginase.	Ê02/01/1994Ê	Ê02/01/2001	Servier Pharmaceuticals LLC	200 Pier Four Blvd		Boston	Massachusetts	2210	USA	39589
658	Acute lymphoblastic leukemia	522	done		5154	of acute lymphocytic leukemia.	C0023449	Acute lymphocytic leukemia	neop	Treatment of acute lymphocytic leukemia.	"NON-LYMPHOCYTIC LEUKEMIA|NONLYMPHOCYTIC LEUKEMIA, ACUTE|ACUTE NON-LYMPHOCYTIC LEUKEMIA|DOID:8692|MESH:D015470"	CHILDHOOD ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|CHILDHOOD PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ALL IN REMISSION|PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PEDIATRIC ACUTE LYMPHOID LEUKEMIA IN REMISSION|CHILDHOOD ALL IN REMISSION|CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE LYMPHOID LEUKEMIA IN REMISSION|NCI:C7938|UMLS:C0279097	ACUTE LYMPHOID LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA (IN REMISSION)|ACUTE LYMPHOGENOUS LEUKEMIA IN REMISSION|PRECURSOR LYMPHOBLASTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOCYTIC LEUKEMIA IN REMISSION|ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ALL IN REMISSION|NCI:C3586|UMLS:C0153876|SNOMEDCT_US:91856007	Erwinia L-asparaginase	Erwinase	31623	Treatment of acute lymphocytic leukemia.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.	Ê11/18/2011Ê	Ê11/18/2018	"Jazz Pharmaceuticals, Inc."	3180 Porter Drive		Palo Alto	California	94304	USA	15186
851	Acute myeloid leukemia	12757	done		5062	acute nonlymphocytic leukemia.	C0023467	"Leukemia, Myelocytic, Acute"	neop	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Acute myeloid leukemia|GARD:0012757|IDARUBICIN HYDROCHLORIDE|IDARUBICIN HCL FOR INJECTION|IDAMYCIN|GARD:0012757	Acute myeloid leukemia|GARD:0012757|MITOXANTRONE HYDROCHLORIDE|MITOXANTRONE HCL|NOVANTRONE|GARD:0012757	Acute myeloid leukemia|GARD:0012757|PERFOSFAMIDE|PERGAMID|GARD:0012757	Idarubicin HCl for injection	Idamycin	32349	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Designated/Approved	Approved for Orphan Indication		Ê09/27/1990Ê	Ê09/27/1997	"Adria Laboratories, Inc."	P.O. Box 16529		Columbus	Ohio	43216	USA	29388
1089	Acute myeloid leukemia	12757	done		5128	acute nonlymphocytic leukemia.	C0023467	"Leukemia, Myelocytic, Acute"	neop	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Acute myeloid leukemia|GARD:0012757|IDARUBICIN HYDROCHLORIDE|IDARUBICIN HCL FOR INJECTION|IDAMYCIN|GARD:0012757	Acute myeloid leukemia|GARD:0012757|MITOXANTRONE HYDROCHLORIDE|MITOXANTRONE HCL|NOVANTRONE|GARD:0012757	Acute myeloid leukemia|GARD:0012757|PERFOSFAMIDE|PERGAMID|GARD:0012757	Mitoxantrone HCl	Novantrone	31971	"Treatment of acute myelogenous leukemia, also referred to as acute nonlymphocytic leukemia."	Designated/Approved	Approved for Orphan Indication		Ê12/23/1987Ê	Ê12/23/1994	Lederle Laboratories	Division of American Cyanamid Company	401 N. Middletown Road	Pearl River	New York	10965	USA	19287
692	Acute myeloid leukemia	12757	done		4494	for acute myeloid leukemia.	C0023467	"Leukemia, Myelocytic, Acute"	neop	"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia."	Myeloid leukemia|GARD:0008226|FILGRASTIM|NEUPOGEN|GARD:0008226	"Acute myeloid leukemia|GARD:0012757|FILGRASTIM, LICENSE HOLDER UNSPECIFIED|FILGRASTIM|NEUPOGEN|GARD:0012757"		Filgrastim	Neupogen	35376	"Reduction in the duration of neutropenia, fever, antibiotic use, and hospitalization, following induction and consolidation treatment for acute myeloid leukemia."	Designated/Approved	Approved for Orphan Indication	"Reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with acute myeloid leukemia."	Ê04/02/1998Ê	Ê04/02/2005	"Amgen, Inc."	One Amgen Center Dr.		Thousand Oaks	California	91320	USA	101096
643	Acute myeloid leukemia	12757	done		2065	of acute myelogenous leukemia	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myelogenous leukemia	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	PEDIATRIC AML IN REMISSION|PEDIATRIC ACUTE GRANULOCYTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE MYELOBLASTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE MYELOCYTIC LEUKEMIA IN REMISSION|PEDIATRIC ACUTE MYELOGENOUS LEUKEMIA IN REMISSION|PEDIATRIC ACUTE MYELOID LEUKEMIA IN REMISSION|CHILDHOOD AML IN REMISSION|CHILDHOOD ACUTE GRANULOCYTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE MYELOBLASTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE MYELOCYTIC LEUKEMIA IN REMISSION|CHILDHOOD ACUTE MYELOGENOUS LEUKEMIA IN REMISSION|CHILDHOOD ACUTE MYELOID LEUKEMIA IN REMISSION|NCI:C9115|UMLS:C0279096	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	enasidenib	Idhifa	41802	Treatment of acute myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test	Ê08/01/2017Ê	Ê08/01/2024	Celgene Corporation	"Corporate Woods Bldg 32, Suite 900"	9225 Indian Creek Parkway	Overland Park	Kansas	66210	USA	434514
3180	Acute promyelocytic leukemia	538			4415	of acute promyelocytic leukemia.	C0023487	Acute Promyelocytic Leukemia	neop	Treatment of acute promyelocytic leukemia.	Acute promyelocytic leukemia|GARD:0000538|ALITRETINOIN|PANRETIN|GARD:0000538	Acute promyelocytic leukemia|GARD:0000538|MENATETRENONE|MK4(R)|GARD:0000538	Acute promyelocytic leukemia|GARD:0000538|PHENYLBUTYRATE|GARD:0000538	Arsenic trioxide	Trisenox	35857	Treatment of acute promyelocytic leukemia.	Designated/Approved	Approved for Orphan Indication	In combination with tretinoin for treatment of adults with newly-diagnosed low-risk acute promyelocytic leukemia (APL) whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.	Ê01/12/2018Ê	Ê01/12/2025	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road		Frazer	Pennsylvania	19355	USA	109697
3180	Acute promyelocytic leukemia	538			4415	of acute promyelocytic leukemia.	C0023487	Acute Promyelocytic Leukemia	neop	Treatment of acute promyelocytic leukemia.	Acute promyelocytic leukemia|GARD:0000538|ALITRETINOIN|PANRETIN|GARD:0000538	Acute promyelocytic leukemia|GARD:0000538|MENATETRENONE|MK4(R)|GARD:0000538	Acute promyelocytic leukemia|GARD:0000538|PHENYLBUTYRATE|GARD:0000538	Arsenic trioxide	Trisenox	35857	Treatment of acute promyelocytic leukemia.	Designated/Approved	Approved for Orphan Indication	"For induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation of PML/RAR-alpha gene expression."	Ê09/25/2000Ê	Ê09/25/2007	"Teva Branded Pharmaceutical Products R&D, Inc."	41 Moores Road		Frazer	Pennsylvania	19355	USA	109697
3178	Acute promyelocytic leukemia	538			4871	of acute promyelocytic leukemia.	C0023487	Acute Promyelocytic Leukemia	neop	Treatment of acute promyelocytic leukemia.	Acute promyelocytic leukemia|GARD:0000538|ALITRETINOIN|PANRETIN|GARD:0000538	Acute promyelocytic leukemia|GARD:0000538|MENATETRENONE|MK4(R)|GARD:0000538	Acute promyelocytic leukemia|GARD:0000538|PHENYLBUTYRATE|GARD:0000538	Tretinoin	Vesanoid	33170	Treatment of acute promyelocytic leukemia.	Designated/Approved	Approved for Orphan Indication	Induction of remission in patients with acute promyelocytic leukemia who are refractory to or unable to tolerate anthracycline based cytotoxic chemotherapeutic regimens.	Ê11/22/1995Ê	Ê11/22/2002	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA	50990
1264	Acute Radiation Syndrome		MISSING		2221	at risk of developing myelosuppression	C0854467	Myelosuppression	fndg	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	PEGFILGRASTIM|NEULASTA	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED|FILGRASTIM|NEUPOGEN"		Pegfilgrastim	Neulasta	41598	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Designated/Approved	Approved for Orphan Indication	To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome)	Ê11/13/2015Ê	Ê11/13/2022	"Amgen, Inc."	One Amgen Center Drive	M/S 17-1-C	Thousand Oaks	California	91320	USA	413013
2245	Acute Radiation Syndrome		MISSING		2222	at risk of developing myelosuppression	C0854467	Myelosuppression	fndg	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	PEGFILGRASTIM|NEULASTA	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED|FILGRASTIM|NEUPOGEN"		filgrastim	Neupogen	41598	Treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident	Designated/Approved	Approved for Orphan Indication	To increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome).	Ê03/30/2015Ê	Ê03/30/2022	"Amgen, Inc."	One Amgen Center Drive	M/S 17-1-C	Thousand Oaks	California	91320	USA	413113
Missing	Acute radiation syndrome		MISSING		1231	(hematopoietic syndrome	C0018939	Hematological Disease	dsyn	Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)				sargramostim	Leukine	42683	Treatment of individuals acutely exposed to myelosuppressive doses of radiation (hematopoietic syndrome of acute radiation syndrome)	Designated/Approved	Approved for Orphan Indication	LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]).	Ê03/29/2018Ê	Ê03/29/2025	"Partner Therapeutics, Inc."	19 Muzzey Street		Lexington	Massachusetts	2421	USA	541816
3627	ADA deficiency	5748			5250	for ADA deficiency	C0268124	Adenosine deaminase deficiency	dsyn	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Severe combined immunodeficiency|GARD:0007628|PEGADEMASE BOVINE|ADAGEN|GARD:0007628	ADA deficiency|GARD:0005748|PEGADEMASE BOVINE|ADAGEN|GARD:0005748	SEVERE COMBINED IMMUNODEFICIENCY|SEVERE COMBINED IMMUNODEFICIENCY DISEASE|DOID:627|MESH:D016511	Pegademase bovine	Adagen	30831	For enzyme replacement therapy for ADA deficiency in patients with severe combined immunodeficiency.	Designated/Approved	Approved for Orphan Indication		Ê03/21/1990Ê	Ê03/21/1997	"Sigma-tau Pharmaceuticals, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA	2084
Missing	"Adenocarcinoma, metastatic"		MISSING	Not a rare disease	4862	of metastatic adenocarcinoma	C0334277	"Adenocarcinoma, metastatic"	neop	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum				levoleucovorin	Fusilev	33225	For use in combination chemotherapy with the approved agent 5-fluorouracil in the palliative treatment of metastatic adenocarcinoma of the colon and rectum	Designated/Approved	Approved for Orphan Indication	For use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer	Ê04/29/2011Ê	Ê04/29/2018	Acrotech Biopharma LLC	279 Princeton Hightstown Road		East Windsor	New Jersey	8520	USA	48590
2716	Adult T-cell leukemia/lymphoma	13103	approximate		3613	of T-cell lymphoma	C0079772	T-Cell Lymphoma	neop	Treatment of T-cell lymphoma	REFRACTORY T-CELL NON-HODGKIN'S LYMPHOMA|REFRACTORY T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY T-CELL LYMPHOMA|REFRACTORY T-CELL AND NK-CELL NON-HODGKIN'S LYMPHOMA|T-CELL LYMPHOMA REFRACTORY|NCI:C8664|UMLS:C0854827	REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA REFRACTORY|NCI:C8671|UMLS:C0854834	"REFRACTORY UNSPECIFIED PERIPHERAL T-CELL LYMPHOMA|REFRACTORY PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED|NCI:C9339|UMLS:C0854852"	pralatrexate	Folotyn	38918	Treatment of T-cell lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with relapsed or refractory peripheral T-cell lymphoma	Ê09/24/2009Ê	Ê09/24/2016	Acrotech Biopharma LLC	279 Princeton Hightstown Road		East Windsor	New Jersey	8520	USA	225306
3103	Adult T-cell leukemia/lymphoma	13103	approximate		3937	of T-cell non-Hodgkin's lymphoma	C0079772	T-Cell Lymphoma	neop	Treatment of T-cell non-Hodgkin's lymphoma	REFRACTORY T-CELL NON-HODGKIN'S LYMPHOMA|REFRACTORY T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY T-CELL LYMPHOMA|REFRACTORY T-CELL AND NK-CELL NON-HODGKIN'S LYMPHOMA|T-CELL LYMPHOMA REFRACTORY|NCI:C8664|UMLS:C0854827	REFRACTORY T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY T-CELL NON-HODGKIN'S LYMPHOMA|REFRACTORY T-CELL LYMPHOMA|T-CELL LYMPHOMA REFRACTORY|REFRACTORY T-CELL AND NK-CELL NON-HODGKIN'S LYMPHOMA|NCIT:C8664|NCI:C8664|UMLS:C0854827	REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN LYMPHOMA|REFRACTORY MATURE T-CELL AND NK-CELL NON-HODGKIN'S LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA REFRACTORY|REFRACTORY MATURE T- AND NK-CELL LYMPHOMA|REFRACTORY PERIPHERAL T-CELL LYMPHOMA|NCI:C8689|UMLS:C1335727	vorinostat	Zolinza	38062	Treatment of T-cell non-Hodgkin's lymphoma	Designated/Approved	Approved for Orphan Indication	"Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistant or recurrent disease on or following two systemic therapies."	Ê10/06/2006Ê	Ê10/06/2013	"Merck & Co., Inc."	"P. O. Box 2000, RY 32-605"		Rahway	New Jersey	7065	USA	174203
1521	AIDS-associated catabolism/weight loss.		MISSING		4793	of AIDS-associated catabolism/weight loss.	C0001175	Acquired Immunodeficiency Syndrome	dsyn	Treatment of AIDS-associated catabolism/weight loss.	SERMORELIN ACETATE|GEREF	SOMATROPIN|SOMATROPIN FOR INJECTION|SEROSTIM	"PROPIONIC ACIDEMIA|HYPERGLYCINEMIA WITH KETOACIDOSIS AND LACTIC ACIDOSIS, PROPIONIC TYPE|KETOTIC GLYCINEMIA|PCC DEFICIENCY|PROPIONYL COA CARBOXYLASE DEFICIENCY"	Somatropin for injection	Serostim	33557	Treatment of AIDS-associated catabolism/weight loss.	Designated/Approved	Approved for Orphan Indication	Treatment of AIDS wasting or cachexia.	Ê08/23/1996Ê	Ê08/23/2003	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA	60491
1058	AIDS-associated catabolism/weight loss.		MISSING		5081	confirmed diagnosis	C0011900	Diagnosis	fndg	"Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS."				Megestrol acetate	Megace	32246	"Treatment of patients with anorexia, cachexia, or significant weight loss (=/>10% of baseline body weight) and confirmed diagnosis of AIDS."	Designated/Approved	Approved for Orphan Indication	"Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome."	Ê09/10/1993Ê	Ê09/10/2000	Bristol-Myers Squibb Pharmaceutical Research Institute	2400 West Lloyd Expressway		Evansville	Indiana	47721	USA	26187
219	Alpha-1 antitrypsin deficiency	5784	done		5226	in the alpha-1-proteinase inhibitor congenital deficiency state.	C0221757	alpha 1-Antitrypsin Deficiency	dsyn	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Alpha-1 antitrypsin deficiency|GARD:0005784|.ALPHA.1-PROTEINASE INHIBITOR (HUMAN)|ALPHA1-PROTEINASE INHIBITOR (HUMAN)|PROLASTIN|GARD:0005784	HEMOPHILIA A|CLASSICAL HEMOPHILIA|FACTOR VIII DEFICIENCY|HAEMOPHILIA A	HEMOPHILIA B|CHRISTMAS DISEASE|FACTOR IX DEFICIENCY|ROYAL DISEASE	Alpha1-proteinase inhibitor (human)	Prolastin	31023	For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state.	Designated/Approved	Approved for Orphan Indication	For chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable panacinar emphysema.	Ê12/02/1987Ê	Ê12/02/1994	Bayer Corporation	"Pharmaceutical Division, Biological Products"	400 Morgan Lane	New Haven	Connecticut	6516	USA	3084
3185	Alpha-thalassemia	621			1819	in alpha-thalassemia	C0002312	alpha-Thalassemia	dsyn	Treatment of chronic iron overload in alpha-thalassemia	IRON OVERLOAD|DOID:2350|MESH:D019190	Alpha-thalassemia|GARD:0000621|DEFERASIROX|EXJADE|GARD:0000621	Thalassemia|GARD:0007756|DEFERASIROX|EXJADE|GARD:0007756	deferasirox	Exjade; Jadenu Sprinkles	42059	Treatment of chronic iron overload in alpha-thalassemia	Designated/Approved	Approved for Orphan Indication	Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and serum ferritin greater than 300 mcg/L.	Ê01/23/2013Ê	Ê01/23/2020	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	354411
3185	Alpha-thalassemia	621			1819	in alpha-thalassemia	C0002312	alpha-Thalassemia	dsyn	Treatment of chronic iron overload in alpha-thalassemia	IRON OVERLOAD|DOID:2350|MESH:D019190	Alpha-thalassemia|GARD:0000621|DEFERASIROX|EXJADE|GARD:0000621	Thalassemia|GARD:0007756|DEFERASIROX|EXJADE|GARD:0007756	deferasirox	Exjade; Jadenu Sprinkles	42059	Treatment of chronic iron overload in alpha-thalassemia	Designated/Approved	Approved for Orphan Indication	Treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes and with a liver iron concentration (LIC) of at least 5 milligrams of iron per gram of liver dry weight (mg Fe/g dw) and a serum ferritin greater than 300 mcg/L.	Ê05/18/2017Ê	ÊN/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	354411
3124	Alveolar echinococcosis	207			4536	alveolar echinococcosis	C0948954	Alveolar echinococcosis	dsyn	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	Alveolar echinococcosis|GARD:0000207|ALBENDAZOLE|ALBENZA|GARD:0000207			Albendazole	Albenza	35081	Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).	Designated/Approved	Approved for Orphan Indication	"Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus."	Ê06/11/1996Ê	Ê06/11/2003	"Impax Laboratories, LLC"	400 Crossing Boulevard	Third Floor	Bridgewater	New Jersey	8807	USA	94195
3189	Amebiasis	652			3989	of amebiasis	C0002438	Amebiasis	dsyn	Treatment of amebiasis	Amebiasis|GARD:0000652|AURANOFIN|RIDAURA|GARD:0000652	Amebiasis|GARD:0000652|MILTEFOSINE|IMPAVIDO|GARD:0000652	Amebiasis|GARD:0000652|NITAZOXANIDE|CRYPTAZ|GARD:0000652	Tinidazole	Tindamax	37853	Treatment of amebiasis	Designated/Approved	Approved for Orphan Indication	Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica in both adults and pediatric patients older than three years of age. It is not indicated for the treatment of asymptomatic cyst passage.	Ê05/17/2004Ê	Ê05/17/2011	"Presutti Laboratories, Inc."	1607 N. Douglas Avenue		Arlington Heights	Illinois	60004	USA	173603
3685	Amyotrophic lateral sclerosis	5786			1732	of amyotrophic lateral sclerosis	C0002736	Amyotrophic Lateral Sclerosis	dsyn	Treatment of amyotrophic lateral sclerosis	"Amyotrophic lateral sclerosis|GARD:0005786|GLIADIN|SUPEROXIDE DISMUTASE, GLIADIN|ETR019|GARD:0005786"	Amyotrophic lateral sclerosis|GARD:0005786|OZANEZUMAB|ANTI-NOGO-A MONOCLONAL ANTIBODY|GARD:0005786	Amyotrophic lateral sclerosis|GARD:0005786|GABAPENTIN|NEURONTIN|GARD:0005786	edaravone	Radicava	42136	Treatment of amyotrophic lateral sclerosis	Designated/Approved	Approved for Orphan Indication	Treatment of amyotrophic lateral sclerosis (ALS)	Ê05/05/2017Ê	Ê05/05/2024	Mitsubishi Tanabe Pharma Corporation	"17-10, Nihonbashi-Koamicho"	"Chuo-ku, Tokyo 103-8405"				Japan	478215
3653	Amyotrophic lateral sclerosis	5786			4709	of amyotrophic lateral sclerosis.	C0002736	Amyotrophic Lateral Sclerosis	dsyn	Treatment of amyotrophic lateral sclerosis.	"Amyotrophic lateral sclerosis|GARD:0005786|GLIADIN|SUPEROXIDE DISMUTASE, GLIADIN|ETR019|GARD:0005786"	Amyotrophic lateral sclerosis|GARD:0005786|OZANEZUMAB|ANTI-NOGO-A MONOCLONAL ANTIBODY|GARD:0005786	Amyotrophic lateral sclerosis|GARD:0005786|GABAPENTIN|NEURONTIN|GARD:0005786	Riluzole	Rilutek	34044	Treatment of amyotrophic lateral sclerosis.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.	Ê12/12/1995Ê	Ê12/12/2002	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	"500 Arcola Road, P.O. Box 1200"		Collegeville	Pennsylvania	19426	USA	72792
2804	Amyotrophic lateral sclerosis	5786	done		693	of amyotrophic lateral sclerosis	C0002736	Amyotrophic Lateral Sclerosis	dsyn	Treatment of amyotrophic lateral sclerosis (ALS)	Amyotrophic lateral sclerosis|GARD:0005786|SARSASAPOGENIN|GARD:0005786	Amyotrophic lateral sclerosis|GARD:0005786|TIRASEMTIV|GARD:0005786	Amyotrophic lateral sclerosis|GARD:0005786|FILGRASTIM|GARD:0005786	riluzole oral film	Exservan	43123	Treatment of amyotrophic lateral sclerosis (ALS)	Designated/Approved	Approved for Orphan Indication	EXSERVAN is indicated for the treatment of amyotrophic lateral sclerosis (ALS).	Ê11/22/2019Ê	ÊTBD	Aquestive Therapeutics	30 Technology Drive South		Warren	New Jersey	7059	USA	563216
3654	Amyotrophic lateral sclerosis	5786			1283	of amyotrophic lateral sclerosis (ALS).	C0002736	Amyotrophic Lateral Sclerosis	dsyn	Treatment of amyotrophic lateral sclerosis (ALS).	Amyotrophic lateral sclerosis|GARD:0005786|SARSASAPOGENIN|GARD:0005786	Amyotrophic lateral sclerosis|GARD:0005786|TIRASEMTIV|GARD:0005786	Amyotrophic lateral sclerosis|GARD:0005786|FILGRASTIM|GARD:0005786	riluzole oral suspension	Tiglutik	42628	Treatment of amyotrophic lateral sclerosis (ALS).	Designated/Approved	Approved for Orphan Indication	TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).	Ê12/13/2019Ê	ÊTBD	Italfarmaco SpA	54 Via dei Lavoratori		Cinisello Balsamo			Italy	508715
3654	Amyotrophic lateral sclerosis	5786			1283	of amyotrophic lateral sclerosis (ALS).	C0002736	Amyotrophic Lateral Sclerosis	dsyn	Treatment of amyotrophic lateral sclerosis (ALS).	Amyotrophic lateral sclerosis|GARD:0005786|SARSASAPOGENIN|GARD:0005786	Amyotrophic lateral sclerosis|GARD:0005786|TIRASEMTIV|GARD:0005786	Amyotrophic lateral sclerosis|GARD:0005786|FILGRASTIM|GARD:0005786	riluzole oral suspension	Tiglutik	42628	Treatment of amyotrophic lateral sclerosis (ALS).	Designated/Approved	Approved for Orphan Indication	TIGLUTIK is indicated for the treatment of amyotrophic lateral sclerosis (ALS).	Ê09/05/2018Ê	ÊN/A	Italfarmaco SpA	54 Via dei Lavoratori		Cinisello Balsamo			Italy	508715
362	Anaplastic large cell lymphoma	3112	approximate		1291	of primary cutaneous CD30-positive T-cell lymphoproliferative disorders	C1371159	Primary cutaneous CD30+ T-cell lymphoproliferative disorder	neop	Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders	Anaplastic large cell lymphoma|GARD:0003112|BRENTUXIMAB VEDOTIN|ADCETRIS|GARD:0003112			Brentuximab vedotin	Adcetris	42620	Treatment of primary cutaneous CD30-positive T-cell lymphoproliferative disorders	Designated/Approved	Approved for Orphan Indication	For adult patients with primary cutaneous anaplastic large cell lymphoma who have received prior systemic therapy	Ê11/09/2017Ê	Ê11/09/2024	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA	536516
3401	Anaplastic large cell lymphoma	3112			3277	"anaplastic large cell lymphoma,"	C0206180	Ki-1+ Anaplastic Large Cell Lymphoma	neop	"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranodal NK/T-cell lymphoma."				brentuximab vedotin	Adcetris	39744	"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranodal NK/T-cell lymphoma."	Designated/Approved	Approved for Orphan Indication	"ADCETRIS is indicated for the treatment of adult patients with previously untreated sALCL or other CD30-expressing PTCL, including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone"	Ê11/16/2018Ê	Ê11/16/2025	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA	268908
3401	Anaplastic large cell lymphoma	3112			3277	"anaplastic large cell lymphoma,"	C0206180	Ki-1+ Anaplastic Large Cell Lymphoma	neop	"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranodal NK/T-cell lymphoma."				brentuximab vedotin	Adcetris	39744	"Treatment of peripheral T-cell lymphoma, including anaplastic large cell lymphoma, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, adult T-cell leukemia/lymphoma, enteropathy-associated T-cell lymphoma, and extranodal NK/T-cell lymphoma."	Designated/Approved	Approved for Orphan Indication	The treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen	Ê08/19/2011Ê	Ê08/19/2018	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA	268908
3193	Anaplastic thyroid cancer	664			1298	whose tumors	C0027651	Neoplasms	neop	Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.	Anaplastic thyroid cancer|GARD:0000664|TRAMETINIB|DABRAFENIB AND TRAMETINIB|TAFINLAR(R) CAPSULES A ND MEKINIST(R) TABLETS|GARD:0000664	Anaplastic thyroid cancer|GARD:0000664|DABRAFENIB|DABRAFENIB AND TRAMETINIB|TAFINLAR(R) CAPSULES A ND MEKINIST(R) TABLETS|GARD:0000664		dabrafenib and trametinib	Tafinlar(R) Capsules A Nd Mekinist(R) Tablets	42614	Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.	Designated/Approved	Approved for Orphan Indication	"TAFINLAR is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options"	Ê05/04/2018Ê	Ê05/04/2025	Novartis Pharmaceuticals Corporation	1 Health Plaza	Building 337	East Hanover	New Jersey	7936	USA	521616
3193	Anaplastic thyroid cancer	664			1298	whose tumors	C0027651	Neoplasms	neop	Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.	Anaplastic thyroid cancer|GARD:0000664|TRAMETINIB|DABRAFENIB AND TRAMETINIB|TAFINLAR(R) CAPSULES A ND MEKINIST(R) TABLETS|GARD:0000664	Anaplastic thyroid cancer|GARD:0000664|DABRAFENIB|DABRAFENIB AND TRAMETINIB|TAFINLAR(R) CAPSULES A ND MEKINIST(R) TABLETS|GARD:0000664		dabrafenib and trametinib	Tafinlar(R) Capsules A Nd Mekinist(R) Tablets	42614	Treatment of patients with anaplastic thyroid cancer and locally advanced or metastatic papillary thyroid cancer whose tumors harbor a BRAF V600 mutation.	Designated/Approved	Approved for Orphan Indication	"MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation and with no satisfactory locoregional treatment options"	Ê05/04/2018Ê	Ê05/04/2025	Novartis Pharmaceuticals Corporation	1 Health Plaza	Building 337	East Hanover	New Jersey	7936	USA	521616
2125	anthracycline extravasation during chemotherapy		MISSING		3931	of anthracycline extravasation	C0015376	Extravasation	patf	Treatment of anthracycline extravasation during chemotherapy	DEXRAZOXANE|TOTECT(R)			dexrazoxane	Totect(R)	38071	Treatment of anthracycline extravasation during chemotherapy	Designated/Approved	Approved for Orphan Indication	Treatment of extravasation resulting from IV anthracycline chemotherapy	Ê09/06/2007Ê	Ê09/06/2014	"Clinigen, Inc."	790 Township Line Road	Suite 120	Yardley	Pennsylvania	19067	USA	181103
5358	Anthrax	8157			3973	of anthrax	C0003175	Anthrax disease	dsyn	Treatment of anthrax	ANTHRAX DISEASE|ANTHRAX|INHALATIONAL ANTHRAX|DOID:7427|MESH:D000881	Anthrax|GARD:0008157|ANTHRAX IMMUNE GLOBULIN|GARD:0008157	Anthrax|GARD:0008157|ANTHRAX IMMUNE GLOBULIN (HUMAN)|GARD:0008157	raxibacumab	Abthraxtm	37937	Treatment of anthrax	Designated/Approved	Approved for Orphan Indication	"Treatment of inhalation anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs,"	Ê12/14/2012Ê	Ê12/14/2019	"Human Genome Sciences, Inc."	14200 Shady Grove Road		Rockville	Maryland	20850	USA	175503
5362	Anthrax	8157			3320	of inhalational anthrax	C0155866	Inhalational anthrax	dsyn	Treatment of inhalational anthrax	ANTHRAX DISEASE|ANTHRAX|INHALATIONAL ANTHRAX|DOID:7427|MESH:D000881	Anthrax|GARD:0008157|ANTHRAX IMMUNE GLOBULIN (HUMAN)|GARD:0008157	Anthrax|GARD:0008157|OBILTOXAXIMAB|ANTHIM|GARD:0008157	anthrax immune globulin (human)	n/a	39658	Treatment of inhalational anthrax	Designated/Approved	Approved for Orphan Indication	Treatment of inhalational anthrax in adult and pediatric patients in combination with appropriate antibacterial drugs	Ê03/24/2015Ê	Ê03/24/2022	Cangene Corp. - Emergent Biosolutions	155 Innovation Drive	R3T 5Y3	"Winnipeg, MB"			Canada	263008
5360	Anthrax	8157			2134	of anthrax disease	C0003175	Anthrax disease	dsyn	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Anthrax|GARD:0008157|ANTHRAX VACCINE ADSORBED|BIOTHRAX|GARD:0008157			Anthrax Vaccine Adsorbed	Biothrax	41740	For post-exposure prophylaxis of anthrax disease resulting from suspected or confirmed Bacillus anthracis exposure	Designated/Approved	Approved for Orphan Indication	"For post-exposure prophylaxis of disease following suspected or confirmed Bacillus anthracis exposure, when administered in conjunction with recommended antibacterial drugs."	Ê11/23/2015Ê	Ê11/23/2022	Emergent BioDefense Operations Lansing LLC	300 Proessional Drive		Gaithersburg	Maryland	20879	USA	424914
2595	Anthrax	8157	done		3628					Treatment of exposure to B. anthracis spores	Anthrax|GARD:0008157|OBILTOXAXIMAB|ANTHIM|GARD:0008157	ANTHRAX|BLACK BAINE|MALIGNANT EDEMA|MALIGNANT PUSTULE|RAGPICKER DISEASE|SIBERIAN PLAGUE|WOOLSORTER'S DISEASE		obiltoxaximab	Anthim	38877	Treatment of exposure to B. anthracis spores	Designated/Approved	Approved for Orphan Indication	Treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or are not appropriate.	Ê03/18/2016Ê	Ê03/18/2023	"Elusys Therapeutics, Inc."	25 Riverside Drive	P.O. Box 102	Pine Brook	New Jersey	7058	USA	224306
3730	Aplastic anemia	5836			2234	of aplastic anemia	C0002874	Aplastic Anemia	dsyn	Treatment of aplastic anemia	REFRACTORY SEVERE APLASTIC ANEMIA|NCIT:C153295|NCI:C153295	Aplastic anemia|GARD:0005836|MOLGRAMOSTIM|LEUCOMAX|GARD:0005836	Aplastic anemia|GARD:0005836|ETIOCHOLANEDIONE|GARD:0005836	eltrombopag	Promacta	41586	Treatment of aplastic anemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.	Ê08/26/2014Ê	Ê08/26/2021	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA	410213
3730	Aplastic anemia	5836			2234	of aplastic anemia	C0002874	Aplastic Anemia	dsyn	Treatment of aplastic anemia	REFRACTORY SEVERE APLASTIC ANEMIA|NCIT:C153295|NCI:C153295	Aplastic anemia|GARD:0005836|MOLGRAMOSTIM|LEUCOMAX|GARD:0005836	Aplastic anemia|GARD:0005836|ETIOCHOLANEDIONE|GARD:0005836	eltrombopag	Promacta	41586	Treatment of aplastic anemia	Designated/Approved	Approved for Orphan Indication	PROMACTA is indicated in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia.	Ê11/16/2018Ê	Ê11/16/2025	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA	410213
371	As preparative therapy in the treatment of malignancies with bone marrow transplantation.		MISSING		4624	of malignancies	C0006826	Malignant Neoplasms	neop	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	BUSULFAN|BUSULFEX			Busulfan	Busulfex	34543	As preparative therapy in the treatment of malignancies with bone marrow transplantation.	Designated/Approved	Approved for Orphan Indication	For use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia.	Ê02/04/1999Ê	Ê02/04/2006	Otsuka Pharmaceutical Company		Tokyo				Japan	83094
234	Aspergillosis	5856	approximate		4787	of invasive fungal infections.	C1262313	Invasive fungal diseases	dsyn	Treatment of invasive fungal infections.	"FUNGAL INFECTIOUS DISEASE|FUNGAL INFECTION, PULMONARY|FUNCGAL INFECTION|DOID:1564|MESH:D008172"	Aspergillosis |GARD:0005856|NYSTATIN|LIPOSOMAL NYSTATIN|NYOTRAN|GARD:0005856	INVASIVE ASPERGILLOSIS|ASPERGILLOSIS|DOID:50073|MESH:D001228	Amphotericin B lipid complex	Abelcet	33577	Treatment of invasive fungal infections.	Designated/Approved	Approved for Orphan Indication	Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy.	Ê10/18/1996Ê	Ê10/18/2003	"Liposome Company, Inc."	One Research Way		Princeton	New Jersey	8540	USA	57891
3735	Aspergillosis	5856			2379	of invasive aspergillosis	C0238013	invasive aspergillosis	dsyn	Treatment of invasive aspergillosis	"INVASIVE PULMONARY ASPERGILLOSIS|PULMONARY ASPERGILLOSES, INVASIVE|ASPERGILLOSIS, INVASIVE PULMONARY|PULMONARY ASPERGILLOSIS, INVASIVE|PULMONARY ASPERGILLOSIS INVASIVE|PULMONARY ASPERGILLOSIS - INVASIVE|MESH:D055744|UMLS:C0276653|SNOMEDCT_US:3214003"	INVASIVE ASPERGILLOSIS|ASPERGILLOSIS|DOID:50073|MESH:D001228	Aspergillosis|GARD:0005856|POSACONAZOLE|NOXAFIL|GARD:0005856	isavuconazonium sulfate	Cresemba	41400	Treatment of invasive aspergillosis	Designated/Approved	Approved for Orphan Indication	Treatment of invasive aspergillosis in patients 18 years of age and older	Ê03/06/2015Ê	Ê03/06/2022	Astellas Pharma Global Development Inc.	1 Astellas Way		Northbrook	Illinois	60062	USA	394913
3019	Autosomal dominant polycystic kidney disease	10413	done		2614	of autosomal dominant polycystic kidney disease	C0085413	"Polycystic Kidney, Autosomal Dominant"	dsyn	Treatment of autosomal dominant polycystic kidney disease	Autosomal dominant polycystic kidney disease|GARD:0010413|VENGLUSTAT|GARD:0010413	Autosomal dominant polycystic kidney disease|GARD:0010413|LIXIVAPTAN|GARD:0010413	Autosomal dominant polycystic kidney disease|GARD:0010413|TOLVAPTAN|SAMSCA|GARD:0010413	tolvaptan	Jynarque	41005	Treatment of autosomal dominant polycystic kidney disease	Designated/Approved	Approved for Orphan Indication	JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD)	Ê04/23/2018Ê	Ê04/23/2025	"Otsuka Pharmaceuticals Co., Ltd."	"2-9, Kanda-Tsukasamachi"	101-8535	Tokyo			Japan	347311
1329	Autosomal recessive protein C deficiency	13041	approximate		4749	in congenital protein C deficiency	C0398625	Protein C Deficiency	dsyn	"For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans."	Autosomal recessive protein C deficiency|GARD:0013041|PROTEIN C|PROTEIN C CONCENTRATE|CEPROTIN|GARD:0013041			Protein C concentrate	Ceprotin	33778	"For replacement therapy in congenital protein C deficiency for the prevention and treatment of thrombosis, pulmonary emboli, and purpura fulminans."	Designated/Approved	Approved for Orphan Indication	Prevention and treatment of venous thrombosis and purpura fulminans	Ê03/30/2007Ê	Ê03/30/2014	"Baxalta US, Inc."	One Baxter Way		West Lake Village	California	91362	USA	65392
2546	Avitaminosis		MISSING		3941	of vitamin deficiency	C0376286	Avitaminosis	dsyn	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	PHYTONADIONE|MULTI-VITAMIN INFUSION WITHOUT VITAMIN K|M.V.I.-12			multi-vitamin infusion without vitamin K	M.V.I.-12	38054	Prevention of vitamin deficiency and thromboembolic complications in people receiving home parenteral nutrition and warfarin-type anticoagulant therapy	Designated/Approved	Approved for Orphan Indication	Prevention of vitamin deficiency and thrombormbolic complications in people receiving home parenteral nutrition who also receive warfarin-type anticoagulant therapy	Ê09/09/2004Ê	Ê09/09/2011	Mayne Pharma (USA) Inc.	Mack-Cali Centre II	Second Floor	Paramus	New Jersey	7652	USA	182003
2815	B-cell lymphoma	5877	approximate		3852	of non-Hodgkin T-cell lymphomas	C0079772	T-Cell Lymphoma	neop	Treatment of non-Hodgkin T-cell lymphomas	Hodgkin lymphoma|GARD:0002714|AUTOLOGOUS EPSTEIN-BARR VIRUS SPECIFIC T-CELLS|GARD:0002714	B-cell lymphoma|GARD:0005877|ROMIDEPSIN|ISTODAX|GARD:0005877	B-cell lymphoma|GARD:0005877|ROMIDEPSIN|ISTODAX|GARD:0005877	romidepsin	Istodax	38260	Treatment of non-Hodgkin T-cell lymphomas	Designated/Approved	Approved for Orphan Indication	Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy	Ê06/16/2011Ê	Ê06/16/2018	Celgene Corporation	One Broadway	14th Floor	Cambridge	Massachusetts	2142	USA	193404
2815	B-cell lymphoma	5877	approximate		3852	of non-Hodgkin T-cell lymphomas	C0079772	T-Cell Lymphoma	neop	Treatment of non-Hodgkin T-cell lymphomas	Hodgkin lymphoma|GARD:0002714|AUTOLOGOUS EPSTEIN-BARR VIRUS SPECIFIC T-CELLS|GARD:0002714	B-cell lymphoma|GARD:0005877|ROMIDEPSIN|ISTODAX|GARD:0005877	B-cell lymphoma|GARD:0005877|ROMIDEPSIN|ISTODAX|GARD:0005877	romidepsin	Istodax	38260	Treatment of non-Hodgkin T-cell lymphomas	Designated/Approved	Approved for Orphan Indication	Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy	Ê11/05/2009Ê	Ê11/05/2016	Celgene Corporation	One Broadway	14th Floor	Cambridge	Massachusetts	2142	USA	193404
3790	B-cell lymphoma	5877			1436	of primary mediastinal B-cell lymphoma.	C1334665	Mediastinal Lymphoma	neop	Treatment of primary mediastinal B-cell lymphoma.	PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA REFRACTORY|REFRACTORY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA|REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA|NCI:C8875|UMLS:C0855154	REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA|REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA|REFRACTORY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA|PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA REFRACTORY|NCIT:C8875|NCI:C8875|UMLS:C0855154	B-cell lymphoma|GARD:0005877|PEMBROLIZUMAB|KETRUDA|GARD:0005877	axicabtagene ciloleucel	Yescarta	42480	Treatment of primary mediastinal B-cell lymphoma.	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma"	Ê10/18/2017Ê	Ê10/18/2024	"Kite Pharma, Inc."	2225 Colorado Avenue		Santa Monica	California	90404	USA	515915
2660	B-cell lymphoma	5877	approximate		1521	of primary mediastinal B cell lymphoma.	C1334665	Mediastinal Lymphoma	neop	Treatment of primary mediastinal B cell lymphoma.	PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA REFRACTORY|REFRACTORY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA|REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA|NCI:C8875|UMLS:C0855154	REFRACTORY PRIMARY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA|REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA|REFRACTORY MEDIASTINAL (THYMIC) LARGE B-CELL CELL LYMPHOMA|PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA REFRACTORY|NCIT:C8875|NCI:C8875|UMLS:C0855154	B-cell lymphoma|GARD:0005877|PEMBROLIZUMAB|KETRUDA|GARD:0005877	pembrolizumab	Keytruda	42383	Treatment of primary mediastinal B cell lymphoma.	Designated/Approved	Approved for Orphan Indication	"KEYTRUDA is indicated for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after 2 or more prior lines of therapy"	Ê06/13/2018Ê	Ê06/13/2025	"Merck, Sharp & Dohme Corp."	One Merck Drive		Whitehouse Station	New Jersey	8889	USA	495415
2349	B-cell lymphoma	5877	done		4620	of B-cell non-Hodgkin's lymphoma.	C0079731	B-Cell Lymphomas	neop	Treatment of B-cell non-Hodgkin's lymphoma.	REFRACTORY B-CELL NON-HODGKIN LYMPHOMA|REFRACTORY B-CELL LYMPHOMA|REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA|B-CELL LYMPHOMA REFRACTORY|NCIT:C8842|NCI:C8842|UMLS:C0855090	REFRACTORY B-CELL NON-HODGKIN LYMPHOMA|REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA|B-CELL LYMPHOMA REFRACTORY|REFRACTORY B-CELL LYMPHOMA|NCI:C8842|UMLS:C0855090	REFRACTORY T-CELL NON-HODGKIN'S LYMPHOMA|REFRACTORY T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY T-CELL LYMPHOMA|REFRACTORY T-CELL AND NK-CELL NON-HODGKIN'S LYMPHOMA|T-CELL LYMPHOMA REFRACTORY|NCI:C8664|UMLS:C0854827	ibritumomab tiuxetan	Zevalin	34583	Treatment of B-cell non-Hodgkin's lymphoma.	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan?) refractory follicular non-Hodgkin?s lymphoma"	Ê02/19/2002Ê	Ê02/19/2009	Acrotech Biopharma LLC	279 Princeton Hightstown Road		East Windsor	New Jersey	8520	USA	84894
3755	B-cell lymphoma	5877			4632	of non-Hodgkin's B-cell lymphoma	C0079731	B-Cell Lymphomas	neop	Treatment of non-Hodgkin's B-cell lymphoma	REFRACTORY B-CELL NON-HODGKIN LYMPHOMA|REFRACTORY B-CELL LYMPHOMA|REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA|B-CELL LYMPHOMA REFRACTORY|NCIT:C8842|NCI:C8842|UMLS:C0855090	REFRACTORY B-CELL NON-HODGKIN LYMPHOMA|REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA|B-CELL LYMPHOMA REFRACTORY|REFRACTORY B-CELL LYMPHOMA|NCI:C8842|UMLS:C0855090	REFRACTORY T-CELL NON-HODGKIN'S LYMPHOMA|REFRACTORY T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY T-CELL LYMPHOMA|REFRACTORY T-CELL AND NK-CELL NON-HODGKIN'S LYMPHOMA|T-CELL LYMPHOMA REFRACTORY|NCI:C8664|UMLS:C0854827	rituximab	Rituxan	34498	Treatment of non-Hodgkin's B-cell lymphoma	Designated/Approved	Approved for Orphan Indication		Ê11/26/1997Ê	Ê11/26/2004	"Genentech, Inc."	"1 DNA Way, MS 242"		South San Francisco	California	94080	USA	79793
3774	B-cell lymphoma	5877			4637	of non-Hodgkin's B-cell lymphoma.	C0079731	B-Cell Lymphomas	neop	Treatment of non-Hodgkin's B-cell lymphoma.	REFRACTORY B-CELL NON-HODGKIN LYMPHOMA|REFRACTORY B-CELL LYMPHOMA|REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA|B-CELL LYMPHOMA REFRACTORY|NCIT:C8842|NCI:C8842|UMLS:C0855090	REFRACTORY B-CELL NON-HODGKIN LYMPHOMA|REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA|B-CELL LYMPHOMA REFRACTORY|REFRACTORY B-CELL LYMPHOMA|NCI:C8842|UMLS:C0855090	REFRACTORY T-CELL NON-HODGKIN'S LYMPHOMA|REFRACTORY T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY T-CELL LYMPHOMA|REFRACTORY T-CELL AND NK-CELL NON-HODGKIN'S LYMPHOMA|T-CELL LYMPHOMA REFRACTORY|NCI:C8664|UMLS:C0854827	Tositumomab and iodine I 131 tositumomab	Bexxar	34470	Treatment of non-Hodgkin's B-cell lymphoma.	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy"	Ê06/27/2003Ê	Ê06/27/2010	GlaxoSmithKline LLC	Corporation Service Company	"2711 Centerville Road, Suite 400"	Wilmington	Delaware	19808	USA	79493
2352	B-cell lymphoma	5877	approximate		2363	of small lymphocytic lymphoma	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of small lymphocytic lymphoma	REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA|B-CELL SMALL LYMPHOCYTIC LYMPHOMA REFRACTORY|REFRACTORY B-CELL SMALL LYMPHOCYTIC LYMPHOMA|NCIT:C8846|NCI:C8846|UMLS:C0855097	B-CELL SMALL LYMPHOCYTIC LYMPHOMA REFRACTORY|REFRACTORY B-CELL SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA|NCI:C8846|UMLS:C0855097	Chronic lymphocytic leukemia|GARD:0006104|DUVELISIB|GARD:0006104	ibrutinib	Imbruvica	41424	Treatment of small lymphocytic lymphoma	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and indicated for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) with 17p deletion.	Ê05/06/2016Ê	Ê05/06/2023	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA	395513
1187	Bacterial corneal ulcer		MISSING	Not a rare disease	4836	of bacterial corneal ulcers.	C0339215	Bacterial corneal ulcer	dsyn	Treatment of bacterial corneal ulcers.	OFLOXACIN|OCUFLOX OPHTHALMIC SOLUTION	GRANULOMATOSIS WITH POLYANGIITIS|GPA|MIDLINE GRANULOMATOSIS|NECROTIZING RESPIRATORY GRANULOMATOSIS|PATHERGIC GRANULOMATOSIS|WEGENERâS DISEASE|WEGENER GRANULOMATOSIS|WEGENERâS GRANULOMATOSIS		Ofloxacin	Ocuflox Ophthalmic Solution	33346	Treatment of bacterial corneal ulcers.	Designated/Approved	Approved for Orphan Indication	Treatment of bacterial corneal ulcers.	Ê05/22/1996Ê	Ê05/22/2003	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92713	USA	56791
2710	Barrett esophagus	20	done	Not a rare disease	4140	in Barrett's Esophagus	C0004763	Barrett Esophagus	dsyn	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy				porfimer	Photofrin	37183	For the ablation of High-Grade Dysplasia in Barrett's Esophagus in patients who are not considered to be candidates for esophagectomy	Designated/Approved	Approved for Orphan Indication	For the ablation of high-grade dysplasia in Barrett's esophagus patients who do not undergo esophagectomy	Ê08/01/2003Ê	Ê08/01/2010	Axcan Scandipharm Inc.	22 Inverness Parkway	Suite 310	Birmingham	Alabama	35242	USA	146601
1870	Behcet Syndrome	848	done		2451	of Behcet's disease	C0004943	Behcet Syndrome	dsyn	Treatment of Behcet's disease	"BehÃ§et disease|GARD:0000848|ADALIMUMAB, LICENSE HOLDER UNSPECIFIED|ADALIMUMAB|GARD:0000848"	BehÃ§et disease|GARD:0000848|APREMILAST|GARD:0000848	BehÃ§et disease|GARD:0000848|GEVOKIZUMAB|GARD:0000848	apremilast	Otezla	41291	Treatment of Behcet's disease	Designated/Approved	Approved for Orphan Indication	OTEZLA is indicated for the treatment of adult patients with oral ulcers associated with Beh_s Disease.	Ê07/19/2019Ê	Ê07/19/2026	Amgen Inc.	One Amgen Center Drive	Mailstop: 27-2-D	Thousand Oaks	California	91320	USA	384812
1525	Bidirectional tachycardia	878	done		5045	of life-threatening ventricular tachyarrhythmias 2.	C1517874	Life Threatening Adverse Event	fndg	1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias	Bidirectional tachycardia|GARD:0000878|SOTALOL HYDROCHLORIDE|SOTALOL HCL|BETAPACE|GARD:0000878			Sotalol HCl	Betapace	32409	1. Treatment of life-threatening ventricular tachyarrhythmias 2. Prevention of life treatening ventricular tachyarrhythmias	Designated/Approved	Approved for Orphan Indication	Treatment of life-threatening ventricular tachyarrhythmias	Ê10/30/1992Ê	Ê10/30/1999	"Berlex Laboratories, Inc."	300 Fairfield Road		Wayne	New Jersey	7470	USA	30088
597	Bidirectional tachycardia		MISSING	Not a disease	5235	of potentially life threatening digitalis intoxication	C1517874	Life Threatening Adverse Event	fndg	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	DIGOXIN IMMUNE FAB (OVINE)|DIGIBIND			Digoxin immune FAB (Ovine)	Digibind	30987	Treatment of potentially life threatening digitalis intoxication in patients who are refractory to management by conventional therapy.	Designated/Approved	Approved for Orphan Indication		Ê04/22/1986Ê	Ê04/22/1993	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA	2584
230	Bidirectional tachycardia	878	approximate		4647	ventricular fibrillation.	C0042510	Ventricular Fibrillation	dsyn	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Familial ventricular tachycardia|GARD:0002263|AMIODARONE HYDROCHLORIDE|AMIODARONE HCL|CORDARONE|GARD:0002263	Bidirectional tachycardia|GARD:0000878|AMIODARONE HYDROCHLORIDE|AMIODARONE HCL|CORDARONE|GARD:0000878		Amiodarone HCl	Cordarone	34409	For the acute treatment and prophylaxis of life-threatening ventricular tachycardia or ventricular fibrillation.	Designated/Approved	Approved for Orphan Indication	For initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy.	Ê08/03/1995Ê	Ê08/03/2002	Wyeth-Ayerst Laboratories	P.O. Box 8299		Philadelphia	Pennsylvania	19101	USA	77293
Missing	Bladder cancer	12210			4636	of carcinoma in situ	C0007099	Carcinoma in Situ	neop	Treatment of carcinoma in situ of the urinary bladder.	SOFT TISSUE SARCOMA|STS			Valrubicin	Valstar	34477	Treatment of carcinoma in situ of the urinary bladder.	Designated/Approved	Approved for Orphan Indication	For intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality.	Ê09/25/1998Ê	Ê09/25/2005	"Anthra Pharmaceuticals, Inc."	"103 Carnegie Center, Suite 102"		Princeton	New Jersey	8540	USA	82194
5861	Blastic plasmacytoid dendritic cell	10556			2360	of blastic plasmacytoid dendritic cell neoplasm	C1301363	Blastic plasmacytoid dendritic cell neoplasm	neop	Treatment of blastic plasmacytoid dendritic cell neoplasm	REFRACTORY BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM|NCIT:C156104|NCI:C156104	Blastic plasmacytoid dendritic cell|GARD:0010556|SL-401|HUMAN INTERLEUKIN-3 GENETICALLY CONJUGATED TO DIPHTHERIA TOXIN PROTEIN|GARD:0010556	DT(388)IL3 FUSION PROTEIN SL-401|SL-401|DIPHTHERIA TOXIN(388)-INTERLEUKIN-3 FUSION PROTEIN|DT(388)-IL3 FUSION PROTEIN|DT388IL3 FUSION PROTEIN|IL3R-TARGETING FUSION PROTEIN SL-401|NCIT:C64769|NCI:C64769|UMLS:C1831974	Tagraxofusp-erzs	Elzonris	41431	Treatment of blastic plasmacytoid dendritic cell neoplasm	Designated/Approved	Approved for Orphan Indication	ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.	Ê12/21/2018Ê	Ê12/21/2025	"Stemline Therapeutics, Inc."	750 Lexington Avenue	11th floor	New York	New York	10022	USA	397413
357	Blepharospasm		MISSING		5253	blepharospasms	C0005747	Blepharospasm	dsyn	Treatment of strabismus and blepharospasms	BOTULINUM TOXIN TYPE A|BOTOX	BOTULINUM TOXIN TYPE A|BOTOX		Botulinum toxin type A	Botox	30763	Treatment of strabismus and blepharospasms	Designated/Approved	Approved for Orphan Indication	Treatment of strabismus associated with dystonia in adults (patients 12 years of age and above)	Ê12/29/1989Ê	Ê12/29/1996	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92713	USA	483
357	Blepharospasm		MISSING		5253	blepharospasms	C0005747	Blepharospasm	dsyn	Treatment of strabismus and blepharospasms	BOTULINUM TOXIN TYPE A|BOTOX	BOTULINUM TOXIN TYPE A|BOTOX		Botulinum toxin type A	Botox	30763	Treatment of strabismus and blepharospasms	Designated/Approved	Approved for Orphan Indication	Treatment of blepharospasm associated with dystonia in adults (patients 12 years of age and above)	Ê12/30/1989Ê	Ê12/30/1996	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92713	USA	483
3213	Botulism	943			5016	of infant botulism.	C0238027	"Botulism, Infantile"	dsyn	Treatment of infant botulism.	INFANT BOTULISM|DOID:50354|MESH:D001906	Botulism|GARD:0000943|BABYBIG|BOTULISM IMMUNE GLOBULIN|GARD:0000943	BOTULISM	Botulism immune globulin	Babybig	32539	Treatment of infant botulism.	Designated/Approved	Approved for Orphan Indication	Indicated for treatment of infant botulism caused by type A or type B Clostridium botulinum.	Ê10/23/2003Ê	Ê10/23/2010	California Department of Health Services	2151 Berkeley Way		Berkeley	California	94704	USA	34488
1951	Botulism	943	done		2757					Treatment of botulism.	INFANT BOTULISM|DOID:50354|MESH:D001906	"Botulism|GARD:0000943|BOTULISM ANTITOXIN HEPTAVALENT (A, B, C, D, E, F, G) (EQUINE)|GARD:0000943"	Botulism|GARD:0000943|BABYBIG|BOTULISM IMMUNE GLOBULIN|GARD:0000943	"botulism antitoxin heptavalent (A, B, C, D, E, F, G) (Equine)"	n/a	40723	Treatment of botulism.	Designated/Approved	Approved for Orphan Indication	"Treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin (BoNT) serotypes A, B, C, D, E, F or G in adults and pediatric patients."	Ê03/22/2013Ê	Ê03/22/2020	Cangene Corporation	155 Innovation Drive	"Winnipeg, Manitoba R3T5Y3"				Canada	345011
1052	Burns and Wounds		MISSING	Not a rare disease	4897	on excised burn wounds.	C0595940	Burns and Wounds	fndg	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	MAFENIDE ACETATE|MAFENIDE ACETATE SOLUTION|SULFAMYLON SOLUTION			Mafenide acetate solution	Sulfamylon Solution	33072	For use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.	Designated/Approved	Approved for Orphan Indication		Ê06/05/1998Ê	Ê06/05/2005	"Mylan Laboratories, Inc."	781 Chestnut Ridge Road	P.O. Box 4310	Morgantown	West Virginia	26504	USA	47890
1313	Calcium renal calculus		MISSING	Not a rare disease	5238	of calcium renal stones	C1959799	Calcium renal calculus	dsyn	1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	POTASSIUM CITRATE|UROCIT-K			Potassium citrate	Urocit-K	30987	1. Prevention of calcium renal stones in patients with hypocitraturia 2. For avoidance of the complication of calcium stone formation in patients with uric lithiasis.	Designated/Approved	Approved for Orphan Indication	Prevention of recurring calcium conating stines associated with a deficiency in the urine.	Ê08/07/1985Ê	Ê08/07/1992	University of Texas Health Science Center at Dallas	5323 Harry Hines Blvd		Dallas	Texas	75235	USA	9685
3070	Capecitabine poisoning		MISSING		3195					An antidote in the treatment of 5-fluorouracil or capecitabine poisoning	URIDINE TRIACETATE			uridine triacetate	n/a	39934	An antidote in the treatment of 5-fluorouracil or capecitabine poisoning	Designated/Approved	Approved for Orphan Indication	"For the emergency treatment of adult and pediatric patients following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration"	Ê12/11/2015Ê	Ê12/11/2022	Wellstat Therapeutics Corp.	14200 Shady Grove Road	Suite 600	Rockville	Maryland	20850	USA	273808
335	Carbamoyl phosphate synthetase 1 deficiency 	7269	done		5173	with urea cycle enzymopathy	C0520572	Enzymopathy	dsyn	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	 Ornithine transcarbamylase deficiency |GARD:0008391|BENZOIC ACID|BENZOATE AND PHENYLACETATE|BENZOATE|UCEPHAN|GARD:0008391	 Ornithine transcarbamylase deficiency |GARD:0008391|PHENYL ACETATE|BENZOATE AND PHENYLACETATE|PHENYLACETATE|UCEPHAN|GARD:0008391	Carbamoyl phosphate synthetase 1 deficiency |GARD:0007269|BENZOIC ACID|BENZOATE AND PHENYLACETATE|BENZOATE|UCEPHAN|GARD:0007269	Benzoate and phenylacetate	Ucephan	31433	"For adjunctive therapy in the prevention and treatment of hyperammonemia in patients with urea cycle enzymopathy due to carbamylphosphate synthetase, ornithine, transcarbamylase, or argininosuccinate synthetase deficiency."	Designated/Approved	Approved for Orphan Indication		Ê12/23/1987Ê	Ê12/23/1994	ImmunexImmunex	2525 McGaw Avenue	P.O. Box 19791	Irvine	California	92623	USA	11385
3827	Carcinoid syndrome	5994			2632	of carcinoid syndrome	C0024586	Malignant Carcinoid Syndrome	dsyn	Treatment of carcinoid syndrome in patients with neuroendocrine tumors	Carcinoid syndrome|GARD:0005994|TELOTRISTAT ETIPRATE|GARD:0005994	Carcinoid|GARD:0009316|TELOTRISTAT ETIPRATE|GARD:0009316	Neuroendocrine tumor|GARD:0013445|TELOTRISTAT ETIPRATE|GARD:0013445	telotristat etiprate	Xermelo	40977	Treatment of carcinoid syndrome in patients with neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.	Ê02/28/2017Ê	Ê02/28/2024	"Lexicon Pharmaceuticals, Inc."	8800 Technology Forest Drive		The Woodlands	Texas	77381	USA	266308
3828	Carcinoid syndrome	5994			2718	of carcinoid syndrome	C0024586	Malignant Carcinoid Syndrome	dsyn	Treatment of carcinoid syndrome	Carcinoid syndrome|GARD:0005994|TELOTRISTAT ETIPRATE|GARD:0005994	Carcinoid syndrome|GARD:0005994|LANREOTIDE ACETATE|GARD:0005994	Carcinoid|GARD:0009316|TELOTRISTAT ETIPRATE|GARD:0009316	lanreotide acetate	n/a	40794	Treatment of carcinoid syndrome	Designated/Approved	Approved for Orphan Indication	"treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy"	Ê09/15/2017Ê	Ê09/15/2024	"Ipsen Biopharmaceuticals, Inc."	106 Allen Road		Basking Ridge	New Jersey	7920	USA	347111
5635	Carcinoid tumor	9316			4383	with malignant carcinoid tumors.	C0391970	"Carcinoid tumor, malignant"	neop	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Carcinoid tumor|GARD:0009316|OCTREOTIDE|SANDOSTATIN LAR|GARD:0009316	Carcinoid|GARD:0009316|OCTREOTIDE|SANDOSTATIN LAR|GARD:0009316	CARCINOID SYNDROME|CARCINOID APUDOMA|CARCINOID CANCER|CARCINOID DISEASE|FUNCTIONING ARGENTAFFINOMA|FUNCTIONING CARCINOID|MALIGNANT CARCINOID SYNDROME|NEUROENDOCRINE TUMOR CARCINOID TYPE	Octreotide	Sandostatin Lar	36031	Treatment of severe diarrhea and flushing associated with malignant carcinoid tumors.	Designated/Approved	Approved for Orphan Indication	Supression of severe diarrhea and flushing associated with malignant carcinoid syndrome.	Ê11/25/1998Ê	Ê11/25/2005	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA	114698
584	Cardiomyopathies		MISSING	Not a disease	4783	of cardiomyopathy	C0878544	Cardiomyopathies	dsyn	For the prevention of cardiomyopathy associated with doxorubicin administration.	DEXRAZOXANE|ZINECARD			Dexrazoxane	Zinecard	33589	For the prevention of cardiomyopathy associated with doxorubicin administration.	Designated/Approved	Approved for Orphan Indication	Cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300mg/m2.	Ê05/26/1995Ê	Ê05/26/2002	Pharmacia & Upjohn	7000 Portage Road		Kalamazoo	Michigan	49001	USA	63291
2869	Castleman disease	12656	done		3629	of Castleman's disease	C0017531	Angiolymphoid hyperplasia	dsyn	Treatment of Castleman's disease	Castleman disease|GARD:0012656|SILTUXIMAB|SYLVANT|GARD:0012656	CASTLEMAN DISEASE|ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA|ANGIOMATOUS LYMPHOID|CASTLEMAN TUMOR|GIANT BENIGN LYMPHOMA|GIANT LYMPH NODE HYPERPLASIA|HAMARTOMA OF THE LYMPHATICS	MULTICENTRIC CASTLEMAN DISEASE|MCD|PLASMABLASTIC MULTICENTRIC CASTLEMAN DISEASE|PMCD|MULTICENTRIC PLASMA CELL VARIANT OF CASTLEMAN'S DISEASE|IDIOPATHIC MULTICENTRIC CASTLEMAN'S DISEASE|MULTICENTRIC GIANT LYMPH NODE HYPERPLASIA|GARD:0009644|ORPHA:93686|ORPHANET:93686	siltuximab	Sylvant	38863	Treatment of Castleman's disease	Designated/Approved	Approved for Orphan Indication	Treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.	Ê04/23/2014Ê	Ê04/23/2021	EUSA Pharma (UK) Ltd.	Breakspear Park	Breakspear Way	Hertfordshire			United Kingdom	200605
355	Cerebral palsy	10450	done		4786	in pediatric cerebral palsy patients	C0007789	Cerebral Palsy	dsyn	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients	Cerebral palsy|GARD:0010450|BOTULINUM TOXIN TYPE A|BOTOX|GARD:0010450			botulinum toxin type A	Botox	33578	Treatment of dynamic muscle contracture in pediatric cerebral palsy patients	Designated/Approved	Approved for Orphan Indication	BOTOX is indicated for the treatment of upper limb spasticity in pediatric patients 2 to 17 years of age.	Ê06/20/2019Ê	Ê06/20/2026	"Allergan, Inc."	2525 Dupont Drive	T1-2A	Irvine	California	92623	USA	56591
356	Cerebral palsy	10450	done		4293	in pediatric cerebral palsy patients.	C0007789	Cerebral Palsy	dsyn	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Cerebral palsy|GARD:0010450|BOTULINUM TOXIN TYPE A|DYSPORT|GARD:0010450			Botulinum toxin type A	Dysport	36453	Treatment of dynamic muscle contractures in pediatric cerebral palsy patients.	Designated/Approved	Approved for Orphan Indication	Treatment of lower limb spasticity in pediatric patients 2 years of age and older	Ê07/29/2016Ê	Ê07/29/2023	"Ipsen Biopharmaceuticals, Inc."	650 East Kendall Street		Cambridge	Massachusetts	2142	USA	128299
5864	Cervical dystonia	10668			4777					Treatment of cervical dystonia.	CERVICAL DYSTONIA|DOID:50840|MESH:D014103	Cervical dystonia|GARD:0010668|DAXIBOTULINUMTOXIN A|DAXIBOTULINUMTOXINA|GARD:0010668	Cervical dystonia|GARD:0010668|BOTULINUM TOXIN TYPE B|MYOBLOC|GARD:0010668	Botulinum toxin type B	Myobloc	33619	Treatment of cervical dystonia.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.	Ê12/08/2000Ê	Ê12/08/2007	"Soltice Neurosciences, LLC"	4010 Dupont Circle	Suite L-07	Louisville	Kentucky	40207	USA	64791
5865	Cervical dystonia	10668			5152					Treatment of cervical dystonia.	CERVICAL DYSTONIA|DOID:50840|MESH:D014103	Cervical dystonia|GARD:0010668|DAXIBOTULINUMTOXIN A|DAXIBOTULINUMTOXINA|GARD:0010668	Cervical dystonia|GARD:0010668|BOTULINUM TOXIN TYPE B|MYOBLOC|GARD:0010668	Botulinum toxin type A	Botox	31644	Treatment of cervical dystonia.	Designated/Approved	Approved for Orphan Indication	Treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia.	Ê12/21/2000Ê	Ê12/21/2007	"Allergan, Inc."	2525 Dupont Drive	P.O. Box 19534	Irvine	California	92623	USA	9885
1929	Chagas disease	6030	done	Not a rare disease	945	of Chagas disease	C0041234	Chagas Disease	dsyn	Treatment of Chagas disease	Chagas disease|GARD:0006030|BENZNIDAZOLE|GARD:0006030	Chagas disease|GARD:0006030|NIFURTIMOX|GARD:0006030	Chagas disease|GARD:0006030|NIFURTIMOX|LAMPIT|GARD:0006030	benznidazole	n/a	41743	Treatment of Chagas disease	Designated/Approved	Approved for Orphan Indication	"Treatment of Chagas disease (American trypanosomiasis), caused by Trypanosoma cruzi, in pediatric patients 2 to 12 years of age."	Ê08/29/2017Ê	Ê08/29/2024	"Chemo Research, S.L."		"Edificio Nectar, c/Quintanapalla, 2, 3 planta"	Madrid			Spain	425214
1604	Childhood acute lymphoblastic leukemia	9240	done		5233	of refractory childhood acute lymphocytic leukemia.	C0023452	"Leukemia, Lymphocytic, Acute, L1"	neop	Treatment of refractory childhood acute lymphocytic leukemia.	Childhood acute lymphoblastic leukemia|GARD:0009240|TENIPOSIDE|VUMON FOR INJECTION|GARD:0009240			Teniposide	Vumon For Injection	30987	Treatment of refractory childhood acute lymphocytic leukemia.	Designated/Approved	Approved for Orphan Indication	Induction therapy in patients with refractory childhood acute lymphoblastic leukemia when used in combination with other approved anticancer agents.	Ê07/14/1992Ê	Ê07/14/1999	Bristol-Myers Squibb Pharmaceutical Research Institute	5 Research Parkway	P.O. Box 5100	Wallingford	Connecticut	6492	USA	883
1094	Cholesterol gallstones		MISSING		5249	of cholesterol gallstones	C0856727	Cholesterol gallstones	dsyn	For dissolution of cholesterol gallstones retained in the common bile duct.	MONOCTANOIN|MONOOCTANOIN|MOCTANIN			Monooctanoin	Moctanin	30832	For dissolution of cholesterol gallstones retained in the common bile duct.	Designated/Approved	Approved for Orphan Indication		Ê10/31/1985Ê	Ê10/31/1992	"Ethitek Pharmaceuticals, Inc."	"7855 Gross Point Road, Unit L"		Skokie	Illinois	60077	USA	2484
569	Chronic graft versus host disease	10964	approximate		4711	of acute renal allograft rejection.	C3273245	Acute Rejection	fndg	Prevention of acute renal allograft rejection.	Acute graft versus host disease|GARD:0006544|DACLIZUMAB|ZENAPAX|GARD:0006544			Daclizumab	Zenapax	34033	Prevention of acute renal allograft rejection.	Designated/Approved	Approved for Orphan Indication	"Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids."	Ê12/10/1997Ê	Ê12/10/2004	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA	67692
330	Chronic graft versus host disease	10964	MISSING		4426	of solid organ rejection.	C0815080	organ rejection	patf	Prophylaxis of solid organ rejection.	BASILIXIMAB|SIMULECT	ALEFACEPT|AMEVIVE	ANTI-T CELL RECEPTOR MURINE MONOCLONAL ANTIBODY	Basiliximab	Simulect	35776	Prophylaxis of solid organ rejection.	Designated/Approved	Approved for Orphan Indication	Prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.	Ê05/12/1998Ê	Ê05/12/2005	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA	109197
1920	Chronic graft versus host disease	10964	MISSING		3395	of organ rejection	C0815080	organ rejection	patf	Prophylaxis of organ rejection in renal allograft recipients	BELATACEPT|NULOJIX			belatacept	Nulojix	39498	Prophylaxis of organ rejection in renal allograft recipients	Designated/Approved	Approved for Orphan Indication	Prophylaxis of organ rejection in adult patients receiving kidney transplants	Ê06/15/2011Ê	Ê06/15/2018	Bristol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA	253907
2824	Chronic graft versus host disease	10964	approximate		1241	of graft versus host disease	C0018133	Graft-vs-Host Disease	dsyn	Treatment of graft versus host disease	Chronic graft versus host disease |GARD:0010964|CYCLOSPORINE|GARD:0010964	 Acute graft versus host disease|GARD:0006544|CYCLOSPORINE|GARD:0006544	STEROID REFRACTORY GRAFT VERSUS HOST DISEASE|STEROID REFRACTORY GVHD|STEROID REFRACTORY CGVHD|NCIT:C147114|NCI:C147114	ruxolitinib	Jakafi	42677	Treatment of graft versus host disease	Designated/Approved	Approved for Orphan Indication	Treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older.	Ê05/24/2019Ê	Ê05/24/2026	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA	542716
2955	Chronic graft versus host disease	10964	MISSING		2198	of organ rejection	C0815080	organ rejection	patf	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	ORGAN REJECTION	TACROLIMUS|ENVARSUS XR		tacrolimus	Envarsus Xr	41628	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Designated/Approved	Approved for Orphan Indication	Prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations in combination with other immunosuppressants	Ê07/10/2015Ê	Ê07/10/2022	"Veloxis Pharmaceuticals, Inc."	1001 Winstead Drive	Suite 310	Cary	North Carolina	27513	USA	407113
2955	Chronic graft versus host disease	10964	MISSING		2198	of organ rejection	C0815080	organ rejection	patf	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	ORGAN REJECTION	TACROLIMUS|ENVARSUS XR		tacrolimus	Envarsus Xr	41628	Prophylaxis of organ rejection in patients receiving allogeneic kidney transplant	Designated/Approved	Approved for Orphan Indication	ENVARSUS XR is indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants.	Ê12/19/2018Ê	ÊTBD	"Veloxis Pharmaceuticals, Inc."	1001 Winstead Drive	Suite 310	Cary	North Carolina	27513	USA	407113
1585	Chronic graft versus host disease	10964	MISSING		3768	of organ rejection	C0815080	organ rejection	patf	Prophylaxis of organ rejection in patients receiving heart transplants.	TACROLIMUS|PROGRAF	ORGAN REJECTION		Tacrolimus	Prograf	38509	Prophylaxis of organ rejection in patients receiving heart transplants.	Designated/Approved	Approved for Orphan Indication	Prophylaxis of organ rejection in patients receiving allogenic heart transplants.	Ê03/29/2006Ê	Ê03/29/2013	"Astellas Pharma US, Inc."	Three Parkway North		Deerfield	Illinois	60015	USA	203305
1586	Chronic graft versus host disease	10964	approximate		1266					"Prevention of rejection in kidney, liver or heart transplant in pediatric patients."	TACROLIMUS|TACROLIMUS GRANULES FOR ORAL SUSPENSION			Tacrolimus granules for oral suspension	Prograf	42647	"Prevention of rejection in kidney, liver or heart transplant in pediatric patients."	Designated/Approved	Approved for Orphan Indication	"PROGRAF Granules (tacrolimus for oral suspension) for the prevention of rejection in heart, kidney or liver transplant in pediatric patients."	Ê05/24/2018Ê	Ê05/24/2025	"Astellas Pharma Global Development, Inc."	1 Astellas Way		Northbrook	Illinois	60062	USA	534516
1626	Chronic graft versus host disease	10964	approximate		3501					Conditioning treatment prior to hematopoietic stem cell transplantation	THIOTEPA|TEPADINA	"CONDITIONINGS, TRANSPLANTATION|CONDITIONING, TRANSPLANTATION|TRANSPLANTATION CONDITIONINGS|TRANSPLANTATION CONDITIONING|UMLS:C0376450|MESH:D019172"	MELPHALAN|EVOMELA	Thiotepa	Tepadina	39174	Conditioning treatment prior to hematopoietic stem cell transplantation	Designated/Approved	Approved for Orphan Indication	Indicated for reducing the risk of graft rejection when used in conjunction with high-dose busulfan and cyclophosphamide as a preparative regimen for allogenic hematopoietic progenitor (stem) cell transplantation for pediatric patients with class 3 beta-thalassemia	Ê01/26/2017Ê	Ê01/26/2024	ADIENNE S.A.	"Via Zurigo, 46"		Lugano			Switzerland	237807
5903	Chronic graft versus host disease	10964			1367	of chronic Graft versus Host disease.	C0867389	Chronic graft-versus-host disease	dsyn	Treatment of chronic Graft versus Host disease.				ibrutinib	Imbruvica	42544	Treatment of chronic Graft versus Host disease.	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.	Ê08/02/2017Ê	Ê08/02/2024	"Pharmacyclics, LLC"	995 East Arques Avenue		Sunnyvale	California	94085	USA	525616
3839	Chronic granulomatous disease	6100			5044	of chronic granulomatous disease.	C0018203	Chronic granulomatous disease	dsyn	Treatment of chronic granulomatous disease.	CHRONIC GRANULOMATOUS DISEASE	Chronic granulomatous disease|GARD:0006100|INTERFERON GAMMA-1B|INTERFERON GAMMA 1-B|ACTIMMUNE|GARD:0006100	Chronic granulomatous disease|GARD:0006100|T-CELL DEPLETED STEM CELL ENRICHED CELLULAR PRODUCT FROM PERIPHEAL B LOOD STEM CELLS|GARD:0006100	Interferon gamma 1-b	Actimmune	32416	Treatment of chronic granulomatous disease.	Designated/Approved	Approved for Orphan Indication		Ê12/20/1990Ê	Ê12/20/1997	Horizon Therapeutic Ireland DAC	"Connaught House, 1st Floor"	1 Burlington Road	Dublin 4			Ireland	29788
776	Chronic inflammatory demyelinating polyneuropathy	6102	done		2018	of chronic inflammatory demyelinating polyneuropathy	C0393819	"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"	dsyn	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	"Chronic inflammatory demyelinating polyneuropathy|GARD:0006102|HUMAN IMMUNOGLOBULIN G|IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN), 20% LIQUID|HIZENTRA|GARD:0006102"	Chronic inflammatory demyelinating polyneuropathy|GARD:0006102|GL-2045|RECOMBINANT MULTIMERIZED HUMAN IGG1 FC|GARD:0006102	Chronic inflammatory demyelinating polyneuropathy|GARD:0006102|IMMUNE GLOBULIN (HUMAN)|GAMUNEX(R)-C|GARD:0006102	"Immune Globulin Subcutaneous (Human), 20% Liquid"	Hizentra	41869	Treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.	Ê03/15/2018Ê	Ê03/15/2025	CSL Behring	1020 First Avenue	PO Box 61501	King of Prussia	Pennsylvania	19406	USA	439914
3842	Chronic inflammatory demyelinating polyneuropathy	6102			3888	of chronic inflammatory demyelinating polyneuropathy	C0393819	"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating"	dsyn	Treatment of chronic inflammatory demyelinating polyneuropathy	"Chronic inflammatory demyelinating polyneuropathy|GARD:0006102|HUMAN IMMUNOGLOBULIN G|IMMUNE GLOBULIN SUBCUTANEOUS (HUMAN), 20% LIQUID|HIZENTRA|GARD:0006102"	Chronic inflammatory demyelinating polyneuropathy|GARD:0006102|HYALURONIDASE (HUMAN RECOMBINANT)|IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE)|GARD:0006102	Chronic inflammatory demyelinating polyneuropathy|GARD:0006102|IVIG|IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE)|GARD:0006102	Immune Globulin (Human)	Gamunex(R)-C	38195	Treatment of chronic inflammatory demyelinating polyneuropathy	Designated/Approved	Approved for Orphan Indication	Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse	Ê09/12/2008Ê	Ê09/12/2015	"Grifols Therapeutics, Inc."	8368 US 70 Business Hwy West		Clayton	North Carolina	27520	USA	185604
3872	Chronic lymphocytic leukemia	6104			1326	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia (CLL)	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	rituximab and recombinant human hyaluronidase	Rituxin Sc	42604	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide	Ê06/22/2017Ê	Ê06/22/2024	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	545616
3887	Chronic lymphocytic leukemia	6104			1729	of chronic lymphocytic leukemia (CLL).	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia (CLL).	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	acalabrutinib	n/a	42137	Treatment of chronic lymphocytic leukemia (CLL).	Designated/Approved	Approved for Orphan Indication	CALQUENCE is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).	Ê11/21/2019Ê	Ê11/21/2026	"Acerta Pharma, LLC (a member of the AstraZeneca Group)"	121 Oyster Point Blvd.		South San Francisco	California	94080	USA	477415
3876	Chronic lymphocytic leukemia	6104			2045	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	bendamustine for 50 ml admixture	Bendeka	41822	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.	Ê12/07/2015Ê	Ê12/07/2022	"Eagle Pharmaceuticals, Inc."	50 Tice Blvd	Suite 315	Woodcliff Lake	New Jersey	7677	USA	431814
3893	Chronic lymphocytic leukemia	6104			2533	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	venetoclax	Venclexta	41172	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).	Ê05/15/2019Ê	Ê05/15/2026	"AbbVie, Inc"	1 North Waukegan Road	"Dept. PA72, Bldg. AP30"	North Chicago	Illinois	60064	USA	375612
3893	Chronic lymphocytic leukemia	6104			2533	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	venetoclax	Venclexta	41172	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	"VENCLEXTA (venetoclax) indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy."	Ê06/08/2018Ê	Ê06/08/2025	"AbbVie, Inc"	1 North Waukegan Road	"Dept. PA72, Bldg. AP30"	North Chicago	Illinois	60064	USA	375612
3893	Chronic lymphocytic leukemia	6104			2533	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	venetoclax	Venclexta	41172	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy"	Ê04/11/2016Ê	Ê04/11/2023	"AbbVie, Inc"	1 North Waukegan Road	"Dept. PA72, Bldg. AP30"	North Chicago	Illinois	60064	USA	375612
3849	Chronic lymphocytic leukemia	6104			2617	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia (CLL)	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	ibrutinib	Imbruvica	41005	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion	Ê07/28/2014Ê	Ê07/28/2021	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA	368012
3849	Chronic lymphocytic leukemia	6104			2617	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia (CLL)	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	ibrutinib	Imbruvica	41005	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy	Ê02/12/2014Ê	Ê02/12/2021	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA	368012
3849	Chronic lymphocytic leukemia	6104			2617	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia (CLL)	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	ibrutinib	Imbruvica	41005	Treatment of chronic lymphocytic leukemia (CLL)	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of patients with chronic lymphocytic leukemia	Ê03/04/2016Ê	Ê03/04/2023	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA	368012
3894	Chronic lymphocytic leukemia	6104			2646	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	obinutuzumab	Gazyva	40956	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)."	Ê11/01/2013Ê	Ê11/01/2020	"Genentech Inc., a member of the Roche Group"	1 DNA Way		South San Francisco	California	94080	USA	359911
3889	Chronic lymphocytic leukemia	6104			3224	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	ofatumumab	Arzerra	39882	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	For extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL.	Ê01/19/2016Ê	Ê01/19/2023	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	275809
3889	Chronic lymphocytic leukemia	6104			3224	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	ofatumumab	Arzerra	39882	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	"ARZERRA (ofatumumab) is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate."	Ê04/17/2014Ê	Ê04/17/2021	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	275809
3889	Chronic lymphocytic leukemia	6104			3224	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	ofatumumab	Arzerra	39882	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of chronic lymphocytic leukemia (CLL) refractory to alemtuzumab and fludarabine	Ê10/26/2009Ê	Ê10/26/2016	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	275809
3889	Chronic lymphocytic leukemia	6104			3224	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	ofatumumab	Arzerra	39882	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Arzerra in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL).	Ê08/30/2016Ê	ÊN/A	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	275809
3878	Chronic lymphocytic leukemia	6104			3467	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	Bendamustine hydrochloride	Treanda	39311	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with chronic lymphocytic leukemia	Ê03/20/2008Ê	Ê03/20/2015	"Cephalon, Inc."	41 Moores Road		Frazer	Pennsylvania	19355	USA	244807
3863	Chronic lymphocytic leukemia	6104			3951	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	rituximab	Rituxan	38015	Treatment of chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients previously untreated for CD20-positive chronic lymphocytic leukemia in combination wih fludarbine and cyclophosphamide	Ê02/18/2010Ê	Ê02/18/2017	"Genentech, Inc."	1DNA Way	MS 241A	South San Francisco	California	94080	USA	177603
3860	Chronic lymphocytic leukemia	6104			4437	of chronic lymphocytic leukemia.	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia.	CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CLL|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCI:C7886|UMLS:C0278791	REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOGENOUS LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|REFRACTORY CLL|CHRONIC LYMPHOCYTIC LEUKEMIA REFRACTORY|REFRACTORY CHRONIC LYMPHOID LEUKEMIA|NCIT:C7886|NCI:C7886|UMLS:C0278791	CHRONIC LYMPHOCYTIC LEUKEMIA IN REMISSION|CLL IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN REMISSION|CHRONIC LYMPHOCYTIC LEUKEMIA (IN REMISSION)|CHRONIC LYMPHOID LEUKEMIA IN REMISSION|CHRONIC LYMPHOGENOUS LEUKEMIA IN REMISSION|NCIT:C3587|NCI:C3587|UMLS:C0153878	alemtuzumab	Campath	35723	Treatment of chronic lymphocytic leukemia.	Designated/Approved	Approved for Orphan Indication	The treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy.	Ê05/07/2001Ê	Ê05/07/2008	Genzyme Corporation	4545 Horizon Hill Blvd.		San Antonio	Texas	78229	USA	107197
3853	Chronic lymphocytic leukemia	6104			3430	of B-cell chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of B-cell chronic lymphocytic leukemia	Chronic lymphocytic leukemia|GARD:0006104|ACADESINE|GARD:0006104	Chronic lymphocytic leukemia|GARD:0006104|ALEMTUZUMAB|CAMPATH|GARD:0006104	Chronic lymphocytic leukemia|GARD:0006104|FLUDARABINE PHOSPHATE ORAL TABLETS|GARD:0006104	Fludarabine phosphate oral tablets	n/a	39434	Treatment of B-cell chronic lymphocytic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen	Ê12/18/2008Ê	Ê12/18/2015	"Sanofi-Aventis U.S., Inc."	55 Corproate Drive	P. O. Box 5925	Bridgewater	New Jersey	8807	USA	250607
3905	Chronic lymphocytic leukemia	6104			2262	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Chronic lymphocytic leukemia|GARD:0006104|DUVELISIB|GARD:0006104	Chronic lymphocytic leukemia|GARD:0006104|MOR-208|HUMANIZED FC ENGINEERED MONOCLONAL ANTIBODY AGAINST CD19|GARD:0006104	Chronic lymphocytic leukemia|GARD:0006104|IDELALISIB|ZYDELIG|GARD:0006104	idelalisib	Zydelig	41562	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Designated/Approved	Approved for Orphan Indication	"Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities; and Zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies."	Ê07/23/2014Ê	Ê07/23/2021	"Gilead Sciences, Inc."	199 E. Blaine St		Seattle	Washington	98102	USA	405913
3869	Chronic lymphocytic leukemia	6104			2400	of chronic lymphocytic leukemia	C0023434	Chronic Lymphocytic Leukemia	neop	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Chronic lymphocytic leukemia|GARD:0006104|DUVELISIB|GARD:0006104	Chronic lymphocytic leukemia|GARD:0006104|MOR-208|HUMANIZED FC ENGINEERED MONOCLONAL ANTIBODY AGAINST CD19|GARD:0006104	Chronic lymphocytic leukemia|GARD:0006104|IDELALISIB|ZYDELIG|GARD:0006104	duvelisib	Copiktra	41379	Treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies	Ê09/24/2018Ê	Ê09/24/2025	"Verastem, Inc."	117 Kendrick Street	Suite 500	Needham	Massachusetts	2494	USA	394413
700	Chronic lymphocytic leukemia	6104	done		5005	refractory CLL.	C0278791	refractory chronic lymphocytic leukemia	neop	"Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL."	Chronic lymphocytic leukemia|GARD:0006104|FLUDARABINE PHOSPHATE|FLUDARA|GARD:0006104	Chronic lymphocytic leukemia|GARD:0006104|FLUDARABINE PHOSPHATE|FLUDARA|GARD:0006104	CHRONIC LYMPHOCYTIC LEUKEMIA|CHRONIC LYMPHOID LEUKEMIA|CLL|SLL (SMALL LYMPHOCYTIC LYMPHOMA)	Fludarabine phosphate	Fludara	32616	"Treatment of chronic lymphocytic leukemia (CLL), including refractory CLL."	Designated/Approved	Approved for Orphan Indication		Ê04/18/1991Ê	Ê04/18/1998	"Berlex Laboratories, Inc."	"15049 San Pablo Avenue, P.O. Box 4099"		Richmond	California	94804	USA	27688
1950	Chronic myeloid leukemia	6105	done		3230	of chronic myelogenous leukemia	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myelogenous leukemia	"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CHRONIC MYELOGENOUS LEUKEMIA (CML) IN REMISSION|CML IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|NCIT:C3589|NCI:C3589|UMLS:C0153888"	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	"CHRONIC LEUKEMIA|LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE|DOID:1036|MESH:D015464"	bosutinib	Bosulif	39868	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	BOSULIF is indicated for the treatment of adult patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML).	Ê12/19/2017Ê	Ê12/19/2024	Pfizer Inc.	445 Eastern Point Road		Groton	Connecticut	6340	USA	274808
1950	Chronic myeloid leukemia	6105	done		3230	of chronic myelogenous leukemia	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myelogenous leukemia	"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CHRONIC MYELOGENOUS LEUKEMIA (CML) IN REMISSION|CML IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|NCIT:C3589|NCI:C3589|UMLS:C0153888"	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	"CHRONIC LEUKEMIA|LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE|DOID:1036|MESH:D015464"	bosutinib	Bosulif	39868	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance, or intolerance to prior therapy"	Ê09/04/2012Ê	Ê09/04/2019	Pfizer Inc.	445 Eastern Point Road		Groton	Connecticut	6340	USA	274808
2566	Chronic myeloid leukemia	6105	done		3646	of chronic myelogenous leukemia	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myelogenous leukemia	"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CHRONIC MYELOGENOUS LEUKEMIA (CML) IN REMISSION|CML IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|NCIT:C3589|NCI:C3589|UMLS:C0153888"	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	"CHRONIC LEUKEMIA|LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE|DOID:1036|MESH:D015464"	nilotinib	Tasigna	38834	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	For the use for chronic phase (CP) and accelerated phase (AP) Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant to or intolerant to prior therapy that included imatinib.	Ê10/29/2007Ê	Ê10/29/2014	Novartis Pharmaceutical Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	220806
2566	Chronic myeloid leukemia	6105	done		3646	of chronic myelogenous leukemia	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myelogenous leukemia	"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CHRONIC MYELOGENOUS LEUKEMIA (CML) IN REMISSION|CML IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|NCIT:C3589|NCI:C3589|UMLS:C0153888"	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	"CHRONIC LEUKEMIA|LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE|DOID:1036|MESH:D015464"	nilotinib	Tasigna	38834	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	TASIGNA (nilotinib) is indicated for the treatment of pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase and pediatric patients greater than or equal to 1 year of age with chronic phase Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.	Ê03/22/2018Ê	Ê03/22/2025	Novartis Pharmaceutical Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	220806
2607	Chronic myeloid leukemia	6105	done		3669	of chronic myelogenous leukemia	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myelogenous leukemia	"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CHRONIC MYELOGENOUS LEUKEMIA (CML) IN REMISSION|CML IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|NCIT:C3589|NCI:C3589|UMLS:C0153888"	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	"CHRONIC LEUKEMIA|LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE|DOID:1036|MESH:D015464"	omacetaxine mepesuccinate	Synribo	38786	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI)	Ê10/26/2012Ê	Ê10/26/2019	IVAX International GmbH	Alpenstrasse 2	8640 Rapperswil	Frazer			Switzerland	218205
573	Chronic myeloid leukemia	6105	done		3708	of chronic myelogenous leukemia	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myelogenous leukemia	"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CHRONIC MYELOGENOUS LEUKEMIA (CML) IN REMISSION|CML IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|NCIT:C3589|NCI:C3589|UMLS:C0153888"	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	"CHRONIC LEUKEMIA|LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE|DOID:1036|MESH:D015464"	dasatinib	Sprycel	38684	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib	Ê06/28/2006Ê	Ê06/28/2013	Bristol-Myers Squibb Company	"3401 Princeton Pike, B-3043C"		Lawrence Township	New Jersey	8648	USA	212405
573	Chronic myeloid leukemia	6105	done		3708	of chronic myelogenous leukemia	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myelogenous leukemia	"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CHRONIC MYELOGENOUS LEUKEMIA (CML) IN REMISSION|CML IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|NCIT:C3589|NCI:C3589|UMLS:C0153888"	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	"CHRONIC LEUKEMIA|LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE|DOID:1036|MESH:D015464"	dasatinib	Sprycel	38684	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase	Ê11/09/2017Ê	Ê11/09/2024	Bristol-Myers Squibb Company	"3401 Princeton Pike, B-3043C"		Lawrence Township	New Jersey	8648	USA	212405
856	Chronic myeloid leukemia	6105	done		4201	of chronic myelogenous leukemia	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myelogenous leukemia	"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CHRONIC MYELOGENOUS LEUKEMIA (CML) IN REMISSION|CML IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|NCIT:C3589|NCI:C3589|UMLS:C0153888"	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	"CHRONIC LEUKEMIA|LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE|DOID:1036|MESH:D015464"	Imatinib	Gleevec	36922	Treatment of chronic myelogenous leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy"	Ê05/10/2001Ê	Ê05/10/2008	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA	140100
873	Chronic myeloid leukemia	6105	done		5002	of chronic myelogenous leukemia.	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myelogenous leukemia.	"CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CHRONIC MYELOGENOUS LEUKEMIA (CML) IN REMISSION|CML IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|NCIT:C3589|NCI:C3589|UMLS:C0153888"	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	"CHRONIC LEUKEMIA|LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE|DOID:1036|MESH:D015464"	Interferon alfa-2a	Roferon A	32665	Treatment of chronic myelogenous leukemia.	Designated/Approved	Approved for Orphan Indication	Treatment of chronic myelogenous leukemia.	Ê10/19/1995Ê	Ê10/19/2002	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA	36989
3917	Chronic myeloid leukemia	6105			3094	of chronic myeloid leukemia	C0023473	"Myeloid Leukemia, Chronic"	neop	Treatment of chronic myeloid leukemia	"CHRONIC MYELOID LEUKEMIA IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE IN REMISSION|CHRONIC MYELOGENOUS LEUKEMIA IN REMISSION|CHRONIC GRANULOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOCYTIC LEUKEMIA IN REMISSION|CHRONIC MYELOID LEUKEMIA (IN REMISSION)|CML IN REMISSION|NCI:C3589|UMLS:C0153888|SNOMEDCT_US:92817004"	Chronic myeloid leukemia|GARD:0006105|REPLICATION-INCOMPETENT GM-CSF-EXPRESSING GENE-MODIFIED ALLOGENEIC CHRONIC MYELOID LEUKEMIA CANCER CELL LINES|GVAX CHRONIC MYELOID LEUKEMIA|GARD:0006105	Chronic myeloid leukemia|GARD:0006105|TETRANDRINE|GARD:0006105	ponatinib	Iclusig	40137	Treatment of chronic myeloid leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy."	Ê12/14/2012Ê	Ê12/14/2019	ARIAD Pharmaceuticals Inc.	26 Landsdowne Street		Cambridge	Massachusetts	2139	USA	294709
5987	Chronic thromboembolic pulmonary hypertension	13124			2284	of chronic thromboembolic pulmonary hypertension	C2363973	Chronic thromboembolic pulmonary hypertension	dsyn	Treatment of chronic thromboembolic pulmonary hypertension	Chronic thromboembolic pulmonary hypertension|GARD:0013124|SELEXIPAG|UPTRAVI|GARD:0013124	Thromboembolic pulmonary hypertension|GARD:0013124|SELEXIPAG|UPTRAVI|GARD:0013124	Chronic thromboembolic pulmonary hypertension|GARD:0013124|CYLEXIN|NEUTROPHIL-ENDOTHELIAL INTERACTION INHIBITOR|GARD:0013124	riociguat	Adempas	41536	Treatment of chronic thromboembolic pulmonary hypertension	Designated/Approved	Approved for Orphan Indication	"Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) WHO Group 4, after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class"	Ê10/08/2013Ê	Ê10/08/2020	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd.		Whippany	New Jersey	7981	USA	406913
2496	Churg-Strauss Syndrome	13452	done		2746	of Churg-Strauss Syndrome	C0008728	Churg-Strauss Syndrome	dsyn	Treatment of Churg-Strauss Syndrome	Granulomatosis eosinofÃ­lica con poliangitis|GARD:0013452|MEPOLIZUMAB|GARD:0013452	CHURG-STRAUSS SYNDROME|EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS|DOID:3049|MESH:D015267	CHURG STRAUSS SYNDROME|ALLERGIC ANGIITIS AND GRANULOMATOSIS|ALLERGIC GRANULOMATOSIS|ALLERGIC GRANULOMATOSIS AND ANGIITIS|CHURG-STRAUSS VASCULITIS|CSS|EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS|EGPA	mepolizumab	Nucala	40738	Treatment of Churg-Strauss Syndrome	Designated/Approved	Approved for Orphan Indication	NUCALA prefilled autoinjector and single syringe device is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).	Ê06/06/2019Ê	ÊN/A	GlaxoSmithKline LLC	Corporation Service Company	1250 S. Collegeville Rd.	Collegeville	Pennsylvania	19426	USA	345111
2496	Churg-Strauss Syndrome	13452	done		2746	of Churg-Strauss Syndrome	C0008728	Churg-Strauss Syndrome	dsyn	Treatment of Churg-Strauss Syndrome	Granulomatosis eosinofÃ­lica con poliangitis|GARD:0013452|MEPOLIZUMAB|GARD:0013452	CHURG-STRAUSS SYNDROME|EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS|DOID:3049|MESH:D015267	CHURG STRAUSS SYNDROME|ALLERGIC ANGIITIS AND GRANULOMATOSIS|ALLERGIC GRANULOMATOSIS|ALLERGIC GRANULOMATOSIS AND ANGIITIS|CHURG-STRAUSS VASCULITIS|CSS|EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS|EGPA	mepolizumab	Nucala	40738	Treatment of Churg-Strauss Syndrome	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Eosinophilic Granulomatosis Polyangiitis (EGPA)	Ê12/12/2017Ê	Ê12/12/2024	GlaxoSmithKline LLC	Corporation Service Company	1250 S. Collegeville Rd.	Collegeville	Pennsylvania	19426	USA	345111
2244	Clostridium difficile infection		MISSING		2889	of pediatric Clostridium difficile infection	C0343386	Clostridium difficile infection	dsyn	Treatment of pediatric Clostridium difficile infection	Clostridium septicum infection|GARD:0011969|CADAZOLID|GARD:0011969	FIDAXOMICIN|DIFICID	Clostridium septicum infection|GARD:0011969|METRONIDAZOLE|GARD:0011969	fidaxomicin	Dificid	40525	Treatment of pediatric Clostridium difficile infection	Designated/Approved	Approved for Orphan Indication	DIFICID is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).	Ê01/24/2020Ê	ÊTBD	"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc."	20 Weystrasse		Luzern			Switzerland	325210
5658	Coccidioidomycosis	9525			3418	of Coccidioidomycosis	C0009186	Coccidioidomycosis	dsyn	For the diagnosis of Coccidioidomycosis	Coccidioidomycosis|GARD:0009525|COCCIDIOIDIN SD SKIN TEST ANTIGEN|GARD:0009525	NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE|MYCOBACTERIA OTHER THAN TUBERCULOSIS (MOTT)|NONTUBERCULOUS MYCOBACTERIAL DISEASE|NONTUBERCULOSIS MYCOBACTERIUM|NTM		coccidioidin SD Skin Test Antigen	n/a	39435	For the diagnosis of Coccidioidomycosis	Designated/Approved	Approved for Orphan Indication	"For the detection of delayed type hypersensitivity to C. immitis in individuals, 18-64 years of age, with a history of pulmonary coccidioidomy-cosis"	Ê07/29/2011Ê	ÊN/A	"Allermed Labortories, Inc."	7203 Convoy Court		San Diego	California	92111	USA	246007
982	"Colorectal cancer, childhood"	9320	approximate		5148	of metastatic colorectal cancer.	C0948380	metastatic colorectal cancer	neop	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	"Colorectal cancer, childhood|GARD:0009320|LEUCOVORIN|LEUCOVORIN CALCIUM|GARD:0009320"	COLORECTAL CANCER|METASTATIC COLORECTAL CANCER|DOID:9256|MESH:D015179	"Colorectal cancer, childhood|GARD:0009320|LEUCOVORIN CALCIUM|WELLCOVORIN|GARD:0009320"	Leucovorin	Leucovorin Calcium	31754	For use in combination with 5-fluorouracil for the treatment of metastatic colorectal cancer.	Designated/Approved	Approved for Orphan Indication	For use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer.	Ê12/12/1991Ê	Ê12/12/1998	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA	16786
2032	"Congenital bile acid synthesis defect, type 1 "	9813	done		3999					Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	" Congenital bile acid synthesis defect, type 2|GARD:0010045|CHOLIC ACID|CHOLBAM|GARD:0010045"	"Congenital bile acid synthesis defect, type 1 |GARD:0009813|CHOLIC ACID|CHOLBAM|GARD:0009813"		cholic acid	Cholbam	37820	Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism	Designated/Approved	Approved for Orphan Indication	Treatment of bile acid synthesis disorders due to single enzyme defects	Ê03/17/2015Ê	Ê03/17/2022	"Retrophin, Inc."	777 Third Avenue	22nd Floor	New York	New York	10017	USA	170503
5163	Congenital sucrase-isomaltase deficiency	7710			4663	of congenital sucrase-isomaltase deficiency	C1283620	"Sucrase-isomaltase deficiency, congenital"	dsyn	Treatment of congenital sucrase-isomaltase deficiency	Congenital sucrase-isomaltase deficiency|GARD:0007710|SACROSIDASE|SUCRAID|GARD:0007710	CONGENITAL SUCRASE-ISOMALTASE DEFICIENCY|CSID|CONGENITAL SUCROSE-ISOMALTASE MALABSORPTION|SI DEFICIENCY|CONGENITAL SUCROSE INTOLERANCE|DISACCHARIDE INTOLERANCE I	"MICROVILLUS INCLUSION DISEASE|CONGENITAL FAMILIAL PROTRACTED DIARRHEA|CONGENITAL MICROVILLUS ATROPHY|DAVIDSON'S DISEASE|FAMILIAL ENTEROPATHY, MICROVILLUS"	Sacrosidase	Sucraid	34313	Treatment of congenital sucrase-isomaltase deficiency	Designated/Approved	Approved for Orphan Indication	"Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency."	Ê04/09/1998Ê	Ê04/09/2005	"QOL Medical, LLC"	4445 North Highway	"A1A, 241"	Vero Beach	Florida	32963	USA	78693
2798	Corneal ectasia		MISSING		2683	of corneal ectasia	C0155135	Corneal ectasia	dsyn	Treatment of corneal ectasia following refractive surgery	CORNEAL ECTASIA|CORNEAL INJURIES|DOID:1436|MESH:D065306	RIBOFLAVIN|RIBOFLAVIN OPHTHALMIC SOLUTION ULTRAVIOLET-A (UVA) IRRADIATION|PHOTREXA VISCOUS	KERATOCONUS|PROGRESSIVE KERATOCONUS|DOID:10126|MESH:D007640	riboflavin ophthalmic solution ultraviolet-A (UVA) irradiation	Photrexa Viscous	40879	Treatment of corneal ectasia following refractive surgery	Designated/Approved	Approved for Orphan Indication	Treatment of corneal ectasia following refractive surgery	Ê07/15/2016Ê	Ê07/15/2023	"Avedro, Inc."	230 Third Avenue		Waltham	Massachusetts	2451	USA	352511
2370	Crohn's disease	10232	done	Not a rare disease	4544	of Crohn's disease	C0010346	Crohn Disease	dsyn	Treatment of Crohn's disease	"Pediatric Crohn's disease|GARD:0009856|BECLOMETHASONE DIPROPIONATE|BECLOMETHASONE 17,21-DIPROPRIONATE|GARD:0009856"	CROHN'S DISEASE|ILEITIS|ENTERITIS|GRANULOMATOUS COLITIS|GRANULOMATOUS ENTERITIS|GARD:0010232|OMIM:266600	Crohn's disease|GARD:0010232|THALIDOMIDE|THALOMID|GARD:0010232	infliximab	Remicade	35017	Treatment of Crohn's disease	Designated/Approved	Approved for Orphan Indication	"Treatment of moderately to severely active Crohn's disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn's disease for the reduction in the number of draining enterocutaneous fistula(s)."	Ê08/24/1998Ê	Ê08/24/2005	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA	92495
Missing	Cryopyrin-associated periodic syndrome	10927			3826	of CIAS1-Associated Periodic Syndromes	C1424250	NLRP3 gene	gngm	Treatment of CIAS1-Associated Periodic Syndromes	Cryopyrin-associated periodic syndrome|GARD:0010927|CANAKINUMAB|ILARIS|GARD:0010927	Cryopyrin-associated periodic syndrome|GARD:0010927|ANAKINRA|KINERET|GARD:0010927	MUCKLE-WELLS SYNDROME|MWS	Rilonacept	Arcalyst	38341	Treatment of CIAS1-Associated Periodic Syndromes	Designated/Approved	Approved for Orphan Indication	Treatment of Cryopyrin-Assisted Periodic Syndromes (CAPS)	Ê02/27/2008Ê	Ê02/27/2015	"Regeneron Pharmaceuticals, Inc."	777 Old Saw Mill River Road		Tarrytown	New York	10591	USA	196904
5897	Cryopyrin-associated periodic syndrome	10927			2967	of cryopyrin-associated periodic syndromes	C2316212	Cryopyrin-Associated Periodic Syndromes	dsyn	Treatment of cryopyrin-associated periodic syndromes	Cryopyrin-associated periodic syndrome|GARD:0010927|CANAKINUMAB|ILARIS|GARD:0010927	Cryopyrin-associated periodic syndrome|GARD:0010927|ANAKINRA|KINERET|GARD:0010927	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME|FAMILIAL COLD URTICARIA|FCAS|FCU	anakinra	Kineret	40409	Treatment of cryopyrin-associated periodic syndromes	Designated/Approved	Approved for Orphan Indication	Treatment of neonatal-onset multisystem inflammatory disease (NOMID)	Ê12/21/2012Ê	Ê12/21/2019	Swedish Orphan Biovitrum AB (publ)	SE-011276		Stockholm			Sweden	312110
5896	Cryopyrin-associated periodic syndrome	10927			3429	of cryopyrin-associated periodic syndromes	C2316212	Cryopyrin-Associated Periodic Syndromes	dsyn	Treatment of cryopyrin-associated periodic syndromes	Cryopyrin-associated periodic syndrome|GARD:0010927|CANAKINUMAB|ILARIS|GARD:0010927	Cryopyrin-associated periodic syndrome|GARD:0010927|ANAKINRA|KINERET|GARD:0010927	FAMILIAL COLD AUTOINFLAMMATORY SYNDROME|FAMILIAL COLD URTICARIA|FCAS|FCU	canakinumab	Ilaris	39434	Treatment of cryopyrin-associated periodic syndromes	Designated/Approved	Approved for Orphan Indication	"Treatment of cryopyrin-associated periodic syndromes (CAPS), in adults and children 4 years of age and older."	Ê06/17/2009Ê	Ê06/17/2016	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	250507
3931	Cryptosporidiosis	6219			4484	of cryptosporidiosis.	C0010418	Cryptosporidiosis	dsyn	Treatment of cryptosporidiosis.	Cryptosporidiosis|GARD:0006219|NITAZOXANIDE|ALINIA|GARD:0006219	Cryptosporidiosis|GARD:0006219|BOVINE WHEY PROTEIN CONCENTRATE|IMMUNO-C|GARD:0006219	"Cryptosporidiosis|GARD:0006219|CRYPTOSPORIDIUM PARVUM|BOVINE IMMUNOGLOBULIN CONCENTRATE, CRYPTOSPORIDIUM PARVUM|SPORIDIN-G|GARD:0006219"	Nitazoxanide	Alinia	35411	Treatment of cryptosporidiosis.	Designated/Approved	Approved for Orphan Indication	Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia	Ê11/22/2002Ê	Ê11/22/2009	"Romark Laboratories, L.C."	6200 Courtney Campbell Causeway	Suite 880	Tampa	Florida	33607	USA	91895
519	Cushing's syndrome	6224	approximate		4959	in differentiating pituitary	C0032002	Pituitary Diseases	dsyn	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Cushing's syndrome|GARD:0006224|CORTICORELIN OVINE TRIFLUTATE|ACTHREL|GARD:0006224			Corticorelin ovine triflutate	Acthrel	32836	For use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushings syndrome.	Designated/Approved	Approved for Orphan Indication	To differentiate between pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.	Ê05/23/1996Ê	Ê05/23/2003	"Ferring Laboratories, Inc."	"400 Rella Boulevard, Suite 201"		Suffern	New York	10901	USA	35089
2647	Cushing's syndrome	6224	done		3159	of Cushing's disease	C0221406	Pituitary-dependent Cushing's disease	dsyn	Treatment of Cushing's disease	Cushing's syndrome|GARD:0006224|FLUASTERONE|GARD:0006224	Cushing's syndrome|GARD:0006224|OSILODROSTAT|GARD:0006224	Cushing's syndrome|GARD:0006224|PASIREOTIDE|SIGNIFOR|GARD:0006224	pasireotide	Signifor	40018	Treatment of Cushing's disease	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative	Ê12/14/2012Ê	Ê12/14/2019	Novartis Pharmaceuticals Corporation	One Health Plaza	"Bldg 104, 3K28"	East Hanover	New Jersey	7936	USA	288709
2647	Cushing's syndrome	6224	done		3159	of Cushing's disease	C0221406	Pituitary-dependent Cushing's disease	dsyn	Treatment of Cushing's disease	Cushing's syndrome|GARD:0006224|FLUASTERONE|GARD:0006224	Cushing's syndrome|GARD:0006224|OSILODROSTAT|GARD:0006224	Cushing's syndrome|GARD:0006224|PASIREOTIDE|SIGNIFOR|GARD:0006224	pasireotide	Signifor	40018	Treatment of Cushing's disease	Designated/Approved	Approved for Orphan Indication	SIGNIFOR LAR is indicated for the treatment of patients with Cushings disease for whom pituitary surgery is not an option or has not been curative.	Ê06/29/2018Ê	Ê06/29/2025	Novartis Pharmaceuticals Corporation	One Health Plaza	"Bldg 104, 3K28"	East Hanover	New Jersey	7936	USA	288709
2522	Cushing's syndrome	6224	done		3475					Treatment of the clinical manifestations of endogenous Cushing's syndrone	Cushing's syndrome|GARD:0006224|MIFEPRISTONE|KORLYM|GARD:0006224			mifepristone	Korlym	39268	Treatment of the clinical manifestations of endogenous Cushing's syndrone	Designated/Approved	Approved for Orphan Indication	for the control of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.	Ê02/17/2012Ê	Ê02/17/2019	"Corcept Therapeutics, Inc."	149 Commonwealth Drive		Menlo Park	California	94025	USA	239507
3953	Cutaneous T-cell lymphoma	6226			2923	with cutaneous T-cell lymphoma.	C0079773	"Lymphoma, T-Cell, Cutaneous"	neop	Treatment of patients with cutaneous T-cell lymphoma.	Cutaneous T-cell lymphoma|GARD:0006226|BEXAROTENE|TARGRETIN|GARD:0006226	Cutaneous T-cell lymphoma|GARD:0006226|DENILEUKIN DIFTITOX|ONTAK|GARD:0006226	Cutaneous T-cell lymphoma|GARD:0006226|MOGAMULIZUMAB|GARD:0006226	mogamulizumab	Poteligeo	40484	Treatment of patients with cutaneous T-cell lymphoma.	Designated/Approved	Approved for Orphan Indication	POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or S_ry syndrome (SS) after at least one prior systemic therapy.	Ê08/08/2018Ê	Ê08/08/2025	Kyowa Kirin Pharmaceutical Development Inc.	212 Carnegie Center # 101		Princeton	New Jersey	8540	USA	322010
3939	Cutaneous T-cell lymphoma	6226			4510	with cutaneous T-cell lymphoma	C0079773	"Lymphoma, T-Cell, Cutaneous"	neop	Treatment of patients with cutaneous T-cell lymphoma	Cutaneous T-cell lymphoma|GARD:0006226|BEXAROTENE|TARGRETIN|GARD:0006226	Cutaneous T-cell lymphoma|GARD:0006226|DENILEUKIN DIFTITOX|ONTAK|GARD:0006226	Cutaneous T-cell lymphoma|GARD:0006226|MOGAMULIZUMAB|GARD:0006226	denileukin diftitox	Ontak	35298	Treatment of patients with cutaneous T-cell lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.	Ê02/05/1999Ê	Ê02/05/2006	"Eisai, Inc."	300 Tice Boulevard		Woodcliff Lake	New Jersey	7677	USA	99396
3949	Cutaneous T-cell lymphoma	6226			4315	of cutaneous T-cell lymphoma.	C0079773	"Lymphoma, T-Cell, Cutaneous"	neop	Treatment of cutaneous T-cell lymphoma.	Cutaneous T-cell lymphoma|GARD:0006226|FENRETINIDE|GARD:0006226	Cutaneous T-cell lymphoma|GARD:0006226|PENTOSTATIN|NIPENT|GARD:0006226	Cutaneous T-cell lymphoma|GARD:0006226|PELDESINE|GARD:0006226	Bexarotene	Targretin	36329	Treatment of cutaneous T-cell lymphoma.	Designated/Approved	Approved for Orphan Indication	Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.	Ê12/29/1999Ê	Ê12/29/2006	"Eisai, Inc."	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA	124699
4010	Cystic fibrosis	6233			4107	with cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Cystic fibrosis|GARD:0006233|AZTREONAM|CAYSTON|GARD:0006233			aztreonam	Cayston	37327	Inhalation therapy for control of gram-negative bacteria in the respiratory tract of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	To improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa	Ê02/22/2010Ê	Ê02/22/2017	Gilead Sciences (formerly Corus Pharma)	199 East Blaine St		Seattle	Washington	98102	USA	155002
1709	Cystic fibrosis	6233	done		492	of Cystic Fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of Cystic Fibrosis	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS GENE THERAPY|GARD:0006233	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE|GARD:0006233	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS TR GENE THERAPY (RECOMBINANT ADENOVIRUS)|ADGVCFTR.10|GARD:0006233	elexacaftor/tezacaftor/ivacaftor	Trikafta	43341	Treatment of Cystic Fibrosis	Designated/Approved	Approved for Orphan Indication	TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene	Ê10/21/2019Ê	Ê10/21/2026	Vertex Pharmaceuticals Inc.	50 Northern Avenue		Boston	Massachusetts	2210	USA	647618
3961	Cystic fibrosis	6233			2048	of cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of cystic fibrosis	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS GENE THERAPY|GARD:0006233	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE|GARD:0006233	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS TR GENE THERAPY (RECOMBINANT ADENOVIRUS)|ADGVCFTR.10|GARD:0006233	lumacaftor/ivacaftor	Orkambi	41820	Treatment of cystic fibrosis	Designated/Approved	Approved for Orphan Indication	ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 2 years and older who are homozygous for the F508del mutation in the CFTR gene.	Ê08/07/2018Ê	Ê08/07/2025	Vertex Pharmaceuticals Inc.	50 Northern Avenue		Boston	Massachusetts	2210	USA	434814
3961	Cystic fibrosis	6233			2048	of cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of cystic fibrosis	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS GENE THERAPY|GARD:0006233	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE|GARD:0006233	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS TR GENE THERAPY (RECOMBINANT ADENOVIRUS)|ADGVCFTR.10|GARD:0006233	lumacaftor/ivacaftor	Orkambi	41820	Treatment of cystic fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis in patients age 12 years and older who are homozygous for F508del mutation in the CFTR gene	Ê07/02/2015Ê	Ê07/02/2022	Vertex Pharmaceuticals Inc.	50 Northern Avenue		Boston	Massachusetts	2210	USA	434814
3961	Cystic fibrosis	6233			2048	of cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of cystic fibrosis	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS GENE THERAPY|GARD:0006233	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE|GARD:0006233	Cystic fibrosis|GARD:0006233|CYSTIC FIBROSIS TR GENE THERAPY (RECOMBINANT ADENOVIRUS)|ADGVCFTR.10|GARD:0006233	lumacaftor/ivacaftor	Orkambi	41820	Treatment of cystic fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis (CF) in patients age 6 years and older who are homozygous for the F508del mutation in the CFTR gene	Ê09/28/2016Ê	Ê09/28/2023	Vertex Pharmaceuticals Inc.	50 Northern Avenue		Boston	Massachusetts	2210	USA	434814
3992	Cystic fibrosis	6233			4857	with cystic fibrosis.	C0010674	Cystic Fibrosis	dsyn	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Cystic fibrosis|GARD:0006233|DORNASE ALFA|PULMOZYME|GARD:0006233			Dornase alfa	Pulmozyme	33254	To reduce mucous viscosity and enable the clearance of airway secretions in patients with cystic fibrosis.	Designated/Approved	Approved for Orphan Indication	In conjunction with standard therapies in the management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function.	Ê12/30/1993Ê	Ê12/30/2000	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	48090
3960	Cystic fibrosis	6233			3549	with cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of patients with cystic fibrosis	Cystic fibrosis|GARD:0006233|FENRETINIDE|GARD:0006233	Cystic fibrosis|GARD:0006233|HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (HCFTR) MESSENGER RNA (MRNA) COMPLEXED WITH BRANCHED POLYETHYLENEIMINE (BPEI)|GARD:0006233	Cystic fibrosis|GARD:0006233|LEVOFLOXACIN|GARD:0006233	ivacaftor	Kalydeco	39071	Treatment of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis (CF) in patients age 12 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.	Ê08/15/2018Ê	Ê08/15/2025	"Vertex Pharmaceuticals, Inc."	50 Northern Avenue		Boston	Massachusetts	2210	USA	228306
3960	Cystic fibrosis	6233			3549	with cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of patients with cystic fibrosis	Cystic fibrosis|GARD:0006233|FENRETINIDE|GARD:0006233	Cystic fibrosis|GARD:0006233|HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (HCFTR) MESSENGER RNA (MRNA) COMPLEXED WITH BRANCHED POLYETHYLENEIMINE (BPEI)|GARD:0006233	Cystic fibrosis|GARD:0006233|LEVOFLOXACIN|GARD:0006233	ivacaftor	Kalydeco	39071	Treatment of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 6 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data	Ê04/29/2019Ê	Ê04/29/2026	"Vertex Pharmaceuticals, Inc."	50 Northern Avenue		Boston	Massachusetts	2210	USA	228306
3960	Cystic fibrosis	6233			3549	with cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of patients with cystic fibrosis	Cystic fibrosis|GARD:0006233|FENRETINIDE|GARD:0006233	Cystic fibrosis|GARD:0006233|HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (HCFTR) MESSENGER RNA (MRNA) COMPLEXED WITH BRANCHED POLYETHYLENEIMINE (BPEI)|GARD:0006233	Cystic fibrosis|GARD:0006233|LEVOFLOXACIN|GARD:0006233	ivacaftor	Kalydeco	39071	Treatment of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R; and treatment of CF in patients age 6 years and older who have an R117H mutation in the CFTR gene."	Ê12/29/2014Ê	Ê12/29/2021	"Vertex Pharmaceuticals, Inc."	50 Northern Avenue		Boston	Massachusetts	2210	USA	228306
3960	Cystic fibrosis	6233			3549	with cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of patients with cystic fibrosis	Cystic fibrosis|GARD:0006233|FENRETINIDE|GARD:0006233	Cystic fibrosis|GARD:0006233|HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (HCFTR) MESSENGER RNA (MRNA) COMPLEXED WITH BRANCHED POLYETHYLENEIMINE (BPEI)|GARD:0006233	Cystic fibrosis|GARD:0006233|LEVOFLOXACIN|GARD:0006233	ivacaftor	Kalydeco	39071	Treatment of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	"Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R ; and treatment of CF in patients age 2 years and older who have an R117H mutation in the CFTR gene."	Ê03/17/2015Ê	Ê03/17/2022	"Vertex Pharmaceuticals, Inc."	50 Northern Avenue		Boston	Massachusetts	2210	USA	228306
3960	Cystic fibrosis	6233			3549	with cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of patients with cystic fibrosis	Cystic fibrosis|GARD:0006233|FENRETINIDE|GARD:0006233	Cystic fibrosis|GARD:0006233|HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (HCFTR) MESSENGER RNA (MRNA) COMPLEXED WITH BRANCHED POLYETHYLENEIMINE (BPEI)|GARD:0006233	Cystic fibrosis|GARD:0006233|LEVOFLOXACIN|GARD:0006233	ivacaftor	Kalydeco	39071	Treatment of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene.	Ê01/31/2012Ê	Ê01/31/2019	"Vertex Pharmaceuticals, Inc."	50 Northern Avenue		Boston	Massachusetts	2210	USA	228306
3960	Cystic fibrosis	6233			3549	with cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of patients with cystic fibrosis	Cystic fibrosis|GARD:0006233|FENRETINIDE|GARD:0006233	Cystic fibrosis|GARD:0006233|HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (HCFTR) MESSENGER RNA (MRNA) COMPLEXED WITH BRANCHED POLYETHYLENEIMINE (BPEI)|GARD:0006233	Cystic fibrosis|GARD:0006233|LEVOFLOXACIN|GARD:0006233	ivacaftor	Kalydeco	39071	Treatment of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.	Ê07/31/2017Ê	Ê07/31/2024	"Vertex Pharmaceuticals, Inc."	50 Northern Avenue		Boston	Massachusetts	2210	USA	228306
3960	Cystic fibrosis	6233			3549	with cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of patients with cystic fibrosis	Cystic fibrosis|GARD:0006233|FENRETINIDE|GARD:0006233	Cystic fibrosis|GARD:0006233|HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (HCFTR) MESSENGER RNA (MRNA) COMPLEXED WITH BRANCHED POLYETHYLENEIMINE (BPEI)|GARD:0006233	Cystic fibrosis|GARD:0006233|LEVOFLOXACIN|GARD:0006233	ivacaftor	Kalydeco	39071	Treatment of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	"Treatment of cystic fibrosis (CF) in patients age 6 years and older who have one of the following mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R."	Ê02/21/2014Ê	Ê02/21/2021	"Vertex Pharmaceuticals, Inc."	50 Northern Avenue		Boston	Massachusetts	2210	USA	228306
3960	Cystic fibrosis	6233			3549	with cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of patients with cystic fibrosis	Cystic fibrosis|GARD:0006233|FENRETINIDE|GARD:0006233	Cystic fibrosis|GARD:0006233|HUMAN CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (HCFTR) MESSENGER RNA (MRNA) COMPLEXED WITH BRANCHED POLYETHYLENEIMINE (BPEI)|GARD:0006233	Cystic fibrosis|GARD:0006233|LEVOFLOXACIN|GARD:0006233	ivacaftor	Kalydeco	39071	Treatment of patients with cystic fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of cystic fibrosis (CF) in patients age 2 years and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.	Ê05/17/2017Ê	Ê05/17/2024	"Vertex Pharmaceuticals, Inc."	50 Northern Avenue		Boston	Massachusetts	2210	USA	228306
3989	Cystic fibrosis	6233			994	of cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of cystic fibrosis (CF)	Cystic fibrosis|GARD:0006233|IVACAFTOR|TEZACAFTOR AND IVACAFTOR COMBINATION THERAPY|GARD:0006233	Cystic fibrosis|GARD:0006233|CTP-656|D9-IVACAFTOR|GARD:0006233	CYSTIC FIBROSIS|CYSTIC FIBROSIS (CF) IN PATIENTS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE|DOID:1485|MESH:D003550	Tezacaftor and Ivacaftor combination therapy	Symdeko	42901	Treatment of cystic fibrosis (CF)	Designated/Approved	Approved for Orphan Indication	"SYMDEKO a combination of tezacaftor and ivacaftor, is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence"	Ê02/12/2018Ê	Ê02/12/2025	Vertex Pharmaceuticals Inc.	50 Northern Avenue		Boston	Massachusetts	2210	USA	577517
3989	Cystic fibrosis	6233			994	of cystic fibrosis	C0010674	Cystic Fibrosis	dsyn	Treatment of cystic fibrosis (CF)	Cystic fibrosis|GARD:0006233|IVACAFTOR|TEZACAFTOR AND IVACAFTOR COMBINATION THERAPY|GARD:0006233	Cystic fibrosis|GARD:0006233|CTP-656|D9-IVACAFTOR|GARD:0006233	CYSTIC FIBROSIS|CYSTIC FIBROSIS (CF) IN PATIENTS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE|DOID:1485|MESH:D003550	Tezacaftor and Ivacaftor combination therapy	Symdeko	42901	Treatment of cystic fibrosis (CF)	Designated/Approved	Approved for Orphan Indication	SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.	Ê06/21/2019Ê	Ê06/21/2026	Vertex Pharmaceuticals Inc.	50 Northern Avenue		Boston	Massachusetts	2210	USA	577517
4028	Cystic fibrosis	6233			4611	in cystic fibrosis patients.	C0010674	Cystic Fibrosis	dsyn	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Cystic fibrosis|GARD:0006233|LIPOSOMAL AMIKACIN|ARIKACE|GARD:0006233	Cystic fibrosis|GARD:0006233|TOBRAMYCIN FOR INHALATION|TOBI|GARD:0006233	CYSTIC FIBROSIS|CF|FIBROCYSTIC DISEASE OF PANCREAS|MUCOVISCIDOSIS|PANCREATIC FIBROSIS	Tobramycin for inhalation	Tobi	34620	Treatment of bronchopulmonary infections of Pseudomonas aeruginosa in cystic fibrosis patients.	Designated/Approved	Approved for Orphan Indication	Management of cystic fibrosis patients with P.aeruginosa.	Ê12/22/1997Ê	Ê12/22/2004	Mylan Specialty LP	781 Chestnut Ridge Road	Regulatory Affairs-Greenbag Road	Morgantown	West Virginia	26505	USA	84494
Missing	Cysticercosis	8194			4535	neurocysticercosis	C0338437	Neurocysticercosis	dsyn	"Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis."				Albendazole	Albenza	35082	"Treatment of neurocysticercosis due to Taenia solium as: 1) chemotherapy of parenchymal, subarachnoidal and racemose (cysts in spinal fluid) neurocysticercosis in symptomatic cases and 2) prophylaxis of epilepsy and other sequelae in asymptomatic neurocysticercosis."	Designated/Approved	Approved for Orphan Indication	"Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium."	Ê06/11/1996Ê	Ê06/11/2003	"Impax Laboratories, LLC"	400 Crossing Boulevard	Third Floor	Bridgewater	New Jersey	8807	USA	94295
4070	Cystinosis	6236			4444	in cystinosis patients.	C2931187	Nephropathic cystinosis	dsyn	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Cystinosis|GARD:0006236|CYSTEAMINE HYDROCHLORIDE|CYSTARAN|GARD:0006236	CYSTINOSIS		Cysteamine hydrochloride	Cystaran	35661	Treatment of corneal cystine crystal accumulation in cystinosis patients.	Designated/Approved	Approved for Orphan Indication	Treatment of corneal cystine crystal accumulation in patients with cystinosis	Ê10/02/2012Ê	Ê10/02/2019	"Leadiant Biosciences, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA	105997
4067	Cystinosis	6236			3575	of cystinosis	C2931187	Nephropathic cystinosis	dsyn	Treatment of cystinosis	Cystinosis|GARD:0006236|CYSTEAMINE|CYSTAGON|GARD:0006236	CYSTINOSIS|NEPHROPATHIC CYSTINOSIS|DOID:1064|MESH:D003554	Cystinosis|GARD:0006236|PHOSPHOCYSTEAMINE|GARD:0006236	cysteamine enteric coated	Procysbi	39014	Treatment of cystinosis	Designated/Approved	Approved for Orphan Indication	PROCYSBI is indicated for the management of nephropathic cystinosis in adults and children ages 6 years and older.	Ê04/30/2013Ê	Ê04/30/2020	"Horizon Therapeutics USA, Inc."	150 S. Saunders Road	Suite 100	Lake Forest	Illinois	60045	USA	231006
4067	Cystinosis	6236			3575	of cystinosis	C2931187	Nephropathic cystinosis	dsyn	Treatment of cystinosis	Cystinosis|GARD:0006236|CYSTEAMINE|CYSTAGON|GARD:0006236	CYSTINOSIS|NEPHROPATHIC CYSTINOSIS|DOID:1064|MESH:D003554	Cystinosis|GARD:0006236|PHOSPHOCYSTEAMINE|GARD:0006236	cysteamine enteric coated	Procysbi	39014	Treatment of cystinosis	Designated/Approved	Approved for Orphan Indication	PROCYSBI is indicated for the treatment of nephropathic cystinosis in adults and pediatric patients 1 year of age and older.	Ê12/22/2017Ê	Ê12/22/2024	"Horizon Therapeutics USA, Inc."	150 S. Saunders Road	Suite 100	Lake Forest	Illinois	60045	USA	231006
4067	Cystinosis	6236			3575	of cystinosis	C2931187	Nephropathic cystinosis	dsyn	Treatment of cystinosis	Cystinosis|GARD:0006236|CYSTEAMINE|CYSTAGON|GARD:0006236	CYSTINOSIS|NEPHROPATHIC CYSTINOSIS|DOID:1064|MESH:D003554	Cystinosis|GARD:0006236|PHOSPHOCYSTEAMINE|GARD:0006236	cysteamine enteric coated	Procysbi	39014	Treatment of cystinosis	Designated/Approved	Approved for Orphan Indication	PROCYSBI is indicated for the treatment of nephropathic cystinosis in adult and pediatric patients 2 years of age and older.	Ê08/14/2015Ê	Ê08/14/2022	"Horizon Therapeutics USA, Inc."	150 S. Saunders Road	Suite 100	Lake Forest	Illinois	60045	USA	231006
4066	Cystinosis	6236			4854	of nephropathic cystinosis.	C0015624	Fanconi Syndrome	dsyn	Treatment of nephropathic cystinosis.	Nephropathic cystinosis|GARD:0009120|CYSTEAMINE|GARD:0009120	Nephropathic cystinosis|GARD:0009755|CYSTEAMINE|GARD:0009755	CYSTINOSIS|NEPHROPATHIC CYSTINOSIS|DOID:1064|MESH:D003554	Cysteamine	Cystagon	33263	Treatment of nephropathic cystinosis.	Designated/Approved	Approved for Orphan Indication	Treatment of nephropathic cystinosis in adults and children.	Ê08/15/1994Ê	Ê08/15/2001	"Mylan Laboratories, Inc."	781 Chestnut Ridge Road	P.O. Box 4310	Morgantown	West Virginia	26504	USA	55690
4074	Cystinuria	6237			5174	with homozygous cystinuria.	C0010691	Cystinuria	dsyn	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Cystinuria|GARD:0006237|TIOPRONIN|THIOLA|GARD:0006237			Tiopronin	Thiola	31429	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Designated/Approved	Approved for Orphan Indication	"THIOLA is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone."	Ê06/28/2019Ê	Ê06/28/2026	Mission Pharmacal Company	P.O. Box 786099		San Antonio	Texas	78278	USA	12386
4074	Cystinuria	6237			5174	with homozygous cystinuria.	C0010691	Cystinuria	dsyn	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Cystinuria|GARD:0006237|TIOPRONIN|THIOLA|GARD:0006237			Tiopronin	Thiola	31429	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Designated/Approved	Approved for Orphan Indication	"THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone."	Ê06/28/2019Ê	ÊN/A	Mission Pharmacal Company	P.O. Box 786099		San Antonio	Texas	78278	USA	12386
4074	Cystinuria	6237			5174	with homozygous cystinuria.	C0010691	Cystinuria	dsyn	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Cystinuria|GARD:0006237|TIOPRONIN|THIOLA|GARD:0006237			Tiopronin	Thiola	31429	Prevention of cystine nephrolithiasis in patients with homozygous cystinuria.	Designated/Approved	Approved for Orphan Indication	"Indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification or who have adverse reactions to d-penicillamine."	Ê08/11/1988Ê	Ê08/11/1995	Mission Pharmacal Company	P.O. Box 786099		San Antonio	Texas	78278	USA	12386
4073	Cystinuria	6237			4640	of homocystinuria.	C0019880	Homocystinuria	dsyn	Treatment of homocystinuria.	Homocystinuria|GARD:0010770|BETAINE|CYSTADANE|GARD:0010770	HOMOCYSTINURIA|DOID:9263|MESH:D006712	Cystinuria|GARD:0006237|BETAINE|CYSTADANE|GARD:0006237	Betaine	Cystadane	34470	Treatment of homocystinuria.	Designated/Approved	Approved for Orphan Indication	Treatment of homocystinuria to decrease elevated homocysteine blood levels.	Ê10/25/1996Ê	Ê10/25/2003	Orphan Europe SARL	70 Avenue du G_ral de Gaulle		Puteaux			France	81794
5660	Cytomegalovirus (CMV) infection	9531			4573	of cytomegalovirus retinitis.	C0206178	Cytomegalovirus Retinitis	dsyn	Treatment of cytomegalovirus retinitis.	Cytomegalovirus retinitis|GARD:0009531|MONOCLONAL ANTIBODY TO CYTOMEGALOVIRUS (HUMAN)|GARD:0009531	CYTOMEGALOVIRUS RETINITIS|CYTOMEGALOVIRUS (CMV) RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)|DOID:80160|MESH:D017726	Cytomegalovirus retinitis|GARD:0009531|GANCICLOVIR SODIUM|CYTOVENE|GARD:0009531	Ganciclovir intravitreal implant	Vitrasert Implant	34857	Treatment of cytomegalovirus retinitis.	Designated/Approved	Approved for Orphan Indication	Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome.	Ê03/04/1996Ê	Ê03/04/2003	"Bausch & Lomb Surgical, Chiron Vision Products"	9342 Jeronimo Road		Irvine	California	92718	USA	86494
541	Cytomegalovirus (CMV) infection		MISSING		5122	of primary cytomegalovirus disease	C0277554	primary disorders	dsyn	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	HUMAN CYTOMEGALOVIRUS IMMUNE GLOBULIN|CYTOMEGALOVIRUS IMMUNE GLOBULIN (HUMAN)|CYTOGAM			Cytomegalovirus immune globulin (human)	Cytogam	31992	Prevention or attenuation of primary cytomegalovirus disease in immunosuppressed recipients of organ transplants.	Designated/Approved	Approved for Orphan Indication	"#1) Attenuation of primary CMV disease associated with kidney transplant recipients who are seronegative for CMV and who receive a kidney from a CMV seropositve donor; #2) Prophylaxis of CMV disease associated transplantation of kidney (all other), lung, liver, pancreas and heart."	Ê12/04/1998Ê	Ê12/04/2005	CSL Behring LLC	1020 First Avenue	P. O. Box 61501	King of Prussia	Pennsylvania	19406	USA	15386
3422	Diffuse Large B-Cell Lymphoma	3178			1205	of diffuse large B-cell lymphoma	C0079744	Diffuse Large B-Cell Lymphoma	neop	Treatment of diffuse large B-cell lymphoma	DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|NCI:C8853|UMLS:C0855112	REFRACTORY EXTRANODAL DIFFUSE LARGE B-CELL LYMPHOMA|NCIT:C138018|NCI:C138018	REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY|NCIT:C8853|NCI:C8853|UMLS:C0855112	polatuzumab vedotin-piiq	Polivy	42716	Treatment of diffuse large B-cell lymphoma	Designated/Approved	Approved for Orphan Indication	"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies."	Ê06/10/2019Ê	Ê06/10/2026	"Genentech, Inc."	1 DNA Way	MS# 451A	South San Francisco	California	94080	USA	547416
3408	Diffuse Large B-Cell Lymphoma	3178			1293	of diffuse large B-cell lymphoma	C0079744	Diffuse Large B-Cell Lymphoma	neop	Treatment of diffuse large B-cell lymphoma	DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|NCI:C8853|UMLS:C0855112	REFRACTORY EXTRANODAL DIFFUSE LARGE B-CELL LYMPHOMA|NCIT:C138018|NCI:C138018	REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY|NCIT:C8853|NCI:C8853|UMLS:C0855112	rituximab and recombinant human hyaluronidase	Rituxan Sc	42620	Treatment of diffuse large B-cell lymphoma	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens"	Ê06/22/2017Ê	Ê06/22/2024	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	546516
3424	Diffuse Large B-Cell Lymphoma	3178			1851	of diffuse large B-cell lymphoma	C0079744	Diffuse Large B-Cell Lymphoma	neop	Treatment of diffuse large B-cell lymphoma	DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|NCI:C8853|UMLS:C0855112	REFRACTORY EXTRANODAL DIFFUSE LARGE B-CELL LYMPHOMA|NCIT:C138018|NCI:C138018	REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY|NCIT:C8853|NCI:C8853|UMLS:C0855112	tisagenlecleucel-T	Kymriah	42038	Treatment of diffuse large B-cell lymphoma	Designated/Approved	Approved for Orphan Indication	"KYMRIAH is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of Adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma"	Ê05/01/2018Ê	Ê05/01/2025	Novartis Pharmaceuticals Corporation	"One Health Plaza,"	Bldg 315 - Room 3650B	East Hanover	New Jersey	7936	USA	463114
3431	Diffuse Large B-Cell Lymphoma	3178			2140	of diffuse large B-cell lymphoma	C0079744	Diffuse Large B-Cell Lymphoma	neop	Treatment of diffuse large B-cell lymphoma	DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|NCI:C8853|UMLS:C0855112	REFRACTORY EXTRANODAL DIFFUSE LARGE B-CELL LYMPHOMA|NCIT:C138018|NCI:C138018	REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA REFRACTORY|NCIT:C8853|NCI:C8853|UMLS:C0855112	axicabtagene ciloleucel	Yescarta	41725	Treatment of diffuse large B-cell lymphoma	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma"	Ê10/18/2017Ê	Ê10/18/2024	"Kite Pharma, Inc."	2225 Colorado Avenue		Santa Monica	California	90404	USA	423914
3125	Dilated cardiomyopathy	221			1458	with dilated cardiomyopathy.	C0007193	"Cardiomyopathy, Dilated"	dsyn	Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.	Dilated cardiomyopathy|GARD:0000221|IVABRADINE|GARD:0000221			ivabradine	Corlanor	42452	Treatment of pediatric patients (0 through 16 years of age) with dilated cardiomyopathy.	Designated/Approved	Approved for Orphan Indication	"Corlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged 6 months and older, who are in sinus rhythm with an elevated heart rate."	Ê04/22/2019Ê	Ê04/22/2026	"Amgen, Inc.,"	1 Amgen Center Drive	Mail Stop 27-2-D	Thousand Oaks	California	91320	USA	511915
Missing	Dravet syndrome	10430			726	of Dravet syndrome	C0751122	Infantile Severe Myoclonic Epilepsy	dsyn	Treatment of Dravet syndrome	Dravet syndrome|GARD:0010430|STIRIPENTOL|DIACOMIT|GARD:0010430	Dravet syndrome|GARD:0010430|CANNABIDIOL|GARD:0010430	Dravet syndrome|GARD:0010430|CANNABIDIOL|GARD:0010430	cannabidiol	Epidiolex	41592	Treatment of Dravet syndrome	Designated/Approved	Approved for Orphan Indication	EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.	Ê09/28/2018Ê	Ê09/28/2025	GW Research Ltd.	68 TW Anderson Drive P.O. Box 13628		Research Triangle Park	North Carolina	27709	USA	409313
5841	Dravet syndrome	10430			3273	of Dravet syndrome	C0751122	Infantile Severe Myoclonic Epilepsy	dsyn	Treatment of Dravet syndrome	Dravet syndrome|GARD:0010430|STIRIPENTOL|DIACOMIT|GARD:0010430	Dravet syndrome|GARD:0010430|CANNABIDIOL|GARD:0010430	Dravet syndrome|GARD:0010430|CANNABIDIOL|GARD:0010430	stiripentol	Diacomit	39751	Treatment of Dravet syndrome	Designated/Approved	Approved for Orphan Indication	DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam.	Ê08/20/2018Ê	Ê08/20/2025	Biocodex	"7, avenue Gallieni"	94250 Gentilly				France	266108
223	Drug induced dyskinesia	8236	done	Not a rare disease	1764	of levodopa-induced dyskinesia	C0023570	Levodopa	aapp	Treatment of levodopa-induced dyskinesia	Drug induced dyskinesia|GARD:0008236|DIPRAGLURANT|GARD:0008236	Drug induced dyskinesia|GARD:0008236|AMANTADINE HYDROCHLORIDE|NURELIN|GARD:0008236	Drug induced dyskinesia|GARD:0008236|AMANTADINE HYDROCHLORIDE|AMANTADINE HCL|GARD:0008236	Amantadine hydrochloride	Gocovri	42103	Treatment of levodopa-induced dyskinesia	Designated/Approved	Approved for Orphan Indication	treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy with or without concomitant dopminergic medications	Ê08/24/2017Ê	Ê08/24/2024	"Adamas Pharmaceuticals, Inc."	1900 Powell Street	Suite 750	Emeryville	California	94608	USA	413213
4109	Duchenne muscular dystrophy	6291			2319	of Duchenne muscular dystrophy	C0013264	"Muscular Dystrophy, Duchenne"	dsyn	Treatment of Duchenne muscular dystrophy	Duchenne muscular dystrophy|GARD:0006291|GIVINOSTAT|GARD:0006291	Duchenne muscular dystrophy|GARD:0006291|COSYNTROPIN|GARD:0006291	Duchenne muscular dystrophy|GARD:0006291|GOLODIRSEN|GARD:0006291	deflazacort	Emflaza	41502	Treatment of Duchenne muscular dystrophy	Designated/Approved	Approved for Orphan Indication	Treatment of Duchenne Muscular Dystrophy in patients 5 years of age and older	Ê02/09/2017Ê	Ê02/09/2024	"PTC Therapeutics, Inc."	100 Corporate Court		South Plainfield	New Jersey	7080	USA	403413
4109	Duchenne muscular dystrophy	6291			2319	of Duchenne muscular dystrophy	C0013264	"Muscular Dystrophy, Duchenne"	dsyn	Treatment of Duchenne muscular dystrophy	Duchenne muscular dystrophy|GARD:0006291|GIVINOSTAT|GARD:0006291	Duchenne muscular dystrophy|GARD:0006291|COSYNTROPIN|GARD:0006291	Duchenne muscular dystrophy|GARD:0006291|GOLODIRSEN|GARD:0006291	deflazacort	Emflaza	41502	Treatment of Duchenne muscular dystrophy	Designated/Approved	Approved for Orphan Indication	EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.	Ê06/07/2019Ê	Ê06/07/2026	"PTC Therapeutics, Inc."	100 Corporate Court		South Plainfield	New Jersey	7080	USA	403413
4104	Duchenne muscular dystrophy	6291			3451	of Duchenne Muscular Dystrophy.	C0013264	"Muscular Dystrophy, Duchenne"	dsyn	Treatment of Duchenne Muscular Dystrophy.	Duchenne muscular dystrophy|GARD:0006291|GIVINOSTAT|GARD:0006291	Duchenne muscular dystrophy|GARD:0006291|COSYNTROPIN|GARD:0006291	Duchenne muscular dystrophy|GARD:0006291|GOLODIRSEN|GARD:0006291	eteplirsen	Exondys 51	39378	Treatment of Duchenne Muscular Dystrophy.	Designated/Approved	Approved for Orphan Indication	Treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping	Ê09/19/2016Ê	Ê09/19/2023	"Sarepta Therapeutics, Inc."	215 First Street	Suite 415	Cambridge	Massachusetts	2142	USA	248407
4094	Duchenne muscular dystrophy	6291			567	of Duchenne muscular dystrophy	C0013264	"Muscular Dystrophy, Duchenne"	dsyn	Treatment of Duchenne muscular dystrophy (DMD)	Duchenne muscular dystrophy|GARD:0006291|GOLODIRSEN|GARD:0006291	Muscular dystrophy|GARD:0007922|GOLODIRSEN|GARD:0007922	Duchenne muscular dystrophy|GARD:0006291|VASOMERA|GARD:0006291	golodirsen	Vyondys 53	43242	Treatment of Duchenne muscular dystrophy (DMD)	Designated/Approved	Approved for Orphan Indication	VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.	Ê12/12/2019Ê	Ê12/12/2026	"Sarepta Therapeutics, Inc."	215 First Street		Cambridge	Massachusetts	2142	USA	636818
212	elevations of serum and urinary uric acid levels		MISSING	Not a rare disease	4736	"lymphoma,"	C0024299	Lymphoma	neop	"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy."	ALLOPURINOL SODIUM|ALOPRIM FOR INJECTION			Allopurinol sodium	Aloprim For Injection	33893	"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy."	Designated/Approved	Approved for Orphan Indication	"Management of patients with leukemia, lymphoma, and solid tumor malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels and who cannot tolerate oral therapy."	Ê05/17/1996Ê	Ê05/17/2003	"Catalytica Pharmaceuticals, Inc"	PO Box 1887		Greenville	North Carolina	27835	USA	68392
126	Envenomation	ORPHANET:449285	MISSING	Not a disease	4657	by North American crotalid snakes.	C0425358	North American origin (finding)	fndg	Treatment of envenomations inflicted by North American crotalid snakes.	"AGKISTRODON PISCIVORUS IMMUNE FAB ANTIVENIN (OVINE)|ANTIVENIN, CROTALIDAE POLYVALENT IMMUNE FAB (OVINE)|CROFAB"	"CROTALUS SCUTULATUS IMMUNE FAB ANTIVENIN (OVINE)|ANTIVENIN, CROTALIDAE POLYVALENT IMMUNE FAB (OVINE)|CROFAB"	"CROTALUS ADAMANTEUS IMMUNE FAB ANTIVENIN (OVINE)|ANTIVENIN, CROTALIDAE POLYVALENT IMMUNE FAB (OVINE)|CROFAB"	"Antivenin, crotalidae polyvalent immune Fab (ovine)"	Crofab	34346	Treatment of envenomations inflicted by North American crotalid snakes.	Designated/Approved	Approved for Orphan Indication	Treatment of minimal and moderate North American Crotalidae envenomation	Ê10/02/2000Ê	Ê10/02/2007	"Protherics, Inc."	"1207 17th Ave. S., Suite 103"		Nashville	Tennessee	37212	USA	78993
Missing	Envenomation	ORPHANET:449285	MISSING		3950					Treatment of envenomation by Crotaline snakes				Antivenin crotaline (pit-viper) equine immune F(ab)2)	Anavip	38015	Treatment of envenomation by Crotaline snakes	Designated/Approved	Approved for Orphan Indication	Management of adult and pediatric patients with North American rattlesnake envenomation	Ê05/06/2015Ê	ÊN/A	"Rare Disease Therapeutics, Inc."	12975 Brookprinter Place	Suite 170	Poway	California	92064	USA	177503
Missing	Envenomation	ORPHANET:449285	MISSING		4244					Treatment of scorpion envenomations requiring medical attention.				Centruroides immune F(ab)2	Anascorp	36689	Treatment of scorpion envenomations requiring medical attention.	Designated/Approved	Approved for Orphan Indication	Treatment of clinical signs of scorpion envenomation	Ê08/04/2011Ê	Ê08/04/2018	"Rare Disease Therapeutics, Inc."	12975 Brookprinter Drive	Suite 170	Poway	California	92064	USA	135900
4164	Erdheim-Chester disease	6369			1335	of Erdheim-Chester Disease	C0878675	Erdheim-Chester Disease	dsyn	Treatment of Erdheim-Chester Disease	REFRACTORY ERDHEIM-CHESTER DISEASE|CL523792|NCIT:C136489|NCI:C136489	Erdheim-Chester disease|GARD:0006369|VEMURAFENIB|ZELBORAL|GARD:0006369	ERDHEIM CHESTER DISEASE|ECD|LIPOID GRANULOMATOSIS	vemurafenib	Zelboraf	42584	Treatment of Erdheim-Chester Disease	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Erdheim-Chester Disease with BRAF V600 mutation	Ê11/06/2017Ê	Ê11/06/2024	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	529616
Missing	Esophageal cancer	6383			1000	of esophageal carcinoma	C0152018	Esophageal carcinoma	neop	Treatment of esophageal carcinoma	"RECURRENT ESOPHAGEAL CANCER|RECURRENT ESOPHAGEAL CARCINOMA|ESOPHAGEAL CARCINOMA, RECURRENT|OESOPHAGEAL CARCINOMA RECURRENT|RECURRENT CANCER OF ESOPHAGUS|RECURRENT CANCER OF THE ESOPHAGUS|RECURRENT CARCINOMA OF ESOPHAGUS|RECURRENT CARCINOMA OF THE ESOPHAGUS|RECURRENT ESOPHAGUS CANCER|RELAPSED CANCER OF ESOPHAGUS|RELAPSED CANCER OF THE ESOPHAGUS|RELAPSED CARCINOMA OF ESOPHAGUS|RELAPSED CARCINOMA OF THE ESOPHAGUS|RELAPSED ESOPHAGEAL CANCER|RELAPSED ESOPHAGUS CARCINOMA|NCI:C3999|UMLS:C0854761"	"RECURRENT ESOPHAGEAL CARCINOMA|RECURRENT ESOPHAGEAL CANCER|RECURRENT ESOPHAGUS CANCER|RECURRENT CARCINOMA OF THE ESOPHAGUS|ESOPHAGEAL CARCINOMA, RECURRENT|RECURRENT CANCER OF ESOPHAGUS|RELAPSED CARCINOMA OF ESOPHAGUS|RELAPSED ESOPHAGUS CARCINOMA|OESOPHAGEAL CARCINOMA RECURRENT|RELAPSED ESOPHAGEAL CANCER|RECURRENT CANCER OF THE ESOPHAGUS|RELAPSED CANCER OF THE ESOPHAGUS|RELAPSED CANCER OF ESOPHAGUS|RECURRENT CARCINOMA OF ESOPHAGUS|RELAPSED CARCINOMA OF THE ESOPHAGUS|NCIT:C3999|NCI:C3999|UMLS:C0854761"	RECURRENT ESOPHAGEAL SQUAMOUS CELL CARCINOMA|RECURRENT SQUAMOUS CELL CARCINOMA OF ESOPHAGUS|RECURRENT ESOPHAGEAL SQUAMOUS CELL CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS|NCIT:C8633|NCI:C8633|UMLS:C0854769	pembrolizumab	Keytruda	42901	Treatment of esophageal carcinoma	Designated/Approved	Approved for Orphan Indication	"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 (CPS =10) as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy."	Ê07/30/2019Ê	Ê07/30/2026	"Merck, Sharp & Dohme, subsidiary of Merck & Co., Inc."	1 Merck Drive		Whitehouse Station	New Jersey	8889	USA	578717
Missing	Esophageal cancer	6383			5001	esophageal carcinoma.	C0152018	Esophageal carcinoma	neop	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.				Porfimer sodium	Photofrin	32665	For the photodynamic therapy of patients with primary or recurrent obstructing (either partially or completely) esophageal carcinoma.	Designated/Approved	Approved for Orphan Indication	"Photodynamic therapy with PHOTOFRIN for the palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who cannot be satisfactorily treated with Nd:YAG laser therapy."	Ê12/27/1995Ê	Ê12/27/2002	"QLT Phototherapeutics, Inc."	Lederle Laboratories	401 North Middletown Road	Pearl River	New York	10965	USA	35589
662	Esophageal varices	6384	done	Not a rare disease	5255	bled	C0019080	Hemorrhage	patf	"Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding."	ESOPHAGEAL VARICES|DOID:112|MESH:D004932	Esophageal varices|GARD:0006384|ETHANOLAMINE OLEATE|ETHAMOLIN|GARD:0006384	Esophageal varices|GARD:0006384|ETHANOLAMINE OLEATE|ETHAMOLIN|GARD:0006384	Ethanolamine oleate	Ethamolin	30763	"Treatment of patients with esophageal varices that have recently bled, to prevent rebleeding."	Designated/Approved	Approved for Orphan Indication		Ê12/22/1988Ê	Ê12/22/1995	QOL Medical	"4445 North Highway A1A, 241"		Vero Beach	Florida	32963	USA	1484
4432	Essential thrombocythemia	6594			5088	of essential thrombocythemia.	C0040028	"Thrombocythemia, Essential"	dsyn	Treatment of essential thrombocythemia.	Essential thrombocythemia|GARD:0006594|RUXOLITINIB PHOSPHATE|JAKAFI|GARD:0006594	Essential thrombocythemia|GARD:0006594|PACRITINIB|GARD:0006594	Essential thrombocythemia|GARD:0006594|PEGYLATED PROLINE INTERFERON ALPHA-2B|GARD:0006594	Anagrelide	Agrylin	32169	Treatment of essential thrombocythemia.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms.	Ê03/14/1997Ê	Ê03/14/2004	Roberts Pharmaceutical Corp.	Meridian Center III	6 Industrial Way West	Eatontown	New Jersey	7724	USA	20887
685	Fabry disease	6400	done		5089	of Fabry's disease.	C0002986	Fabry Disease	dsyn	Treatment of Fabry's disease.	Fabry disease|GARD:0006400|AGALSIDASE ALFA|ALPHA-GALACTOSIDASE A|CC-GALACTOSIDASE|GARD:0006400	Fabry disease|GARD:0006400|AGALSIDASE ALFA|ALPHA-GALACTOSIDASE A|FABRASE|GARD:0006400	"Fabry disease|GARD:0006400|MIGLUSTAT|1,5-(BUTYLIMINO)-1,5 DIDEOXY,D-GLUCITOL|GARD:0006400"	Ceramide trihexosidase/alpha-galactosidase A	Fabrazyme	32161	Treatment of Fabry's disease.	Designated/Approved	Approved for Orphan Indication	For use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types	Ê04/24/2003Ê	Ê04/24/2010	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA	15286
4184	Fabry disease	6400			3946	of Fabry Disease	C0002986	Fabry Disease	dsyn	Treatment of Fabry Disease	Fabry disease|GARD:0006400|MIGALASTAT HYDROCHLORIDE|GARD:0006400	Fabry disease|GARD:0006400|LUCERASTAT|GARD:0006400	Fabry disease|GARD:0006400|ALPHA-GALACTOSIDASE A|REPLAGAL|GARD:0006400	migalastat hydrochloride	Galafold	38042	Treatment of Fabry Disease	Designated/Approved	Approved for Orphan Indication	GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data	Ê08/10/2018Ê	Ê08/10/2025	"Amicus Therapeutics, Inc."	1 Cedarbrook Drive		Cranbury	New Jersey	8512	USA	180003
3281	Factor VII deficiency	2238			3859	with congenital factor VII deficiency	C0015503	Factor VII Deficiency	dsyn	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Factor VII deficiency|GARD:0002238|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0002238	Factor VII deficiency|GARD:0002238|CSL-689|RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR VIIA WITH ALBUMIN (RVIIA-FP)|GARD:0002238	FACTOR VII DEFICIENCY|ALEXANDER'S DISEASE|CONGENITAL FACTOR VII DEFICIENCY|INHERITED FACTOR VII DEFICIENCY	Coagulation factor VIIa (recombinant)	Novoseven	38240	Treatment of bleeding episodes in patients with congenital factor VII deficiency	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in patients with Factor VII Deficiency	Ê07/11/2005Ê	Ê07/11/2012	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA	185904
3282	Factor VII deficiency	2238			3860	with congenital Factor VII deficiency	C0015503	Factor VII Deficiency	dsyn	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Factor VII deficiency|GARD:0002238|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0002238	HEMOPHILIA B|CHRISTMAS DISEASE|FACTOR IX DEFICIENCY|ROYAL DISEASE		Coagulation factor VIIa (recombinant)	Novoseven	38240	Prevention of bleeding episodes in patients with congenital Factor VII deficiency	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in patients with congenital F VII deficiency	Ê07/11/2005Ê	Ê07/11/2012	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA	189904
4186	Factor X deficiency	6404			3441	of hereditary factor X deficiency	C0272327	Hereditary factor X deficiency disease	dsyn	Treatment of hereditary factor X deficiency	Factor X deficiency|GARD:0006404|HUMAN FACTOR X|COAGADEX|GARD:0006404	"BIOTINIDASE DEFICIENCY|BTD DEFICIENCY|INFANTILE MULTIPLE CARBOXYLASE DEFICIENCY|JUVENILE MULTIPLE CARBOXYLASE DEFICIENCY|LATE-ONSET MULTIPLE CARBOXYLASE DEFICIENCY|MULTIPLE CARBOXYLASE DEFICIENCY, DUE TO BIOTINIDASE DEFICIENCY"	FAMILIAL HYPOPHOSPHATEMIA|HEREDITARY TYPE I HYPOPHOSPHATEMIA (HPDR I)|HEREDITARY TYPE II HYPOPHOSPHATEMIA (HPDR II)|HYPOPHOSPHATEMIC D-RESISTANT RICKETS I|HYPOPHOSPHATEMIC D-RESISTANT RICKETS II|PHOSPHATE DIABETES|X-LINKED HYPOPHOSPHATEMIA (XLH)|X-LINKED VITAMIN D-RESISTANT RICKETS	Coagulation factor X (human)	Coagadex	39394	Treatment of hereditary factor X deficiency	Designated/Approved	Approved for Orphan Indication	Treatment of adults and adolescents (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild hereditary Factor X deficiency	Ê10/20/2015Ê	Ê10/20/2022	Bio Products Laboratory Limited	Dagger Lane	"Hertfordshire, WD6 3BX"				United Kingdom	246907
4186	Factor X deficiency	6404			3441	of hereditary factor X deficiency	C0272327	Hereditary factor X deficiency disease	dsyn	Treatment of hereditary factor X deficiency	Factor X deficiency|GARD:0006404|HUMAN FACTOR X|COAGADEX|GARD:0006404	"BIOTINIDASE DEFICIENCY|BTD DEFICIENCY|INFANTILE MULTIPLE CARBOXYLASE DEFICIENCY|JUVENILE MULTIPLE CARBOXYLASE DEFICIENCY|LATE-ONSET MULTIPLE CARBOXYLASE DEFICIENCY|MULTIPLE CARBOXYLASE DEFICIENCY, DUE TO BIOTINIDASE DEFICIENCY"	FAMILIAL HYPOPHOSPHATEMIA|HEREDITARY TYPE I HYPOPHOSPHATEMIA (HPDR I)|HEREDITARY TYPE II HYPOPHOSPHATEMIA (HPDR II)|HYPOPHOSPHATEMIC D-RESISTANT RICKETS I|HYPOPHOSPHATEMIC D-RESISTANT RICKETS II|PHOSPHATE DIABETES|X-LINKED HYPOPHOSPHATEMIA (XLH)|X-LINKED VITAMIN D-RESISTANT RICKETS	Coagulation factor X (human)	Coagadex	39394	Treatment of hereditary factor X deficiency	Designated/Approved	Approved for Orphan Indication	COAGADEX is indicated in adults and children with hereditary Factor X deficiency for routine prophylaxis to reduce the frequency of bleeding episodes; on-demand treatment and control of bleeding episodes; and perioperative management of bleeding in patients with mild and moderate hereditary Factor X deficiency.	Ê09/21/2018Ê	Ê09/21/2025	Bio Products Laboratory Limited	Dagger Lane	"Hertfordshire, WD6 3BX"				United Kingdom	246907
5888	Factor XIII deficiency	10766			3978	with congential factor XIII deficiency	C0015530	Factor XIII Deficiency	dsyn	Prophylaxis of bleeding associated with congential factor XIII deficiency	Factor XIII deficiency|GARD:0010766|CATRIDECACOG|COAGULATION FACTOR XIII A-SUBUNIT (RECOMBINANT)|TRETTEN|GARD:0010766			coagulation factor XIII A-subunit (recombinant)	Tretten	37931	Prophylaxis of bleeding associated with congential factor XIII deficiency	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis of bleeding in patients with congenital Factor XIII A-subunit deficiency.	Ê12/23/2013Ê	Ê12/23/2020	"Novo Nordisk, Inc."	800 Scudders Mill Rd.		Plainsboro	New Jersey	8536	USA	174803
5885	Factor XIII deficiency	10766			5220	of congenital factor XIII deficiency	C0015530	Factor XIII Deficiency	dsyn	Treatment of congenital factor XIII deficiency	Factor XIII deficiency|GARD:0010766|FACTOR XIII CONCENTRATE (HUMAN)|CORIFACT|GARD:0010766	Factor XIII deficiency|GARD:0010766|FACTOR XIII CONCENTRATE (HUMAN)|CORIFACT|GARD:0010766	FACTOR XIII DEFICIENCY|CONGENITAL FACTOR XIII DEFICIENCY|DOID:2211|MESH:D005177	factor XIII concentrate (human)	Corifact	31063	Treatment of congenital factor XIII deficiency	Designated/Approved	Approved for Orphan Indication	For the routine prophylactic treatment of congenital factor XIII deficiency	Ê02/17/2011Ê	Ê02/17/2018	CSL Behring LLC	1020 First Ave.	PO Box 61501	King of Prussia	Pennsylvania	19406	USA	4484
5885	Factor XIII deficiency	10766			5220	of congenital factor XIII deficiency	C0015530	Factor XIII Deficiency	dsyn	Treatment of congenital factor XIII deficiency	Factor XIII deficiency|GARD:0010766|FACTOR XIII CONCENTRATE (HUMAN)|CORIFACT|GARD:0010766	Factor XIII deficiency|GARD:0010766|FACTOR XIII CONCENTRATE (HUMAN)|CORIFACT|GARD:0010766	FACTOR XIII DEFICIENCY|CONGENITAL FACTOR XIII DEFICIENCY|DOID:2211|MESH:D005177	factor XIII concentrate (human)	Corifact	31063	Treatment of congenital factor XIII deficiency	Designated/Approved	Approved for Orphan Indication	Indicated for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency.	Ê01/24/2013Ê	Ê01/24/2020	CSL Behring LLC	1020 First Ave.	PO Box 61501	King of Prussia	Pennsylvania	19406	USA	4484
5615	Fallopian tube cancer	9162			570	of Fallopian Tube Cancer	C0153579	Malignant neoplasm of fallopian tube	neop	Treatment of Fallopian Tube Cancer	Fallopian tube cancer|GARD:0009162|PELAREOREP|REOLYSIN|GARD:0009162	REFRACTORY FALLOPIAN TUBE CARCINOMA|REFRACTORY FALLOPIAN TUBE CANCER|NCIT:C152047|NCI:C152047	Fallopian tube cancer|GARD:0009162|PATUPILONE|GARD:0009162	olaparib	Lynparza	43235	Treatment of Fallopian Tube Cancer	Designated/Approved	Approved for Orphan Indication	"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy."	Ê08/17/2017Ê	Ê08/17/2024	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA	417613
5615	Fallopian tube cancer	9162			570	of Fallopian Tube Cancer	C0153579	Malignant neoplasm of fallopian tube	neop	Treatment of Fallopian Tube Cancer	Fallopian tube cancer|GARD:0009162|PELAREOREP|REOLYSIN|GARD:0009162	REFRACTORY FALLOPIAN TUBE CARCINOMA|REFRACTORY FALLOPIAN TUBE CANCER|NCIT:C152047|NCI:C152047	Fallopian tube cancer|GARD:0009162|PATUPILONE|GARD:0009162	olaparib	Lynparza	43235	Treatment of Fallopian Tube Cancer	Designated/Approved	Approved for Orphan Indication	"Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza."	Ê12/19/2018Ê	Ê12/19/2025	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA	417613
Missing	Fallopian tube cancer	9162			2903	of fallopian tube carcinoma	C0238122	Fallopian Tube Carcinoma	neop	Treatment of fallopian tube carcinoma	REFRACTORY FALLOPIAN TUBE CARCINOMA|REFRACTORY FALLOPIAN TUBE CANCER|NCIT:C152047|NCI:C152047	PEC PROTOCOL|CEP COMBINATION|UMLS:C0055065|MESH:C058575	OVARIAN CANCER	bevacizumab	Avastin	40505	Treatment of fallopian tube carcinoma	Designated/Approved	Approved for Orphan Indication	"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer."	Ê12/06/2016Ê	Ê12/06/2023	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	318010
Missing	Fallopian tube cancer	9162			2903	of fallopian tube carcinoma	C0238122	Fallopian Tube Carcinoma	neop	Treatment of fallopian tube carcinoma	REFRACTORY FALLOPIAN TUBE CARCINOMA|REFRACTORY FALLOPIAN TUBE CANCER|NCIT:C152047|NCI:C152047	PEC PROTOCOL|CEP COMBINATION|UMLS:C0055065|MESH:C058575	OVARIAN CANCER	bevacizumab	Avastin	40505	Treatment of fallopian tube carcinoma	Designated/Approved	Approved for Orphan Indication	"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer."	Ê06/13/2018Ê	Ê06/13/2025	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	318010
Missing	Fallopian tube cancer	9162			2903	of fallopian tube carcinoma	C0238122	Fallopian Tube Carcinoma	neop	Treatment of fallopian tube carcinoma	REFRACTORY FALLOPIAN TUBE CARCINOMA|REFRACTORY FALLOPIAN TUBE CANCER|NCIT:C152047|NCI:C152047	PEC PROTOCOL|CEP COMBINATION|UMLS:C0055065|MESH:C058575	OVARIAN CANCER	bevacizumab	Avastin	40505	Treatment of fallopian tube carcinoma	Designated/Approved	Approved for Orphan Indication	"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received no more than 2 prior chemotherapy regimens."	Ê11/14/2014Ê	Ê11/14/2021	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	318010
Missing	Fallopian tube cancer	9162			2917	of primary peritoneal carcinoma.	C1514428	Primary peritoneal carcinoma	neop	Treatment of primary peritoneal carcinoma.	REFRACTORY PRIMARY PERITONEAL CARCINOMA|REFRACTORY PRIMARY PERITONEAL CANCER|NCIT:C152046|NCI:C152046	GOBLET CELL CARCINOID|MUCINOUS CARCINOID|ADENOCARCINOID +/-EX GCC|GOBLET CELL TUMORS (GCT)|MUCINOUS ADENOCARCINOIDS|MICROGLANDULAR-GCC|COMPOSITE GCC-ADENOCARCINOMA|MIXED CRYPT CELL CARCINOMA|ADENOCARCINOMA EX GCC|APPENDICEAL CRYPT CELL ADENOCARCINOMA|GOBLET CELL CARCINOMA|GCC|GOBLET CELL ADENOCARCINOID|GOBLET CELL TUMOR	"OVARIAN CANCER|OVARIAN CARCINOMA|CANCER, OVARIAN|CANCERS, OVARIAN|OVARIAN CANCERS|CANCERS, OVARY|OVARY CANCERS|CANCER, OVARY|CANCER OF THE OVARY|CANCER OF OVARY|OVARY CANCER|MALIGNANT NEOPLASM OF OVARY|MALIGNANT NEOPLASM OF THE OVARY|MALIGNANT OVARIAN NEOPLASM|MALIGNANT OVARIAN TUMOR|MALIGNANT TUMOR OF OVARY|MALIGNANT TUMOR OF THE OVARY|OVARIAN MALIGNANT TUMOR|CA - CANCER OF OVARY|GTRT000015091|UMLS:C1140680|HP:0100615|MESH:D010051|NCI:C7431|OMIM:167000|MTHU025028|ORPHANET:213500|SNOMEDCT_US:363443007"	bevacizumab	Avastin	40484	Treatment of primary peritoneal carcinoma.	Designated/Approved	Approved for Orphan Indication	"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens"	Ê11/14/2014Ê	Ê11/14/2021	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	317810
Missing	Fallopian tube cancer	9162			2917	of primary peritoneal carcinoma.	C1514428	Primary peritoneal carcinoma	neop	Treatment of primary peritoneal carcinoma.	REFRACTORY PRIMARY PERITONEAL CARCINOMA|REFRACTORY PRIMARY PERITONEAL CANCER|NCIT:C152046|NCI:C152046	GOBLET CELL CARCINOID|MUCINOUS CARCINOID|ADENOCARCINOID +/-EX GCC|GOBLET CELL TUMORS (GCT)|MUCINOUS ADENOCARCINOIDS|MICROGLANDULAR-GCC|COMPOSITE GCC-ADENOCARCINOMA|MIXED CRYPT CELL CARCINOMA|ADENOCARCINOMA EX GCC|APPENDICEAL CRYPT CELL ADENOCARCINOMA|GOBLET CELL CARCINOMA|GCC|GOBLET CELL ADENOCARCINOID|GOBLET CELL TUMOR	"OVARIAN CANCER|OVARIAN CARCINOMA|CANCER, OVARIAN|CANCERS, OVARIAN|OVARIAN CANCERS|CANCERS, OVARY|OVARY CANCERS|CANCER, OVARY|CANCER OF THE OVARY|CANCER OF OVARY|OVARY CANCER|MALIGNANT NEOPLASM OF OVARY|MALIGNANT NEOPLASM OF THE OVARY|MALIGNANT OVARIAN NEOPLASM|MALIGNANT OVARIAN TUMOR|MALIGNANT TUMOR OF OVARY|MALIGNANT TUMOR OF THE OVARY|OVARIAN MALIGNANT TUMOR|CA - CANCER OF OVARY|GTRT000015091|UMLS:C1140680|HP:0100615|MESH:D010051|NCI:C7431|OMIM:167000|MTHU025028|ORPHANET:213500|SNOMEDCT_US:363443007"	bevacizumab	Avastin	40484	Treatment of primary peritoneal carcinoma.	Designated/Approved	Approved for Orphan Indication	"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer."	Ê06/13/2018Ê	Ê06/13/2025	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	317810
Missing	Fallopian tube cancer	9162			2917	of primary peritoneal carcinoma.	C1514428	Primary peritoneal carcinoma	neop	Treatment of primary peritoneal carcinoma.	REFRACTORY PRIMARY PERITONEAL CARCINOMA|REFRACTORY PRIMARY PERITONEAL CANCER|NCIT:C152046|NCI:C152046	GOBLET CELL CARCINOID|MUCINOUS CARCINOID|ADENOCARCINOID +/-EX GCC|GOBLET CELL TUMORS (GCT)|MUCINOUS ADENOCARCINOIDS|MICROGLANDULAR-GCC|COMPOSITE GCC-ADENOCARCINOMA|MIXED CRYPT CELL CARCINOMA|ADENOCARCINOMA EX GCC|APPENDICEAL CRYPT CELL ADENOCARCINOMA|GOBLET CELL CARCINOMA|GCC|GOBLET CELL ADENOCARCINOID|GOBLET CELL TUMOR	"OVARIAN CANCER|OVARIAN CARCINOMA|CANCER, OVARIAN|CANCERS, OVARIAN|OVARIAN CANCERS|CANCERS, OVARY|OVARY CANCERS|CANCER, OVARY|CANCER OF THE OVARY|CANCER OF OVARY|OVARY CANCER|MALIGNANT NEOPLASM OF OVARY|MALIGNANT NEOPLASM OF THE OVARY|MALIGNANT OVARIAN NEOPLASM|MALIGNANT OVARIAN TUMOR|MALIGNANT TUMOR OF OVARY|MALIGNANT TUMOR OF THE OVARY|OVARIAN MALIGNANT TUMOR|CA - CANCER OF OVARY|GTRT000015091|UMLS:C1140680|HP:0100615|MESH:D010051|NCI:C7431|OMIM:167000|MTHU025028|ORPHANET:213500|SNOMEDCT_US:363443007"	bevacizumab	Avastin	40484	Treatment of primary peritoneal carcinoma.	Designated/Approved	Approved for Orphan Indication	"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer."	Ê12/06/2016Ê	Ê12/06/2023	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	317810
Missing	FAMILIAL AMYLOIDOSIS	6611			2574	of transthyretin amyloidosis	C0268407	Senile cardiac amyloidosis	dsyn	Treatment of transthyretin amyloidosis (ATTR amyloidosis)	"HEREDITARY AMYLOIDOSIS (DISEASE)|AMYLOIDOSIS, FAMILIAL|FAMILIAL AMYLOIDOSIS|AMYLOIDOSIS HEREDITARY|HEREDITARY AMYLOIDOSIS|UMLS:C0206246|NCIT:C84555|ORPHANET:444116|MESH:D028226|SCTID:367601000119103|GARD:0006611|MONDO:0018634"	Familial transthyretin amyloidosis|GARD:0000656|TOLCAPONE|GARD:0000656	Familial transthyretin amyloidosis|GARD:0000656|REVUSIRAN|GARD:0000656	Inotersen	Tegsedi	41114	Treatment of transthyretin amyloidosis (ATTR amyloidosis)	Designated/Approved	Approved for Orphan Indication	TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.	Ê10/05/2018Ê	Ê10/05/2025	"Akcea Therapeutics, Inc."	22 Boston Wharf Road	9th Floor	Boston	Massachusetts	2210	USA	374512
646	Familial breast cancer	10415	approximate		4298	of breast cancer.	C0006142	Malignant neoplasm of breast	neop	Treatment of breast cancer.	BREAST ELEVATION DIFFERENCE SINCE CANCER TREATMENT|BREAST ELEVATION (HOW HIGH THE BREAST IS)|NCIT:C103336|NCI:C103336|UMLS:C3641218	BREAST SIZE DIFFERENCE SINCE CANCER TREATMENT|BREAST SIZE|NCIT:C103332|NCI:C103332|UMLS:C3539027	BREAST SHAPE DIFFERENCE SINCE CANCER TREATMENT|BREAST SHAPE|NCIT:C103335|NCI:C103335|UMLS:C3641217	Epirubicin	Ellence	36417	Treatment of breast cancer.	Designated/Approved	Approved for Orphan Indication	Component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.	Ê09/15/1999Ê	Ê09/15/2006	Pharmacia & Upjohn Company	0634-298-113	7000 Portage Rd.	Kalamazoo	Michigan	49001	USA	121498
2738	Familial breast cancer	10415	approximate		3754	of breast cancer	C0006142	Malignant neoplasm of breast	neop	Reduction of the risk of breast cancer in postmenopausal women	FEMALE BREAST CANCER|BREAST CANCER|BREAST CANCER IN POSTMENOPAUSAL WOMEN AT HIGH RISK FOR INVASIVE BREAST CANCER|DOID:50671|MESH:D001943	Familial breast cancer|GARD:0010415|RALOXIFENE|EVISTA|GARD:0010415	FEMALE BREAST CANCER|BREAST CANCER|BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS|DOID:50671|MESH:D001943	raloxifene	Evista	38547	Reduction of the risk of breast cancer in postmenopausal women	Designated/Approved	Approved for Orphan Indication	Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer	Ê09/13/2007Ê	Ê09/13/2014	Eli Lilly and Company	Lilly Corporate Center	Drop Code 1853	Indianapolis	Indiana	46285	USA	197504
2056	Familial Dupuytren contracture	12165	done	Not a rare disease	4518	Dupuytren's disease	C0013312	Dupuytren Contracture	dsyn	Treatment of advanced (involutional or residual stage) Dupuytren's disease	Familial Dupuytren contracture|GARD:0012165|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|XIAFLEX|GARD:0012165			collagenase clostridium histolyticum	Xiaflex	35208	Treatment of advanced (involutional or residual stage) Dupuytren's disease	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Dupuytren's contracture with a palpable cord	Ê02/02/2010Ê	Ê02/02/2017	"Auxilium Pharmaceuticals, Inc."	40 Valley Stream Parkway		Malvern	Pennsylvania	19335	USA	92595
593	Familial focal epilepsy with variable foci	13295	approximate		4768	"with epilepsy,"	C0014544	Epilepsy	dsyn	"For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity."	Familial focal epilepsy with variable foci|GARD:0013295|DIAZEPAM|DIAZEPAM VISCOUS SOLUTION FOR RECTAL ADMINISTRATION|GARD:0013295			Diazepam viscous solution for rectal administration	Diastat	33659	"For the management of selected, refractory, patients with epilepsy, on stable regimens of antiepileptic drugs (AEDs), who require intermittent use of diazepam to control bouts of increased seizure activity."	Designated/Approved	Approved for Orphan Indication		Ê07/29/1997Ê	Ê07/29/2004	Valeant Pharmaceuticals	3300 Hyland Avenue		Costa Mesa	California	92626	USA	61591
2220	Familial hypercholesterolemia	10416	done	Not a rare disease	2291	of homozygous familial hypercholesterolemia	C0020445	"Hypercholesterolemia, Familial"	dsyn	Treatment of homozygous familial hypercholesterolemia	Familial hypercholesterolemia|GARD:0010416|AEM-28|APOLIPOPROTEIN E MIMETIC PEPTIDE|GARD:0010416	Familial hypercholesterolemia|GARD:0010416|IMPLITAPIDE|GARD:0010416	Familial hypercholesterolemia|GARD:0010416|SELADELPAR LYSINE DIHYDRATE|2-[4-[[(2R)-2-ETHOXY-3-[4-(TRIFLUOROMETHYL)PHENOXY]PROPYL]THIO]-2-METHYLPHENOXY]ACETIC ACID (1:1) LYSINE DIHYDRATE|GARD:0010416	evolocumab	Repatha	41529	Treatment of homozygous familial hypercholesterolemia	Designated/Approved	Approved for Orphan Indication	"As an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) in patients with HoFH who require additional lowering of LDL-C."	Ê08/27/2015Ê	Ê08/27/2022	Amgen Inc.	One Amgen Center Drive	M/S 17 2 B	Thousand Oaks	California	91320	USA	404113
2456	Familial hypercholesterolemia	10416	done	Not a rare disease	3448	of homozygous familial hypercholesterolemia	C0020445	"Hypercholesterolemia, Familial"	dsyn	Treatment of homozygous familial hypercholesterolemia	Familial hypercholesterolemia|GARD:0010416|AEM-28|APOLIPOPROTEIN E MIMETIC PEPTIDE|GARD:0010416	Familial hypercholesterolemia|GARD:0010416|IMPLITAPIDE|GARD:0010416	Familial hypercholesterolemia|GARD:0010416|SELADELPAR LYSINE DIHYDRATE|2-[4-[[(2R)-2-ETHOXY-3-[4-(TRIFLUOROMETHYL)PHENOXY]PROPYL]THIO]-2-METHYLPHENOXY]ACETIC ACID (1:1) LYSINE DIHYDRATE|GARD:0010416	lomitapide	Juxtapid	39378	Treatment of homozygous familial hypercholesterolemia	Designated/Approved	Approved for Orphan Indication	"Adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)."	Ê12/21/2012Ê	Ê12/21/2019	"Aegerion Pharmaceuticals, Inc."	"101 Main St., Suite 1850"		Cambridge	Massachusetts	2142	USA	245907
2528	Familial hypercholesterolemia	10416	done	Not a rare disease	3638	of homozygous familial hypercholesterolemia	C0020445	"Hypercholesterolemia, Familial"	dsyn	Treatment of homozygous familial hypercholesterolemia	Familial hypercholesterolemia|GARD:0010416|AEM-28|APOLIPOPROTEIN E MIMETIC PEPTIDE|GARD:0010416	Familial hypercholesterolemia|GARD:0010416|IMPLITAPIDE|GARD:0010416	Familial hypercholesterolemia|GARD:0010416|SELADELPAR LYSINE DIHYDRATE|2-[4-[[(2R)-2-ETHOXY-3-[4-(TRIFLUOROMETHYL)PHENOXY]PROPYL]THIO]-2-METHYLPHENOXY]ACETIC ACID (1:1) LYSINE DIHYDRATE|GARD:0010416	mipomersen	Kynamro	38860	Treatment of homozygous familial hypercholesterolemia	Designated/Approved	Approved for Orphan Indication	"Adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH)."	Ê01/29/2013Ê	Ê01/29/2020	"Kastle Therapeutics, LLC"	181 West Madison Street	Suite 3745	Chicago	Illinois	60602	USA	221406
2820	Familial hypercholesterolemia	10416	done	Not a rare disease	2163	of pediatric homozygous familial hypercholesterolemia	C0020445	"Hypercholesterolemia, Familial"	dsyn	For the treatment of pediatric homozygous familial hypercholesterolemia	Familial hypercholesterolemia|GARD:0010416|ROSUVASTATIN|CRESTOR|GARD:0010416	DYSLIPIDEMIA|DOID:3146|MESH:D050171	DYSBETALIPOPROTEINEMIA|MESH:D006952	rosuvastatin	Crestor	41684	For the treatment of pediatric homozygous familial hypercholesterolemia	Designated/Approved	Approved for Orphan Indication	"An adjunct to diet to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents 7 to 17 years of age with homozygous familial hypercholesterolemia, either alone or with other lipid-lowering treatments (e.g., LDL apheresis)."	Ê05/27/2016Ê	Ê05/27/2023	"iPR Pharmaceuticals, Inc."	1 MedImmune Way		Gaithersburg	Maryland	20878	USA	420513
2113	Familial hypertrophic cardiomyopathy	7229	approximate		2294	of hypertrophic obstructive cardiomyopathy	C0007194	Hypertrophic Cardiomyopathy	dsyn	Treatment of hypertrophic obstructive cardiomyopathy	"Familial hypertrophic cardiomyopathy|GARD:0007229|ALCOHOL, DEHYDRATED|DEHYDRATED ALCOHOL|ABLYSINOL|GARD:0007229"	"Familial hypertrophic cardiomyopathy|GARD:0007229|MYK-461|6-{[(1S)-1-PHENYLETHYL]AMINO}-3-(PROPAN-2-YL)-1,2,3,4 TETRAHYDROPYRIMIDINE-2,4-DIONE|GARD:0007229"	PEDIATRIC CARDIOMYOPATHY|ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY (ARVC)|ASYMMETRICAL SEPTAL HYPERTROPHY|FAMILIAL CONGESTIVE CARDIOMYOPATHY|FAMILIAL DILATED CARDIOMYOPATHY (FDC)|HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY (HOCM)|IDIOPATHIC DILATED CARDIOMYOPATHY|IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS|NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY	dehydrated alcohol	Ablysinol	41528	Treatment of hypertrophic obstructive cardiomyopathy	Designated/Approved	Approved for Orphan Indication	ABLYSINOL is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy.	Ê06/21/2018Ê	Ê06/21/2025	"Belcher Pharmaceuticals, LLC"	6911 Bryan Dairy Road		Largo	Florida	33777	USA	402513
2133	Familial periodic paralysis	6422	approximate		2962	of primary periodic paralyses	C0030443	Familial Periodic Paralysis	dsyn	Treatment of primary periodic paralyses	Familial periodic paralysis|GARD:0006422|DICHLORPHENAMIDE|GARD:0006422			dichlorphenamide	n/a	40423	Treatment of primary periodic paralyses	Designated/Approved	Approved for Orphan Indication	"Treatment of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, and related variants"	Ê08/07/2015Ê	Ê08/07/2022	Strongbridge US Inc.	900 Northbrook Drives	Suite 200	trevose	Pennsylvania	19053	USA	314210
1086	Familial prostate cancer	4520	approximate		4508	of hormone refractory prostate cancer.	C1328504	Hormone refractory prostate cancer	neop	Treatment of hormone refractory prostate cancer.	PROSTATE CANCER|HORMONE-REFRACTORY METASTATIC PROSTATE CANCER|DOID:10283|MESH:D011471	Familial prostate cancer|GARD:0004520|MITOXANTRONE|NOVANTRONE|GARD:0004520	Familial prostate cancer|GARD:0004520|SURAMIN|METARET|GARD:0004520	Mitoxantrone	Novantrone	35298	Treatment of hormone refractory prostate cancer.	Designated/Approved	Approved for Orphan Indication	In combination with corticosteroids as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer.	Ê11/13/1996Ê	Ê11/13/2003	Serono	One Technology Place		Rockland	Massachusetts	2370	USA	96696
2960	Familial transthyretin amyloidosis	656	done		2653	amyloid cardiomyopathy.	C0268407	Senile cardiac amyloidosis	dsyn	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Familial transthyretin amyloidosis|GARD:0000656|TAFAMIDIS MEGLUMINE|GARD:0000656			tafamidis meglumine	Vyndaqel; Vyndamax	40956	Treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy.	Designated/Approved	Approved for Orphan Indication	VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.	Ê05/03/2019Ê	Ê05/03/2026	"FoldRx Pharmaceuticals, Inc., a subsidiary of Pfizer Inc."	445 Eastern Point Road		Groton	Connecticut	6340	USA	363312
2950	Familial transthyretin amyloidosis	656	done		2596	of transthyretin-mediated amyloidosis	C0268407	Senile cardiac amyloidosis	dsyn	Treatment of transthyretin-mediated amyloidosis	Familial transthyretin amyloidosis|GARD:0000656|TOLCAPONE|GARD:0000656	Familial transthyretin amyloidosis|GARD:0000656|REVUSIRAN|GARD:0000656	Familial transthyretin amyloidosis|GARD:0000656|SYNTHETIC DOUBLE-STRANDED SIRNA OLIGONUCLEOTIDE THAT IS COVALENTLY LINKED TO A LIGAND CONTAINING THREE N-ACETYLGALACTOSAMINE RESIDUES AND THAT IS TARGETED AGAINST TRANSTHRYETIN MRNA|VUTRISIRAN (ALN-TTRSC02)|GARD:0000656	patisiran	Onpattro	41074	Treatment of transthyretin-mediated amyloidosis	Designated/Approved	Approved for Orphan Indication	ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.	Ê08/10/2018Ê	Ê08/10/2025	"Alnylam Pharmaceuticals, Inc."	300 Third Street		Cambridge	Maryland	2142	USA	371112
4200	Fascioliasis	6428			1076	of fascioliasis	C0015652	Fascioliasis	dsyn	Treatment of fascioliasis	Fascioliasis|GARD:0006428|TRICLABENDAZOLE|TRICLATHERA(TM)|GARD:0006428	Fascioliasis|GARD:0006428|TRICLABENDAZOLE|EGATEN|GARD:0006428	G-1476|RILANID|RILANIDE|UMLS:C0539019|UMLS:C0539017|MESH:C105977	triclabendazole	Egaten	42842	Treatment of fascioliasis	Designated/Approved	Approved for Orphan Indication	EGATEN is indicated for the treatment of fascioliasis in patients 6 years of age and older.	Ê02/13/2019Ê	Ê02/13/2026	Novartis Pharmaceuticals Corporation	1 Health Plaza		East Hanover	New Jersey	7936	USA	564216
2315	"Fibrinogen deficiency, congenital"	2320	done		3382	of fibrinogen deficient patients.	C0016006	Fibrinogen	aapp	Treatment of fibrinogen deficient patients.	"Fibrinogen deficiency, congenital|GARD:0002320|FIBRINOGEN HUMAN|FIBRINOGEN (HUMAN)|GARD:0002320"	"Fibrinogen deficiency, congenital|GARD:0002320|FIBRINOGEN HUMAN|RECOMBINANT HUMAN FIBRINOGEN|GARD:0002320"	"Fibrinogen deficiency, congenital|GARD:0002320|FIBRINOGEN HUMAN|HUMAN FIBRINOGEN CONCENTRATE, PASTEURIZED|RIASTAP|GARD:0002320"	"human fibrinogen concentrate, pasteurized"	Riastap	39520	Treatment of fibrinogen deficient patients.	Designated/Approved	Approved for Orphan Indication	Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia)	Ê01/16/2009Ê	Ê01/16/2016	"CSL Behring, LLC"	1020 First Avenue	P.O. Box 61501	King of Prussia	Pennsylvania	19406	USA	245107
3286	Fibrosarcoma	2327			3695	of dermatofibrosarcoma protuberans	C0206647	Dermatofibrosarcoma	neop	Treatment of dermatofibrosarcoma protuberans	Dermatofibrosarcoma protuberans|GARD:0009569|IMATINIB MESYLATE|GLEEVEC|GARD:0009569	Fibrosarcoma|GARD:0002327|IMATINIB MESYLATE|GLEEVEC|GARD:0002327	"AGGRESSIVE SYSTEMIC MASTOCYTOSIS|MASTOCYTOSIS, SYSTEMIC|AGGRESSIVE SYSTEMIC MASTOCYTOSIS (D816V C-KIT MUTATION STATUS NEGATIVE/C-KIT MUTATIONAL STATUS UNKNOWN)|DOID:4798|MESH:D034721"	imatinib mesylate	Gleevec	38705	Treatment of dermatofibrosarcoma protuberans	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP)"	Ê10/19/2006Ê	Ê10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA	208805
3288	Follicular lymphoma	2356			1318	of follicular lymphoma	C0024301	"Lymphoma, Follicular"	neop	Treatment of follicular lymphoma	Follicular lymphoma|GARD:0002356|RITUXIMAB|RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE|GARD:0002356	Follicular lymphoma|GARD:0002356|DARATUMUMAB|GARD:0002356	Follicular lymphoma|GARD:0002356|IBRUTINIB|GARD:0002356	rituximab and recombinant human hyaluronidase	Rituxan Sc	42604	Treatment of follicular lymphoma	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with relapsed or refractory, follicular lymphoma as a single agent; previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy; and non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy."	Ê06/22/2017Ê	Ê06/22/2024	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	529816
3307	Follicular lymphoma	2356			1431	of follicular lymphoma.	C0024301	"Lymphoma, Follicular"	neop	Treatment of follicular lymphoma.	Follicular lymphoma|GARD:0002356|RITUXIMAB|RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE|GARD:0002356	Follicular lymphoma|GARD:0002356|DARATUMUMAB|GARD:0002356	Follicular lymphoma|GARD:0002356|IBRUTINIB|GARD:0002356	axicabtagene ciloleucel	Yescarta	42485	Treatment of follicular lymphoma.	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma"	Ê10/18/2017Ê	Ê10/18/2024	"Kite Pharma, Inc."	2225 Colorado Avenue		Santa Monica	California	90404	USA	515615
3301	Follicular lymphoma	2356			1759	of follicular lymphoma	C0024301	"Lymphoma, Follicular"	neop	Treatment of follicular lymphoma	Follicular lymphoma|GARD:0002356|RITUXIMAB|RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE|GARD:0002356	Follicular lymphoma|GARD:0002356|DARATUMUMAB|GARD:0002356	Follicular lymphoma|GARD:0002356|IBRUTINIB|GARD:0002356	obinutuzumab	Gazyva	42109	Treatment of follicular lymphoma	Designated/Approved	Approved for Orphan Indication	"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen; and in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma"	Ê11/16/2017Ê	Ê11/16/2024	"Genentech Inc., a member of the Roche Group"	1 DNA Way		South San Francisco	California	94080	USA	473415
3301	Follicular lymphoma	2356			1759	of follicular lymphoma	C0024301	"Lymphoma, Follicular"	neop	Treatment of follicular lymphoma	Follicular lymphoma|GARD:0002356|RITUXIMAB|RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE|GARD:0002356	Follicular lymphoma|GARD:0002356|DARATUMUMAB|GARD:0002356	Follicular lymphoma|GARD:0002356|IBRUTINIB|GARD:0002356	obinutuzumab	Gazyva	42109	Treatment of follicular lymphoma	Designated/Approved	Approved for Orphan Indication	"GAZYVA, in combination with bendamustine followed by GAZYVA monotherapy, is indicated for the treatment of patients with follicular lymphoma (FL) who relapsed after, or are refractory to, a rituximab-containing regimen"	Ê02/26/2016Ê	Ê02/26/2023	"Genentech Inc., a member of the Roche Group"	1 DNA Way		South San Francisco	California	94080	USA	473415
3303	Follicular lymphoma	2356			1848	of follicular lymphoma	C0024301	"Lymphoma, Follicular"	neop	Treatment of follicular lymphoma	Follicular lymphoma|GARD:0002356|RITUXIMAB|RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE|GARD:0002356	Follicular lymphoma|GARD:0002356|DARATUMUMAB|GARD:0002356	Follicular lymphoma|GARD:0002356|IBRUTINIB|GARD:0002356	copanlisib	Aliqopa	42040	Treatment of follicular lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies	Ê09/14/2017Ê	Ê09/14/2024	Bayer US LLC	100 Bayer Boulevard	P. O. Box 915	Hanover	New Jersey	7981	USA	463314
3304	Follicular lymphoma	2356			2279	of follicular lymphoma	C0024301	"Lymphoma, Follicular"	neop	Treatment of follicular lymphoma	Follicular lymphoma|GARD:0002356|RITUXIMAB|RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE|GARD:0002356	Follicular lymphoma|GARD:0002356|DARATUMUMAB|GARD:0002356	Follicular lymphoma|GARD:0002356|IBRUTINIB|GARD:0002356	idelalisib	Zydelig	41543	Treatment of follicular lymphoma	Designated/Approved	Approved for Orphan Indication	Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies.	Ê07/23/2014Ê	Ê07/23/2021	"Gilead Sciences, Inc."	199 E. Blaine St		Seattle	Washington	98102	USA	405813
3299	Follicular lymphoma	2356			2285	of follicular lymphoma	C0024301	"Lymphoma, Follicular"	neop	Treatment of follicular lymphoma	Follicular lymphoma|GARD:0002356|RITUXIMAB|RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE|GARD:0002356	Follicular lymphoma|GARD:0002356|DARATUMUMAB|GARD:0002356	Follicular lymphoma|GARD:0002356|IBRUTINIB|GARD:0002356	lenalidomide	Revlimid	41534	Treatment of follicular lymphoma	Designated/Approved	Approved for Orphan Indication	"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated follicular lymphoma (FL)."	Ê05/28/2019Ê	Ê05/28/2026	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA	390813
3290	Follicular lymphoma	2356			2334	of follicular lymphoma	C0024301	"Lymphoma, Follicular"	neop	Treatment of follicular lymphoma	Follicular lymphoma|GARD:0002356|RITUXIMAB|RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE|GARD:0002356	Follicular lymphoma|GARD:0002356|DARATUMUMAB|GARD:0002356	Follicular lymphoma|GARD:0002356|IBRUTINIB|GARD:0002356	duvelisib	Copiktra	41487	Treatment of follicular lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with relapsed or refractory follicular lymphoma after at least two prior therapies	Ê09/24/2018Ê	Ê09/24/2025	"Verastem, Inc."	117 Kendrick Street	Suite 500	Needham	Massachusetts	2494	USA	399913
1152	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.		MISSING	Not a disease	5211	in detoxified formerly opioid-dependent individuals.	C1415386	HIST1H1C gene	gngm	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	NALTREXONE HYDROCHLORIDE|NALTREXONE HCL|TREXAN			Naltrexone HCl	Trexan	31117	For blockade of the pharmacological effects of exogenously administered opioids as an adjunct to the maintenance of the opioid-free state in detoxified formerly opioid-dependent individuals.	Designated/Approved	Approved for Orphan Indication		Ê11/30/1984Ê	Ê11/30/1991	DuPont Pharmaceuticals	E.I. Du Pont De Nemours & Co.		Wilmington	Delaware	19898	USA	6085
2025	"For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age"		MISSING		5244	due to systemic disease	C0442893	Systemic disease	dsyn	"For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age"	CHENODIOL|CHENIX			chenodiol	Chenix	30946	"For patients with radiolucent stones in well opacifying gallbladders, in whom elective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age"	Designated/Approved	Approved for Orphan Indication		Ê07/28/1983Ê	Ê07/28/1990	Solvay	901 Sawyer Road		Marietta	Georgia	30062	USA	3384
271	"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable."		MISSING		4670	to	C0041260	Tryptophanase	aapp	"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable."	APROTININ|TRASYLOL			Aprotinin	Trasylol	34290	"For prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable."	Designated/Approved	Approved for Orphan Indication		Ê12/29/1993Ê	Ê12/29/2000	Bayer Corporation	Pharmaceutical Division	400 Morgan Lane	West Haven	Connecticut	6516	USA	66992
1761	For the intravenous treatment of moderate to severe acetaminophen overdose		MISSING	Not a disease	4141					For the intravenous treatment of moderate to severe acetaminophen overdose	ACETYLCYSTEINE|MUCOMYST/MUCOMYST 10 IV	ACETYLCYSTEINE|ACETADOTE		acetylcysteine	Acetadote	37183	For the intravenous treatment of moderate to severe acetaminophen overdose	Designated/Approved	Approved for Orphan Indication	"For the use of Acetadote(registered TM) Injection, administered intravenously within 8 to 10 hours after ingestion of a potentially heptotoxic quantity of acetaminophen, to prevent or lessen hepatic injur"	Ê01/23/2004Ê	Ê01/23/2011	"Cumberland Pharmaceuticals, Inc."	209 10th Street South	Suite 332	Nashville	Tennessee	37203	USA	148401
2689	For use as a replacement solution in patients undergoing continuous renal replacement therapy		MISSING	Not a disease	2157					For use as a replacement solution in patients undergoing continuous renal replacement therapy	BIOCARBONATE INFUSATE|BICARBONATE INFUSATE|NORMOCARB HF	"PHOXILIUM|CALCIUM CHLORIDE|MAGNESIUM CHLORIDE|SODIUM CHLORIDE|POTASSIUM CHLORIDE|SODIUM BICARBONATE|DEXTROSE, UNSPECIFIED FORM|LACTIC ACID, DL-|SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM"		phoxilium	n/a	41684	For use as a replacement solution in patients undergoing continuous renal replacement therapy	Designated/Approved	Approved for Orphan Indication	As a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialzable substances	Ê01/13/2015Ê	Ê01/13/2022	"Gambro Renal Products, Inc."	1845 Mason Avenue		Daytona Beach	Florida	32117	USA	382012
1312	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine		MISSING	Not a disease	3836	as a thyroid blocking agent	C0279175	Thyroid preparations	aapp	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine	POTASSIUM IODIDE|POTASSIUM IODIDE ORAL SOLUTION|THYROSHIELD			Potassium Iodide Oral Solution	Thyroshield	38308	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine	Designated/Approved	Approved for Orphan Indication	For use as a thyroid blocking agent in pediatric patients exposed to radiactive iodine	Ê01/12/2005Ê	ÊN/A	"Fleming & Company, Pharmaceuticals"	1733 Gilsinn Lane		Fenton	Missouri	63026	USA	190304
691	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.		MISSING	Not a disease	4562					For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED|FILGRASTIM|NEUPOGEN"			Filgrastim	Neupogen	34897	For use in the mobilization of peripheral blood progenitor cells for collection in patients who will receive myeloablative or myelosuppressive chemotherapy.	Designated/Approved	Approved for Orphan Indication	For use in the mobilization of hematopoietic progenitor cells into the peripheral blood collection by leukapheresis.	Ê12/28/1995Ê	Ê12/28/2002	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA	89395
5512	Gastrointestinal Stromal Tumors	8598			1530	of gastrointestinal stromal tumors	C0238198	Gastrointestinal Stromal Tumors	neop	Treatment of gastrointestinal stromal tumors	Gastrointestinal Stromal Tumors|GARD:0008598|MASITINIB|GARD:0008598	Gastrointestinal Stromal Tumors|GARD:0008598|RETASPIMYCIN|GARD:0008598	Gastrointestinal Stromal Tumors|GARD:0008598|PONATINIB|ICLUSIG(R)|GARD:0008598	avapritinib	Ayvakit	42375	Treatment of gastrointestinal stromal tumors	Designated/Approved	Approved for Orphan Indication	"AYVAKIT is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations"	Ê01/09/2020Ê	ÊTBD	Blueprint Medicines Corporation	45 Sidney Street	Suite 200	Cambridge	Massachusetts	2139	USA	500415
5510	Gastrointestinal Stromal Tumors	8598			2867	Treatment gastrointestinal stromal tumors	C0238198	Gastrointestinal Stromal Tumors	neop	Treatment gastrointestinal stromal tumors	Gastrointestinal Stromal Tumors|GARD:0008598|MASITINIB|GARD:0008598	Gastrointestinal Stromal Tumors|GARD:0008598|RETASPIMYCIN|GARD:0008598	Gastrointestinal Stromal Tumors|GARD:0008598|PONATINIB|ICLUSIG(R)|GARD:0008598	regorafenib	Stivarga	40555	Treatment gastrointestinal stromal tumors	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate."	Ê02/25/2013Ê	Ê02/25/2020	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd	P. O. Box 915	Whippany	New Jersey	7981	USA	329410
5513	Gastrointestinal Stromal Tumors	8598			4137	of gastrointestinal stromal tumors	C0238198	Gastrointestinal Stromal Tumors	neop	Treatment of gastrointestinal stromal tumors	Gastrointestinal Stromal Tumors|GARD:0008598|MASITINIB|GARD:0008598	Gastrointestinal Stromal Tumors|GARD:0008598|RETASPIMYCIN|GARD:0008598	Gastrointestinal Stromal Tumors|GARD:0008598|PONATINIB|ICLUSIG(R)|GARD:0008598	imatinib mesylate	Gleevec	37196	Treatment of gastrointestinal stromal tumors	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST)	Ê02/01/2002Ê	Ê02/01/2009	Novartis Pharmaceuticals Corp.	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA	149201
5513	Gastrointestinal Stromal Tumors	8598			4137	of gastrointestinal stromal tumors	C0238198	Gastrointestinal Stromal Tumors	neop	Treatment of gastrointestinal stromal tumors	Gastrointestinal Stromal Tumors|GARD:0008598|MASITINIB|GARD:0008598	Gastrointestinal Stromal Tumors|GARD:0008598|RETASPIMYCIN|GARD:0008598	Gastrointestinal Stromal Tumors|GARD:0008598|PONATINIB|ICLUSIG(R)|GARD:0008598	imatinib mesylate	Gleevec	37196	Treatment of gastrointestinal stromal tumors	Designated/Approved	Approved for Orphan Indication	Adjuvant treatment of adult patients following complete resection Kit (CD 117) positive gastrointestinal stromal tumors (GIST).	Ê12/19/2008Ê	Ê12/19/2015	Novartis Pharmaceuticals Corp.	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA	149201
200	Gaucher disease	8233	done		5209	with Gaucher's disease type I.	C1961835	"Gaucher Disease, Type 1"	dsyn	For replacement therapy in patients with Gaucher's disease type I.	Gaucher disease type 1 |GARD:0002441|IMIGLUCERASE|CEREZYME|GARD:0002441	 Gaucher disease type 2 |GARD:0002442|IMIGLUCERASE|CEREZYME|GARD:0002442	 Gaucher disease type 3|GARD:0002443|IMIGLUCERASE|CEREZYME|GARD:0002443	Alglucerase injection	Ceredase	31117	For replacement therapy in patients with Gaucher's disease type I.	Designated/Approved	Approved for Orphan Indication	"Long-term enzyme replacement therapy for children, adolescents and adult patients with a confirmed diagnosis of Type I Gaucher disease who exhibit signs and symptoms that are severe enough to result in one or more of the following conditions: a) moderate-to-severe anemia; b) thrombocytopenia with bleeding tendency; c) bone disease; d) significant hepatomegaly or splenomegaly."	Ê04/05/1991Ê	Ê04/05/1998	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA	5585
858	Gaucher disease	8233	done		4794	III Gaucher's disease.	C0017205	Gaucher Disease	dsyn	"Replacement therapy in patients with types I, II, and III Gaucher's disease."	Gaucher disease type 1 |GARD:0002441|IMIGLUCERASE|CEREZYME|GARD:0002441	 Gaucher disease type 2 |GARD:0002442|IMIGLUCERASE|CEREZYME|GARD:0002442	 Gaucher disease type 3|GARD:0002443|IMIGLUCERASE|CEREZYME|GARD:0002443	Imiglucerase	Cerezyme	33547	"Replacement therapy in patients with types I, II, and III Gaucher's disease."	Designated/Approved	Approved for Orphan Indication	Enzyme replacement therapy in patients with type I Gaucher's disease.	Ê05/23/1994Ê	Ê05/23/2001	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA	62491
5487	Gaucher disease	8233			3169	of Gaucher disease	C0017205	Gaucher Disease	dsyn	Treatment of Gaucher disease	Gaucher disease|GARD:0008233|AMBROXOL|GARD:0008233	Gaucher disease|GARD:0008233|ISOFAGOMINE TARTRATE|GARD:0008233	Gaucher disease|GARD:0008233|MODIFIED CHOLERA TOXIN|GARD:0008233	velaglucerase-alfa	Vpriv	39972	Treatment of Gaucher disease	Designated/Approved	Approved for Orphan Indication	Treatment of Type I Gaucher Disease	Ê02/26/2010Ê	ÊN/A	"Shire Human Genetics Therapies, Inc."	700 Main Street		Cambridge	Massachusetts	2139	USA	283509
5489	Gaucher disease	8233			4397	of Gaucher disease.	C0017205	Gaucher Disease	dsyn	Treatment of Gaucher disease.	Gaucher disease|GARD:0008233|AMBROXOL|GARD:0008233	Gaucher disease|GARD:0008233|ISOFAGOMINE TARTRATE|GARD:0008233	Gaucher disease|GARD:0008233|MODIFIED CHOLERA TOXIN|GARD:0008233	miglustat	Zavesca	35944	Treatment of Gaucher disease.	Designated/Approved	Approved for Orphan Indication	"Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access)."	Ê07/31/2003Ê	Ê07/31/2010	IC-MedTech Corporation	9902 Indian Creek Lane		San Diego	California	92021	USA	112598
1589	Gaucher disease	8233	done		3127	of Gaucher's disease	C0017205	Gaucher Disease	dsyn	Treatment of Gaucher's disease	GAUCHER'S DISEASE|GAUCHER DISEASE|GAUCHER'S DISEASE TYPE I|DOID:1926|MESH:D005776	GAUCHER'S DISEASE|GAUCHER DISEASE|DOID:1926|MESH:D005776	Gaucher disease|GARD:0008233|LEVCYCLOSERINE|L-CYCLOSERINE|GARD:0008233	Taliglucerase alfa	Elelyso For Injection	40059	Treatment of Gaucher's disease	Designated/Approved	Approved for Orphan Indication	Use as long-term enzyme replacement therapy in patients with Type 1 Gaucher disease	Ê05/01/2012Ê	ÊN/A	"Pfizer, Inc."	235 East 42nd Street		New York	New York	10017	USA	191004
5491	Gaucher disease	8233			3293	of Type I Gaucher disease	C0017205	Gaucher Disease	dsyn	Treatment of Type I Gaucher disease	GAUCHER'S DISEASE|GAUCHER DISEASE|GAUCHER'S DISEASE TYPE I|DOID:1926|MESH:D005776	Gaucher disease|GARD:0008233|ELIGLUSTAT|CERDELGA|GARD:0008233	Gaucher disease|GARD:0008233|MIGLUSTAT|ZAVESCA|GARD:0008233	eliglustat	Cerdelga	39708	Treatment of Type I Gaucher disease	Designated/Approved	Approved for Orphan Indication	"Long-term treatment of adult patients with Gaucher disease type 1 who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test."	Ê08/19/2014Ê	Ê08/19/2021	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA	265408
5984	Giant cell tumor of bone	13046			2875	with giant cell tumor	C0017525	Giant Cell Tumors	neop	Treatment of patients with giant cell tumor of bone	Giant cell tumor of bone|GARD:0013046|DENOSUMAB|XGEVA|GARD:0013046	TENOSYNOVIAL GIANT CELL TUMOR|GIANT CELL TUMOR OF THE TENDON SHEATH (GCTTS)|TSGCT	OSTEOSARCOMA|OSTEOGENIC SARCOMA	denosumab	Xgeva	40532	Treatment of patients with giant cell tumor of bone	Designated/Approved	Approved for Orphan Indication	Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.	Ê06/13/2013Ê	Ê06/13/2020	"Amgen, Inc."	One Amgen Center Drive		Thousand Oaks	California	91320	USA	324110
3012	Giardiasis		MISSING		4101	of giardiasis	C0017536	Giardiasis	dsyn	Treatment of giardiasis	CESTODIASIS	ASCITES|ASCITES DUE TO VARIOUS CANCERS|MESH:D001201	TINIDAZOLE|TINDAMAX	tinidazole	Tindamax	37364	Treatment of giardiasis	Designated/Approved	Approved for Orphan Indication	Treatment of giardiasis caused by G. duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age	Ê05/17/2004Ê	Ê05/17/2011	"Presutti Laboratories, Inc."	1607 N. Douglas Avenue		Arlington Heights	Illinois	60004	USA	155402
2576	Giardiasis		MISSING		4111	of intestinal giardiasis	C0017536	Giardiasis	dsyn	Treatment of intestinal giardiasis	NITAZOXANIDE|ALINIA	TROPICAL SPRUE|HILL DIARRHEA|TROPICAL DIARRHEA	KERATOMALACIA	nitazoxanide	Alinia	37301	Treatment of intestinal giardiasis	Designated/Approved	Approved for Orphan Indication	Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia	Ê11/22/2002Ê	Ê11/22/2009	"Romark Laboratories, L.C."	6200 Courtney Campbell Causeway	Suite 880	Tampa	Florida	33607	USA	150401
2532	Glaucoma		MISSING		3414	of refractory glaucoma	C0017601	Glaucoma	dsyn	Treatment of refractory glaucoma as an adjunct to surgery	MITOMYCIN|MITOMYCIN-C	MITOMYCIN|MITOMYCIN-C|MITOSOL	STURGE WEBER SYNDROME|DIMITRI DISEASE|ENCEPHALOFACIAL ANGIOMATOSIS|ENCEPHALOTRIGEMINAL ANGIOMATOSIS|LEPTOMENINGEAL ANGIOMATOSIS|STURGE-KALISCHER-WEBER SYNDROME|STURGE-WEBER-KRABBE SYNDROME|STURGE-WEBER PHAKOMATOSIS|SWS	mitomycin-C	Mitosol	39455	Treatment of refractory glaucoma as an adjunct to surgery	Designated/Approved	Approved for Orphan Indication	An adjunct to ab externo glaucoma surgery.	Ê02/07/2012Ê	Ê02/07/2019	"Mobius Therapeutics, LLC"	1141 South 7th Street		St. Louis	Missouri	63104	USA	251407
4252	Glioma	6513			3633	of malignant glioma	C0555198	Malignant Glioma	neop	Treatment of malignant glioma	Glioma|GARD:0006513|BUTYLIDENEPHTHALIDE|GARD:0006513	REFRACTORY MALIGNANT GLIOMA|NCIT:C142855|NCI:C142855	Glioma|GARD:0006513|CHLOROTOXIN|GARD:0006513	bevacizumab	Avastin	38863	Treatment of malignant glioma	Designated/Approved	Approved for Orphan Indication	Treatment of glioblastoma with progressive disease following prior therapy	Ê05/05/2009Ê	Ê05/05/2016	"Genentech, Inc."	"1 DNA Way, MS 241B"		South San Francisco	California	94080	USA	222906
4300	Glioma	6513			4951	of malignant glioma.	C0555198	Malignant Glioma	neop	Treatment of malignant glioma.	Glioma|GARD:0006513|BUTYLIDENEPHTHALIDE|GARD:0006513	REFRACTORY MALIGNANT GLIOMA|NCIT:C142855|NCI:C142855	Glioma|GARD:0006513|CHLOROTOXIN|GARD:0006513	polifeprosan 20 with carmustine	Gliadel	32855	Treatment of malignant glioma.	Designated/Approved	Approved for Orphan Indication	As an adjunct to surgery to prolong survival in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated	Ê09/23/1996Ê	Ê09/23/2003	"Guilford Pharmaceuticals, Inc."	6611 Tributary Street		Baltimore	Maryland	21224	USA	37089
4300	Glioma	6513			4951	of malignant glioma.	C0555198	Malignant Glioma	neop	Treatment of malignant glioma.	Glioma|GARD:0006513|BUTYLIDENEPHTHALIDE|GARD:0006513	REFRACTORY MALIGNANT GLIOMA|NCIT:C142855|NCI:C142855	Glioma|GARD:0006513|CHLOROTOXIN|GARD:0006513	polifeprosan 20 with carmustine	Gliadel	32855	Treatment of malignant glioma.	Designated/Approved	Approved for Orphan Indication	Expanding the indication to include patients with malignant glioma undergoing primary surgical resection.	Ê02/25/2003Ê	Ê02/25/2010	"Guilford Pharmaceuticals, Inc."	6611 Tributary Street		Baltimore	Maryland	21224	USA	37089
4305	Glioma	6513			4376	of recurrent malignant glioma.	C0555198	Malignant Glioma	neop	Treatment of recurrent malignant glioma.	Glioma|GARD:0006513|PHENYL ACETATE|PHENYLACETATE|GARD:0006513	Glioma|GARD:0006513|SODIUM PHENYLBUTYRATE|GARD:0006513	Glioma|GARD:0006513|PHENYLACETATE|GARD:0006513	temozolomide	Temodar	36073	Treatment of recurrent malignant glioma.	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine"	Ê08/11/1999Ê	Ê08/11/2006	Schering-Plough Research Institute	2000 Galloping Hill Rd.		Kenilworth	New Jersey	7033	USA	116798
4305	Glioma	6513			4376	of recurrent malignant glioma.	C0555198	Malignant Glioma	neop	Treatment of recurrent malignant glioma.	Glioma|GARD:0006513|PHENYL ACETATE|PHENYLACETATE|GARD:0006513	Glioma|GARD:0006513|SODIUM PHENYLBUTYRATE|GARD:0006513	Glioma|GARD:0006513|PHENYLACETATE|GARD:0006513	temozolomide	Temodar	36073	Treatment of recurrent malignant glioma.	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with newly diagnosed glioblastoma multiforme concomitatly with radiotherapy and then as maintenance treatment	Ê03/15/2005Ê	Ê03/15/2012	Schering-Plough Research Institute	2000 Galloping Hill Rd.		Kenilworth	New Jersey	7033	USA	116798
4271	Glioma	6513			2458	for malignant glioma	C0555198	Malignant Glioma	neop	Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)				5-aminolevulinic acid	Gleolan	41289	Visualization of malignant tissue during surgery for malignant glioma (WHO grades III and IV)	Designated/Approved	Approved for Orphan Indication	Optical imaging agent indicated in patients with glioma (suspected World Health Organization Grades III or IV on preoperative imaging) as an adjunct for the visualization of malignant tissue during surgery	Ê06/06/2017Ê	Ê06/06/2024	NX Development Corporation	1827 South Bayshore Lane		Miami	Florida	33133	USA	387312
1387	Glycogen storage disease type 2	5714	done		4447	of glycogen storage disease type II.	C0017921	Glycogen storage disease type II	dsyn	Treatment of glycogen storage disease type II.	Glycogen storage disease type 2|GARD:0005714|CLENBUTEROL|GARD:0005714	Glycogen storage disease type 2|GARD:0005714|TRIHEPTANOIN|TRIHEPTANOIN-SASOL SPECIAL OIL|GARD:0005714	"Glycogen storage disease type 2|GARD:0005714|HUMAN ACID PRECURSOR ALPHA-GLUCOSIDASE, RECOMBINANT|ALGLUCOSIDASE ALFA|GARD:0005714"	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	35661	Treatment of glycogen storage disease type II.	Designated/Approved	Approved for Orphan Indication	"Myozyme for use in patients with Pompe disease (GAA deficiency). Alglucosidase alfa has been shown to improve ventilator-free survival in patients with infantile onset Pompe disease as compared to an untreated historical control, whereas use of Alphaglucosidase in patients with other forms of Pompe disease has not been adequately studied to assure safety and efficacy."	Ê04/28/2006Ê	Ê04/28/2013	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA	106597
1387	Glycogen storage disease type 2	5714	done		4447	of glycogen storage disease type II.	C0017921	Glycogen storage disease type II	dsyn	Treatment of glycogen storage disease type II.	Glycogen storage disease type 2|GARD:0005714|CLENBUTEROL|GARD:0005714	Glycogen storage disease type 2|GARD:0005714|TRIHEPTANOIN|TRIHEPTANOIN-SASOL SPECIAL OIL|GARD:0005714	"Glycogen storage disease type 2|GARD:0005714|HUMAN ACID PRECURSOR ALPHA-GLUCOSIDASE, RECOMBINANT|ALGLUCOSIDASE ALFA|GARD:0005714"	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	35661	Treatment of glycogen storage disease type II.	Designated/Approved	Approved for Orphan Indication	(Lumizyme) Patients with Pompe disease (acid alpha-glucosidase (GAA deficiency)).	Ê08/01/2014Ê	ÊN/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA	106597
1387	Glycogen storage disease type 2	5714	done		4447	of glycogen storage disease type II.	C0017921	Glycogen storage disease type II	dsyn	Treatment of glycogen storage disease type II.	Glycogen storage disease type 2|GARD:0005714|CLENBUTEROL|GARD:0005714	Glycogen storage disease type 2|GARD:0005714|TRIHEPTANOIN|TRIHEPTANOIN-SASOL SPECIAL OIL|GARD:0005714	"Glycogen storage disease type 2|GARD:0005714|HUMAN ACID PRECURSOR ALPHA-GLUCOSIDASE, RECOMBINANT|ALGLUCOSIDASE ALFA|GARD:0005714"	Recombinant human acid alpha-glucosidase; alglucosidase alfa	1. Myozyme 2. Lumizyme	35661	Treatment of glycogen storage disease type II.	Designated/Approved	Approved for Orphan Indication	"Lumizyme for patients 8 years and older with late (non-infantile) onset Pompe disease (GAA deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of Lumizyme (alglucosidase alfa) have not been evaluated in controlled clinical trials in infantile-onset patients, or in late (non-infantile) onset patients less than 8 years of age"	Ê05/24/2010Ê	ÊN/A	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA	106597
2810	Granulomatosis with polyangiitis 	7880	done		3673	with anti-neutrophil cytoplasmic antibody-associated vasculitis	C2717865	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	dsyn	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"				rituximab	Rituxan	38762	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	Designated/Approved	Approved for Orphan Indication	"RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegeners Granulomatosis) and Microscopic Polyangiitis (MPA)"	Ê09/27/2019Ê	Ê09/27/2026	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	216305
2810	Granulomatosis with polyangiitis 	7880	done		3673	with anti-neutrophil cytoplasmic antibody-associated vasculitis	C2717865	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis	dsyn	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"				rituximab	Rituxan	38762	"Treatment of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (Wegener's Granulomatosis, Microscopic Polyangiitis, and Churg-Strauss Syndrome)"	Designated/Approved	Approved for Orphan Indication	For the use of Rituxan (rituximab) in combination with glucocorticoids for the treatment of patients with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA). )	Ê04/19/2011Ê	Ê04/19/2018	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	216305
Missing	Graves disease	6549			2376	of active thyroid eye disease	C0339143	Thyroid associated opthalmopathies	dsyn	Treatment of active thyroid eye disease	MYOTONIC DYSTROPHY|CURSCHMANN-BATTEN-STEINERT SYNDROME|DM|DYSTROPHIA MYOTONIA|MYOTONIA ATROPHICA|STEINERT DISEASE|MYOTONIC MUSCULAR DYSTROPHY|PROXIMAL MYOTONIC MYOPATHY (PROMM)|RICKER SYNDROME	PRADER-WILLI SYNDROME|PRADER-LABHART-WILLI SYNDROME|PWS|WILLI-PRADER SYNDROME	MECP2 DUPLICATION SYNDROME|TRISOMY XQ28|XQ28 DUPLICATION SYNDROME	teprotumumab	n/a	41400	Treatment of active thyroid eye disease	Designated/Approved	Approved for Orphan Indication	TEPEZZA is indicated for the treatment of Thyroid Eye Disease.	Ê01/21/2020Ê	ÊTBD	"Horizon Pharma Ireland, Ltd."	c/o Horizon Pharma USA Inc.	150 South Saunders Road	Lake Forest	Illinois	60045	USA	387812
4364	Growth hormone deficiency	6552			3491	of growth hormone deficiency	C0271561	Somatotropin deficiency	dsyn	Diagnosis of growth hormone deficiency	Growth hormone deficiency|GARD:0006552|MACIMORELIN ACETATE|PEPTIDOMIMETIC ANALOG OF HEXARELIN|GARD:0006552	GROWTH HORMONE DEFICIENCY	LARON SYNDROME|GROWTH HORMONE INSENSITIVITY SYNDROME|PITUITARY DWARFISM II|GROWTH HORMONE RECEPTOR DEFICIENCY|PRIMARY GROWTH HORMONE RESISTANCE|PRIMARY GROWTH HORMONE INSENSITIVITY|LARON DWARFISM|LARON TYPE PITUITARY DWARFISM I|GARD:0006859|OMIM:262500|ORPHA:633|ORPHANET:633|UMLS:C0271568	macimorelin acetate	Macrelin	39216	Diagnosis of growth hormone deficiency	Designated/Approved	Approved for Orphan Indication	For the diagnosis of adult growth hormone deficiency	Ê12/20/2017Ê	Ê12/20/2024	Strongbridge Ireland Ltd	10 Earlsfort Terrace		Dublin			Ireland	225506
4359	Growth hormone deficiency	6552			5050	with growth failure.	C0015544	Failure to Thrive	dsyn	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Growth hormone deficiency|GARD:0006552|SOMATROPIN (RDNA ORIGIN)|SAIZEN|GARD:0006552	Growth hormone deficiency|GARD:0006552|SERMORELIN ACETATE|GEREF|GARD:0006552	GROWTH HORMONE DEFICIENCY	Sermorelin acetate	Geref	32400	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Designated/Approved	Approved for Orphan Indication		Ê09/26/1997Ê	Ê09/26/2004	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA	24687
4365	Growth hormone deficiency	6552			5140	with growth failure.	C0015544	Failure to Thrive	dsyn	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Growth hormone deficiency|GARD:0006552|SOMATROPIN (RDNA ORIGIN)|SAIZEN|GARD:0006552	Growth hormone deficiency|GARD:0006552|SERMORELIN ACETATE|GEREF|GARD:0006552	GROWTH HORMONE DEFICIENCY	Somatropin (rDNA origin)	Saizen	31842	Treatment of idiopathic or organic growth hormone deficiency in children with growth failure.	Designated/Approved	Approved for Orphan Indication	Long term treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.	Ê10/08/1996Ê	ÊN/A	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA	15486
4367	Growth hormone deficiency	6552			4492	for growth hormone deficiency	C0271561	Somatotropin deficiency	dsyn	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Growth hormone deficiency|GARD:0006552|SOMATROPIN FOR INJECTION|NUTROPIN|GARD:0006552			Somatropin for injection	Nutropin	35387	As replacement therapy for growth hormone deficiency in adults after epiphyseal closure.	Designated/Approved	Approved for Orphan Indication		Ê12/15/1997Ê	Ê12/15/2004	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	100396
4366	Growth hormone deficiency	6552			4619	with growth hormone deficiency.	C0271561	Somatotropin deficiency	dsyn	Treatment of adults with growth hormone deficiency.	Growth hormone deficiency|GARD:0006552|SOMATROPIN|GENOTROPIN|GARD:0006552	GROWTH HORMONE INSENSITIVITY|GHI|GH INSENSITIVITY|GROWTH HORMONE RESISTANCE|GROWTH HORMONE UNRESPONSIVENESS|LARON SYNDROME	"21-HYDROXYLASE DEFICIENCY|CONGENITAL ADRENAL HYPERPLASIA DUE TO 21-HYDROXYLASE DEFICIENCY|CYP21 DEFICIENCY|21 HYDROXYLASE DEFICIENCY|ADRENAL HYPERPLASIA, CONGENITAL, DUE TO 21-HYDROXYLASE DEFICIENCY|GARD:0005757|OMIM:201910"	Somatropin	Genotropin	34583	Treatment of adults with growth hormone deficiency.	Designated/Approved	Approved for Orphan Indication		Ê10/31/1997Ê	Ê10/31/2004	Pharmacia & Upjohn	7000 Portage Road		Kalamazoo	Michigan	49001	USA	83594
1520	Growth hormone deficiency	6552	approximate		5157	growth failure	C0015544	Failure to Thrive	dsyn	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Growth hormone deficiency|GARD:0006552|SOMATROPIN|SOMATROPIN FOR INJECTION|HUMATROPE|GARD:0006552			Somatropin for injection	Humatrope	31575	For the long-term treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.	Designated/Approved	Approved for Orphan Indication		Ê03/08/1987Ê	Ê03/08/1994	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA	11285
4524	Growth hormone deficiency	6552			4094	of growth hormone insensitivity syndrome	C0271568	Laron Syndrome	dsyn	Treatment of growth hormone insensitivity syndrome (GHIS)	Growth Hormone Insensitivity Syndrome|GARD:0006859|MECASERMIN RINFABATE|IPLEX|GARD:0006859	Growth Hormone Insensitivity Syndrome|GARD:0006859|MECASERMIN|INCRELEX|GARD:0006859	GROWTH HORMONE INSENSITIVITY|GHI|GH INSENSITIVITY|GROWTH HORMONE RESISTANCE|GROWTH HORMONE UNRESPONSIVENESS|LARON SYNDROME	mecasermin rinfabate	Iplex	37393	Treatment of growth hormone insensitivity syndrome (GHIS)	Designated/Approved	Approved for Orphan Indication	Treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone	Ê12/12/2005Ê	Ê12/12/2012	"Insmed, Inc."	10 Finderne Ave	Building 10	Bridgewater	New Jersey	8807	USA	156302
4523	Growth hormone deficiency	6552			4539	of growth hormone insensitivity syndrome.	C0271568	Laron Syndrome	dsyn	Treatment of growth hormone insensitivity syndrome.	Growth Hormone Insensitivity Syndrome|GARD:0006859|MECASERMIN|INCRELEX|GARD:0006859	Growth Hormone Insensitivity Syndrome|GARD:0006859|MECASERMIN RINFABATE|IPLEX|GARD:0006859	GROWTH HORMONE INSENSITIVITY|GHI|GH INSENSITIVITY|GROWTH HORMONE RESISTANCE|GROWTH HORMONE UNRESPONSIVENESS|LARON SYNDROME	Mecasermin	Increlex	35045	Treatment of growth hormone insensitivity syndrome.	Designated/Approved	Approved for Orphan Indication	Long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.	Ê08/30/2005Ê	Ê08/30/2012	"Ipsen Biopharmaceuticals, Inc."	106 Allen Road		Basking Ridge	New Jersey	7920	USA	93695
1512	Growth hormone deficiency	6552	approximate	Not a disease	5139	growth failure	C0015544	Failure to Thrive	dsyn	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	SOMATROPIN|NUTROPIN			Somatropin	Nutropin	31842	For use in the long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated/Approved	Approved for Orphan Indication		Ê10/17/1985Ê	Ê10/17/1992	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	12586
1516	Growth hormone deficiency	6552	approximate		4289	growth failure	C0015544	Failure to Thrive	dsyn	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	SOMATROPIN|SOMATROPIN (RDNA ORIGIN)|NUTROPIN DEPOT	Growth hormone deficiency|GARD:0006552|GROWTH HORMONE RELEASING HEXAPEPTIDE|HIS-D-TRP-ALA-TRP-D-PHE-LYS NH2|SKF-110679|GARD:0006552	Growth hormone deficiency|GARD:0006552|SOMATORELIN|GROWTH HORMONE RELEASING FACTOR|GARD:0006552	Somatropin (rDNA origin)	Nutropin Depot	36461	Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion.	Designated/Approved	Approved for Orphan Indication	Long-term treatment of growth failure due to a lack of adequate endogenous growth hormone secetion for once- or twice-a-month administration.	Ê12/22/1999Ê	ÊN/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	115098
2925	Growth hormone deficiency	6552	approximate	Not a disease	4205	of growth failure	C0015544	Failure to Thrive	dsyn	Treatment of growth failure in children who were born small for gestational age.	SOMATROPIN|SOMATROPIN [RDNA]|SOMATROPIN (RDNA)|GENOTROPIN	RUSSELL SILVER SYNDROME|RSS|RUSSELL-SILVER DWARFISM|RUSSELL SYNDROME|SILVER-RUSSELL DWARFISM|SILVER-RUSSELL SYNDROME|SILVER SYNDROME|SRS	GROWTH HORMONE DEFICIENCY	somatropin [rDNA]	Genotropin	36887	Treatment of growth failure in children who were born small for gestational age.	Designated/Approved	Approved for Orphan Indication	For long-term treatment of growth failure in children born small for gestational age who fail to manifest catch-up growth by two years of age.	Ê07/25/2001Ê	Ê07/25/2008	Pharmacia and Upjohn Company	7000 Portage Road		Kalamazoo	Michigan	49001	USA	135400
4378	Hairy cell leukemia	6560			3436	of hairy cell leukemia	C0023443	Hairy Cell Leukemia	neop	Treatment of hairy cell leukemia	"REFRACTORY HAIRY CELL LEUKEMIA|HAIRY CELL LEUKEMIA, REFRACTORY|UMLS:C0279780|DOID:711|NCIT:C8030|MONDO:0004110"	HAIRY CELL LEUKEMIA|DOID:285|MESH:D007943	"REFRACTORY HAIRY CELL LEUKEMIA|HAIRY CELL LEUKEMIA, REFRACTORY|CL512813|NCIT:C8030|NCI:C8030"	moxetumomab pasudotox-tdfk	Lumoxiti	39401	Treatment of hairy cell leukemia	Designated/Approved	Approved for Orphan Indication	"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA)."	Ê09/13/2018Ê	Ê09/13/2025	AstraZeneca Pharmaceuticals LP	One MedImmune Way		Gaithersburg	Maryland	20878	USA	248707
4380	Hairy cell leukemia	6560			4866	of hairy cell leukemia.	C0023443	Hairy Cell Leukemia	neop	Treatment of hairy cell leukemia.	"REFRACTORY HAIRY CELL LEUKEMIA|HAIRY CELL LEUKEMIA, REFRACTORY|UMLS:C0279780|DOID:711|NCIT:C8030|MONDO:0004110"	HAIRY CELL LEUKEMIA|DOID:285|MESH:D007943	"REFRACTORY HAIRY CELL LEUKEMIA|HAIRY CELL LEUKEMIA, REFRACTORY|CL512813|NCIT:C8030|NCI:C8030"	Cladribine	Leustatin Injection	33192	Treatment of hairy cell leukemia.	Designated/Approved	Approved for Orphan Indication		Ê02/26/1993Ê	Ê02/26/2000	R. W. Johnson Pharmaceutical Research Institute	"Route 202, P.O. Box 300"		Raritan	New Jersey	8869	USA	51690
4379	Hairy cell leukemia	6560			5115	of hairy cell leukemia	C0023443	Hairy Cell Leukemia	neop	Treatment of hairy cell leukemia	"REFRACTORY HAIRY CELL LEUKEMIA|HAIRY CELL LEUKEMIA, REFRACTORY|UMLS:C0279780|DOID:711|NCIT:C8030|MONDO:0004110"	HAIRY CELL LEUKEMIA|DOID:285|MESH:D007943	"REFRACTORY HAIRY CELL LEUKEMIA|HAIRY CELL LEUKEMIA, REFRACTORY|CL512813|NCIT:C8030|NCI:C8030"	pentostatin for injection	Nipent	32030	Treatment of hairy cell leukemia	Designated/Approved	Approved for Orphan Indication	Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.	Ê10/11/1991Ê	Ê10/11/1998	"SuperGen, Inc."	"Two Annabel Lane, Suite 220"		San Ramon	California	94583	USA	21287
491	Hansen's disease	6886	done		5248	"of lepromatous leprosy,"	C0023348	"Leprosy, Lepromatous"	dsyn	"Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum."	Hansen's disease|GARD:0006886|CLOFAZIMINE|LAMPRENE|GARD:0006886			Clofazimine	Lamprene	30844	"Treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum."	Designated/Approved	Approved for Orphan Indication		Ê12/15/1986Ê	Ê12/15/1993	Novartis Pharmaceutical Corporation	59 Route 10		East Hanover	New Jersey	7936	USA	2684
1620	Hansen's disease	6886	done		4559	of erythema nodosum leprosum.	C0343467	Erythema nodosum leprosum	dsyn	Treatment of erythema nodosum leprosum.	"LEPROMATOUS LEPROSY|LEPROSY, LEPROMATOUS|ERYTHEMA NODOSUM LEPROSUM|DOID:10887|MESH:D015440"	Hansen's disease|GARD:0006886|THALIDOMIDE|THALOMID|GARD:0006886	Hansen's disease|GARD:0006886|CLOFAZIMINE|LAMPRENE|GARD:0006886	Thalidomide	Thalomid	34906	Treatment of erythema nodosum leprosum.	Designated/Approved	Approved for Orphan Indication	Acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences.	Ê07/16/1998Ê	Ê07/16/2005	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA	90795
2981	Head and neck cancer	12425	done		1984	in sentinel lymph node detection	C0677944	Sentinel node (disorder)	dsyn	"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck"	Head and neck cancer|GARD:0012425|TECHNETIUM TC-99M TILMANOCEPT|TECHNETIUM TC 99M TILMANOCEPT|LYMPHOSEEK|GARD:0012425			technetium Tc 99m tilmanocept	Lymphoseek	41899	"Use in sentinel lymph node detection (SLN) with a hand-held gamma-counter, with scintigraphic imaging, in patients with cancer of the head and neck"	Designated/Approved	Approved for Orphan Indication	"Guiding sentinel lymph node biopsy, using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity."	Ê06/13/2014Ê	Ê06/13/2021	"Cardinal Health 414, LLC"	7000 Cardinal Place		Dublin	Ohio	43017	USA	427814
5591	Hemoglobinemia	8712			2471	acquired methemoglobinemia	C0271905	Acquired methemoglobinemia	dsyn	Treatment of hereditary and acquired methemoglobinemia	Hemoglobinemia|GARD:0008712|METHYLENE BLUE|METHYLENE BLUE0.5%|PROVAYBLUE|GARD:0008712			methylene blue0.5%	Provayblue	41261	Treatment of hereditary and acquired methemoglobinemia	Designated/Approved	Approved for Orphan Indication	For treatment of pediatric and adult patients with acquired methemoglobinemia.	Ê04/08/2016Ê	Ê04/08/2023	Provepharm SAS	Technopote de Chateau-Combert	13013 Marseille				France	385512
4389	Hemolytic uremic syndrome	6588			3197	of atypical hemolytic uremic syndrome	C2931788	Atypical Hemolytic Uremic Syndrome	dsyn	Treatment of atypical hemolytic uremic syndrome	Atypical hemolytic uremic syndrome|GARD:0008702|RAVULIZUMAB SUBCUTANEOUS|GARD:0008702	Atypical hemolytic uremic syndrome|GARD:0008702|CCX-168|ANTAGONIST OF THE COMPLEMENT 5A RECEPTOR|GARD:0008702	Atypical hemolytic uremic syndrome|GARD:0008702|RECOMBINANT HUMAN MINIBODY AGAINST COMPLEMENT COMPONENT|MUBODINA(R)|GARD:0008702	eculizumab	Soliris	39932	Treatment of atypical hemolytic uremic syndrome	Designated/Approved	Approved for Orphan Indication	For the treatment of atypical Hemolytic Uremic Syndrome (aHUS)	Ê09/23/2011Ê	Ê09/23/2018	"Alexion Pharmaceuticals, Inc."	121 Seaport Boulevard		Boston	Massachusetts	2210	USA	279509
4396	Hemophagocytic lymphohistiocytosis	6589			3036	of hemophagocytic lymphohistiocytosis	C0024291	"Lymphohistiocytosis, Hemophagocytic"	dsyn	Treatment of hemophagocytic lymphohistiocytosis	"FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS|FAMILIAL HISTIOCYTIC RETICULOSIS|HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|FHL|RETICULOSES, FAMILIAL HISTIOCYTIC|LYMPHOHISTIOCYTOSES, FAMILIAL ERYTHROPHAGOCYTIC|HISTIOCYTIC RETICULOSIS, FAMILIAL|HISTIOCYTIC RETICULOSES, FAMILIAL|ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSES, FAMILIAL|FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSES|LYMPHOHISTIOCYTOSIS, FAMILIAL ERYTHROPHAGOCYTIC|FAMILIAL HISTIOCYTIC RETICULOSES|FAMILIAL HEMOPHAGOCYTIC RETICULOSES|HEMOPHAGOCYTIC RETICULOSES, FAMILIAL|RETICULOSES, FAMILIAL HEMOPHAGOCYTIC|RETICULOSIS, FAMILIAL HEMOPHAGOCYTIC|HYMPHOHISTIOCYTOSES, PRIMARY HEMOPHAGOCYTIC|HEMOPHAGOCYTIC HISTIOCYTOSES, FAMILIAL|HISTIOCYTOSIS, FAMILIAL HEMOPHAGOCYTIC|HISTIOCYTOSES, FAMILIAL HEMOPHAGOCYTIC|HEMOPHAGOCYTIC HYMPHOHISTIOCYTOSES, PRIMARY|HEMOPHAGOCYTIC HISTIOCYTOSIS, FAMILIAL|PRIMARY HEMOPHAGOCYTIC HYMPHOHISTIOCYTOSES|HEMOPHAGOCYTIC HYMPHOHISTIOCYTOSIS, PRIMARY|FAMILIAL HEMOPHAGOCYTIC HISTIOCYTOSES|HYMPHOHISTIOCYTOSIS, PRIMARY HEMOPHAGOCYTIC|HEMOPHAGOCYTIC RETICULOSIS, FAMILIAL|ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL|PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, FAMILIAL|RETICULOSIS, FAMILIAL HISTIOCYTIC|FAMILIAL HEMOPHAGOCYTIC HISTIOCYTOSIS|FAMILIAL HEMOPHAGOCYTIC RETICULOSIS|PRIMARY HEMOPHAGOCYTIC HYMPHOHISTIOCYTOSIS|FAMILIAL HEMOPHAGOCYTIC LYMPHOCYTOSES|FAMILIAL HEMOPHAGOCYTIC LYMPHOCYTOSIS|FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES|HEMOPHAGOCYTIC LYMPHOCYTOSES, FAMILIAL|HEMOPHAGOCYTIC LYMPHOCYTOSIS, FAMILIAL|HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES, FAMILIAL|HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES, PRIMARY|HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS, PRIMARY|LYMPHOCYTOSES, FAMILIAL HEMOPHAGOCYTIC|LYMPHOCYTOSIS, FAMILIAL HEMOPHAGOCYTIC|LYMPHOHISTIOCYTOSES, FAMILIAL HEMOPHAGOCYTIC|LYMPHOHISTIOCYTOSES, PRIMARY HEMOPHAGOCYTIC|LYMPHOHISTIOCYTOSIS, FAMILIAL HEMOPHAGOCYTIC|LYMPHOHISTIOCYTOSIS, PRIMARY HEMOPHAGOCYTIC|PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSES|HPLH|FEL|FHLH|GENETIC HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|FEL - FAMILIAL ERYTHROPHAGOCYTIC LYMPHOHISTIOCYTOSIS|FHL - FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|GTRT000014293|UMLS:C0272199|MESH:D051359|NCI:C61276|OMIM:267700|SNOMEDCT_US:724641002|SNOMEDCT_US:398250003"	REFRACTORY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS|NCIT:C153297|NCI:C153297	Hemophagocytic lymphohistiocytosis|GARD:0006589|TADEKINIG ALFA|GARD:0006589	Emapalumab-lzsg	Gamifant	40263	Treatment of hemophagocytic lymphohistiocytosis	Designated/Approved	Approved for Orphan Indication	"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy."	Ê11/20/2018Ê	Ê11/20/2025	Swedish Orphan Biovitrum AB	SE-112	75 Stockholm	Stockholm			Sweden	302910
4405	Hemophilia A	6591			2405	in hemophilia A	C0019069	Hemophilia A	dsyn	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Hemophilia A|GARD:0006591|ANTI-INHIBITOR COAGULANT COMPLEX|FEIBA|GARD:0006591	Hemophilia|GARD:0010418|ANTI-INHIBITOR COAGULANT COMPLEX|FEIBA|GARD:0010418		anti-inhibitor coagulant complex	Feiba	41376	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in hemophilia A and B patients with inhibitors	Ê12/16/2013Ê	Ê12/16/2020	"Baxalta US, Inc."	One Baxter Way		West Lake Village	California	91362	USA	393913
4407	Hemophilia A	6591			4975	with hemophilia A.	C0019069	Hemophilia A	dsyn	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Hemophilia A|GARD:0006591|ANTIHEMOPHILIC FACTOR (RECOMBINANT)|KOGENATE|GARD:0006591	Hemophilia|GARD:0010418|ANTIHEMOPHILIC FACTOR (RECOMBINANT)|KOGENATE|GARD:0010418		Antihemophilic factor (recombinant)	Kogenate	32776	Prophylaxis and treatment of bleeding in individuals with hemophilia A or for prophylaxis when surgery is required in individuals with hemophilia A.	Designated/Approved	Approved for Orphan Indication	Treatment and prophylaxis of bleeding in patients with hemophilia A (not von Willebrand's disease)	Ê02/25/1993Ê	Ê02/25/2000	Bayer Corporation	1884 Miles Avenue		Elkhart	Indiana	46515	USA	39289
259	Hemophilia A	6591	done		4532	with hemophilia A	C0019069	Hemophilia A	dsyn	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	"Hemophilia A|GARD:0006591|ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT|ANTIHEMOPHILIC FACTOR (RECOMBINANT)|REFACTO, XYNTHA|GARD:0006591"	"Hemophilia A|GARD:0006591|ANTIHEMOPHILIC FACTOR (RECOMBINANT)|REFACTO, XYNTHA|GARD:0006591"	"Hemophilia|GARD:0010418|ANTIHEMOPHILIC FACTOR (RECOMBINANT)|REFACTO, XYNTHA|GARD:0010418"	Antihemophilic factor (recombinant)	"Refacto, Xyntha"	35103	For the control and prevention of hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia).	Designated/Approved	Approved for Orphan Indication		Ê03/06/2000Ê	ÊN/A	"Wyeth Pharmaceuticals, Inc."	P. O. Box 8299		Philadelphia	Pennsylvania	19101	USA	94495
4403	Hemophilia A	6591			5073	to Factor VIII	C0015506	Factor VIII	aapp	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Hemophilia A|GARD:0006591|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0006591	Hemophilia|GARD:0010418|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0010418	Hemophilia A|GARD:0006591|LONG ACTING RECOMBINANTFACTOR VIIA-CTP3|GARD:0006591	Coagulation factor VIIa (recombinant)	Novoseven	32300	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.	Ê03/25/1999Ê	Ê03/25/2006	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA	26588
508	Hemophilia A	6591	done		3906	with hemophilia A	C0019069	Hemophilia A	dsyn	"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors"	Hemophilia A|GARD:0006591|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0006591	Hemophilia|GARD:0010418|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0010418	Hemophilia B|GARD:0008732|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0008732	Coagulation factor VIIa (recombinant)	Novoseven	38156	"Prevention of bleeding episodes in patients with hemophilia A or B, with or without inhibitors"	Designated/Approved	Approved for Orphan Indication	Prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX	Ê08/12/2005Ê	Ê08/12/2012	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA	186104
4401	Hemophilia A	6591			2186	of hemophilia A	C0019069	Hemophilia A	dsyn	Treatment of hemophilia A	Hemophilia A|GARD:0006591|MAXADFVIII|GARD:0006591	Hemophilia|GARD:0010418|MAXADFVIII|GARD:0010418	HEMOPHILIA A (DISORDER)|HEMOPHILIA A|DOID:12134|MESH:D006467	emicizumab-kxwh	Hemlibra	41649	Treatment of hemophilia A	Designated/Approved	Approved for Orphan Indication	HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.	Ê10/04/2018Ê	Ê10/04/2025	Genentech	1 DNA Way	MS 355e	South San Francisco	California	94080	USA	416913
4401	Hemophilia A	6591			2186	of hemophilia A	C0019069	Hemophilia A	dsyn	Treatment of hemophilia A	Hemophilia A|GARD:0006591|MAXADFVIII|GARD:0006591	Hemophilia|GARD:0010418|MAXADFVIII|GARD:0010418	HEMOPHILIA A (DISORDER)|HEMOPHILIA A|DOID:12134|MESH:D006467	emicizumab-kxwh	Hemlibra	41649	Treatment of hemophilia A	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors	Ê11/16/2017Ê	Ê11/16/2024	Genentech	1 DNA Way	MS 355e	South San Francisco	California	94080	USA	416913
641	Hemophilia A	6591	done		2909	of hemophilia A	C0019069	Hemophilia A	dsyn	Treatment of hemophilia A	Hemophilia A|GARD:0006591|MAXADFVIII|GARD:0006591	Hemophilia|GARD:0010418|MAXADFVIII|GARD:0010418	HEMOPHILIA A (DISORDER)|HEMOPHILIA A|DOID:12134|MESH:D006467	"antihemophilic factor (recombinant), Fc fusion protein"	Eloctate	40505	Treatment of hemophilia A	Designated/Approved	Approved for Orphan Indication	"Indicated in adults and children with Hemophilia A (congenital Factor VIII deficiency) for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes."	Ê06/06/2014Ê	Ê06/06/2021	"Bioverativ Therapeutics, Inc."	225 2nd Avenue		Waltham	Massachusetts	2451	USA	321610
1462	Hemophilia A	6591	approximate		3939	of episodic bleeding	C3279402	Episodic bleeding	fndg	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	"Hemophilia A|GARD:0006591|SUSOCTOCOG ALFA|ANTIHEMOPHILIC FACTOR (RECOMBINANT), PORCINE SEQUENCE|OBIZUR|GARD:0006591"	HEMOPHILIA B|CHRISTMAS DISEASE|FACTOR IX DEFICIENCY|ROYAL DISEASE		"antihemophilic factor (recombinant), porcine sequence"	Obizur	38062	Treatment and prevention of episodic bleeding in patients with inhibitor antibodies to human coagulation factor VIII	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in adults with acquired hemophilia A.	Ê10/23/2014Ê	Ê10/23/2021	"Baxalta US, Inc."	1 Baxter Way	Mail Box Number 1A-3	Westlake Village	California	91362	USA	181403
4410	Hemophilia A	6591			4856	of mild hemophilia A	C0272324	Mild hereditary factor VIII deficiency disease	dsyn	Treatment of mild hemophilia A and von Willebrand's disease.	"Von Willebrand disease|GARD:0007867|ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN), DRIED, PASTEURIZED|HUMATE-P|GARD:0007867"	Hemophilia A|GARD:0006591|DESMOPRESSIN ACETATE|GARD:0006591	Hemophilia|GARD:0010418|DESMOPRESSIN ACETATE|GARD:0010418	Desmopressin acetate	n/a	33260	Treatment of mild hemophilia A and von Willebrand's disease.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with hemophilia A or von Willebrand's disease (type I) whose factor VIII coagulant activity level is greater than 5%.	Ê03/07/1994Ê	Ê03/07/2001	"Ferring Pharmaceuticals, Inc."	100 Interpace Parkway		Parsippany-Troy Hills	New Jersey	7054	USA	51490
503	Hemophilia A 	6591	approximate		3895	Factor IX	C0015491	factor IX	aapp	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	 Hemophilia B|GARD:0008732|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0008732	Hemophilia A |GARD:0006591|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN|GARD:0006591	HEMOPHILIA A|CLASSICAL HEMOPHILIA|FACTOR VIII DEFICIENCY|HAEMOPHILIA A	Coagulation Factor VIIa (Recombinant)	Novoseven	38184	Treatment of bleeding episodes in patients with acquired inhibitors to Factor VIII or Factor IX	Designated/Approved	Approved for Orphan Indication	Treatment of bleeding episodes in surgical interventions or invasive procedures in patients with acquired hemophilia	Ê10/13/2006Ê	Ê10/13/2013	"Novo Nordisk, Inc."	100 College Road West		Princeton	New Jersey	8540	USA	186204
1845	Hemophilia A 	6591	MISSING	Not a disease	1825	the anticoagulant effect	C0520996	Anticoagulant effect	ortf	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	ANDEXANET ALFA			"Coagulation factor Xa (recombinant), inactivated-zhzo"	Andexxa	42058	For reversing the anticoagulant effect of direct or indirect factor Xa inhibitors in patients experiencing a serious uncontrolled bleeding event or who require urgent or emergent surgery	Designated/Approved	Approved for Orphan Indication	"Coagulation factor Xa (recombinant), inactivated-zhzo is indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding"	Ê05/03/2018Ê	Ê05/03/2025	"Portola Pharmaceuticals, Inc."	270 East Grand Avenue		South San Francisco	California	94080	USA	437414
2356	Hemophilia A 	6591	MISSING	Not a disease	1714	the anticoagulant effect	C0520996	Anticoagulant effect	ortf	To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure	IDARUCIZUMAB			idarucizumab	n/a	42152	To reverse the anticoagulant effect of dabigatran due to uncontrolled life-threatening bleeding requiring urgent intervention or a need to undergo an emergency surgery/urgent invasive procedure	Designated/Approved	Approved for Orphan Indication	For use in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding	Ê10/16/2015Ê	Ê10/16/2022	"Boehringer Ingelheim Pharmaceuticals, Inc."	PO Box 368	900 Ridgebury Road	Ridgefield	Connecticut	6877	USA	445714
5597	Hemophilia B	8732			4613	of hemophilia B.	C0008533	Hemophilia B	dsyn	Treatment of hemophilia B.	HEMOPHILIA B|DOID:12259|MESH:D002836	Hemophilia B|GARD:0008732|BAX-499|INHIBITOR OF TISSUE FACTOR PATHWAY INHIBITOR (TFPI)|GARD:0008732	 Hemophilia B|GARD:0008732|MARSTACIMAB|HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST TISSUE FACTOR PATHWAY INHIBITOR|PF-06741086|GARD:0008732	Coagulation Factor IX (recombinant)	Benefix	34610	Treatment of hemophilia B.	Designated/Approved	Approved for Orphan Indication	"For the control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency and Christmas disease), including control and prevention of bleeding in surgical settings."	Ê02/11/1997Ê	Ê02/11/2004	"Genetics Institute, Inc."	87 Cambridge Park Drive		Cambridge	Massachusetts	2140	USA	82294
502	Hemophilia B	8732	done		4904	with hemophilia B	C0008533	Hemophilia B	dsyn	"For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis."	Hemophilia B|GARD:0008732|COAGULATION FACTOR IX (HUMAN)|ALPHANINE|GARD:0008732	Hemophilia B|GARD:0008732|COAGULATION FACTOR IX (HUMAN)|ALPHANINE|GARD:0008732	Hemophilia|GARD:0010418|COAGULATION FACTOR IX (HUMAN)|ALPHANINE|GARD:0010418	Coagulation Factor IX (human)	Alphanine	33059	"For use as replacement therapy in patients with hemophilia B for the prevention and control of bleeding episodes, and during surgery to correct defective hemostasis."	Designated/Approved	Approved for Orphan Indication		Ê12/31/1990Ê	Ê12/31/1997	Alpha Therapeutic Corporation	5555 Valley Boulevard		Los Angeles	California	90032	USA	45890
5601	Hemophilia B	8732			4996	of the hemorrhagic complications	C0940931	hemorrhage as a complication	dsyn	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Hemophilia B|GARD:0008732|COAGULATION FACTOR IX (HUMAN)|COAGULATION FACTOR IX|MONONINE|GARD:0008732	Hemophilia|GARD:0010418|COAGULATION FACTOR IX (HUMAN)|COAGULATION FACTOR IX|MONONINE|GARD:0010418		Coagulation factor IX	Mononine	32686	Replacement treatment and prophylaxis of the hemorrhagic complications of hemophilia B.	Designated/Approved	Approved for Orphan Indication	"Prevention and control of bleeding in factor IX deficiency, also known as hemophilia B or Christmas disease."	Ê08/20/1992Ê	Ê08/20/1999	Armour Pharmaceutical Company	"500 Arcola Road, P.O. Box 1200"		Collegeville	Pennsylvania	19426	USA	36189
5600	Hemophilia B	8732			2610	(hemophilia B	C0008533	Hemophilia B	dsyn	Treatment of patients with congenital factor IX deficiency (hemophilia B).	Hemophilia B|GARD:0008732|COAGULATION FACTOR IX (RECOMBINANT)|BENEFIX|GARD:0008732	Hemophilia|GARD:0010418|COAGULATION FACTOR IX (RECOMBINANT)|BENEFIX|GARD:0010418	Hemophilia B|GARD:0008732|IDELVION|RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR IX WITH ALBUMIN (RIX-FP)|GARD:0008732	recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP)	Idelvion	41026	Treatment of patients with congenital factor IX deficiency (hemophilia B).	Designated/Approved	Approved for Orphan Indication	"Indicated in children and adults with hemophilia B (congenital Factor IX deficiency) for the (1) on-demand control and prevention of bleeding episodes, (2) perioperative management of bleeding, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	Ê03/04/2016Ê	Ê03/04/2023	"CSL Behring, LLC"	1020 First Avenue	P.O. Box 61501	King of Prussia	Pennsylvania	19406	USA	366712
134	Hemophilia B	8732	done		3272	Christmas disease	C0008533	Hemophilia B	dsyn	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Hemophilia B|GARD:0008732|COAGULATION FACTOR IX (RECOMBINANT)|BENEFIX|GARD:0008732	Hemophilia|GARD:0010418|COAGULATION FACTOR IX (RECOMBINANT)|BENEFIX|GARD:0010418	"Hemophilia B|GARD:0008732|EFTRENONACOG ALFA|COAGULATION FACTOR IX (RECOMBINANT), FC FUSION PROTEIN|ALPROLIX|GARD:0008732"	"Coagulation factor IX (recombinant), Fc fusion protein"	Alprolix	39751	Control and prevention of hemorrhagic episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease)	Designated/Approved	Approved for Orphan Indication	"Adults and children with Hemophilia B for control and prevention of bleeding episodes, perioperative management, and routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	Ê03/28/2014Ê	Ê03/28/2021	"Bioverativ Therapeutics, Inc."	225 2nd Avenue		Waltham	Massachusetts	2451	USA	261508
5598	Hemophilia B	8732			2508	to	C0041260	Tryptophanase	aapp	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Hemophilia B|GARD:0008732|COAGULATION FACTOR IX (RECOMBINANT)|RIXUBIS|GARD:0008732	Hemophilia|GARD:0010418|COAGULATION FACTOR IX (RECOMBINANT)|RIXUBIS|GARD:0010418		coagulation factor IX (recombinant)	Rixubis	41213	Prophylactic use to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (routine prophylaxis in patients where there is no evidence or suspicion of bleeding)	Designated/Approved	Approved for Orphan Indication	"Adults with Hemophilia B for (1) control and prevention of bleeding episodes, (2) perioperative management, and (3) routine prophylaxis to prevent or reduce the frequency of bleeding episodes."	Ê06/26/2013Ê	Ê06/26/2020	"Baxalta US, Inc."	One Baxter Way		Westlake Village	California	91362	USA	377412
1064	Hemorrhagic cystitis		MISSING		5185	of ifosfamide-induced hemorrhagic cystitis.	C0085692	Hemorrhagic cystitis	dsyn	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	HEMORRHAGIC CYSTITIS|CYSTITIS|IFOSFAMIDE-INDUCED HEMORRHAGIC CYSTITIS|DOID:50859|MESH:D003556	MESNA|MESNEX		Mesna	Mesnex	31365	For use as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.	Designated/Approved	Approved for Orphan Indication		Ê12/30/1988Ê	Ê12/30/1995	Degussa Corporation	65 Challenger Road		Ridgefield Park	New Jersey	7660	USA	8685
978	Heparin-induced thrombocytopenia	2650	done		4476	of heparin-associated thrombocytopenia type II.	C0040034	Thrombocytopenia	fndg	Treatment of heparin-associated thrombocytopenia type II.	Heparin-induced thrombocytopenia|GARD:0002650|LEPIRUDIN|REFLUDEN|GARD:0002650	MUCOPOLYSACCHARIDOSES|MPS|MPS DISORDER	GAUCHER DISEASE|CEREBROSIDE LIPIDOSIS SYNDROME|GAUCHER SPLENOMEGALY|GLUCOCEREBROSIDASE DEFICIENCY|GLUCOCEREBROSIDOSIS|GLUCOSYLCERAMIDASE DEFICIENCY|GLUCOSYL CEREBROSIDE LIPIDOSIS|KERASIN LIPOIDOSIS|KERASIN THESAURISMOSIS|LIPID HISTIOCYTOSIS (KERASIN TYPE)|SPHINGOLIPIDOSIS 1	Lepirudin	Refluden	35474	Treatment of heparin-associated thrombocytopenia type II.	Designated/Approved	Approved for Orphan Indication	For anticoagulation in patients with heparin-induced thrombocytopenia and associated thromboembolic disease in order to prevent further thromboembolic complications.	Ê03/06/1998Ê	Ê03/06/2005	Hoechst Marion Roussel	Frankfurt am Main	P.O. Box 1140	Marburg			Germany	102796
5855	Hepatic encephalopathy	10452			4419	of hepatic encephalopathy	C0019151	Hepatic Encephalopathy	dsyn	Treatment of hepatic encephalopathy	HEPATIC ENCEPHALOPATHY|DOID:13413|MESH:D006501	Hepatic encephalopathy|GARD:0010452|SODIUM PHENYLACETATE|SODIUM PHENYLACETATE/SODIUM BENZOATE 10%/10% INJECTION|AMMONUL(R)|GARD:0010452	Hepatic encephalopathy|GARD:0010452|SODIUM ALUMINOSILICATE|GARD:0010452	rifaximin	Normix	35836	Treatment of hepatic encephalopathy	Designated/Approved	Approved for Orphan Indication	Reduction in the risk of overt hepatic encephalopathy (HE) recurrence in patients greater than or equal to 18 years of age	Ê03/24/2010Ê	Ê03/24/2017	"Salix Pharmaceuticals, Inc."	400 Somerset Corporate Blvd		Somerset	New Jersey	8807	USA	109497
5978	Hepatic veno-occlusive disease	13004			4018	of hepatic veno-occlusive disease	C0019156	Hepatic Veno-Occlusive Disease	dsyn	For the treatment of hepatic veno-occlusive disease	Hepatic veno-occlusive disease|GARD:0013004|DEFIBROTIDE|DEFITELIO|GARD:0013004	HEPATIC VENO-OCCLUSIVE DISEASE|MESH:D006504	HEPATIC VENOOCCLUSIVE DISEASE WITH IMMUNODEFICIENCY|VODI|HEPATIC VENO-OCCLUSIVE DISEASE WITH IMMUNODEFICIENCY|VENO-OCCLUSIVE DISEASE AND IMMUNODEFICIENCY SYNDROME|FAMILIAL VENO-OCCLUSIVE DISEASE WITH IMMUNODEFICIENCY|HEPATIC VENO-OCCLUSIVE DISEASE-IMMUNODEFICIENCY SYNDROME|VODI SYNDROME|GTRT000002320|UMLS:C1856128|MESH:C537257|OMIM:235550|OMIM:604457|ORPHANET:79124	defibrotide	Defitelio	37762	For the treatment of hepatic veno-occlusive disease	Designated/Approved	Approved for Orphan Indication	"For the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT)."	Ê03/30/2016Ê	Ê03/30/2023	"Jazz Pharmaceuticals, Inc."	3180 Porter Dr.		Palo Alto	California	94304	USA	168803
2305	Hepatitis B		MISSING	Not a rare disease	3377	of hepatitis B recurrence	C0019163	Hepatitis B	dsyn	Prevention of hepatitis B recurrence following orthotopic liver transplant	HEPATITIS B IMMUNE GLOBULIN (HUMAN)|HEPAGAM			hepatitis B immune globulin (human)	Hepagam	39531	Prevention of hepatitis B recurrence following orthotopic liver transplant	Designated/Approved	Approved for Orphan Indication	Prevention of hepatitis B recurrence following liver transplantation in HBsAG-positive liver transplant patients	Ê04/06/2007Ê	Ê04/06/2014	Cangene Corporation	155 Innovation Drive					Canada	228506
2413	"Hepatitis C, Chronic"		MISSING	Not a rare disease	1258	of chronic hepatitis C virus (HCV) infection	C0524910	"Hepatitis C, Chronic"	dsyn	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	LEDIPASVIR|LEDIPASVIR/SOFOSBUVIR|HARVONI	SOFOSBUVIR|LEDIPASVIR/SOFOSBUVIR|HARVONI	PARITAPREVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR/ PARITAPREVIR /RITONAVIR|TECHNIVIEÂ® TABLETS	ledipasvir/sofosbuvir	Harvoni	42655	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	Designated/Approved	Approved for Orphan Indication	"Treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis"	Ê04/07/2017Ê	Ê04/07/2024	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	535916
2413	"Hepatitis C, Chronic"		MISSING	Not a rare disease	1258	of chronic hepatitis C virus (HCV) infection	C0524910	"Hepatitis C, Chronic"	dsyn	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	LEDIPASVIR|LEDIPASVIR/SOFOSBUVIR|HARVONI	SOFOSBUVIR|LEDIPASVIR/SOFOSBUVIR|HARVONI	PARITAPREVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR/ PARITAPREVIR /RITONAVIR|TECHNIVIEÂ® TABLETS	ledipasvir/sofosbuvir	Harvoni	42655	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	Designated/Approved	Approved for Orphan Indication	"HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin, and genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin"	Ê08/28/2019Ê	Ê08/28/2026	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	535916
2413	"Hepatitis C, Chronic"		MISSING	Not a rare disease	1258	of chronic hepatitis C virus (HCV) infection	C0524910	"Hepatitis C, Chronic"	dsyn	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	LEDIPASVIR|LEDIPASVIR/SOFOSBUVIR|HARVONI	SOFOSBUVIR|LEDIPASVIR/SOFOSBUVIR|HARVONI	PARITAPREVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR/ PARITAPREVIR /RITONAVIR|TECHNIVIEÂ® TABLETS	ledipasvir/sofosbuvir	Harvoni	42655	Treatment of chronic hepatitis C virus (HCV) infection in pediatric patients	Designated/Approved	Approved for Orphan Indication	"HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin, and genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin"	Ê08/28/2019Ê	ÊN/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	535916
2276	"Hepatitis C, Chronic"		MISSING	Not a rare disease	1181	with chronic hepatitis C virus infection	C0524910	"Hepatitis C, Chronic"	dsyn	Treatment of pediatric patients with chronic hepatitis C virus infection	PARITAPREVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR/ PARITAPREVIR /RITONAVIR|TECHNIVIEÂ® TABLETS	OMBITASVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR /PARITAPREVIR/RITONAVIR|TECHNIVIEÂ® TABLETS	RITONAVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR/PARITAPREVIR/ RITONAVIR|TECHNIVIEÂ® TABLETS	glecaprevir and pibrentasvir	Mavyret	42744	Treatment of pediatric patients with chronic hepatitis C virus infection	Designated/Approved	Approved for Orphan Indication	"MAVYRET is indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult and pediatric patients 12 years and older or weighing at least 45 kg with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both."	Ê04/30/2019Ê	Ê04/30/2026	"AbbVie, Inc."	1 Waukegan Road		North Chicago	Illinois	60044	USA	550516
2793	"Hepatitis C, Chronic"		MISSING	Not a rare disease	4029	of chronic hepatitis C	C0524910	"Hepatitis C, Chronic"	dsyn	Treatment of chronic hepatitis C in pediatric patients	RIBAVIRIN|REBETOL	PARITAPREVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR/ PARITAPREVIR /RITONAVIR|TECHNIVIEÂ® TABLETS	OMBITASVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR /PARITAPREVIR/RITONAVIR|TECHNIVIEÂ® TABLETS	ribavirin	Rebetol	37715	Treatment of chronic hepatitis C in pediatric patients	Designated/Approved	Approved for Orphan Indication	Treatment of chronic hepatitis C among previously untreated pediatric patients at least three years of age or older.	Ê07/29/2003Ê	Ê07/29/2010	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA	162402
2918	"Hepatitis C, Chronic"		MISSING		1246	of pediatric chronic hepatitis C virus infection	C0524910	"Hepatitis C, Chronic"	dsyn	Treatment of pediatric chronic hepatitis C virus infection	SOFOSBUVIR|SOVALDI	PARITAPREVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR/ PARITAPREVIR /RITONAVIR|TECHNIVIEÂ® TABLETS	OMBITASVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR /PARITAPREVIR/RITONAVIR|TECHNIVIEÂ® TABLETS	sofosbuvir	Sovaldi	42668	Treatment of pediatric chronic hepatitis C virus infection	Designated/Approved	Approved for Orphan Indication	Treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 12 years of age and older or weighing at least 35 kg without cirrhosis or with compensated cirrhosis for use in combination with ribavirin	Ê04/07/2017Ê	Ê04/07/2024	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	541716
2918	"Hepatitis C, Chronic"		MISSING		1246	of pediatric chronic hepatitis C virus infection	C0524910	"Hepatitis C, Chronic"	dsyn	Treatment of pediatric chronic hepatitis C virus infection	SOFOSBUVIR|SOVALDI	PARITAPREVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR/ PARITAPREVIR /RITONAVIR|TECHNIVIEÂ® TABLETS	OMBITASVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR /PARITAPREVIR/RITONAVIR|TECHNIVIEÂ® TABLETS	sofosbuvir	Sovaldi	42668	Treatment of pediatric chronic hepatitis C virus infection	Designated/Approved	Approved for Orphan Indication	SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin	Ê08/28/2019Ê	Ê08/28/2026	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	541716
2918	"Hepatitis C, Chronic"		MISSING		1246	of pediatric chronic hepatitis C virus infection	C0524910	"Hepatitis C, Chronic"	dsyn	Treatment of pediatric chronic hepatitis C virus infection	SOFOSBUVIR|SOVALDI	PARITAPREVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR/ PARITAPREVIR /RITONAVIR|TECHNIVIEÂ® TABLETS	OMBITASVIR|OMBITASVIR/PARITAPREVIR/RITONAVIR|OMBITASVIR /PARITAPREVIR/RITONAVIR|TECHNIVIEÂ® TABLETS	sofosbuvir	Sovaldi	42668	Treatment of pediatric chronic hepatitis C virus infection	Designated/Approved	Approved for Orphan Indication	SOVALDI is indicated for the treatment of chronic HCV genotype 2 or 3 infection in pediatric patients 3 years of age and older without cirrhosis or with compensated cirrhosis for use in combination with ribavirin	Ê08/28/2019Ê	ÊN/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	541716
773	Hereditary angioedema	5979	done		4348	acquired C1-esterase inhibitor deficiency.	C0413236	Acquired C1 esterase inhibitor deficiency	dsyn	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	 Acquired angioedema|GARD:0008605|HUMAN C1-ESTERASE INHIBITOR|C1-ESTERASE INHIBITOR (RECOMBINANT)|RUCONEST|GARD:0008605	Hereditary angioedema |GARD:0005979|HUMAN C1-ESTERASE INHIBITOR|C1-ESTERASE INHIBITOR (RECOMBINANT)|RUCONEST|GARD:0005979		C1-esterase inhibitor (recombinant)	Ruconest	36214	Treatment of (acute attacks of) angioedema caused by hereditary or acquired C1-esterase inhibitor deficiency.	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema (HAE) in adult and adolescent patients.	Ê07/16/2014Ê	Ê07/16/2021	Pharming Group N.V.	P. O. Box 451 Darwinweg 24	2300 Al Leiden	Leiden			Netherlands	123599
3819	Hereditary angioedema	5979			2214	of angioedema	C0002994	Angioedema	patf	Treatment of angioedema	HEREDITARY ANGIOEDEMA|DOID:14735|MESH:D054179	Acquired angioedema|GARD:0008605|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0008605	Hereditary angioedema|GARD:0005979|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0005979	lanadelumab-flyo	Takhzyro	41604	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	Prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older	Ê08/23/2018Ê	Ê08/23/2025	Dyax Corporation	55 Network Drive		Burlington	Massachusetts	1803	USA	397213
380	Hereditary angioedema	5979	done		3893	of angioedema	C0002994	Angioedema	patf	Treatment of angioedema	HEREDITARY ANGIOEDEMA|DOID:14735|MESH:D054179	Acquired angioedema|GARD:0008605|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0008605	Hereditary angioedema|GARD:0005979|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0005979	C1 esterase inhibitor (human)	Cinryze(R)	38184	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	"CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adults, adolescents and pediatric patients (6 years old and above) with Hereditary Angioedema (HAE)."	Ê06/20/2018Ê	Ê06/20/2025	"ViroPharma Biologics, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA	185804
380	Hereditary angioedema	5979	done		3893	of angioedema	C0002994	Angioedema	patf	Treatment of angioedema	HEREDITARY ANGIOEDEMA|DOID:14735|MESH:D054179	Acquired angioedema|GARD:0008605|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0008605	Hereditary angioedema|GARD:0005979|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0005979	C1 esterase inhibitor (human)	Cinryze(R)	38184	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	Routine prophylaxis against angioedema attacks in patients with Hereditary Angioedema (HAE)	Ê10/10/2008Ê	Ê10/10/2015	"ViroPharma Biologics, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA	185804
2353	Hereditary angioedema	5979	done		3966	of angioedema	C0002994	Angioedema	patf	Treatment of angioedema	HEREDITARY ANGIOEDEMA|DOID:14735|MESH:D054179	Acquired angioedema|GARD:0008605|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0008605	Hereditary angioedema|GARD:0005979|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0005979	icatibant	Firazyr	37950	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema in adults 18 years of age and older	Ê08/25/2011Ê	Ê08/25/2018	Shire	300 Shire Way		Lexington	Massachusetts	2421	USA	176203
2168	Hereditary angioedema	5979	done		4041	of angioedema	C0002994	Angioedema	patf	Treatment of angioedema	HEREDITARY ANGIOEDEMA|DOID:14735|MESH:D054179	Acquired angioedema|GARD:0008605|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0008605	Hereditary angioedema|GARD:0005979|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0005979	ecallantide	Kalbitor	37656	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older	Ê03/28/2014Ê	Ê03/28/2021	"Dyax Corp. (an indirect, wholly-owned subsidiary of Shire plc.)"	650 East Kendall Street		Cambridge	Massachusetts	2142	USA	160802
2168	Hereditary angioedema	5979	done		4041	of angioedema	C0002994	Angioedema	patf	Treatment of angioedema	HEREDITARY ANGIOEDEMA|DOID:14735|MESH:D054179	Acquired angioedema|GARD:0008605|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0008605	Hereditary angioedema|GARD:0005979|C1 ESTERASE INHIBITOR (HUMAN)|CINRYZE(R)|GARD:0005979	ecallantide	Kalbitor	37656	Treatment of angioedema	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema in patients 16 years of age and older	Ê12/01/2009Ê	Ê12/01/2016	"Dyax Corp. (an indirect, wholly-owned subsidiary of Shire plc.)"	650 East Kendall Street		Cambridge	Massachusetts	2142	USA	160802
772	Hereditary angioedema	5979	done		4733	of hereditary angioedema.	C0019243	"Angioedemas, Hereditary"	dsyn	Prevention and/or treatment of acute attacks of hereditary angioedema.	"Hereditary angioedema|GARD:0005979|HUMAN C1-ESTERASE INHIBITOR|C1-ESTERASE-INHIBITOR, HUMAN, PASTEURIZED|BERINERT|GARD:0005979"	"Hereditary angioedema|GARD:0005979|HUMAN C1-ESTERASE INHIBITOR|C1-ESTERASE-INHIBITOR, HUMAN, PASTEURIZED|BERINERT|GARD:0005979"	"HEREDITARY ANGIOEDEMA|ANGIONEUROTIC EDEMA, HEREDITARY|C1-INH|C1NH|COMPLEMENT COMPONENT 1 INHIBITOR DEFICIENCY|COMPLEMENT COMPONENT C1, REGULATORY COMPONENT DEFICIENCY|ESTERASE INHIBITOR DEFICIENCY|HAE|HANE"	"C1-esterase-inhibitor, human, pasteurized"	Haegarda	33893	Prevention and/or treatment of acute attacks of hereditary angioedema.	Designated/Approved	Approved for Orphan Indication	Treatment of acute attacks of hereditary angioedema.	Ê10/08/2009Ê	Ê10/08/2016	CSL Behring LLC	1020 First Ave.	PO Box 61501	King of Prussia	Pennsylvania	19406	USA	67592
772	Hereditary angioedema	5979	done		4733	of hereditary angioedema.	C0019243	"Angioedemas, Hereditary"	dsyn	Prevention and/or treatment of acute attacks of hereditary angioedema.	"Hereditary angioedema|GARD:0005979|HUMAN C1-ESTERASE INHIBITOR|C1-ESTERASE-INHIBITOR, HUMAN, PASTEURIZED|BERINERT|GARD:0005979"	"Hereditary angioedema|GARD:0005979|HUMAN C1-ESTERASE INHIBITOR|C1-ESTERASE-INHIBITOR, HUMAN, PASTEURIZED|BERINERT|GARD:0005979"	"HEREDITARY ANGIOEDEMA|ANGIONEUROTIC EDEMA, HEREDITARY|C1-INH|C1NH|COMPLEMENT COMPONENT 1 INHIBITOR DEFICIENCY|COMPLEMENT COMPONENT C1, REGULATORY COMPONENT DEFICIENCY|ESTERASE INHIBITOR DEFICIENCY|HAE|HANE"	"C1-esterase-inhibitor, human, pasteurized"	Haegarda	33893	Prevention and/or treatment of acute attacks of hereditary angioedema.	Designated/Approved	Approved for Orphan Indication	For routine prophylaxis to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients.	Ê06/22/2017Ê	Ê06/22/2024	CSL Behring LLC	1020 First Ave.	PO Box 61501	King of Prussia	Pennsylvania	19406	USA	67592
285	Hereditary antithrombin deficiency	6148	done		3431	to	C0041260	Tryptophanase	aapp	"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures"	Antithrombin deficiency|GARD:0012690|ATRYN|RECOMBINANT HUMAN ANTITHROMBIN|GARD:0012690	Hereditary antithrombin deficiency|GARD:0006148|ANTITHROMBIN ALFA|RECOMBINANT HUMAN ANTITHROMBIN|ATRYN|GARD:0006148		recombinant human antithrombin	Atryn	39423	"Treatment of congenital antithrombin deficiency to prevent the occurrence of serious, potentially life-threatening venous thromboembolisms which may develop as a result of surgical or obstetrical procedures"	Designated/Approved	Approved for Orphan Indication	"Prevention of peri-operative and peri-partum thromboembolic events, in hereditary antithrombin deficient patients."	Ê02/06/2009Ê	Ê02/06/2016	"GTC Biotherapeutics, Inc."	175 Crossing Blvd		Framingham	Massachusetts	1702	USA	246807
264	Hereditary antithrombin deficiency	6148	done		5215	with hereditary antithrombin III deficiency	C2586031	Hereditary antithrombin III deficiency	dsyn	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Hereditary antithrombin deficiency|GARD:0006148|ANTITHROMBIN III HUMAN|ANTITHROMBIN III (HUMAN)|ATNATIV|GARD:0006148			Antithrombin III (human)	Atnativ	31086	For the treatment of patients with hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.	Designated/Approved	Approved for Orphan Indication		Ê12/13/1989Ê	Ê12/13/1996	Pharmacia & Upjohn AB	Lindhagensgatan 133	Stockholm				Sweden	5084
263	Hereditary antithrombin deficiency	6148	done		5228	pulmonary emboli.	C0034065	Pulmonary Embolism	dsyn	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Hereditary antithrombin deficiency|GARD:0006148|ANTITHROMBIN III HUMAN|ANTITHROMBIN III (HUMAN)|THROMBATE III|GARD:0006148			Antithrombin III (human)	Thrombate Iii	31012	For replacement therapy in congenital deficiency of AT-III for prevention and treatment of thrombosis and pulmonary emboli.	Designated/Approved	Approved for Orphan Indication		Ê12/30/1991Ê	Ê12/30/1998	Bayer Corporation	"Pharmaceutical Division, Biological Products"	400 Morgan Lane	New Haven	Connecticut	6516	USA	4084
1723	Herpes zoster oticus	7525	approximate		3569	from varicella	C0008049	Chickenpox	dsyn	"Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella"	Herpes zoster oticus|GARD:0007525|HUMAN VARICELLA-ZOSTER IMMUNE GLOBULIN|VARICELLA ZOSTER IMMUNE GLOBULIN (HUMAN)|VARIZIG|GARD:0007525			Varicella Zoster Immune Globulin (Human)	Varizig	39028	"Passive immunization for the treatment of exposed, susceptible individuals who are at risk of complications from varicella"	Designated/Approved	Approved for Orphan Indication	Post exposure prophylaxis of varicella in high risk individuals to reduce the severity of varicella	Ê12/20/2012Ê	Ê12/20/2019	"Cangene bioPharma, Inc."	155 Innovation Drive	Winnipeg	Manitoba R3T5Y3			Canada	228006
1769	Hidradenitis suppurativa	6658	done		1725	Hurley stage 3 disease	C0012634	Disease	dsyn	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)				adalimumab	Humira	42137	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	Designated/Approved	Approved for Orphan Indication	Treatment of moderate to severe hidradenitis suppurativa	Ê09/09/2015Ê	Ê09/09/2022	"AbbVie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA	446414
1769	Hidradenitis suppurativa	6658	done		1725	Hurley stage 3 disease	C0012634	Disease	dsyn	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)				adalimumab	Humira	42137	Treatment of moderate to severe hidradenitis suppurativa (Hurley stage 2 and Hurley stage 3 disease)	Designated/Approved	Approved for Orphan Indication	Treatment of moderate to severe hidradenitis suppurativa in patients 12 years of age and older.	Ê10/16/2018Ê	Ê10/16/2025	"AbbVie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA	446414
2492	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation		MISSING	Not a disease	3261					High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	MELPHALAN|EVOMELA			melphalan	Evomela	39776	High dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation	Designated/Approved	Approved for Orphan Indication	for high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation in patients with multiple myeloma	Ê03/10/2016Ê	Ê03/10/2023	Acrotech Biopharma LLC	279 Princeton Hightstown Road		East Windsor	New Jersey	8520	USA	270008
3385	Hodgkin lymphoma	2714			1536	of Hodgkin lymphoma.	C0019829	Hodgkin Disease	neop	Treatment of Hodgkin lymphoma.				pembrolizumab	Keytruda	42368	Treatment of Hodgkin lymphoma.	Designated/Approved	Approved for Orphan Indication	"Treatment for adult and pediatric patients with refractory classical Hodgkin Lymphoma (cHL), or who have relapsed after 3 or more prior lines of therapy."	Ê03/14/2017Ê	Ê03/14/2024	"Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc"	126 E. Lincoln Avenue	P. O. Box 2000	Rathway	Pennsylvania	7065	USA	502415
3383	Hodgkin lymphoma	2714			2024	of Hodgkin lymphoma	C0019829	Hodgkin Disease	neop	Treatment of Hodgkin lymphoma				nivolumab	Opdivo	41858	Treatment of Hodgkin lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with Classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin	Ê05/17/2016Ê	Ê05/17/2023	Bristol-Myers Squibb Company	Route 206 & Province Line Road	P. O. Box 4000	Princeton	New Jersey	8543	USA	442614
3383	Hodgkin lymphoma	2714			2024	of Hodgkin lymphoma	C0019829	Hodgkin Disease	neop	Treatment of Hodgkin lymphoma				nivolumab	Opdivo	41858	Treatment of Hodgkin lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin; or 3 or more lines of systemic therapy that includes autologous HSCT.	Ê04/25/2017Ê	Ê04/25/2024	Bristol-Myers Squibb Company	Route 206 & Province Line Road	P. O. Box 4000	Princeton	New Jersey	8543	USA	442614
1953	Hodgkin lymphoma	2714	done		3521	of Hodgkin's lymphoma	C0019829	Hodgkin Disease	neop	Treatment of Hodgkin's lymphoma				brentuximab vedotin	Adcetris	39112	Treatment of Hodgkin's lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with classical Hodgkin lymphoma at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.	Ê08/17/2015Ê	Ê08/17/2022	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA	235606
1953	Hodgkin lymphoma	2714	done		3521	of Hodgkin's lymphoma	C0019829	Hodgkin Disease	neop	Treatment of Hodgkin's lymphoma				brentuximab vedotin	Adcetris	39112	Treatment of Hodgkin's lymphoma	Designated/Approved	Approved for Orphan Indication	"ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with chemotherapy."	Ê03/20/2018Ê	Ê03/20/2025	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA	235606
1953	Hodgkin lymphoma	2714	done		3521	of Hodgkin's lymphoma	C0019829	Hodgkin Disease	neop	Treatment of Hodgkin's lymphoma				brentuximab vedotin	Adcetris	39112	Treatment of Hodgkin's lymphoma	Designated/Approved	Approved for Orphan Indication	The treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates	Ê08/19/2011Ê	Ê08/19/2018	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA	235606
2422	human cytomegalovirus viremia		MISSING		2677	disease	C0012634	Disease	dsyn	Prevention of human cytomegalovirus viremia and disease in at risk populations	LETERMOVIR	HUMAN HERPESVIRUS 5|CYTOMEGALOVIRUS DNA VACCINE WITH PLASMIDS EXPRESSING PP65 AND GB GENES	HUMAN HERPESVIRUS 5|CYTOMEGALOVIRUS DNA VACCINE W/COPOLYMER/BENZALKONIUM CHLORIDE	letermovir	Prevymis	40889	Prevention of human cytomegalovirus viremia and disease in at risk populations	Designated/Approved	Approved for Orphan Indication	Cytomegalovirus (CMV) infection	Ê11/08/2017Ê	Ê11/08/2024	Merck Sharpe & Dhome Corporation	"P. O. Box 1000, UG2D-68"		North Wales	Pennsylvania	19454	USA	340211
1748	Human immunodeficiency virus I infection		MISSING		5066	of AIDS.	C0001175	Acquired Immunodeficiency Syndrome	dsyn	Treatment of AIDS.	AIDS TREATMENT RESEARCH|NCIT:C19201|NCI:C19201|UMLS:C1515836	CYTOMEGALOVIRUS RETINITIS|CYTOMEGALOVIRUS (CMV) RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)|DOID:80160|MESH:D017726	TREAT AIDS-RELATED MALIGNANCIES|NCIT:C19089|NCI:C19089|UMLS:C1519635	Zalcitabine	Hivid	32322	Treatment of AIDS.	Designated/Approved	Approved for Orphan Indication	Combination therapy with zidovudine is indicated for the treatment of adult patients with advanced HIV infection (CD4 count < 300) who have demonstrated malignant clinical or immunologic deterioration.	Ê06/19/1992Ê	Ê06/19/1999	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA	28388
3108	Human immunodeficiency virus I infection		MISSING		5199	of AIDS	C0001175	Acquired Immunodeficiency Syndrome	dsyn	Treatment of AIDS	AIDS TREATMENT RESEARCH|NCIT:C19201|NCI:C19201|UMLS:C1515836	CYTOMEGALOVIRUS RETINITIS|CYTOMEGALOVIRUS (CMV) RETINITIS IN PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)|DOID:80160|MESH:D017726	TREAT AIDS-RELATED MALIGNANCIES|NCIT:C19089|NCI:C19089|UMLS:C1519635	zidovudine	Retrovir	31245	Treatment of AIDS	Designated/Approved	Approved for Orphan Indication	Management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocytis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/induccer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun	Ê03/19/1987Ê	Ê03/19/1994	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA	8185
2052	Human immunodeficiency virus I infection		MISSING		997	of human immunodeficiency virus type 1 (HIV-1) infection	C0276500	Human immunodeficiency virus I infection	dsyn	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients	Congenital human immunodeficiency virus|GARD:0010328|COBICISTAT|TYBOSTÂ®|GARD:0010328	BICTEGRAVIR|BICTEGRAVIR/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE	EMTRICITABINE|BICTEGRAVIR/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE	cobicistat	Tybost	42901	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients	Designated/Approved	Approved for Orphan Indication	TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg	Ê08/22/2019Ê	Ê08/22/2026	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	577917
2052	Human immunodeficiency virus I infection		MISSING		997	of human immunodeficiency virus type 1 (HIV-1) infection	C0276500	Human immunodeficiency virus I infection	dsyn	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients	Congenital human immunodeficiency virus|GARD:0010328|COBICISTAT|TYBOSTÂ®|GARD:0010328	BICTEGRAVIR|BICTEGRAVIR/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE	EMTRICITABINE|BICTEGRAVIR/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE	cobicistat	Tybost	42901	Treatment of human immunodeficiency virus type 1 (HIV-1) infection in pediatric patients	Designated/Approved	Approved for Orphan Indication	TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in pediatric patients weighing at least 35 kg coadminstered with atazanavir or weighing at least 40 kg coadministered with darunavir.	Ê10/03/2019Ê	ÊN/A	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	577917
609	Human immunodeficiency virus I infection		MISSING		4859	of AIDS.	C0001175	Acquired Immunodeficiency Syndrome	dsyn	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Congenital human immunodeficiency virus|GARD:0010328|DRONABINOL|MARINOL|GARD:0010328			Dronabinol	Marinol	33253	For the stimulation of appetite and prevention of weight loss in patients with a confirmed diagnosis of AIDS.	Designated/Approved	Approved for Orphan Indication	Treatment of anorexia associated with weight loss in patients with AIDS.	Ê12/22/1992Ê	Ê12/22/1999	"Unimed Pharmaceuticals, Inc."	901 Sawyer Rd.		Marietta	Georgia	30062	USA	54890
842	Human immunodeficiency virus I infection		MISSING		4713	with the human immunodeficiency virus.	C3854222	Human immunodeficiency virus (HIV) II infection category B1	dsyn	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	"Congenital human immunodeficiency virus|GARD:0010328|HUMAN IMMUNOGLOBULIN G|IMMUNE GLOBULIN INTRAVENOUS, HUMAN|IVIG|GAMIMUNE N|GARD:0010328"			"Immune globulin intravenous, human"	Gamimune N	34018	Infection prophylaxis in pediatric patients affected with the human immunodeficiency virus.	Designated/Approved	Approved for Orphan Indication	"For prophylaxis of children with clinical or immunologic evidence of human immunodeficiency virus to decrease the frequency of serious and minor bacterial infections and the frequency of hospitalization, and to increase the time free of serious bacterial infections."	Ê12/27/1993Ê	Ê12/27/2000	Bayer Corporation	"Pharmaceutical Division, Biological Products"	400 Morgan Lane	New Haven	Connecticut	6516	USA	70592
647	Human immunodeficiency virus I infection		MISSING	any immunodeficiency	4815	with HIV infection	C0019693	HIV Infections	dsyn	Treatment of anemia associated with HIV infection or HIV treatment.				Epoetin alfa	Epogen	33420	Treatment of anemia associated with HIV infection or HIV treatment.	Designated/Approved	Approved for Orphan Indication	Treatment of AZT-induced anemia in HIV infected patients.	Ê12/31/1990Ê	Ê12/31/1997	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA	56490
2348	Human immunodeficiency virus I infection		MISSING	Not a rare disease	1952	of HIV-1 infection	C0276500	Human immunodeficiency virus I infection	dsyn	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy				ibalizumab	Trogarzo	41932	Treatment of HIV-1 infection in treatment experienced adult patients with documented multi-antiretroviral class resistance and evidence of HIV-1 replication despite ongoing antiretroviral therapy	Designated/Approved	Approved for Orphan Indication	"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen."	Ê03/06/2018Ê	Ê03/06/2025	Theratechnologies Inc.	2015 Peel Street	5th Floor	Montreal	Quebec		Canada	321910
2193	Human immunodeficiency virus I infection		MISSING	Not a rare disease	1031	of HIV-1 infection	C0276500	Human immunodeficiency virus I infection	dsyn	Treatment of HIV-1 infection in pediatric patients under 12 years of age				emtricitabine and tenofovir alafenamide combination	Descovy(R)	42892	Treatment of HIV-1 infection in pediatric patients under 12 years of age	Designated/Approved	Approved for Orphan Indication	"DESCOVY, indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg and also indicated, in combination with other antiretroviral agents other than protease inhibitors that require a CYP3A inhibitor, for the treatment of HIV-1 infection in pediatric patients weighing at least 25 kg and less than 35 kg."	Ê09/28/2017Ê	ÊTBD	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	569716
1424	Human immunodeficiency virus I infection		MISSING		1175	of pediatric HIV-1 infection	C1319296	Pediatric human immunodeficiency virus infection	dsyn	Use with other antiretroviral agents for the treatment of pediatric HIV-1 infection				Ritonavir powder for oral suspension	Norvir Powder For Oral Suspension	42746	Use with other antiretroviral agents for the treatment of pediatric HIV-1 infection	Designated/Approved	Approved for Orphan Indication	Used in combination with other antiretroviral agents for the treatment of patients with HIV-1 infection	Ê06/07/2017Ê	Ê06/07/2024	AbbVie Inc.	Regulatory Affairs	1 Waukegan Road	North Chicago	Illinois	60044	USA	549816
2986	Human immunodeficiency virus I infection		MISSING		3223	of pediatric HIV infection.	C1319296	Pediatric human immunodeficiency virus infection	dsyn	Treatment of pediatric HIV infection.				tenofovir	Viread	39889	Treatment of pediatric HIV infection.	Designated/Approved	Approved for Orphan Indication	Treatment of HIV infection in combination with other antiretroviral agents in patients 12 to less than 18 years of age	Ê03/24/2010Ê	Ê03/24/2017	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster city	California	94404	USA	276209
1938	Human immunodeficiency virus I infection		MISSING		1051	of Human Immunodeficiency Virus type 1 infection	C0276500	Human immunodeficiency virus I infection	dsyn	Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients				bictegravir/emtricitabine/tenofovir disoproxil fumarate	Biktarvy	42872	Treatment of Human Immunodeficiency Virus type 1 infection in pediatric patients	Designated/Approved	Approved for Orphan Indication	BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 25 kg who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral with no history of treatment failure and no known substitutions associated with resistance to the individual components of BIKTARVY.	Ê06/18/2019Ê	Ê06/18/2026	"Gilead Sciences, Inc."	333 Lakeside Drive		Foster City	California	94404	USA	559316
2088	Huntington disease	6677	done		1938	of Huntington's Disease	C0020179	Huntington Disease	dsyn	Treatment of Huntington's Disease				"d6-tetrabenazine, deutetrabenazine"	Austedo	41948	Treatment of Huntington's Disease	Designated/Approved	Approved for Orphan Indication	Treatment of chorea associated with Huntingtons disease	Ê04/03/2017Ê	Ê04/03/2024	"Teva Branded Pharmaceutical Products R&D, Inc."	3333 N. Torrey Pines Court	Suite 400	La Jolla	California	92037	USA	383212
4474	Huntington disease	6677			4429	of Huntington's disease	C0020179	Huntington Disease	dsyn	Treatment of Huntington's disease				Tetrabenazine	Xenazine	35775	Treatment of Huntington's disease	Designated/Approved	Approved for Orphan Indication	Treatment of chorea associated with Huntington's disease	Ê08/15/2008Ê	Ê08/15/2015	"Prestwick Pharmaceuticals, Inc"	1825 K Street NW	Suite 1475	Washington	District of Columbia	20006	USA	108897
1980	Hyper-IgD syndrome	2788	done		2209	of hyperimmunoglobulinemia D	C0398691	Hyperimmunoglobulinemia D	dsyn	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Hyper-IgD syndrome|GARD:0002788|CANAKINUMAB|ILARIS|GARD:0002788			canakinumab	Ilaris	41613	Treatment of hyperimmunoglobulinemia D and periodic fever syndrome	Designated/Approved	Approved for Orphan Indication	Indicated for Hyperimmunoglobulin D Syndrome (HIDS)/Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients	Ê09/23/2016Ê	Ê09/23/2023	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	412913
2117	hypercalcemia in malignancy		MISSING		2296	in malignancy	C0006826	Malignant Neoplasms	neop	Treatment of hypercalcemia in malignancy	DENOSUMAB|XGEVA	CLODRONATE DISODIUM|DISODIUM CLODRONATE	"ZOLEDRONIC ACID ANHYDROUS|ZOLEDRONATE|ZOMETA, ZABEL"	denosumab	Xgeva	41528	Treatment of hypercalcemia in malignancy	Designated/Approved	Approved for Orphan Indication	To treat hypercalcemia of malignancy refractory to biphosphonate therapy.	Ê12/05/2014Ê	Ê12/05/2021	"Amgen, Inc."	One Amgen Center Drive	MS 17-2-C	Thousand Oaks	California	91320	USA	404213
667	hypercalcemia in malignancy		MISSING		5167	of malignancy	C0006826	Malignant Neoplasms	neop	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	ETIDRONATE DISODIUM|DIDRONEL			Etidronate disodium	Didronel	31492	Treatment of hypercalcemia of malignancy inadequately managed by dietary modification and/or oral hydration.	Designated/Approved	Approved for Orphan Indication		Ê04/21/1987Ê	Ê04/21/1994	"MGI Pharma, Inc."	5775 West Old Shakopee Rd.	Suite 100	Bloomington	Minnesota	55437	USA	12185
1751	hypercalcemia in malignancy		MISSING		4226	of tumor induced hypercalcemia.	C0027651	Neoplasms	neop	Treatment of tumor induced hypercalcemia.	"ZOLEDRONIC ACID ANHYDROUS|ZOLEDRONATE|ZOMETA, ZABEL"	FAMILIAL HYPOPHOSPHATEMIA|HEREDITARY TYPE I HYPOPHOSPHATEMIA (HPDR I)|HEREDITARY TYPE II HYPOPHOSPHATEMIA (HPDR II)|HYPOPHOSPHATEMIC D-RESISTANT RICKETS I|HYPOPHOSPHATEMIC D-RESISTANT RICKETS II|PHOSPHATE DIABETES|X-LINKED HYPOPHOSPHATEMIA (XLH)|X-LINKED VITAMIN D-RESISTANT RICKETS	MULTIPLE ENDOCRINE NEOPLASIA TYPE 2|MEN-2|MEN2 SYNDROME	Zoledronate	"Zometa, Zabel"	36756	Treatment of tumor induced hypercalcemia.	Designated/Approved	Approved for Orphan Indication	Treatment of hypercalcemia of malignancy.	Ê08/20/2001Ê	Ê08/20/2008	Novartis Pharmaceuticals Corp.	59 Route 10		East Hanover	New Jersey	7936	USA	130899
3391	Hypereosinophilic syndrome	2804			3742	of idiopathic hypereosinophilic syndrome	C0206141	Idiopathic Hypereosinophilic Syndrome	dsyn	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Hypereosinophilic syndrome|GARD:0002804|IMATINIB MESYLATE|GLEEVEC|GARD:0002804	EOSINOPHILIC FASCIITIS|DIFFUSE EOSINOPHILIC FASCIITIS|SHULMAN SYNDROME		Imatinib mesylate	Gleevec	38589	Treatment of idiopathic hypereosinophilic syndrome including acute and chronic eosinophilic leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with hypereosinophic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRØ}Ø± fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRØ}Ø± fusion kinase negative or unknown	Ê10/19/2006Ê	Ê10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA	209005
2645	Hyperparathyroidism		MISSING		1596	of pediatric hyperparathyroidism	C0020502	Hyperparathyroidism	dsyn	Treatment of pediatric hyperparathyroidism	ETELCALCETIDE	PARICALCITOL|ZEMPLAR	CINACALCET|SENSIPAR	paricalcitol	Zemplar	42304	Treatment of pediatric hyperparathyroidism	Designated/Approved	Approved for Orphan Indication	Indicated in adults and pediatric patients 10 years of age and older for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 and CKD Stage 5 in patients on hemodialysis or peritoneal dialysis	Ê10/18/2016Ê	Ê10/18/2023	"Abbvie, inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA	492815
444	Hyperphosphatemia (disorder)		MISSING		5025	of hyperphosphatemia	C0085681	Hyperphosphatemia (disorder)	dsyn	Treatment of hyperphosphatemia in end stage renal failure.	CALCIUM ACETATE|PHOS-LO	MEDULLARY SPONGE KIDNEY|CACCHI-RICCI DISEASE|CYSTIC DILATATION OF RENAL COLLECTING TUBES|PRECALYCEAL CANALICULAR ECTASIA|SPONGE KIDNEY|TUBULAR ECTASIA		Calcium acetate	Phos-Lo	32499	Treatment of hyperphosphatemia in end stage renal failure.	Designated/Approved	Approved for Orphan Indication		Ê12/10/1990Ê	Ê12/10/1997	Fresenius Medical Care North America	920 Winter Street		Waltham	Massachusetts	2451	USA	31588
2651	Hyperuricemia		MISSING	Not a disease	4196	of hyperuricemia	C0740394	Hyperuricemia	dsyn	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	PEGLOTICASE|KRYSTEXXA			pegloticase	Krystexxa	36943	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Designated/Approved	Approved for Orphan Indication	Treatment of chronic gout in adult patients refractory to conventional treatment	Ê09/14/2010Ê	Ê09/14/2017	"Horizon Pharma Rheumatology, LLC"	150 S. Saunders RoadDrive	Suite 400	Lake Forest	Illinois	60045	USA	135600
2744	Hyperuricemia		MISSING		4213	chemotherapy-induced hyperuricemia.	C0740394	Hyperuricemia	dsyn	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	RASBURICASE|ELITEK			rasburicase	Elitek	36810	Treatment of malignancy-associated or chemotherapy-induced hyperuricemia.	Designated/Approved	Approved for Orphan Indication	"Initial management of plasma uric acid levels in pediatric patients with leukemia,lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid."	Ê07/12/2002Ê	Ê07/12/2009	Sanofi-Synthelabo Research	9 Great Valley Parkway		Malvern	Pennsylvania	19355	USA	131499
1013	"Hypogonadism, isolated, hypogonadotropic"	2897	done		4612	due to hypogonadotropic hypogonadism.	C0022735	Klinefelter Syndrome	dsyn	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	"Hypogonadism, isolated, hypogonadotropic|GARD:0002897|LUTROPIN ALFA|RECOMBINANT HUMAN LUTEINIZING HORMONE|LUVERIS|GARD:0002897"			Recombinant human luteinizing hormone	Luveris	34614	For use in association with recombinant human follicle stimulating hormone for the treatment of women with chronic anovulation due to hypogonadotropic hypogonadism.	Designated/Approved	Approved for Orphan Indication	"Luveris (lutropin alfa for injection), concomitantly administered with Gonal-f (follitropin alfa for injection), is indicated for stimulation of follicular development in infertile hypogonadotropic hypogonadal women with profound LH deficiency (LH (less than) 1.2 IU/L)."	Ê10/08/2004Ê	Ê10/08/2011	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA	80292
707	"Hypogonadism, isolated, hypogonadotropic"	2897	approximate		4359	due to primary testicular failure.	C1384582	Primary testicular failure	dsyn	"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure."				"Follitropin alfa, recombinant"	Gonal-F	36150	"For the initiation and re-initiation of spermatogenesis in adult males with reproductive failure due to hypothalamic or pituitary dysfunction, hypogonadotropic hypogonadism. AMENDED indication 6/27/00: For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure."	Designated/Approved	Approved for Orphan Indication	For the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.	Ê05/24/2000Ê	Ê05/24/2007	"EMD Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA	119398
4486	Hypoparathyroidism	6733			3465	of hypoparathyroidism	C0020626	Hypoparathyroidism	dsyn	Treatment of hypoparathyroidism	HYPOPARATHYROIDISM|DOID:11199|MESH:D007011	IATROGENIC HYPOPARATHYROIDISM|CL514662|NCIT:C131856|NCI:C131856	Hypoparathyroidism|GARD:0006733|TERIPARATIDE|FORTEO|GARD:0006733	parathyroid hormone	Natpara	39325	Treatment of hypoparathyroidism	Designated/Approved	Approved for Orphan Indication	An adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism	Ê01/23/2015Ê	Ê01/23/2022	"Shire-NPS Pharmaceuticals, Inc."	300 Shire Way		Lexington	Massachusetts	2421	USA	246707
4483	Hypoparathyroidism	6733			5145	to	C0041260	Tryptophanase	aapp	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Pseudohypoparathyroidism|GARD:0007860|TERIPARATIDE|PARATHAR|GARD:0007860	Pseudohypoparathyroidism|GARD:0010758|TERIPARATIDE|PARATHAR|GARD:0010758	Hypoparathyroidism|GARD:0006733|TERIPARATIDE|PARATHAR|GARD:0006733	Teriparatide	Parathar	31786	Diagnostic agent to assist in establishing the diagnosis in patients presenting with clinical and laboratory evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism.	Designated/Approved	Approved for Orphan Indication		Ê12/23/1987Ê	Ê12/23/1994	"Rhone-Poulenc Rorer Pharmaceuticals, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA	14486
4489	Hypophosphatasia	6734			3298	of hypophosphatasia	C0020630	Hypophosphatasia	dsyn	Treatment of hypophosphatasia	HYPOPHOSPHATASIA|DOID:14213|MESH:D007014	Hypophosphatasia|GARD:0006734|RECOMBINANT HUMAN ALKALINE PHOSPHATASE|GARD:0006734	Hypophosphatasia|GARD:0006734|ASFOTASE ALFA|STRENSIQ|GARD:0006734	Asfotase alfa	Strensiq	39703	Treatment of hypophosphatasia	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with perinatal/infantile-and juvenile-onset hypophosphatasia (HPP)	Ê10/23/2015Ê	Ê10/23/2022	"Alexion Pharmaceuticals, Inc."	100 College St.		New Haven	Connecticut	6510	USA	266608
754	Hypothalamic dysfunction	2932	approximate		5135	with hypothalamic amenorrhea	C0341862	Hypothalamic amenorrhea	dsyn	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Hypothalamic dysfunction|GARD:0002932|GONADORELIN ACETATE|LUTREPULSE|GARD:0002932			Gonadorelin acetate	Lutrepulse	31889	For induction of ovulation in women with hypothalamic amenorrhea due to a deficiency or absence in the quantity or pulse pattern of endogenous GnRH secretion.	Designated/Approved	Approved for Orphan Indication		Ê10/10/1989Ê	Ê10/10/1996	"Ferring Laboratories, Inc."	"400 Rella Boulevard, Suite 201"		Suffern	New York	10901	USA	17086
5532	Idiopathic pulmonary fibrosis	8609			2027	of idiopathic pulmonary fibrosis	C0085786	Hamman-Rich syndrome	dsyn	Treatment of idiopathic pulmonary fibrosis	IDIOPATHIC PULMONARY FIBROSIS|DOID:50156|MESH:D054990	Idiopathic pulmonary fibrosis|GARD:0008609|TIPELUKAST|GARD:0008609	Idiopathic pulmonary fibrosis|GARD:0008609|CARLUMAB|GARD:0008609	pirfenidone	Esbriet	38051	Treatment of idiopathic pulmonary fibrosis	Designated/Approved	Approved for Orphan Indication	Treatment of idiopathic pulmonary fibrosis	Ê10/15/2014Ê	Ê10/15/2021	Genentech	1 DNA Way		South San Francisco	California	94080	USA	177903
5535	Idiopathic pulmonary fibrosis	8609			2756	with idiopathic pulmonary fibrosis.	C0085786	Hamman-Rich syndrome	dsyn	Treatment of patients with idiopathic pulmonary fibrosis.	Idiopathic pulmonary fibrosis|GARD:0008609|NINTEDANIB|OFEV|GARD:0008609	"IDIOPATHIC PULMONARY FIBROSIS|FIBROSING ALVEOLITIS, CRYPTOGENIC|FAMILIAL IDIOPATHIC PULMONARY FIBROSIS|FIBROCYSTIC PULMONARY DYSPLASIA|FIBROSING ALVEOLITIS|GARD:0008609|OMIM:178500"	FIBROSING MEDIASTINITIS|MEDIASTINAL FIBROSIS|SCLEROSING MEDIASTINITIS|FM	nintedanib	Ofev	40723	Treatment of patients with idiopathic pulmonary fibrosis.	Designated/Approved	Approved for Orphan Indication	Treatment of idiopathic pulmonary fibrosis	Ê10/15/2014Ê	Ê10/15/2021	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Rd.	PO Box 368	Ridgefield	Connecticut	6877	USA	344511
2189	Idiopathic thrombocytopenic purpura	5194	done		3361	of idiopathic thrombocytopenia purpura	C0398650	Immune thrombocytopenic purpura	dsyn	Treatment of idiopathic thrombocytopenia purpura	Idiopathic thrombocytopenic purpura|GARD:0005194|ELTROMBOPAG|PROMACTA|GARD:0005194	"IMMUNE THROMBOCYTOPENIC PURPURA (DISORDER)|THROMBOCYTOPENIC PURPURA, IMMUNE|CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA|DOID:8924|MESH:D016553"	Idiopathic thrombocytopenic purpura|GARD:0005194|IVIG|IMMUNE GLOBULIN INTRAVEOUS (HUMAN)|GAMMAPLEX|GARD:0005194	eltrombopag	Promacta	39573	Treatment of idiopathic thrombocytopenia purpura	Designated/Approved	Approved for Orphan Indication	"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy"	Ê11/20/2008Ê	Ê11/20/2015	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA	251907
3527	Idiopathic thrombocytopenic purpura	5194			2785	of idiopathic thrombocytopenic purpura	C0398650	Immune thrombocytopenic purpura	dsyn	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Idiopathic thrombocytopenic purpura|GARD:0005194|IVIG|IMMUNE GLOBULIN INTRAVEOUS (HUMAN)|GAMMAPLEX|GARD:0005194	Immune thrombocytopenia|GARD:0006768|IVIG|IMMUNE GLOBULIN INTRAVEOUS (HUMAN)|GAMMAPLEX|GARD:0006768	WAS RELATED DISORDERS|WAS|WISKOTT ALDRICH SYNDROME|X-LINKED CONGENITAL NEUTROPENIA|X-LINKED THROMBOCYTOPENIA	immune globulin intraveous (human)	Gammaplex	40662	Treatment of idiopathic thrombocytopenic purpura (also known as primary immune thrombocytopenia)	Designated/Approved	Approved for Orphan Indication	Idiopathic thrombocytopenic purpura	Ê03/08/2013Ê	ÊN/A	Bio Products Laboratory	Dagger Lane	"Hertfordshire, WD3BX,"	England			United Kingdom	335211
295	Idiopathic thrombocytopenic purpura	5194	done		2723	of idiopathic thrombocytopenic purpura	C0398650	Immune thrombocytopenic purpura	dsyn	Treatment of idiopathic thrombocytopenic purpura	Idiopathic thrombocytopenic purpura|GARD:0005194|VALZIFLOCEPT|RECOMBINANT HUMAN SOLUBLE FC-GAMMA RECEPTOR IIB|GARD:0005194	"IMMUNE THROMBOCYTOPENIC PURPURA (DISORDER)|THROMBOCYTOPENIC PURPURA, IMMUNE|CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA|DOID:8924|MESH:D016553"	Idiopathic thrombocytopenic purpura|GARD:0005194|GMA-161|HUMANIZED ANTI-HUMAN CD16 MONOCLONAL ANTIBODY|GARD:0005194	avatrombopag maleate	n/a	40787	Treatment of idiopathic thrombocytopenic purpura	Designated/Approved	Approved for Orphan Indication	DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment	Ê06/26/2019Ê	Ê06/26/2026	"Dova Pharmaceuticals, Inc."	240 Leigh Farm Road	Suite 245	Durham	North Carolina	27707	USA	325110
2256	Idiopathic thrombocytopenic purpura	5194	approximate		1646	of immune thrombocytopenic purpura	C0398650	Immune thrombocytopenic purpura	dsyn	Treatment of immune thrombocytopenic purpura	"IMMUNE THROMBOCYTOPENIC PURPURA (DISORDER)|THROMBOCYTOPENIC PURPURA, IMMUNE|CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA|DOID:8924|MESH:D016553"	Idiopathic thrombocytopenic purpura|GARD:0005194|HUMAN RHO(D) IMMUNE GLOBULIN|RHO (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN)|WINRHO|WINRHO SD|GARD:0005194	Idiopathic thrombocytopenic purpura|GARD:0005194|ROMIPLOSTIM|NPLATE|GARD:0005194	fostamatinib disodium hexahydrate	n/a	42241	Treatment of immune thrombocytopenic purpura	Designated/Approved	Approved for Orphan Indication	TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.	Ê04/17/2018Ê	Ê04/17/2025	"Rigel Pharmaceuticals, Inc."	1180 Veterans Boulevard		South San Francisco	California	94080	USA	487715
2817	Idiopathic thrombocytopenic purpura	5194	approximate		4033	of immune thrombocytopenic purpura	C0398650	Immune thrombocytopenic purpura	dsyn	Treatment of immune thrombocytopenic purpura	"IMMUNE THROMBOCYTOPENIC PURPURA (DISORDER)|THROMBOCYTOPENIC PURPURA, IMMUNE|CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA|DOID:8924|MESH:D016553"	Idiopathic thrombocytopenic purpura|GARD:0005194|HUMAN RHO(D) IMMUNE GLOBULIN|RHO (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN)|WINRHO|WINRHO SD|GARD:0005194	Idiopathic thrombocytopenic purpura|GARD:0005194|ROMIPLOSTIM|NPLATE|GARD:0005194	romiplostim	Nplate	37707	Treatment of immune thrombocytopenic purpura	Designated/Approved	Approved for Orphan Indication	"Nplate is indicated for the treatment of thrombocytopenia in pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy."	Ê12/14/2018Ê	Ê12/14/2025	"Amgen, Inc."	One Amgen Center Drive	Mail Stop: 27-2-D	Thousand Oaks	California	91320	USA	165402
2817	Idiopathic thrombocytopenic purpura	5194	approximate		4033	of immune thrombocytopenic purpura	C0398650	Immune thrombocytopenic purpura	dsyn	Treatment of immune thrombocytopenic purpura	"IMMUNE THROMBOCYTOPENIC PURPURA (DISORDER)|THROMBOCYTOPENIC PURPURA, IMMUNE|CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA|DOID:8924|MESH:D016553"	Idiopathic thrombocytopenic purpura|GARD:0005194|HUMAN RHO(D) IMMUNE GLOBULIN|RHO (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN)|WINRHO|WINRHO SD|GARD:0005194	Idiopathic thrombocytopenic purpura|GARD:0005194|ROMIPLOSTIM|NPLATE|GARD:0005194	romiplostim	Nplate	37707	Treatment of immune thrombocytopenic purpura	Designated/Approved	Approved for Orphan Indication	"Treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy"	Ê08/22/2008Ê	Ê08/22/2015	"Amgen, Inc."	One Amgen Center Drive	Mail Stop: 27-2-D	Thousand Oaks	California	91320	USA	165402
2817	Idiopathic thrombocytopenic purpura	5194	approximate		4033	of immune thrombocytopenic purpura	C0398650	Immune thrombocytopenic purpura	dsyn	Treatment of immune thrombocytopenic purpura	"IMMUNE THROMBOCYTOPENIC PURPURA (DISORDER)|THROMBOCYTOPENIC PURPURA, IMMUNE|CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA|DOID:8924|MESH:D016553"	Idiopathic thrombocytopenic purpura|GARD:0005194|HUMAN RHO(D) IMMUNE GLOBULIN|RHO (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN)|WINRHO|WINRHO SD|GARD:0005194	Idiopathic thrombocytopenic purpura|GARD:0005194|ROMIPLOSTIM|NPLATE|GARD:0005194	romiplostim	Nplate	37707	Treatment of immune thrombocytopenic purpura	Designated/Approved	Approved for Orphan Indication	"Nplate is indicated for the treatment of thrombocytopenia in adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy"	Ê10/17/2019Ê	Ê10/17/2026	"Amgen, Inc."	One Amgen Center Drive	Mail Stop: 27-2-D	Thousand Oaks	California	91320	USA	165402
1738	Idiopathic thrombocytopenic purpura	5194	approximate		4674	of immune thrombocytopenic purpura.	C0398650	Immune thrombocytopenic purpura	dsyn	Treatment of immune thrombocytopenic purpura.	"IMMUNE THROMBOCYTOPENIC PURPURA (DISORDER)|THROMBOCYTOPENIC PURPURA, IMMUNE|CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIC PURPURA|DOID:8924|MESH:D016553"	Idiopathic thrombocytopenic purpura|GARD:0005194|HUMAN RHO(D) IMMUNE GLOBULIN|RHO (D) IMMUNE GLOBULIN INTRAVENOUS (HUMAN)|WINRHO|WINRHO SD|GARD:0005194	Idiopathic thrombocytopenic purpura|GARD:0005194|ROMIPLOSTIM|NPLATE|GARD:0005194	Rho (D) immune globulin intravenous (human)	Winrho Sd	34282	Treatment of immune thrombocytopenic purpura.	Designated/Approved	Approved for Orphan Indication	Treatment of adults and children with chronic and acute immune thrombocytopenic purpura.	Ê03/24/1995Ê	Ê03/24/2002	"Rh Pharmaceuticals, Inc."	104 Chancellor Matheson Road	R3T 2N2				Canada	74993
438	Infantile apnea	6779	done		5048	of prematurity.	C0021294	"Infant, Premature"	dsyn	Treatment of apnea of prematurity.	APNEA OF PREMATURITY|APNEA|DOID:11163|MESH:D001049	Infantile apnea|GARD:0006779|CAFFEINE|CAFCIT|GARD:0006779	"Infantile apnea|GARD:0006779|ACETYLCYSTEINE|N-ACETYLCYSTEINE|ACETADOTE(C), MUCOMIST(C)|GARD:0006779"	Caffeine	Cafcit	32406	Treatment of apnea of prematurity.	Designated/Approved	Approved for Orphan Indication	Short term treatment of apnea of prematurity in infants between 28 and less than 33 weeks gestational age.	Ê09/21/1999Ê	Ê09/21/2006	"O.P.R. Development, L.P."	1501 Wakarusa Drive		Lawrence	Kansas	66047	USA	31288
5281	Infantile spasms	7887			4014	of infantile spasms	C0037769	West Syndrome	dsyn	Treatment of infantile spasms	Infantile spasms|GARD:0007887|VIGABATRIN|VIGABATRIN AND COSYNTROPIN|GARD:0007887	Infantile spasms|GARD:0007887|COSYNTROPIN|GARD:0007887	Infantile spasms|GARD:0007887|CANNABIDIOL|GARD:0007887	repository corticotropin or adrenocorticotropic hormone	H.P. Acthar Gel	37762	Treatment of infantile spasms	Designated/Approved	Approved for Orphan Indication	To treat infantile spasms	Ê10/15/2010Ê	Ê10/15/2017	"Questcor Pharmaceuticals, Inc."	26118 Research Road		Hayward	California	94545	USA	168103
5278	Infantile spasms	7887			4243	of infantile spasms.	C0037769	West Syndrome	dsyn	Treatment of infantile spasms.	Infantile spasms|GARD:0007887|VIGABATRIN|VIGABATRIN AND COSYNTROPIN|GARD:0007887	Infantile spasms|GARD:0007887|COSYNTROPIN|GARD:0007887	Infantile spasms|GARD:0007887|CANNABIDIOL|GARD:0007887	vigabatrin	Sabril	36689	Treatment of infantile spasms.	Designated/Approved	Approved for Orphan Indication	For infantile spasms (IS) - 1 month to 2 years of age.	Ê08/21/2009Ê	Ê08/21/2016	H. Lundbeck A/S	Four Parkway North		Deerfield	Illinois	60015	USA	135100
1275	Interstitial cystitis	6787	done	Not a rare disease	5194	of interstitial cystitis.	C0282488	Interstitial Cystitis	dsyn	Treatment of interstitial cystitis.	Interstitial cystitis|GARD:0006787|NIFEDIPINE|GARD:0006787	INTERSTITIAL CYSTITIS|DOID:13949|MESH:D018856	Interstitial cystitis|GARD:0006787|PENTOSAN POLYSULFATE SODIUM|ELMIRON|GARD:0006787	Pentosan polysulfate sodium	Elmiron	31266	Treatment of interstitial cystitis.	Designated/Approved	Approved for Orphan Indication	Relief of bladder pain or discomfort associated with interstitial cystitis.	Ê09/26/1996Ê	Ê09/26/2003	Alza Corporation	950 Page Mill Rd.	PO Box 10950	Palo Alto	California	94303	USA	1784
576	Iron Overload		MISSING	Not a disease	4065	of chronic iron overload	C0282193	Iron Overload	dsyn	Treatment of chronic iron overload in patients with transfusion-dependent anemias	DEFERASIROX|EXJADE	IRON OVERLOAD|CHRONIC IRON OVERLOAD|DOID:2350|MESH:D019190	"SHP-602|(S)-4,5-DIHYDRO-2[2-HYDROXY-3-(3,6,9-TRIOXADECYLOXY)PHENYL]-4-METHYL-4-THIAXOLECARBOXYLIC ACID"	Deferasirox	Exjade; Jadenu Sprinkles	37581	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Designated/Approved	Approved for Orphan Indication	Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age or older	Ê11/02/2005Ê	Ê11/02/2012	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Hampshire	7936	USA	161002
576	Iron Overload		MISSING	Not a disease	4065	of chronic iron overload	C0282193	Iron Overload	dsyn	Treatment of chronic iron overload in patients with transfusion-dependent anemias	DEFERASIROX|EXJADE	IRON OVERLOAD|CHRONIC IRON OVERLOAD|DOID:2350|MESH:D019190	"SHP-602|(S)-4,5-DIHYDRO-2[2-HYDROXY-3-(3,6,9-TRIOXADECYLOXY)PHENYL]-4-METHYL-4-THIAXOLECARBOXYLIC ACID"	Deferasirox	Exjade; Jadenu Sprinkles	37581	Treatment of chronic iron overload in patients with transfusion-dependent anemias	Designated/Approved	Approved for Orphan Indication	treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older	Ê05/18/2017Ê	ÊN/A	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Hampshire	7936	USA	161002
910	Japanese encephalitis	6797	done		2525					Prevention of Japanese encephalitis virus in pediatric patients.	"Japanese encephalitis|GARD:0006797|JAPANESE ENCEPHALITIS VACCINE, INACTIVATED, ADSORBED|IXIARO|GARD:0006797"	"Japanese encephalitis|GARD:0006797|JAPANESE ENCEPHALITIS VACCINE, INACTIVATED, ADSORBED|JAPANESE ENCEPHALITIS VIRUS VACCINE INACTIVATED|IXIARO|GARD:0006797"		"Japanese encephalitis vaccine, inactivated, adsorbed"	Ixiaro	41177	Prevention of Japanese encephalitis virus in pediatric patients.	Designated/Approved	Approved for Orphan Indication	IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus (JEV). IXIARO is approved for use in individuals 2 months of age and older.	Ê05/17/2013Ê	Ê05/17/2020	Intercell AG	Campus Vienna Biocenter 3	A-1030	Vienna			Austria	376112
1981	Juvenile idiopathic arthritis	3067	MISSING		3286	juvenile rheumatoid arthritis.	C3495559	Juvenile arthritis	dsyn	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	CANAKINUMAB|ILARIS			canakinumab	Ilaris	39721	Treatment of pediatric (age 16 and under) juvenile rheumatoid arthritis.	Designated/Approved	Approved for Orphan Indication	Treatment of active Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.	Ê05/09/2013Ê	Ê05/09/2020	Novartis Pharmaceuticals Corporation	One Health Plaza	Bldg 135-566G	East Hanover	New Jersey	7936	USA	260408
1767	Juvenile idiopathic arthritis	3067	done	Not a rare disease	3799	of juvenile rheumatoid arthritis	C3495559	Juvenile arthritis	dsyn	Treatment of juvenile rheumatoid arthritis	"Juvenile idiopathic arthritis|GARD:0003067|ANAKINRA|INTERLEUKIN-1 RECEPTOR ANTAGONIST, HUMAN RECOMBINANT|ANTRIL|GARD:0003067"	Juvenile idiopathic arthritis|GARD:0003067|GAMOLENIC ACID|GAMMALINOLENIC ACID|GARD:0003067	Juvenile idiopathic arthritis|GARD:0003067|HUMAN IMMUNOGLOBULIN G|HUMAN GAMMAGLOBULIN|ORALGAM|GARD:0003067	adalimumab	Humira	38432	Treatment of juvenile rheumatoid arthritis	Designated/Approved	Approved for Orphan Indication	Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.	Ê09/30/2014Ê	Ê09/30/2021	AbbVie Inc.	1 North Waukegan Road		North Chicago	Illinois	60064	USA	200905
1767	Juvenile idiopathic arthritis	3067	done	Not a rare disease	3799	of juvenile rheumatoid arthritis	C3495559	Juvenile arthritis	dsyn	Treatment of juvenile rheumatoid arthritis	"Juvenile idiopathic arthritis|GARD:0003067|ANAKINRA|INTERLEUKIN-1 RECEPTOR ANTAGONIST, HUMAN RECOMBINANT|ANTRIL|GARD:0003067"	Juvenile idiopathic arthritis|GARD:0003067|GAMOLENIC ACID|GAMMALINOLENIC ACID|GARD:0003067	Juvenile idiopathic arthritis|GARD:0003067|HUMAN IMMUNOGLOBULIN G|HUMAN GAMMAGLOBULIN|ORALGAM|GARD:0003067	adalimumab	Humira	38432	Treatment of juvenile rheumatoid arthritis	Designated/Approved	Approved for Orphan Indication	Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 4 years of age and older.	Ê02/21/2008Ê	Ê02/21/2015	AbbVie Inc.	1 North Waukegan Road		North Chicago	Illinois	60064	USA	200905
2491	Juvenile idiopathic arthritis	3067	done	Not a rare disease	4063	of juvenile rheumatoid arthritis	C3495559	Juvenile arthritis	dsyn	Treatment of juvenile rheumatoid arthritis	"Juvenile idiopathic arthritis|GARD:0003067|ANAKINRA|INTERLEUKIN-1 RECEPTOR ANTAGONIST, HUMAN RECOMBINANT|ANTRIL|GARD:0003067"	Juvenile idiopathic arthritis|GARD:0003067|GAMOLENIC ACID|GAMMALINOLENIC ACID|GARD:0003067	Juvenile idiopathic arthritis|GARD:0003067|HUMAN IMMUNOGLOBULIN G|HUMAN GAMMAGLOBULIN|ORALGAM|GARD:0003067	meloxicam	Mobic	37582	Treatment of juvenile rheumatoid arthritis	Designated/Approved	Approved for Orphan Indication	For relief of the signs and symptoms of pauciarticular or polyarticular course Juvenile Rheumatoid Arthritis in patients 2 years of age or older	Ê08/11/2005Ê	Ê08/11/2012	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	P. O. Box 368	Ridgefield	Connecticut	6877	USA	160602
3017	Juvenile idiopathic arthritis	3067	done		2557	with polyarticular-course juvenile idiopathic arthritis	C0311221	Polyarticular juvenile rheumatoid arthritis	dsyn	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Juvenile idiopathic arthritis|GARD:0003067|TOCILIZUMAB|ACTEMRA|GARD:0003067			tocilizumab	Actemra	41121	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Designated/Approved	Approved for Orphan Indication	ACTEMRA (tocilizumab) is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older.	Ê04/29/2013Ê	Ê04/29/2020	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	367812
3017	Juvenile idiopathic arthritis	3067	done		2557	with polyarticular-course juvenile idiopathic arthritis	C0311221	Polyarticular juvenile rheumatoid arthritis	dsyn	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Juvenile idiopathic arthritis|GARD:0003067|TOCILIZUMAB|ACTEMRA|GARD:0003067			tocilizumab	Actemra	41121	Treatment of pediatric patients (age 16 years and younger) with polyarticular-course juvenile idiopathic arthritis	Designated/Approved	Approved for Orphan Indication	ACTEMRA (tocilizumab) for subcutaneous injection is indicated for the treatment of active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older	Ê05/11/2018Ê	ÊN/A	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	367812
4504	Kaposi's Sarcoma	6814			4412	of AIDS-related Kaposi's sarcoma.	C0276535	AIDS with Kaposi's sarcoma	neop	Treatment of AIDS-related Kaposi's sarcoma.	KAPOSI SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI SARCOMA|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI'S SARCOMA|KAPOSI'S SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|NCIT:C9113|NCI:C9113|UMLS:C0279085	KAPOSI SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|KAPOSI'S SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI SARCOMA|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI'S SARCOMA|NCI:C9113|UMLS:C0279085	Kaposi's Sarcoma|GARD:0006814|PACLITAXEL|PAXENE|GARD:0006814	Alitretinoin	Panretin	35878	Treatment of AIDS-related Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication	Topical treatment of cutaneous lesions in patients with AIDS-related Kaposi's sarcoma.	Ê02/02/1999Ê	Ê02/02/2006	"Eisai, Inc"	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA	110998
4512	Kaposi's Sarcoma	6814			4465	of AIDS-related Kaposi's sarcoma.	C0276535	AIDS with Kaposi's sarcoma	neop	Treatment of AIDS-related Kaposi's sarcoma.	KAPOSI SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI SARCOMA|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI'S SARCOMA|KAPOSI'S SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|NCIT:C9113|NCI:C9113|UMLS:C0279085	KAPOSI SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|KAPOSI'S SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI SARCOMA|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI'S SARCOMA|NCI:C9113|UMLS:C0279085	Kaposi's Sarcoma|GARD:0006814|PACLITAXEL|PAXENE|GARD:0006814	Paclitaxel	Taxol	35514	Treatment of AIDS-related Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication	For the second line treatment of AIDS-related Kaposi's sarcoma.	Ê08/04/1997Ê	Ê08/04/2004	Bristol-Myers Squibb Pharmaceutical Research Institute	5 Research Parkway	P.O. Box 5100	Wallingford	Connecticut	6492	USA	103497
4506	Kaposi's Sarcoma	6814			5130	of AIDS-related Kaposi's sarcoma.	C0276535	AIDS with Kaposi's sarcoma	neop	Treatment of AIDS-related Kaposi's sarcoma.	KAPOSI SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI SARCOMA|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI'S SARCOMA|KAPOSI'S SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|NCIT:C9113|NCI:C9113|UMLS:C0279085	KAPOSI SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|KAPOSI'S SARCOMA RELATED TO IMMUNOSUPPRESSIVE TREATMENT|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI SARCOMA|IMMUNOSUPPRESSIVE TREATMENT RELATED KAPOSI'S SARCOMA|NCI:C9113|UMLS:C0279085	Kaposi's Sarcoma|GARD:0006814|PACLITAXEL|PAXENE|GARD:0006814	Interferon alfa-2b (recombinant)	Intron A	31952	Treatment of AIDS-related Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication	Treatment of selected patients with AIDS-related Kaposi's sarcoma.	Ê11/21/1988Ê	Ê11/21/1995	Schering Corporation	2000 Galloping Hill Road		Kenilworth	New Jersey	7033	USA	19187
4507	Kaposi's Sarcoma	6814			5094	of AIDS related Kaposi's sarcoma.	C0276535	AIDS with Kaposi's sarcoma	neop	Treatment of AIDS related Kaposi's sarcoma.	Kaposi's Sarcoma|GARD:0006814|PACLITAXEL|PAXENE|GARD:0006814	Kaposi's Sarcoma|GARD:0006814|OGLUFANIDE|L-GLUTAMYL-L-TRYPTOPHAN|GARD:0006814	Kaposi's Sarcoma|GARD:0006814|ALITRETINOIN|PANRETIN|GARD:0006814	Interferon alfa-2a (recombinant)	Roferon-A	32125	Treatment of AIDS related Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication		Ê11/21/1988Ê	Ê11/21/1995	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA	25987
4510	Kaposi's Sarcoma	6814			4698	with advanced HIV-associated Kaposi's sarcoma.	C0036220	Kaposi Sarcoma	neop	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.				Daunorubicin citrate liposome injection	Daunoxome	34103	Treatment of patients with advanced HIV-associated Kaposi's sarcoma.	Designated/Approved	Approved for Orphan Indication	"First line cytotoxic therapy for advanced, HIV related Kaposi's sarcoma."	Ê04/08/1996Ê	Ê04/08/2003	"NeXstar Pharmaceuticals, Inc."	650 Cliffside Drive		San Dimas	California	91773	USA	73693
2764	"Keratitis, hereditary"	3089	approximate		2057	of neurotrophic keratitis	C0339296	Neurotrophic keratitis	dsyn	Treatment of neurotrophic keratitis	"Keratitis, hereditary|GARD:0003089|RHNGF|RECOMBINANT HUMAN NERVE GROWTH FACTOR|GARD:0003089"	NEUROTROPHIC KERATITIS|NEUROTROPHIC KERATOPATHY	"HEREDITARY SENSORY AND AUTONOMIC NEUROPATHY TYPE IV|CONGENITAL INSENSITIVITY TO PAIN WITH ANHIDROSIS (CIPA)|FAMILIAL DYSAUTONOMIA, TYPE II|HEREDITARY SENSORY NEUROPATHY TYPE IV|HSAN IV|HSNAN4"	cenegermin-bkbj	Oxervate	41813	Treatment of neurotrophic keratitis	Designated/Approved	Approved for Orphan Indication	Treatment of neurotrophic keratitis	Ê08/22/2018Ê	Ê08/22/2025	Dompe S.p.A.	Via S. Martino 12-12/A		Milan			Italy	436214
4518	Keratoconus	6824			2721	of keratoconus	C0022578	Keratoconus	dsyn	Treatment of keratoconus	KERATOCONUS|PROGRESSIVE KERATOCONUS|DOID:10126|MESH:D007640	Keratoconus|GARD:0006824|COPPER SULFATE|GARD:0006824	Keratoconus|GARD:0006824|RIBOFLAVIN OPHTHALMIC SOLUTION & ULTRAVIOLET A|PHOTREXA VISCOUS|GARD:0006824	riboflavin ophthalmic solution & ultraviolet A	Photrexa Viscous	40788	Treatment of keratoconus	Designated/Approved	Approved for Orphan Indication	Indicated for use in corneal collagen crosslinking in combination with the KXL System for the treatment of progressive keratoconus	Ê04/15/2016Ê	Ê04/15/2023	"Avedro, Inc."	230 Third Avenue		Waltham	Massachusetts	2451	USA	344911
648	"Kidney Failure, Chronic"		MISSING		5165	with end stage renal disease.	C0022661	"Kidney Failure, Chronic"	dsyn	Treatment of anemia associated with end stage renal disease.	EPOETIN ALFA|EPOETIN ALPHA|PROCRIT	EPOETIN BETA|MAROGEN	ERYTHROPOIETIN|ERYTHROPOIETIN (RECOMBINANT HUMAN)	Epoetin alfa	Epogen	31512	Treatment of anemia associated with end stage renal disease.	Designated/Approved	Approved for Orphan Indication	"Treatment of anemia associated with chronic renal failure, including patients on dialysis (end stage renal disesae) and patients not on dialysis"	Ê06/01/1989Ê	Ê06/01/1996	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA	12486
848	"Kidney Failure, Chronic"		MISSING		4451	end stage renal disease	C0022661	"Kidney Failure, Chronic"	dsyn	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	ICODEXTRIN|ICODEXTRIN 7.5% WITH ELECTROLYTES PERITONEAL DIALYSIS SOLUTION|EXTRANEAL (WITH 7.5% ICODEXTRIN) PERITONEAL DIALYSIS SOLUTIO	ELECTROLYTES NOS|ICODEXTRIN 7.5% WITH ELECTROLYTES PERITONEAL DIALYSIS SOLUTION|ICODEXTRIN|EXTRANEAL (WITH 7.5% ICODEXTRIN) PERITONEAL DIALYSIS SOLUTIO		Icodextrin 7.5% with Electrolytes Peritoneal Dialysis Solution	Extraneal (With 7.5% Icodextrin) Peritoneal Dialysis Solutio	35629	Treatment of those patients having end stage renal disease and requiring peritoneal dialysis treatment.	Designated/Approved	Approved for Orphan Indication	For use as a single daily exchange for the long (8-16 hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure.	Ê12/20/2002Ê	Ê12/20/2009	Baxter Healthcare Corporation	Renal Division	1620 Waukegan Road	McGaw Park	Illinois	60085	USA	105697
1522	"Kidney Failure, Chronic"		MISSING		4988	with chronic renal failure.	C0022661	"Kidney Failure, Chronic"	dsyn	Treatment of growth retardation associated with chronic renal failure.	SOMATROPIN|SOMATROPIN FOR INJECTION|NUTROPIN	AIDS DYSMORPHIC SYNDROME|DYSMORPHIC ACQUIRED IMMUNE DEFICIENCY SYNDROME|DYSMORPHIC AIDS|FETAL ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS)|FETAL AIDS INFECTION|FETAL EFFECTS OF AIDS|HIV EMBRYOPATHY|PERINATAL AIDS	TYROSINEMIA TYPE 1|FAH DEFICIENCY|FUMARYLACETOACETASE DEFICIENCY|FUMARYLACETOACETATE HYDROLASE DEFICIENCY|HEPATORENAL TYROSINEMIA|HEREDITARY TYROSINEMIA TYPE 1	Somatropin for injection	Nutropin	32724	Treatment of growth retardation associated with chronic renal failure.	Designated/Approved	Approved for Orphan Indication	Treatment of children with growth failure associated with chronic renal insufficency.	Ê11/17/1993Ê	Ê11/17/2000	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	34989
Missing	Lambert Eaton myasthenic syndrome	6851			3098	of Lambert-Eaton Myasthenic Syndrome	C0022972	Lambert-Eaton Myasthenic Syndrome	dsyn	Treatment of Lambert-Eaton Myasthenic Syndrome	LAMBERT-EATON MYASTHENIC SYNDROME|DOID:50214|MESH:D015624	Lambert Eaton myasthenic syndrome|GARD:0006851|DYNAMINE|GARD:0006851	"Lambert Eaton myasthenic syndrome|GARD:0006851|AMIFAMPRIDINE|3,4-DIAMINOPYRIDINE|GARD:0006851"	amifampridine phosphate	Firdapse	40129	Treatment of Lambert-Eaton Myasthenic Syndrome	Designated/Approved	Approved for Orphan Indication	FIRDAPSE is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.	Ê11/28/2018Ê	Ê11/28/2025	"Catalyst Pharmaceuticals, Inc."	355 Alhambra Circle	Suite 1250	Coral Gables	Florida	33134	USA	295309
58	Lambert Eaton myasthenic syndrome	6851	done		4863	of Lambert-Eaton myasthenic syndrome.	C0022972	Lambert-Eaton Myasthenic Syndrome	dsyn	Treatment of Lambert-Eaton myasthenic syndrome.	LAMBERT-EATON MYASTHENIC SYNDROME|DOID:50214|MESH:D015624	Lambert Eaton myasthenic syndrome|GARD:0006851|DYNAMINE|GARD:0006851	"Lambert Eaton myasthenic syndrome|GARD:0006851|AMIFAMPRIDINE|3,4-DIAMINOPYRIDINE|GARD:0006851"	amifampridine	Ruzurgi	33225	Treatment of Lambert-Eaton myasthenic syndrome.	Designated/Approved	Approved for Orphan Indication	RUZURGI is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age.	Ê05/06/2019Ê	Ê05/06/2026	"Jacobus Pharmaceutical Company, Inc."	37 Cleveland Lane	P.O. Box 5290	Princeton	New Jersey	8540	USA	51590
1514	Langer mesomelic dysplasia	3553	approximate		3698	of short stature	C0013336	Dwarfism	dsyn	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Langer mesomelic dysplasia|GARD:0003553|SOMATROPIN|HUMATROPE|GARD:0003553	GROWTH HORMONE DEFICIENCY	"CHARGE SYNDROME|CHARGE ASSOCIATION|HALL-HITTNER SYNDROME|COLOBOMA, HEART, ATRESIA OF THE CHOANAE, RETARDATION OF GROWTH AND DEVELOPMENT, GENITAL AND URINARY ANOMALIES, AND EAR ANOMALIES"	Somatropin	Humatrope	38701	Treatment of short stature in pediatric patients with short stature homeobox-containing gene (SHOX) deficiency	Designated/Approved	Approved for Orphan Indication	Treatment of short stature or growth failure in children with SHOX (short stature homeobox-containing gene) deficiency whose epiphyses are not closed	Ê11/01/2006Ê	Ê11/01/2013	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA	211205
4527	Leishmaniasis	6881			3583	of leishmaniasis.	C0023281	Leishmaniasis	dsyn	Treatment of leishmaniasis.	Leishmaniasis|GARD:0006881|OLEYLPHOSPHOCHOLINE|GARD:0006881	"VISCERAL LEISHMANIASIS|LEISHMANIASIS, VISCERAL|DOID:9146|MESH:D007898"	"MUCOCUTANEOUS LEISHMANIASIS|LEISHMANIASIS, MUCOCUTANEOUS|MUCOSAL LEISHMANIASIS|DOID:9155|MESH:D007897"	miltefosine	Impavido	39000	Treatment of leishmaniasis.	Designated/Approved	Approved for Orphan Indication	"Treatment of visceral leishmaniasis due to Leishmania donovani; cutaneous leishmaniasis due to Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis; and mucosal leishmaniasis due to Leishmania braziliensis."	Ê03/19/2014Ê	Ê03/19/2021	Knight Therapeutics (USA)	Corporation Trust Center	1209 Orange Street	Wilmington	Delaware	19801	USA	229406
4529	Leishmaniasis	6881			4490	of visceral leishmaniasis.	C0023290	"Leishmaniasis, Visceral"	dsyn	Treatment of visceral leishmaniasis.	"VISCERAL LEISHMANIASIS|LEISHMANIASIS, VISCERAL|DOID:9146|MESH:D007898"	Leishmaniasis|GARD:0006881|AMINOSIDINE|PAROMOMYCIN|GARD:0006881	Leishmaniasis|GARD:0006881|ENCHOCHLEATE AMPHOTERICIN B|GARD:0006881	Liposomal amphotericin B	Ambisome	35405	Treatment of visceral leishmaniasis.	Designated/Approved	Approved for Orphan Indication	Treatment of visceral leishmaniasis.	Ê08/11/1997Ê	Ê08/11/2004	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA	99596
5722	Lennox-Gastaut syndrome	9912			2058	of Lennox-Gastaut syndrome	C0238111	Lennox-Gastaut syndrome	dsyn	Treatment of Lennox-Gastaut syndrome	LENNOX-GASTAUT SYNDROME|LENNOX GASTAUT SYNDROME|DOID:50561|MESH:D065768	Lennox-Gastaut syndrome|GARD:0009912|PERAMPANEL|FYCOMPA|GARD:0009912	Lennox-Gastaut syndrome|GARD:0009912|CANNABIDIOL|GARD:0009912	cannabidiol	Epidiolex	41697	Treatment of Lennox-Gastaut syndrome	Designated/Approved	Approved for Orphan Indication	EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) in patients 2 years of age and older.	Ê09/28/2018Ê	Ê09/28/2025	GW Research Ltd.	68 TW Anderson Drive P.O. Box 13628		Research Triangle Park	North Carolina	27709	USA	421213
5726	Lennox-Gastaut syndrome	9912			3426	of Lennox-Gastaut Syndrome	C0238111	Lennox-Gastaut syndrome	dsyn	Treatment of Lennox-Gastaut Syndrome	LENNOX-GASTAUT SYNDROME|LENNOX GASTAUT SYNDROME|DOID:50561|MESH:D065768	Lennox-Gastaut syndrome|GARD:0009912|PERAMPANEL|FYCOMPA|GARD:0009912	Lennox-Gastaut syndrome|GARD:0009912|CANNABIDIOL|GARD:0009912	clobazam	Onfi	39434	Treatment of Lennox-Gastaut Syndrome	Designated/Approved	Approved for Orphan Indication	Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome inpatients 2 years of age or older	Ê10/21/2011Ê	Ê10/21/2018	"Lundbeck, Inc."	Four Parkway North		Deerfield	Illinois	60015	USA	248307
5730	Lennox-Gastaut syndrome	9912			3848	of Lennox-Gastaut Syndrome.	C0238111	Lennox-Gastaut syndrome	dsyn	Treatment of Lennox-Gastaut Syndrome.	LENNOX-GASTAUT SYNDROME|LENNOX GASTAUT SYNDROME|DOID:50561|MESH:D065768	Lennox-Gastaut syndrome|GARD:0009912|PERAMPANEL|FYCOMPA|GARD:0009912	Lennox-Gastaut syndrome|GARD:0009912|CANNABIDIOL|GARD:0009912	rufinamide	Banzel	38268	Treatment of Lennox-Gastaut Syndrome.	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome.	Ê11/14/2008Ê	Ê11/14/2015	"Eisai, Inc."	300 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA	193504
5729	Lennox-Gastaut syndrome	9912			4558	of Lennox-Gastaut syndrome.	C0238111	Lennox-Gastaut syndrome	dsyn	Treatment of Lennox-Gastaut syndrome.	LENNOX-GASTAUT SYNDROME|LENNOX GASTAUT SYNDROME|DOID:50561|MESH:D065768	Lennox-Gastaut syndrome|GARD:0009912|PERAMPANEL|FYCOMPA|GARD:0009912	Lennox-Gastaut syndrome|GARD:0009912|CANNABIDIOL|GARD:0009912	Lamotrigine	Lamictal	34934	Treatment of Lennox-Gastaut syndrome.	Designated/Approved	Approved for Orphan Indication	Adjunctive treatment of Lennox-Gastaut syndrome in pediatric and adult patients.	Ê08/24/1998Ê	Ê08/24/2005	Glaxo Wellcome Research and Development	5 Moore Drive	P.O. Box 13398	Research Triangle Park	North Carolina	27709	USA	91695
5720	Lennox-Gastaut syndrome	9912			4730	of Lennox-Gastaut syndrome.	C0238111	Lennox-Gastaut syndrome	dsyn	Treatment of Lennox-Gastaut syndrome.	LENNOX-GASTAUT SYNDROME|LENNOX GASTAUT SYNDROME|DOID:50561|MESH:D065768	Lennox-Gastaut syndrome|GARD:0009912|PERAMPANEL|FYCOMPA|GARD:0009912	Lennox-Gastaut syndrome|GARD:0009912|CANNABIDIOL|GARD:0009912	Topiramate	Topamax	33933	Treatment of Lennox-Gastaut syndrome.	Designated/Approved	Approved for Orphan Indication	As adjunctive therapy in patients two years and older with siezures associated with Lennox-Gastaut syndrome.	Ê08/28/2001Ê	Ê08/28/2008	"Johnson & Johnson Pharmaceutical R & D, LLC"	"Route 202, P.O. Box 300"		Raritan	New Jersey	8869	USA	70792
5731	Lennox-Gastaut syndrome	9912			5018	of Lennox-Gastaut syndrome.	C0238111	Lennox-Gastaut syndrome	dsyn	Treatment of Lennox-Gastaut syndrome.	LENNOX-GASTAUT SYNDROME|LENNOX GASTAUT SYNDROME|DOID:50561|MESH:D065768	Lennox-Gastaut syndrome|GARD:0009912|PERAMPANEL|FYCOMPA|GARD:0009912	Lennox-Gastaut syndrome|GARD:0009912|CANNABIDIOL|GARD:0009912	Felbamate	Felbatol	32532	Treatment of Lennox-Gastaut syndrome.	Designated/Approved	Approved for Orphan Indication	As adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children.	Ê07/29/1993Ê	Ê07/29/2000	Wallace Laboratories	301B College Road East		Princeton	New Jersey	8540	USA	33488
1466	Leukopenia	12757	done		4588	leukopenia	C0023530	Leukopenia	dsyn	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Acute myeloid leukemia|GARD:0012757|SARGRAMOSTIM|LEUKINE|GARD:0012757			Sargramostim	Leukine	34764	To reduce neutropenia and leukopenia and decrease the incidence of death due to infection in patients with acute myelogenous leukemia.	Designated/Approved	Approved for Orphan Indication	Following induction chemotherapy in older adult patients with acute myelogenous leukemia to shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death.	Ê09/15/1995Ê	Ê09/15/2002	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA	81494
693	Leukopenia		MISSING		4878	of neutropenia	C0023530	Leukopenia	dsyn	Treatment of neutropenia associated with bone marrow transplants.	MOLGRAMOSTIM|GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR|LEUCOMAX	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED|FILGRASTIM|NEUPOGEN"	SEVERE CHRONIC NEUTROPENIA|SCN	Filgrastim	Neupogen	33147	Treatment of neutropenia associated with bone marrow transplants.	Designated/Approved	Approved for Orphan Indication	Reduce the duration of neutropenia and neutropenia sequelae in patients with non-myeloid malignancies undergoing ablative chemotherapy followed by BMT.	Ê06/15/1994Ê	Ê06/15/2001	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA	50090
1467	Leukopenia		MISSING		4925	of neutropenia	C0023530	Leukopenia	dsyn	"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment."	SARGRAMOSTIM|LEUKINE			sargramostim	Leukine	32996	"Treatment of neutropenia associated with bone marrow transplant, for the treatment of graft failure and delay of engraftment, and for the promotion of early engraftment."	Designated/Approved	Approved for Orphan Indication		Ê03/05/1991Ê	Ê03/05/1998	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA	44290
4556	Lipodystrophy	6909			4160	of metabolic disorders	C0025517	Metabolic Diseases	dsyn	Treatment of metabolic disorders secondary to lipodystrophy	Lipodystrophy|GARD:0006909|METRELEPTIN|MYALEPT|GARD:0006909	RABSON-MENDENHALL SYNDROME|MENDENHALL SYNDROME	CONGENITAL MUSCULAR DYSTROPHY|CMD	metreleptin	Myalept	37125	Treatment of metabolic disorders secondary to lipodystrophy	Designated/Approved	Approved for Orphan Indication	Adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.	Ê02/24/2014Ê	Ê02/24/2021	"Aegerion Pharnaceuticals, Inc."	245 First Street	18th Floor	Cambridge	Massachusetts	2142	USA	146701
3439	Lymphangioleiomyomatosis	3319			1929	of lymphangioleiomyomatosis	C0751674	Lymphangioleiomyomatosis	neop	Treatment of lymphangioleiomyomatosis	Lymphangioleiomyomatosis|GARD:0003319|SIROLIMUS|RAPAMUNE|GARD:0003319	Lymphangioleiomyomatosis|GARD:0003319|SIROLIMUS|GARD:0003319	Lymphangioleiomyomatosis|GARD:0003319|SIROLIMUS|GARD:0003319	sirolimus	Rapamune	41213	Treatment of lymphangioleiomyomatosis	Designated/Approved	Approved for Orphan Indication	Treatment of lymphangioleiomyomatosis (LAM)	Ê05/28/2015Ê	Ê05/28/2022	"Pfizer, Inc."	500 Arcola Road		Collegeville	Pennsylvania	19426	USA	379312
5924	Lysosomal acid lipase deficiency	12097			2983	of lysosomal acid lipase deficiency	C0043208	Wolman Disease	dsyn	Treatment of lysosomal acid lipase deficiency	WOLMAN DISEASE|LYSOSOMAL ACID LIPASE (LAL) DEFICIENCY|DOID:14497|MESH:D015223	Lysosomal acid lipase deficiency|GARD:0012097|SEBELIPASE ALFA|KANUMA|GARD:0012097	"WOLMAN DISEASE|ACID CHOLESTERYL ESTER HYDROLASE DEFICIENCY, WOLMAN TYPE|LYSOSOMAL ACID LIPASE DEFICIENCY, WOLMAN TYPE|LAL DEFICIENCY, WOLMAN TYPE"	sebelipase alfa	Kanuma	40360	Treatment of lysosomal acid lipase deficiency	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency	Ê12/08/2015Ê	Ê12/08/2022	Alexion Pharmaceuticals	100 College Street		New Haven	Connecticut	6510	USA	309410
1880	Malaria	6961	done		3464	P. falciparum.	C0858318	Plasmodium falciparum infection	dsyn	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Malaria|GARD:0006961|ARTEMETHER|ARTEMETHER/LUMEFANTRINE|COARTEM|GARD:0006961	Malaria|GARD:0006961|LUMEFANTRINE|ARTEMETHER/LUMEFANTRINE|COARTEM|GARD:0006961		artemether/lumefantrine	Coartem	39325	For the treatment of infections due to Plasmodium falciparum or mixed infections including P. falciparum.	Designated/Approved	Approved for Orphan Indication	"Treatment of malaria in patients of 5 kg bodyweight or above with acute, uncomplicated malaria due to Plasmodium falciparum or mixed infections including P. falciparum"	Ê04/07/2009Ê	Ê04/07/2016	Novartis Pharmaceuticals	Bldg 405/4051	One Health Plaza	East Hanover	New Jersey	7936	USA	245507
4559	Malaria	6961			2455	of malaria	C0024530	Malaria	dsyn	Treatment of malaria	Malaria|GARD:0006961|ARTESUNATE|GARD:0006961	MALARIA|ACUTE MALARIA|DOID:12365|MESH:D008288	CESTODIASIS	tafenoquine	Krintafel	41289	Treatment of malaria	Designated/Approved	Approved for Orphan Indication	KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.	Ê07/20/2018Ê	Ê07/20/2025	GlaxoSmithKline Intellectual Property Development Ltd. England	980 Great West Road		"Brentford, Middlesex"			United Kingdom	385812
4573	Malaria	6961			3912	of malaria	C0024530	Malaria	dsyn	Treatment of malaria	Malaria|GARD:0006961|ARTESUNATE|GARD:0006961	MALARIA|ACUTE MALARIA|DOID:12365|MESH:D008288	CESTODIASIS	quinine Sulfate	n/a	38141	Treatment of malaria	Designated/Approved	Approved for Orphan Indication	Treatment of uncomplicated Plasmodium falciparum malaria	Ê08/12/2005Ê	Ê08/12/2012	"AR Holding Company, Inc."	1100 Orthodox Street		Philadelphia	Pennsylvania	19124	USA	185004
4577	Malaria	6961			4796	of mild to moderate acute malaria	C2930826	Acute malaria	dsyn	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	Malaria|GARD:0006961|HALOFANTRINE|HALFAN|GARD:0006961			Halofantrine	Halfan	33546	Treatment of mild to moderate acute malaria caused by susceptible strains of P. falciparum and P. vivax.	Designated/Approved	Approved for Orphan Indication	Treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax.	Ê07/24/1992Ê	Ê07/24/1999	SmithKline Beecham Pharmaceuticals	One Franklin Plaza	P.O. Box 7929	Philadelphia	Pennsylvania	19101	USA	61791
2481	Malaria	6961	done	Not a rare disease	5082	of acute malaria	C2930826	Acute malaria	dsyn	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	Malaria|GARD:0006961|MEFLOQUINE HCL|LARIAM|GARD:0006961	Malaria|GARD:0006961|MEFLOQUINE HCL|LARIAM|GARD:0006961	Malaria|GARD:0006961|MEFLOQUINE HYDROCHLORIDE|MEFLOQUINE HCL|LARIAM|GARD:0006961	mefloquine HCL	Lariam	32246	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	Designated/Approved	Approved for Orphan Indication	Prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs	Ê05/03/1989Ê	Ê05/03/1996	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA	26287
2481	Malaria	6961	done	Not a rare disease	5082	of acute malaria	C2930826	Acute malaria	dsyn	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	Malaria|GARD:0006961|MEFLOQUINE HCL|LARIAM|GARD:0006961	Malaria|GARD:0006961|MEFLOQUINE HCL|LARIAM|GARD:0006961	Malaria|GARD:0006961|MEFLOQUINE HYDROCHLORIDE|MEFLOQUINE HCL|LARIAM|GARD:0006961	mefloquine HCL	Lariam	32246	"For use in the treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax, and for the prophylaxis of Plasmodium falciparum malaria which is resistant to other available drugs"	Designated/Approved	Approved for Orphan Indication	Treatment of acute malaria due to Plasmodium falciparum and Plasmodium vivax	Ê05/02/1989Ê	Ê05/02/1996	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA	26287
4583	Malignant hyperthermia	6964			2316	of malignant hyperthermia syndrome	C0024591	Malignant hyperpyrexia due to anesthesia	dsyn	Treatment of malignant hyperthermia syndrome	Malignant hyperthermia|GARD:0006964|DANTROLENE SODIUM SUSPENSION FOR INJECTION|RYANODEX|GARD:0006964	"MALIGNANT HYPERTHERMIA SUSCEPTIBILITY|HYPERPYREXIA, MALIGNANT|HYPERTHERMIA OF ANESTHESIA|MHS|MALIGNANT HYPERTHERMIA WITH ANESTHESIA|MALIGNANT HYPERTHERMIA|HYPERPYREXIAS, MALIGNANT|MALIGNANT HYPERPYREXIAS|MALIGNANT HYPERTHERMIAS|ANESTHESIA HYPERTHERMIA|ANESTHESIA HYPERTHERMIAS|RELATED HYPERTHERMIAS, ANESTHESIA|HYPERTHERMIAS, ANESTHESIA RELATED|ANESTHESIA RELATED HYPERTHERMIAS|HYPERTHERMIA, ANESTHESIA RELATED|RELATED HYPERTHERMIA, ANESTHESIA|HYPERTHERMIA, MALIGNANT|MALIGNANT HYPERPYREXIA|ANESTHESIA RELATED HYPERTHERMIA|MALIGNANT HYPERTHERMIA SYNDROME|MALIGNANT HYPERTHERMIA OF ANESTHESIA|MALIGNANT HYPERTHERMIA CAUSED BY ANESTHESIA|MALIGNANT HYPERPYREXIA CAUSED BY ANESTHESIA|MALIGNANT HYPERPYREXIA CAUSED BY ANESTHETIC|MALIGNANT HYPERPYREXIA DUE TO ANESTHETIC|MH - MALIGNANT HYPERPYREXIA|MHS - MALIGNANT HYPERTHERMIA|MALIGNANT HYPERPYREXIA DUE TO ANESTHESIA|MALIGNANT HYPERTHERMIA DUE TO ANESTHESIA|GTRT000009525|UMLS:C0024591|HP:0002047|MESH:D008305|NCI:C84869|MTHU023121|ORPHANET:423|SNOMEDCT_US:213026003|SNOMEDCT_US:405501007"	"MALIGNANT HYPERTHERMIA SUSCEPTIBILITY TYPE 3|MALIGNANT HYPERTHERMIA, SUSCEPTIBILITY TO, 3|MHS3|MALIGNANT HYPERPYREXIA SUSCEPTIBILITY TYPE 3|MHS3-RELATED MALIGNANT HYPERTHERMIA SUSCEPTIBILITY|GTRT000002816|UMLS:C1835160|OMIM:154276"	dantrolene sodium suspension for injection	Ryanodex	41502	Treatment of malignant hyperthermia syndrome	Designated/Approved	Approved for Orphan Indication	Treatment of malignant hyperthermia in conjunction with appropriate supportive measures and for the prevention of malignant hyperthermia in patients at high risk.	Ê07/22/2014Ê	Ê07/22/2021	"Eagle Pharmaceuticals, Inc."	50 Tice Blvd	Suite 315	Woodcliff Lake	New Jersey	7677	USA	179703
2661	Malignant mesothelioma	7026	approximate		4154	of malignant pleural mesothelioma	C0812413	Malignant Pleural Mesothelioma	neop	Treatment of malignant pleural mesothelioma	Malignant mesothelioma|GARD:0007026|PEMETREXED DISODIUM|ALIMTA|GARD:0007026	Malignant mesothelioma|GARD:0007026|ARENEGYR|GARD:0007026	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|NONSQUAMOUS NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	pemetrexed disodium	Alimta	37131	Treatment of malignant pleural mesothelioma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery	Ê02/04/2004Ê	Ê02/04/2011	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA	145101
2129	Management of acute repetitive seizures		MISSING		1574					Management of acute repetitive seizures	DIAZEPAM|DIAZEPAM (INTRANASAL)	Status epilepticus|GARD:0010191|DIAZEPAM|DIAZEPAM (INTRANASAL)|GARD:0010191	DUP15Q SYNDROME|15Q11.2-Q13.1 DUPLICATION SYNDROME|INVERTED DUPLICATION 15 (INV DUP15)|PARTIAL TRISOMY 15|ISODICENTRIC CHROMOSOME 15 SYNDROME [IDIC(15)]|INTERSTITIAL DUPLICATION CHROMOSOME 15 [INT DUP(15)]|SUPERNUMERARY MARKER CHROMOSOME 15 (SMC15)|PARTIAL TETRASOMY 15Q|INTERSTITIAL TRIPLICATION 15 [INT TRP(15)]	diazepam (intranasal)	Valtoco	42324	Management of acute repetitive seizures	Designated/Approved	Approved for Orphan Indication	"Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patients usual seizure pattern in patients with epilepsy 6 years of age and older."	Ê01/10/2020Ê	Ê01/10/2027	"Neurelis Pharmaceuticals, Inc."	11682 El Camino Reall	Suite 255	San Diego	California	92130	USA	382512
311	Mantle cell lymphoma	6969	done		1368	of mantle cell lymphoma	C0334634	"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"	neop	Treatment of mantle cell lymphoma	MANTLE CELL LYMPHOMA|DOID:50746|MESH:D020522	MANTLE CELL LYMPHOMA REFRACTORY|REFRACTORY MANTLE CELL LYMPHOMA|NCI:C8862|UMLS:C0855138	REFRACTORY MANTLE CELL LYMPHOMA|MANTLE CELL LYMPHOMA REFRACTORY|NCIT:C8862|NCI:C8862|UMLS:C0855138	zanubrutinib	Brukinsa	42544	Treatment of mantle cell lymphoma	Designated/Approved	Approved for Orphan Indication	BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.	Ê11/14/2019Ê	Ê11/14/2026	"BeiGene USA, Inc."	2955 Campus Drive	Suite 200	San Mateo	California	94403	USA	527416
118	Mantle cell lymphoma	6969	done		1617	of mantle cell lymphoma.	C0334634	"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"	neop	Treatment of mantle cell lymphoma.	MANTLE CELL LYMPHOMA|DOID:50746|MESH:D020522	MANTLE CELL LYMPHOMA REFRACTORY|REFRACTORY MANTLE CELL LYMPHOMA|NCI:C8862|UMLS:C0855138	REFRACTORY MANTLE CELL LYMPHOMA|MANTLE CELL LYMPHOMA REFRACTORY|NCIT:C8862|NCI:C8862|UMLS:C0855138	acalabrutinib	Calquence	42268	Treatment of mantle cell lymphoma.	Designated/Approved	Approved for Orphan Indication	treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy	Ê10/31/2017Ê	Ê10/31/2024	"Acerta Pharma, LLC (a member of the AstraZeneca Group)"	121 Oyster Point Blvd.		South San Francisco	California	94080	USA	488915
4586	Mantle cell lymphoma	6969			2482	of mantle cell lymphoma	C0334634	"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"	neop	Treatment of mantle cell lymphoma	MANTLE CELL LYMPHOMA|DOID:50746|MESH:D020522	MANTLE CELL LYMPHOMA REFRACTORY|REFRACTORY MANTLE CELL LYMPHOMA|NCI:C8862|UMLS:C0855138	REFRACTORY MANTLE CELL LYMPHOMA|MANTLE CELL LYMPHOMA REFRACTORY|NCIT:C8862|NCI:C8862|UMLS:C0855138	ibrutinib	Imbruvica	41246	Treatment of mantle cell lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy	Ê11/13/2013Ê	Ê11/13/2020	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA	383112
4588	Mantle cell lymphoma	6969			2600	of mantle cell lymphoma.	C0334634	"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"	neop	Treatment of mantle cell lymphoma.	MANTLE CELL LYMPHOMA|DOID:50746|MESH:D020522	MANTLE CELL LYMPHOMA REFRACTORY|REFRACTORY MANTLE CELL LYMPHOMA|NCI:C8862|UMLS:C0855138	REFRACTORY MANTLE CELL LYMPHOMA|MANTLE CELL LYMPHOMA REFRACTORY|NCIT:C8862|NCI:C8862|UMLS:C0855138	bortezomib	Velcade	41059	Treatment of mantle cell lymphoma.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with mantle cell lymphoma.	Ê10/08/2014Ê	Ê10/08/2021	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA	226106
4588	Mantle cell lymphoma	6969			2600	of mantle cell lymphoma.	C0334634	"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"	neop	Treatment of mantle cell lymphoma.	MANTLE CELL LYMPHOMA|DOID:50746|MESH:D020522	MANTLE CELL LYMPHOMA REFRACTORY|REFRACTORY MANTLE CELL LYMPHOMA|NCI:C8862|UMLS:C0855138	REFRACTORY MANTLE CELL LYMPHOMA|MANTLE CELL LYMPHOMA REFRACTORY|NCIT:C8862|NCI:C8862|UMLS:C0855138	bortezomib	Velcade	41059	Treatment of mantle cell lymphoma.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy.	Ê12/08/2006Ê	Ê12/08/2013	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA	226106
4593	Mantle cell lymphoma	6969			3202	of mantle cell lymphoma	C0334634	"Malignant lymphoma, lymphocytic, intermediate differentiation, diffuse"	neop	Treatment of mantle cell lymphoma	MANTLE CELL LYMPHOMA|DOID:50746|MESH:D020522	MANTLE CELL LYMPHOMA REFRACTORY|REFRACTORY MANTLE CELL LYMPHOMA|NCI:C8862|UMLS:C0855138	REFRACTORY MANTLE CELL LYMPHOMA|MANTLE CELL LYMPHOMA REFRACTORY|NCIT:C8862|NCI:C8862|UMLS:C0855138	lenalidomide	Revlimid	39930	Treatment of mantle cell lymphoma	Designated/Approved	Approved for Orphan Indication	"Treatment of mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib."	Ê06/05/2013Ê	Ê06/05/2020	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA	278809
6031	Marginal zone lymphoma	13237			1187	of splenic marginal zone lymphoma	C0349632	Splenic Marginal Zone B-Cell Lymphoma	neop	Treatment of splenic marginal zone lymphoma	Marginal zone lymphoma|GARD:0013237|IBRUTINIB|IMBRUVICA|GARD:0013237	Marginal zone lymphoma|GARD:0013237|LENALIDOMIDE|GARD:0013237	Marginal zone lymphoma|GARD:0013237|IDELALISIB|GARD:0013237	lenalidomide	Revlimid	42739	Treatment of splenic marginal zone lymphoma	Designated/Approved	Approved for Orphan Indication	"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL)."	Ê05/28/2019Ê	Ê05/28/2026	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA	475915
6026	Marginal zone lymphoma	13237			1846	of splenic marginal zone lymphoma	C0349632	Splenic Marginal Zone B-Cell Lymphoma	neop	Treatment of splenic marginal zone lymphoma	Marginal zone lymphoma|GARD:0013237|IBRUTINIB|IMBRUVICA|GARD:0013237	Marginal zone lymphoma|GARD:0013237|LENALIDOMIDE|GARD:0013237	Marginal zone lymphoma|GARD:0013237|IDELALISIB|GARD:0013237	ibrutinib	Imbruvica	42040	Treatment of splenic marginal zone lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.	Ê01/18/2017Ê	Ê01/18/2024	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA	462314
6030	Marginal zone lymphoma	13237			1743	of extranodal marginal zone lymphoma	C0242647	Mucosa-Associated Lymphoid Tissue Lymphoma	neop	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	REFRACTORY EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|REFRACTORY EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE) REFRACTORY|REFRACTORY EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)|NCIT:C5090|NCI:C5090|UMLS:C0856011	REFRACTORY EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|REFRACTORY EXTRANODAL MARGINAL ZONE LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE) REFRACTORY|REFRACTORY EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)|NCI:C5090|UMLS:C0856011	Marginal zone lymphoma|GARD:0013237|IBRUTINIB|IMBRUVICA|GARD:0013237	lenalidomide	Revlimid	42123	Treatment of extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue	Designated/Approved	Approved for Orphan Indication	"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL)."	Ê05/28/2019Ê	Ê05/28/2026	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA	476115
6032	Marginal zone lymphoma	13237			1188	of nodal marginal zone lymphoma	C0242647	Mucosa-Associated Lymphoid Tissue Lymphoma	neop	Treatment of nodal marginal zone lymphoma	REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NODAL MARGINAL ZONE B-CELL LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA REFRACTORY|NCIT:C4997|NCI:C4997|UMLS:C0855141	REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NODAL MARGINAL ZONE B-CELL LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA REFRACTORY|NCI:C4997|UMLS:C0855141	Marginal zone lymphoma|GARD:0013237|IBRUTINIB|IMBRUVICA|GARD:0013237	lenalidomide	Revlimid	42739	Treatment of nodal marginal zone lymphoma	Designated/Approved	Approved for Orphan Indication	"REVLIMID in combination with a rituximab product, is indicated for the treatment of adult patients with previously treated marginal zone lymphoma (MZL)."	Ê05/28/2019Ê	Ê05/28/2026	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA	476015
6025	Marginal zone lymphoma	13237			1845	of nodal marginal zone lymphoma	C0242647	Mucosa-Associated Lymphoid Tissue Lymphoma	neop	Treatment of nodal marginal zone lymphoma	REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NODAL MARGINAL ZONE B-CELL LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA REFRACTORY|NCIT:C4997|NCI:C4997|UMLS:C0855141	REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NODAL MARGINAL ZONE B-CELL LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA REFRACTORY|NCI:C4997|UMLS:C0855141	Marginal zone lymphoma|GARD:0013237|IBRUTINIB|IMBRUVICA|GARD:0013237	ibrutinib	Imbruvica	42040	Treatment of nodal marginal zone lymphoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.	Ê01/18/2017Ê	Ê01/18/2024	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA	462214
6027	Marginal zone lymphoma	13237			1512	with extranodal marginal zone lymphoma	C0242647	Mucosa-Associated Lymphoid Tissue Lymphoma	neop	Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)				ibrutinib	Imbruvica	42402	Treatment of patients with extranodal marginal zone lymphoma (mucosa associated lymphoid tissue [MALT type] lymphoma)	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.	Ê01/18/2017Ê	Ê01/18/2024	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA	462114
4603	Mastocytosis	6987			3023	of mastocytosis	C0024899	Mastocytosis	dsyn	Treatment of mastocytosis	Mastocytosis|GARD:0006987|MASITINIB|GARD:0006987	Mastocytosis|GARD:0006987|MIDOSTAURIN|RYDAPT|GARD:0006987	Mastocytosis|GARD:0006987|CROMOLYN SODIUM FOR INHALATION|GARD:0006987	midostaurin	Rydapt	40298	Treatment of mastocytosis	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL)"	Ê04/28/2017Ê	Ê04/28/2024	Novartis Pharmaceuticals Corporation	"One Health Plaza, 105/3W038"		East Hanover	New Jersey	7936	USA	306410
4605	Mastocytosis	6987			5258	of mastocytosis.	C0024899	Mastocytosis	dsyn	Treatment of mastocytosis.	Mastocytosis|GARD:0006987|MASITINIB|GARD:0006987	Mastocytosis|GARD:0006987|MIDOSTAURIN|RYDAPT|GARD:0006987	Mastocytosis|GARD:0006987|CROMOLYN SODIUM FOR INHALATION|GARD:0006987	Cromolyn sodium	Gastrocrom	30749	Treatment of mastocytosis.	Designated/Approved	Approved for Orphan Indication		Ê12/22/1989Ê	Ê12/22/1996	Fisons Corporation	"755 Jefferson Rd., P.O. Box 1710"		Rochester	New York	14603	USA	1183
4602	Mastocytosis	6987			3741	of systemic mastocytosis	C0221013	"Mastocytosis, Systemic"	dsyn	Treatment of systemic mastocytosis without the D816V c-kit mutation	Systemic mastocytosis|GARD:0008616|IMATINIB MESYLATE|GLEEVEC|GARD:0008616	Mastocytosis|GARD:0006987|IMATINIB MESYLATE|GLEEVEC|GARD:0006987	"AGGRESSIVE SYSTEMIC MASTOCYTOSIS|MASTOCYTOSIS, SYSTEMIC|AGGRESSIVE SYSTEMIC MASTOCYTOSIS (D816V C-KIT MUTATION STATUS NEGATIVE/C-KIT MUTATIONAL STATUS UNKNOWN)|DOID:4798|MESH:D034721"	Imatinib mesylate	Gleevec	38604	Treatment of systemic mastocytosis without the D816V c-kit mutation	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with aggressive mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown	Ê10/19/2006Ê	Ê10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA	209205
2841	Maternal hyperphenylalaninemia 	3413	approximate		3957	of hyperphenylalaninemia	C0751435	Hyperphenylalaninaemia	dsyn	Treatment of hyperphenylalaninemia	 Hyperphenylalaninemia due to dehydratase deficiency|GARD:0002843|PHENYLALANINE|PHENYLALANINE AMMONIA-LYASE|PHENYLASE. RAVPAL-PEG|GARD:0002843	Maternal hyperphenylalaninemia |GARD:0003413|PHENYLALANINE|PHENYLALANINE AMMONIA-LYASE|PHENYLASE. RAVPAL-PEG|GARD:0003413	"Maternal hyperphenylalaninemia |GARD:0003413|VALINE|VALINE, ISOLEUCINE AND LEUCINE|VIL|GARD:0003413"	sapropterin	Kuvan	38015	Treatment of hyperphenylalaninemia	Designated/Approved	Approved for Orphan Indication	Indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.	Ê12/13/2007Ê	Ê12/13/2014	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA	181503
1286	Maternal hyperphenylalaninemia 	3413	approximate		4585	of hyperphenylalaninemia	C0751435	Hyperphenylalaninaemia	dsyn	Treatment of hyperphenylalaninemia	 Hyperphenylalaninemia due to dehydratase deficiency|GARD:0002843|PHENYLALANINE|PHENYLALANINE AMMONIA-LYASE|PHENYLASE. RAVPAL-PEG|GARD:0002843	Maternal hyperphenylalaninemia |GARD:0003413|PHENYLALANINE|PHENYLALANINE AMMONIA-LYASE|PHENYLASE. RAVPAL-PEG|GARD:0003413	"Maternal hyperphenylalaninemia |GARD:0003413|VALINE|VALINE, ISOLEUCINE AND LEUCINE|VIL|GARD:0003413"	pegvaliase-pqpz	Palynziq	34766	Treatment of hyperphenylalaninemia	Designated/Approved	Approved for Orphan Indication	Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management	Ê05/24/2018Ê	Ê05/24/2025	BioMarin Pharmaceutical Inc.	105 Digital Drive		Novato	California	94949	USA	88195
3814	Mediterranean fever	5966			2208	of familial mediterranean fever	C0031069	Familial Mediterranean Fever	dsyn	Treatment of familial mediterranean fever	Mediterranean fever|GARD:0005966|RILONACEPT|ARCALYST|GARD:0005966	Familial Mediterranean fever|GARD:0006421|RILONACEPT|ARCALYST|GARD:0006421	Familial Mediterranean fever|GARD:0006421|COLCHICINE|COLCRYS|GARD:0006421	canakinumab	Ilaris	41613	Treatment of familial mediterranean fever	Designated/Approved	Approved for Orphan Indication	Indicated for treatment of Familial Mediterranean Fever (FMF) in adult and pediatric patients	Ê09/23/2016Ê	Ê09/23/2023	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	412813
3816	Mediterranean fever	5966			3460	of familial Mediterranean fever	C0031069	Familial Mediterranean Fever	dsyn	Treatment of familial Mediterranean fever	Mediterranean fever|GARD:0005966|RILONACEPT|ARCALYST|GARD:0005966	Familial Mediterranean fever|GARD:0006421|RILONACEPT|ARCALYST|GARD:0006421	Familial Mediterranean fever|GARD:0006421|COLCHICINE|COLCRYS|GARD:0006421	colchicine	Colcrys	39350	Treatment of familial Mediterranean fever	Designated/Approved	Approved for Orphan Indication	Treatment of familial Mediterranean fever	Ê07/29/2009Ê	Ê07/29/2016	"AR Holding Company, Inc."	1100 Orthodox Street		Philadelphia	Pennsylvania	19124	USA	245807
2053	"Melanoma, familial"	3460	approximate		2176	IV melanoma	C0025202	melanoma	neop	"Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation"	"Melanoma, familial|GARD:0003460|COBIMETINIB|GARD:0003460"			cobimetinib	n/a	41670	"Treatment of stage IIb, IIc, III, and IV melanoma with BRAFV600 mutation"	Designated/Approved	Approved for Orphan Indication	"For the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutation, in combination with vemurafenib. Limitations of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma."	Ê11/10/2015Ê	Ê11/10/2022	"Genentech, Inc."	"1 DNA Way, MS 241A"		South San Francisco	California	94080	USA	419513
Missing	"Melanoma, familial"	3460	approximate		1963	IV melanoma	C0025202	melanoma	neop	Treatment of Stage IIb to Stage IV melanoma	"Melanoma, familial|GARD:0003460|ETARACIZUMAB|ABEGRIN|GARD:0003460"	"Melanoma, familial|GARD:0003460|POLYVALENT, SHED-ANTIGEN MELANOMA VACCINE|GARD:0003460"	"Melanoma, familial|GARD:0003460|MELANOMA PEPTIDE VACCINE|GARD:0003460"	Combination of nivolumab and ipilimumab	n/a	41921	Treatment of Stage IIb to Stage IV melanoma	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma"	Ê09/30/2015Ê	Ê09/30/2022	Bristol-Myers Squibb Company	5 Research Parkway		Wallingford	Connecticut	6492	USA	445014
Missing	"Melanoma, familial"	3460	approximate		2826	of stage IIb-stage IV melanoma	C1336187	Stage IIB Skin Melanoma	neop	Treatment of stage IIb-stage IV melanoma	"Melanoma, familial|GARD:0003460|ETARACIZUMAB|ABEGRIN|GARD:0003460"	"Melanoma, familial|GARD:0003460|POLYVALENT, SHED-ANTIGEN MELANOMA VACCINE|GARD:0003460"	"Melanoma, familial|GARD:0003460|MELANOMA PEPTIDE VACCINE|GARD:0003460"	talimogene laherparepvec	Imlygic	40616	Treatment of stage IIb-stage IV melanoma	Designated/Approved	Approved for Orphan Indication	"Indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery"	Ê10/27/2015Ê	Ê10/27/2022	"BioVex, Inc. (subsidiary of Amgen)"	Amgen	Mail Stop 17-2-B	Thousand Oaks	California	91320	USA	334011
Missing	"Melanoma, familial"	3460	approximate		2495	through IV malignant melanoma	C0025202	melanoma	neop	Treatment of Stage IIB through IV malignant melanoma	"Melanoma, familial|GARD:0003460|IDRONOXIL|(+/-)-CIS-3-(4-HYDROXYPHENYL)-4-(4-METHOXYPHENYL)-3,4-DIHYDRO-2H-CROMEN-7-OL|PHENOXODIOL|GARD:0003460"	"MELANOMA, MALIGNANT|MELANOBLASTOMA|MELANOCARCINOMA|MELANOEPITHELIOMA|MELANOMA|MELANOSARCOMA|MELANOSCIRRHUS|MELANOTIC CARCINOMA|NEVUS PIGMENTOSA"		pembrolizumab	Keytruda	41232	Treatment of Stage IIB through IV malignant melanoma	Designated/Approved	Approved for Orphan Indication	KEYTRUDA is indicated for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.	Ê02/15/2019Ê	Ê02/15/2026	"Merck, Sharp & Dohme Corp."	351 North Sumneytown Pike	UG2CDS-015	North Wales	Pennsylvania	19454	USA	381012
Missing	"Melanoma, familial"	3460	approximate		2495	through IV malignant melanoma	C0025202	melanoma	neop	Treatment of Stage IIB through IV malignant melanoma	"Melanoma, familial|GARD:0003460|IDRONOXIL|(+/-)-CIS-3-(4-HYDROXYPHENYL)-4-(4-METHOXYPHENYL)-3,4-DIHYDRO-2H-CROMEN-7-OL|PHENOXODIOL|GARD:0003460"	"MELANOMA, MALIGNANT|MELANOBLASTOMA|MELANOCARCINOMA|MELANOEPITHELIOMA|MELANOMA|MELANOSARCOMA|MELANOSCIRRHUS|MELANOTIC CARCINOMA|NEVUS PIGMENTOSA"		pembrolizumab	Keytruda	41232	Treatment of Stage IIB through IV malignant melanoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with unresectable or metastatic melanoma.	Ê12/18/2015Ê	Ê12/18/2022	"Merck, Sharp & Dohme Corp."	351 North Sumneytown Pike	UG2CDS-015	North Wales	Pennsylvania	19454	USA	381012
Missing	"Melanoma, familial"	3460	approximate		2495	through IV malignant melanoma	C0025202	melanoma	neop	Treatment of Stage IIB through IV malignant melanoma	"Melanoma, familial|GARD:0003460|IDRONOXIL|(+/-)-CIS-3-(4-HYDROXYPHENYL)-4-(4-METHOXYPHENYL)-3,4-DIHYDRO-2H-CROMEN-7-OL|PHENOXODIOL|GARD:0003460"	"MELANOMA, MALIGNANT|MELANOBLASTOMA|MELANOCARCINOMA|MELANOEPITHELIOMA|MELANOMA|MELANOSARCOMA|MELANOSCIRRHUS|MELANOTIC CARCINOMA|NEVUS PIGMENTOSA"		pembrolizumab	Keytruda	41232	Treatment of Stage IIB through IV malignant melanoma	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor."	Ê09/04/2014Ê	Ê09/04/2021	"Merck, Sharp & Dohme Corp."	351 North Sumneytown Pike	UG2CDS-015	North Wales	Pennsylvania	19454	USA	381012
Missing	"Melanoma, familial"	3460	approximate		2536	through IV melanoma.	C0025202	melanoma	neop	Treatment of Stage IIb through IV melanoma.	"Melanoma, familial|GARD:0003460|IDRONOXIL|(+/-)-CIS-3-(4-HYDROXYPHENYL)-4-(4-METHOXYPHENYL)-3,4-DIHYDRO-2H-CROMEN-7-OL|PHENOXODIOL|GARD:0003460"	"MELANOMA, MALIGNANT|MELANOBLASTOMA|MELANOCARCINOMA|MELANOEPITHELIOMA|MELANOMA|MELANOSARCOMA|MELANOSCIRRHUS|MELANOTIC CARCINOMA|NEVUS PIGMENTOSA"		trametinib and dabrafenib	Mekinist And Tafinlar	41172	Treatment of Stage IIb through IV melanoma.	Designated/Approved	Approved for Orphan Indication	"TAFINLAR is indicated, in combination with trametinib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection"	Ê04/30/2018Ê	Ê04/30/2025	Novartis Pharmaceuticals Corporation	One Health Plaza	Office 337 A13.5B	East Hanover	New Jersey	7936	USA	376812
Missing	"Melanoma, familial"	3460	approximate		2536	through IV melanoma.	C0025202	melanoma	neop	Treatment of Stage IIb through IV melanoma.	"Melanoma, familial|GARD:0003460|IDRONOXIL|(+/-)-CIS-3-(4-HYDROXYPHENYL)-4-(4-METHOXYPHENYL)-3,4-DIHYDRO-2H-CROMEN-7-OL|PHENOXODIOL|GARD:0003460"	"MELANOMA, MALIGNANT|MELANOBLASTOMA|MELANOCARCINOMA|MELANOEPITHELIOMA|MELANOMA|MELANOSARCOMA|MELANOSCIRRHUS|MELANOTIC CARCINOMA|NEVUS PIGMENTOSA"		trametinib and dabrafenib	Mekinist And Tafinlar	41172	Treatment of Stage IIb through IV melanoma.	Designated/Approved	Approved for Orphan Indication	MEKINIST (trametinib) in combination with dabrafenib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for MEKINIST in combination with dabrafenib.	Ê01/08/2014Ê	Ê01/08/2021	Novartis Pharmaceuticals Corporation	One Health Plaza	Office 337 A13.5B	East Hanover	New Jersey	7936	USA	376812
Missing	"Melanoma, familial"	3460	approximate		2536	through IV melanoma.	C0025202	melanoma	neop	Treatment of Stage IIb through IV melanoma.	"Melanoma, familial|GARD:0003460|IDRONOXIL|(+/-)-CIS-3-(4-HYDROXYPHENYL)-4-(4-METHOXYPHENYL)-3,4-DIHYDRO-2H-CROMEN-7-OL|PHENOXODIOL|GARD:0003460"	"MELANOMA, MALIGNANT|MELANOBLASTOMA|MELANOCARCINOMA|MELANOEPITHELIOMA|MELANOMA|MELANOSARCOMA|MELANOSCIRRHUS|MELANOTIC CARCINOMA|NEVUS PIGMENTOSA"		trametinib and dabrafenib	Mekinist And Tafinlar	41172	Treatment of Stage IIb through IV melanoma.	Designated/Approved	Approved for Orphan Indication	TAFINLAR (dabrafenib) in combination with trametinib for treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. This indication is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for TAFINLAR in combination with trametinib.	Ê01/08/2014Ê	Ê01/08/2021	Novartis Pharmaceuticals Corporation	One Health Plaza	Office 337 A13.5B	East Hanover	New Jersey	7936	USA	376812
Missing	"Melanoma, familial"	3460	approximate		2536	through IV melanoma.	C0025202	melanoma	neop	Treatment of Stage IIb through IV melanoma.	"Melanoma, familial|GARD:0003460|IDRONOXIL|(+/-)-CIS-3-(4-HYDROXYPHENYL)-4-(4-METHOXYPHENYL)-3,4-DIHYDRO-2H-CROMEN-7-OL|PHENOXODIOL|GARD:0003460"	"MELANOMA, MALIGNANT|MELANOBLASTOMA|MELANOCARCINOMA|MELANOEPITHELIOMA|MELANOMA|MELANOSARCOMA|MELANOSCIRRHUS|MELANOTIC CARCINOMA|NEVUS PIGMENTOSA"		trametinib and dabrafenib	Mekinist And Tafinlar	41172	Treatment of Stage IIb through IV melanoma.	Designated/Approved	Approved for Orphan Indication	"MEKINIST is indicated, in combination with dabrafenib, for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection"	Ê04/30/2018Ê	Ê04/30/2025	Novartis Pharmaceuticals Corporation	One Health Plaza	Office 337 A13.5B	East Hanover	New Jersey	7936	USA	376812
Missing	"Melanoma, familial"	3460	approximate		2878	through Stage IV melanoma	C0280209	"stage, melanoma"	neop	Treatment of Stage IIb through Stage IV melanoma	"Melanoma, familial|GARD:0003460|IDRONOXIL|(+/-)-CIS-3-(4-HYDROXYPHENYL)-4-(4-METHOXYPHENYL)-3,4-DIHYDRO-2H-CROMEN-7-OL|PHENOXODIOL|GARD:0003460"	"MELANOMA, MALIGNANT|MELANOBLASTOMA|MELANOCARCINOMA|MELANOEPITHELIOMA|MELANOMA|MELANOSARCOMA|MELANOSCIRRHUS|MELANOTIC CARCINOMA|NEVUS PIGMENTOSA"		trametinib	Mekinist	40532	Treatment of Stage IIb through Stage IV melanoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA approved test.	Ê05/29/2013Ê	Ê05/29/2020	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA	325410
Missing	"Melanoma, familial"	3460	approximate		2446	to IV melanoma	C0025202	melanoma	neop	Treatment of Stage IIb to IV melanoma	"Melanoma, familial|GARD:0003460|POLYVALENT, SHED-ANTIGEN MELANOMA VACCINE|GARD:0003460"	"Melanoma, familial|GARD:0003460|ETARACIZUMAB|ABEGRIN|GARD:0003460"	"Melanoma, familial|GARD:0003460|MELANOMA PEPTIDE VACCINE|GARD:0003460"	nivolumab	Opdivo	41297	Treatment of Stage IIb to IV melanoma	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor"	Ê12/22/2014Ê	Ê12/22/2021	Bristol-Myers Squibb Co.	P.O. Box 4000		Princeton	New Jersey	8543	USA	387612
Missing	"Melanoma, familial"	3460	approximate		2446	to IV melanoma	C0025202	melanoma	neop	Treatment of Stage IIb to IV melanoma	"Melanoma, familial|GARD:0003460|POLYVALENT, SHED-ANTIGEN MELANOMA VACCINE|GARD:0003460"	"Melanoma, familial|GARD:0003460|ETARACIZUMAB|ABEGRIN|GARD:0003460"	"Melanoma, familial|GARD:0003460|MELANOMA PEPTIDE VACCINE|GARD:0003460"	nivolumab	Opdivo	41297	Treatment of Stage IIb to IV melanoma	Designated/Approved	Approved for Orphan Indication	Adjuvant treatment of patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection	Ê12/20/2017Ê	Ê12/20/2024	Bristol-Myers Squibb Co.	P.O. Box 4000		Princeton	New Jersey	8543	USA	387612
Missing	"Melanoma, familial"	3460	approximate		4504	of metastatic melanoma.	C0278883	Metastatic melanoma	neop	Treatment of metastatic melanoma.	MELANOMA|UNRESECTABLE OR METASTATIC MELANOMA|DOID:1909|MESH:D008545	METASTATIC MELANOMA|MELANOMA|ADVANCED MELANOMA|DOID:4358|MESH:D008545	METASTATIC RENAL CELL CARCINOMA|RENAL CELL CARCINOMA|DOID:7486|MESH:D002292	Aldesleukin	Proleukin	35318	Treatment of metastatic melanoma.	Designated/Approved	Approved for Orphan Indication	Treatment of adults with metastatic melanoma.	Ê01/09/1998Ê	Ê01/09/2005	Chiron Corporation	4560 Horton St.		Emeryville	California	94608	USA	100696
2382	"Melanoma, familial"	3460	approximate		3909	Stage IV melanoma	C0280209	"stage, melanoma"	neop	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	MUPARFOSTAT|MANNOPENTAOSE PHOSPHATE SULFATE	IPILIMUMAB|YERVOY	 Primary malignant melanoma of the conjunctiva |GARD:0010410|INTETUMUMAB|HUMAN ANTI-INTEGRIN RECEPTOR AVB3/AVB5 MONOCLONAL ANTIBODY|GARD:0010410	ipilimumab	Yervoy	38141	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	Designated/Approved	Approved for Orphan Indication	"For the adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm, who have undergone complete resection including total lymphadenectomy."	Ê10/28/2015Ê	Ê10/28/2022	Bristol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA	177703
2382	"Melanoma, familial"	3460	approximate		3909	Stage IV melanoma	C0280209	"stage, melanoma"	neop	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	MUPARFOSTAT|MANNOPENTAOSE PHOSPHATE SULFATE	IPILIMUMAB|YERVOY	 Primary malignant melanoma of the conjunctiva |GARD:0010410|INTETUMUMAB|HUMAN ANTI-INTEGRIN RECEPTOR AVB3/AVB5 MONOCLONAL ANTIBODY|GARD:0010410	ipilimumab	Yervoy	38141	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	Designated/Approved	Approved for Orphan Indication	Treatment of unresectable or metastatic melanoma	Ê03/25/2011Ê	Ê03/25/2018	Bristol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA	177703
2382	"Melanoma, familial"	3460	approximate		3909	Stage IV melanoma	C0280209	"stage, melanoma"	neop	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	MUPARFOSTAT|MANNOPENTAOSE PHOSPHATE SULFATE	IPILIMUMAB|YERVOY	 Primary malignant melanoma of the conjunctiva |GARD:0010410|INTETUMUMAB|HUMAN ANTI-INTEGRIN RECEPTOR AVB3/AVB5 MONOCLONAL ANTIBODY|GARD:0010410	ipilimumab	Yervoy	38141	"Treatment of high risk Stage II, Stage III, and Stage IV melanoma"	Designated/Approved	Approved for Orphan Indication	treatment of unresectable or metastatic melanoma in adults and pediatric patients (12 years and older)	Ê07/21/2017Ê	Ê07/21/2024	Bristol-Myers Squibb Company	P. O. Box 4000		Princeton	New Jersey	8543	USA	177703
Missing	"Melanoma, familial"	3460	approximate		2877	IV melanoma positive	C0025202	melanoma	neop	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation				vemurafenib	Zelboraf	40532	Treatment of patients with IIb to Stage IV melanoma positive for the BRAF(v600) mutation	Designated/Approved	Approved for Orphan Indication	Treatment of unresectable or metastatic melanoma with the BRAFV600E mutation as detected by an FDA-approved test.	Ê08/17/2011Ê	Ê08/17/2018	"Hoffmann-La Roche, Inc."	340 Kingsland Street		Nutley	New Jersey	7110	USA	325310
Missing	"Melanoma, familial"	3460	approximate		2868	through IV melanoma	C0025202	melanoma	neop	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma				dabrafenib	Tafinlar	40555	Treatment BRAF V600 mutation positive Stage IIB through IV melanoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA approved test.	Ê05/29/2013Ê	Ê05/29/2020	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA	329610
Missing	"Melanoma, familial"	3460	approximate		3370	of malignant melanoma	C0025202	melanoma	neop	Treatment of malignant melanoma stages IIb through IV.				peginterferon alfa-2b	Sylatron	39547	Treatment of malignant melanoma stages IIb through IV.	Designated/Approved	Approved for Orphan Indication	Adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy	Ê03/29/2011Ê	ÊN/A	"Merck, Sharpe & Dohme Corp."	1 Merck Drive		Whitehouse Station	New Jersey	8889	USA	249507
Missing	"Melanoma, familial"	3460	approximate		2228	of Stage IIB-IV melanoma positive	C1336187	Stage IIB Skin Melanoma	neop	Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.				encorafenib + binimetinib	n/a	41597	Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.	Designated/Approved	Approved for Orphan Indication	"MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test"	Ê06/27/2018Ê	Ê06/27/2025	"Array BioPharma, Inc."	100 Cambridgepark Drive	Suite 505	Cambridge	Massachusetts	2140	USA	411613
Missing	"Melanoma, familial"	3460	approximate		2228	of Stage IIB-IV melanoma positive	C1336187	Stage IIB Skin Melanoma	neop	Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.				encorafenib + binimetinib	n/a	41597	Treatment of Stage IIB-IV melanoma positive for the BRAF mutation.	Designated/Approved	Approved for Orphan Indication	"BRAFTOVI is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test"	Ê06/27/2018Ê	Ê06/27/2025	"Array BioPharma, Inc."	100 Cambridgepark Drive	Suite 505	Cambridge	Massachusetts	2140	USA	411613
538	Meningeal Carcinomatosis		MISSING		4697	of neoplastic meningitis.	C0220654	Meningeal Carcinomatosis	neop	Treatment of neoplastic meningitis.	MAFOSFAMIDE	CYTARABINE|CYTARABINE LIPOSOMAL|DEPOCYT	MAFOSFAMIDE|NCIT:C1150|NCI:C1150|NSC:345842|UMLS:C0065506	Cytarabine liposomal	Depocyt	34122	Treatment of neoplastic meningitis.	Designated/Approved	Approved for Orphan Indication	Intrathecal treatment of lymphomatous meningitis.	Ê04/01/1999Ê	Ê04/01/2006	"Pacira Pharmaceuticals, Inc."	10450 Science Center Drive		San Diego	California	92121	USA	73393
998	"Meningitis, Cryptococcal"		MISSING		4487	of cryptococcal meningitis.	C0085436	"Meningitis, Cryptococcal"	dsyn	Treatment of cryptococcal meningitis.	"CRYPTOCOCCAL MENINGITIS|MENINGITIS, CRYPTOCOCCAL|DOID:12052|MESH:D016919"	VT-1129|SELECTIVE INHIBITOR OF FUNGAL LANOSTEROL DEMETHYLASE	AMPHOTERICIN B|LIPOSOMAL AMPHOTERICIN B|AMBISOME	Liposomal amphotericin B	Ambisome	35409	Treatment of cryptococcal meningitis.	Designated/Approved	Approved for Orphan Indication	Treatment of disseminated cryptococcosis including meningitis.	Ê08/11/1997Ê	Ê08/11/2004	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA	99496
5619	Merkel cell carcinoma	9266			1195	of Merkel cell carcinoma	C0007129	Merkel cell carcinoma	neop	Treatment of Merkel cell carcinoma	MERKEL CELL CARCINOMA|DOID:3965|MESH:D015266	Merkel cell carcinoma|GARD:0009266|PEMBROLIZUMAB|KEYTRUDA|GARD:0009266	Merkel cell carcinoma|GARD:0009266|IMGN-901|MAYTANSINOID DM1-CONJUGATED HUMANIZED MONOCLONAL ANTIBODY N901|CD123|GARD:0009266	pembrolizumab	Keytruda	42732	Treatment of Merkel cell carcinoma	Designated/Approved	Approved for Orphan Indication	KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma	Ê12/19/2018Ê	Ê12/19/2025	"Merck, Sharp, and Dohme Corp."	351 North Sumneytown Pike	UG2D-027	North Wales	Pennsylvania	19454	USA	548216
5620	Merkel cell carcinoma	9266			1620	of merkel cell carcinoma.	C0007129	Merkel cell carcinoma	neop	Treatment of merkel cell carcinoma.	MERKEL CELL CARCINOMA|DOID:3965|MESH:D015266	Merkel cell carcinoma|GARD:0009266|PEMBROLIZUMAB|KEYTRUDA|GARD:0009266	Merkel cell carcinoma|GARD:0009266|IMGN-901|MAYTANSINOID DM1-CONJUGATED HUMANIZED MONOCLONAL ANTIBODY N901|CD123|GARD:0009266	avelumab (Recombinant human monoclonal IgG1 antibody against programmed death ligand-1)	Bavencio	42268	Treatment of merkel cell carcinoma.	Designated/Approved	Approved for Orphan Indication	Treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma	Ê03/23/2017Ê	Ê03/23/2024	"EMD Serono Research and Development Institute, Inc."	45A Middlesex Turnpike		Billerica	Massachusetts	1821	USA	491815
670	Metaplastic carcinoma of the breast	10804	approximate		4803	of advanced breast cancer	C0877373	advanced cancer	neop	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Metaplastic carcinoma of the breast|GARD:0010804|EXEMESTANE|AROMASIN|GARD:0010804	BREAST CANCER|BREAST NEOPLASMS|ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN|DOID:1612|MESH:D001943	ESTROGEN-RECEPTOR POSITIVE BREAST CANCER|BREAST NEOPLASMS|ESTROGEN-RECEPTOR POSITIVE EARLY BREAST CANCER|DOID:60075|MESH:D001943	Exemestane	Aromasin	33500	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Designated/Approved	Approved for Orphan Indication	Treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.	Ê10/21/1999Ê	Ê10/21/2006	Pharmacia & Upjohn	7000 Portage Road	Mail Stop: 0636-298-113	Kalamazoo	Michigan	49001	USA	60191
Missing	Metastatic Carcinoma		MISSING	Not a rare disease	4804	of metastatic carcinoma	C1384494	Metastatic Carcinoma	neop	Hormonal therapy of metastatic carcinoma of the breast.				Toremifene	Fareston	33500	Hormonal therapy of metastatic carcinoma of the breast.	Designated/Approved	Approved for Orphan Indication	Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.	Ê05/29/1997Ê	Ê05/29/2004	Orion Corporation	Orionintie 1	0FI-02200	Espoo			Finland	60291
4637	Mucopolysaccharidosis I	C0023786			4441	with mucopolysaccharidosis-I.	C0023786	Mucopolysaccharidosis I	dsyn	Treatment of patients with mucopolysaccharidosis-I.	Mucopolysaccharidosis|GARD:0007065|LARONIDASE|ALDURAZYME|GARD:0007065	MUCOPOLYSACCHARIDOSIS VII|DOID:12803|MESH:D016538	"Mucopolysaccharidosis type VI|GARD:0007095|GALSULFASE|N-ACETYLGALACTOSAMINE-4-SULFATASE, RECOMBINANT HUMAN|NAGLAZYME|GARD:0007095"	laronidase	Aldurazyme	35697	Treatment of patients with mucopolysaccharidosis-I.	Designated/Approved	Approved for Orphan Indication	Treatment for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms	Ê04/30/2003Ê	Ê04/30/2010	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA	106097
4628	Mucopolysaccharidosis II	C0026705			4129	(Hunter Syndrome	C0026705	Mucopolysaccharidosis II	dsyn	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Mucopolysaccharidosis|GARD:0007065|IDURSULFASE|ELAPRASE|GARD:0007065	MUCOPOLYSACCHARIDOSES|MPS|MPS DISORDER	"I CELL DISEASE|GNPTA|INCLUSION CELL DISEASE|LEROY DISEASE|ML DISORDER, TYPE II|ML II|MUCOLIPIDOSIS II|N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE DEFICIENCY"	idursulfase	Elaprase	37223	Long term enzyme replacement therapy for patients with mucopolysaccharidosis II (Hunter Syndrome)	Designated/Approved	Approved for Orphan Indication	"Indicated for patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Idursulfase has been shown to improve walking capacity in these patients"	Ê07/24/2006Ê	Ê07/24/2013	"Shire Human Genetic Therapies, Inc."	700 Main Street		Cambridge	Massachusetts	2139	USA	147301
4636	Mucopolysaccharidosis IV	C0026707			3187	of mucopolysaccharidosis (MPS) Type IV A	C0026707	Mucopolysaccharidosis IV	dsyn	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	Mucopolysaccharidosis|GARD:0007065|ELOSULFASE ALFA|VIMIZIM|GARD:0007065	MUCOPOLYSACCHARIDOSES|MPS|MPS DISORDER	"SCHWARTZ JAMPEL SYNDROME|CHONDRODYSTROPHIC MYOTONIA|MYOTONIC MYOPATHY, DWARFISM, CHONDRODYSTROPHY, OCULAR & FACIAL ANOMALIES|SCHWARTZ-JAMPEL-ABERFELD SYNDROME|SJA SYNDROME|SJS"	elosulfase alfa	Vimizim	39948	Use in the treatment of mucopolysaccharidosis (MPS) Type IV A (Morquio A syndrome)	Designated/Approved	Approved for Orphan Indication	Patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome)	Ê02/14/2014Ê	Ê02/14/2021	BioMarin Pharmaceutical Inc.	105 Digital Drive		Novato	California	94949	USA	280809
718	Mucopolysaccharidosis type VI	7095	done		4349	(Maroteaux-Lamy syndrome	C0026709	Mucopolysaccharidosis VI	dsyn	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	Mucopolysaccharidosis type VI|GARD:0007095|ODIPARCIL|GARD:0007095	Mucopolysaccharidosis|GARD:0007065|ODIPARCIL|GARD:0007065	Mucopolysaccharidosis type VI|GARD:0007095|ADENO ASSOCIATED VIRAL VECTOR CONTAINING HUMAN ARSB GENE|GARD:0007095	"N-acetylgalactosamine-4-sulfatase, recombinant human"	Naglazyme	36208	Treatment of mucopolysaccharidosis Type VI (Maroteaux-Lamy syndrome).	Designated/Approved	Approved for Orphan Indication	For patients with mucopolysaccharidosis VI. Galsulfase has been shown to improve walking and stair-climbing capacity.	Ê05/31/2005Ê	Ê05/31/2012	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA	119898
1700	Mucopolysaccharidosis type VII	7096	done		2658	"(MPS VII,"	C0085132	Mucopolysaccharidosis VII	dsyn	"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)"	MUCOPOLYSACCHARIDOSIS VII|DOID:12803|MESH:D016538	Mucopolysaccharidosis type VII|GARD:0007096|VESTRONIDASE ALFA|RECOMBINANT HUMAN BETA-GLUCURONIDASE|GARD:0007096	Mucopolysaccharidosis|GARD:0007065|VESTRONIDASE ALFA|RECOMBINANT HUMAN BETA-GLUCURONIDASE|GARD:0007065	vestronidase alfa-vjbk	Mepsevii	40955	"Treatment of mucopolysaccharidosis VII (MPS VII, Sly Syndrome)"	Designated/Approved	Approved for Orphan Indication	"Indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (PMS VII, Sly syndrome)."	Ê11/15/2017Ê	Ê11/15/2024	"Ultragenyx Pharmaceutical, Inc."	60 Leveroni Court		Novato	California	94949	USA	359811
5913	Multifocal motor neuropathy	11011			3610	of multifocal motor neuropathy	C0393847	Multifocal motor neuropathy	dsyn	Treatment of multifocal motor neuropathy	Multifocal motor neuropathy|GARD:0011011|IVIG|IMMUNE GLOBULIN INFUSION (HUMAN)|GAMMAGARD LIQUID|GARD:0011011	MULTIFOCAL MOTOR NEUROPATHY|MMN|MMNCB|MULTIFOCAL MOTOR NEUROPATHY WITH CONDUCTION BLOCK	MULTIFOCAL MOTOR NEUROPATHY|MULTIFOCAL MOTOR NEUROPATHY WITH CONDUCTION BLOCK|MMN|MMNCB|GARD:0011011|ORPHA:641|ORPHANET:641	immune globulin infusion (human)	Gammagard Liquid	38918	Treatment of multifocal motor neuropathy	Designated/Approved	Approved for Orphan Indication	Maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN).	Ê06/22/2012Ê	Ê06/22/2019	"Baxalta US, Inc."	One Baxter Way		Westlake Village	California	91362	USA	224906
4702	Multiple myeloma	7108			622	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma (MM)	Multiple myeloma|GARD:0007108|DEXAMETHASONE|GARD:0007108	Multiple myeloma|GARD:0007108|LENALIDOMIDE|REVLIMID|GARD:0007108	Multiple myeloma|GARD:0007108|AUTOLOGOUS CD4+/CD8+ T CELLS EXPRESSING A BCMA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR)|GARD:0007108	dexamethasone	n/a	43185	Treatment of multiple myeloma (MM)	Designated/Approved	Approved for Orphan Indication	HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma	Ê10/03/2019Ê	Ê10/03/2026	Dexcel Pharma Technologies Ltd	Dexcel Street		Or Akiva			Israel	626318
4735	Multiple myeloma	7108			4770	with multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Multiple myeloma|GARD:0007108|MELPHALAN|ALKERAN FOR INJECTION|GARD:0007108			Melphalan	Alkeran For Injection	33658	Treatment of patients with multiple myeloma for whom oral therapy is inappropriate.	Designated/Approved	Approved for Orphan Indication	For the palliative treatment of patients with multiple myeloma for whom oral melphalan is not appropriate.	Ê11/18/1992Ê	Ê11/18/1999	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA	60991
4682	Multiple myeloma	7108			1891	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	selinexor	n/a	42009	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	"XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody."	Ê07/03/2019Ê	Ê07/03/2026	"Karyopharm Therapeutics, Inc."	85 Wells Avenue		Newton	Massachusetts	2459	USA	459014
Missing	Multiple myeloma	7108			2383	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	daratumumab	Darzalex	41400	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant (ASCT) and in patients with relapsed or refractory multiple myeloma who have received at least 1 prior therapy; in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for ASCT; in combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patients who are eligible for ASCT; in combination with bortezomib and dexamethasone in patients who have received at least 1 prior therapy; in combination with pomalidomide and dexamethasone in patients who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor (PI); and as monotherapy, in patients who have received at least 3 prior lines of therapy including a PI and an immunomodulatory agent or who are double-refractory to a PI and an immodulatory agent."	Ê09/26/2019Ê	Ê09/26/2026	"Janssen Biotech, Inc."	920 Route 202 South	PO Box 300	Raritan	New Jersey	8869	USA	397113
Missing	Multiple myeloma	7108			2383	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	daratumumab	Darzalex	41400	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	DARZALEX is indicated for the treatment of adult patients with multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy.	Ê06/27/2019Ê	ÊN/A	"Janssen Biotech, Inc."	920 Route 202 South	PO Box 300	Raritan	New Jersey	8869	USA	397113
Missing	Multiple myeloma	7108			2383	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	daratumumab	Darzalex	41400	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	"DARZALEX is indicated in combination with bortezomib, melphalen, and prednisone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant; and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent."	Ê05/07/2018Ê	Ê05/07/2025	"Janssen Biotech, Inc."	920 Route 202 South	PO Box 300	Raritan	New Jersey	8869	USA	397113
Missing	Multiple myeloma	7108			2383	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	daratumumab	Darzalex	41400	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent."	Ê11/21/2016Ê	Ê11/21/2023	"Janssen Biotech, Inc."	920 Route 202 South	PO Box 300	Raritan	New Jersey	8869	USA	397113
Missing	Multiple myeloma	7108			2383	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	daratumumab	Darzalex	41400	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	"DARZALEX is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy; and in combination with pomalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor; and as monotherapy, for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent."	Ê06/16/2017Ê	Ê06/16/2024	"Janssen Biotech, Inc."	920 Route 202 South	PO Box 300	Raritan	New Jersey	8869	USA	397113
Missing	Multiple myeloma	7108			2383	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	daratumumab	Darzalex	41400	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with multiple myeloma who have received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or are double refractory to a proteasome inhibitor and an immunomodulatory agent	Ê11/16/2015Ê	Ê11/16/2022	"Janssen Biotech, Inc."	920 Route 202 South	PO Box 300	Raritan	New Jersey	8869	USA	397113
4710	Multiple myeloma	7108			2551	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	panobinostat	Farydak	41141	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	"FARYDAK (panobinostat) in combination with bortezomib (BTZ) and dexamethasone (DEX) for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent"	Ê02/23/2015Ê	Ê02/23/2022	"Secura Bio, Inc."	11988 El Camino Real	Suite 650	San Diego	California	92130	USA	376212
4676	Multiple myeloma	7108			2725	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	elotuzumab	Empliciti	40787	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.	Ê11/06/2018Ê	Ê11/06/2025	Bristol-Myers Squibb Co.	P.O. Box 5326		Princeton	New Jersey	8543	USA	348411
4676	Multiple myeloma	7108			2725	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	elotuzumab	Empliciti	40787	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies	Ê11/30/2015Ê	Ê11/30/2022	Bristol-Myers Squibb Co.	P.O. Box 5326		Princeton	New Jersey	8543	USA	348411
4685	Multiple myeloma	7108			2835	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	ixazomib citrate	Ninlaro	40592	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy	Ê11/20/2015Ê	Ê11/20/2022	Millennium Pharmaceuticals	40 Landsdowne St.		Cambridge	Massachusetts	2139	USA	330510
4699	Multiple myeloma	7108			3409	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	carfilzomib	Kyprolis	39465	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.	Ê07/20/2012Ê	Ê07/20/2019	"Onyx Therapeutics, Inc."	249 East Grand Avenue		South San Francisco	California	94080	USA	252507
4704	Multiple myeloma	7108			3822	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	doxorubicin HCL liposome injection	Doxil	38350	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	For use in combination with bortezomib for the treatment of patients with multiple myeloma who have not previously received bortezomib and have at least one prior therapy.	Ê05/17/2007Ê	Ê05/17/2014	Johnson & Johnson Pharmaceutical Research & Dev.	"920 US Highway 202, P. O. Box 300"		Raritan		8869	USA	191704
4713	Multiple myeloma	7108			4053	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	pomalidomide	Pomalyst	37636	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.	Ê02/08/2013Ê	Ê02/08/2020	Celgene Corporation	400 Connell Drive	Suite 7000	Berkeley Heights	New Jersey	7922	USA	161402
4693	Multiple myeloma	7108			4054	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	bortezomib	Velcade	37636	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	First-line therapy of multiple myeloma.	Ê06/20/2008Ê	Ê06/20/2015	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA	163002
4693	Multiple myeloma	7108			4054	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	bortezomib	Velcade	37636	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of multiple myeloma patients who have received at least one prior therapy	Ê03/25/2005Ê	Ê03/25/2012	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA	163002
4693	Multiple myeloma	7108			4054	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	bortezomib	Velcade	37636	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy	Ê05/13/2003Ê	Ê05/13/2010	"Millennium Pharmaceuticals, Inc."	40 Landsdowne Street		Cambridge	Massachusetts	2139	USA	163002
4717	Multiple myeloma	7108			4149	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	lenalidomide	Revlimid	37154	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	"Treatment of multiple myeloma (MM), as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT)"	Ê02/22/2017Ê	Ê02/22/2024	Celgene Corporation	86 Morris Avenue	Suite 7000	Summit	New Jersey	7901	USA	147701
4717	Multiple myeloma	7108			4149	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	lenalidomide	Revlimid	37154	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	REVLIMID in combination with dexamethasone is indicated for the treatment of patients with multiple myeloma (MM).	Ê02/17/2015Ê	Ê02/17/2022	Celgene Corporation	86 Morris Avenue	Suite 7000	Summit	New Jersey	7901	USA	147701
4717	Multiple myeloma	7108			4149	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	lenalidomide	Revlimid	37154	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	For use in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy	Ê06/29/2006Ê	Ê06/29/2013	Celgene Corporation	86 Morris Avenue	Suite 7000	Summit	New Jersey	7901	USA	147701
4688	Multiple myeloma	7108			4372	of multiple myeloma	C0026764	Multiple Myeloma	neop	Treatment of multiple myeloma	Multiple myeloma|GARD:0007108|THALIDOMIDE|THALOMID|GARD:0007108	REFRACTORY PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA/PLASMA CELL MYELOMA|REFRACTORY MULTIPLE MYELOMA|CL388335|NCIT:C7024|NCI:C7024	Multiple myeloma|GARD:0007108|TRICIRIBINE|GARD:0007108	Thalidomide	Thalomid	36082	Treatment of multiple myeloma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with newly diagnosed multiple myeloma	Ê05/25/2006Ê	Ê05/25/2013	Celgene Corporation	7 Powder Horn Dr.		Warren				115598
1909	Multiple sclerosis	10255	done	Not a rare disease	4785	due to multiple sclerosis	C0026769	Multiple Sclerosis	dsyn	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Multiple sclerosis|GARD:0010255|BACLOFEN|GARD:0010255	SYRINGOMYELIA|HYDROMYELIA|MORVAN DISEASE|SYRINGOHYDROMYELIA		baclofen	Ozobax	33588	Treatment of intractable spasticity due to multiple sclerosis or spinal cord injury.	Designated/Approved	Approved for Orphan Indication	"OZOBAX is indicated for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity."	Ê09/18/2019Ê	ÊTBD	"Metacel Pharmaceuticals, LLC"	137 N. Broad Street	Suite E	Winder	Georgia	30680	USA	64091
2092	Multiple sclerosis	10255	done		5133	of multiple sclerosis	C0026769	Multiple Sclerosis	dsyn	Relief of symptoms of multiple sclerosis	Multiple sclerosis|GARD:0010255|DALFAMPRIDINE|AMPYRA|GARD:0010255	TRIGEMINAL NEURALGIA|FOTHERGILL DISEASE|TIC DOULOUREUX|TN|TRIFACIAL NEURALGIA	ACHALASIA|CARDIOSPASM|DYSSYNERGIA ESOPHAGUS|ESOPHAGEAL APERISTALSIS|MEGAESOPHAGUS	dalfampridine	Ampyra	31930	Relief of symptoms of multiple sclerosis	Designated/Approved	Approved for Orphan Indication	Treatment to improve walking in patients with multiple sclerosis	Ê01/22/2010Ê	Ê01/22/2017	Acorda Therapeutics	15 Skyline Dr.		Hawthorne	New York	10532	USA	18186
1087	Multiple sclerosis	10255	approximate		4303	multiple sclerosis.	C0026769	Multiple Sclerosis	dsyn	Treatment of progressive-relapsing multiple sclerosis.	Multiple sclerosis|GARD:0010255|MITOXANTRONE|NOVANTRONE|GARD:0010255	Multiple sclerosis|GARD:0010255|MITOXANTRONE|NOVANTRONE|GARD:0010255	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING|RELAPSING FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	Mitoxantrone	Novantrone	36385	Treatment of progressive-relapsing multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses)."	Ê10/13/2000Ê	Ê10/13/2007	"Serono, Inc."	One Technology Place		Rockland	Massachusetts	2370	USA	128499
1088	Multiple sclerosis	10255	done		4302	of secondary-progressive multiple sclerosis.	C0751965	"Multiple Sclerosis, Secondary Progressive"	dsyn	Treatment of secondary-progressive multiple sclerosis.	Multiple sclerosis|GARD:0010255|MITOXANTRONE|NOVANTRONE|GARD:0010255	Multiple sclerosis|GARD:0010255|INTERFERON BETA-1A|REBIF|GARD:0010255	Multiple sclerosis|GARD:0010255|MITOXANTRONE|NOVANTRONE|GARD:0010255	Mitoxantrone	Novantrone	36385	Treatment of secondary-progressive multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	"Reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly adnormal between relapses)."	Ê10/13/2000Ê	Ê10/13/2007	"Serono, Inc."	One Technoloogy Place		Rockland	Massachusetts	2370	USA	125199
880	Multiple sclerosis	10255	done		4784	of multiple sclerosis.	C0026769	Multiple Sclerosis	dsyn	Treatment of multiple sclerosis.	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING|RELAPSING FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, REMITTING-RELAPSING|RELAPSING-FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING|RELAPSING FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	Interferon beta-1a	Avonex	33588	Treatment of multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	Treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations.	Ê05/17/1996Ê	Ê05/17/2003	"Biogen, Inc."	14 Cambridge Center		Cambridge	Massachusetts	2142	USA	62791
885	Multiple sclerosis	10255	done		5034	of multiple sclerosis.	C0026769	Multiple Sclerosis	dsyn	Treatment of multiple sclerosis.	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING|RELAPSING FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, REMITTING-RELAPSING|RELAPSING-FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING|RELAPSING FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	Interferon beta-1b	Betaseron	32464	Treatment of multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	In ambulatory patients with relapsing-remitting multiple sclerosis to reduce the frequency of clinical exacerbations.	Ê07/23/1993Ê	Ê07/23/2000	Chiron Corp. & Berlex Laboratories	4560 Horton Street		Emeryville	California	94608	USA	31888
751	Multiple sclerosis	10255	done		5104	of multiple sclerosis.	C0026769	Multiple Sclerosis	dsyn	Treatment of multiple sclerosis.	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING|RELAPSING FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, REMITTING-RELAPSING|RELAPSING-FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	"RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING|RELAPSING FORMS OF MULTIPLE SCLEROSIS|DOID:2378|MESH:D020529"	Glatiramer acetate	Copaxone	32090	Treatment of multiple sclerosis.	Designated/Approved	Approved for Orphan Indication	For reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis.	Ê12/20/1996Ê	Ê12/20/2003	Teva Pharmaceuticals USA	1510 Delp Drive		Kulpsville	Pennsylvania	19443	USA	24087
4771	Myasthenia gravis	7122			2062	of Myasthenia Gravis	C0026896	Myasthenia Gravis	dsyn	Treatment of Myasthenia Gravis	Myasthenia gravis|GARD:0007122|TOLEROGEN|GARD:0007122	Myasthenia gravis|GARD:0007122|MONARSEN|GARD:0007122	Myasthenia gravis|GARD:0007122|METHOTREXATE|AMETHOPTERIN|GARD:0007122	eculizumab	Soliris	41802	Treatment of Myasthenia Gravis	Designated/Approved	Approved for Orphan Indication	for the treatment of adult patients with generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AchR) antibody positive	Ê10/23/2017Ê	Ê10/23/2024	"Alexion Pharmaceuticals, Inc."	121 Seaport Boulevard		Boston	Massachusetts	2210	USA	434214
4779	Mycobacterium Avium Complex	7123			4950	of disseminated Mycobacterium avium complex disease	C0012634	Disease	dsyn	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.				Rifabutin	Mycobutin	32860	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.	Designated/Approved	Approved for Orphan Indication	Prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infections.	Ê12/23/1992Ê	Ê12/23/1999	"Adria Laboratories, Inc."	P.O. Box 16529		Columbus	Ohio	43216	USA	41989
3464	Mycosis fungoides	3863			2491	of mycosis fungoides	C0026948	Mycosis Fungoides	neop	Treatment of mycosis fungoides	MYCOSIS FUNGOIDES REFRACTORY|REFRACTORY MYCOSIS FUNGOIDES|NCI:C8687|UMLS:C0854850	REFRACTORY MYCOSIS FUNGOIDES|MYCOSIS FUNGOIDES REFRACTORY|NCIT:C8687|NCI:C8687|UMLS:C0854850	REFRACTORY MYCOSIS FUNGOIDES AND SEZARY SYNDROME|NCIT:C148129|NCI:C148129	brentuximab vedotin	Adcetris	41232	Treatment of mycosis fungoides	Designated/Approved	Approved for Orphan Indication	Treatment for adult patients with CD30-expressing mycosis fungoides who have received prior systemic therapy	Ê11/09/2017Ê	Ê11/09/2024	"Seattle Genetics, Inc."	21823 30th Drive Southeast		Bothell	Washington	98021	USA	362611
3463	Mycosis fungoides	3863			3876	of mycosis fungoides	C0026948	Mycosis Fungoides	neop	Treatment of mycosis fungoides	MYCOSIS FUNGOIDES REFRACTORY|REFRACTORY MYCOSIS FUNGOIDES|NCI:C8687|UMLS:C0854850	REFRACTORY MYCOSIS FUNGOIDES|MYCOSIS FUNGOIDES REFRACTORY|NCIT:C8687|NCI:C8687|UMLS:C0854850	REFRACTORY MYCOSIS FUNGOIDES AND SEZARY SYNDROME|NCIT:C148129|NCI:C148129	meclorethamine	Valchlor	38216	Treatment of mycosis fungoides	Designated/Approved	Approved for Orphan Indication	Topical treatment of Stage 1A and 1B mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.	Ê08/23/2013Ê	Ê08/23/2020	Helsinn Birex Pharmaceuticals Ltd.	Damastown		Mulhuddart			Ireland	188404
4800	Myelodysplastic syndromes	7132			4126	of myelodysplastic syndromes	C3463824	MYELODYSPLASTIC SYNDROME	neop	Treatament of myelodysplastic syndromes	Myelodysplastic syndromes|GARD:0007132|AZACITIDINE|VIDAZA|GARD:0007132			azacitidine	Vidaza	37228	Treatament of myelodysplastic syndromes	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia"	Ê05/19/2004Ê	Ê05/19/2011	Celgene Corporation	9900 W. 109th Street	Suite 300	Overland Park	Kansas	66210	USA	150101
4797	Myelodysplastic syndromes	7132			3731	of myeloproliferative disorders/myelodysplastic syndromes	C1301355	Myelodysplastic-Myeloproliferative Diseases	neop	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Myelodysplastic syndromes|GARD:0007132|IMATINIB MESYLATE|GLEEVEC|GARD:0007132			Imatinib mesylate	Gleevec	38630	Treatment of myeloproliferative disorders/myelodysplastic syndromes associated with platelet-derived growth factor gene re-arrangements	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements	Ê10/19/2006Ê	Ê10/19/2013	Novartis Pharmaceuticals Corporation	One Health Plaza	Mail Code 105/1E870D	East Hanover	New Jersey	7936	USA	209105
4798	Myelodysplastic syndromes	7132			3956	of myelodysplastic syndromes	C3463824	MYELODYSPLASTIC SYNDROME	neop	Treatment of myelodysplastic syndromes	Myelodysplastic syndromes|GARD:0007132|RII RETINAMIDE|GARD:0007132	Myelodysplastic syndromes|GARD:0007132|IDARUBICIN|IDAMYCIN|GARD:0007132	Myelodysplastic syndromes|GARD:0007132|RIGOSERTIB|GARD:0007132	lenalidomide	Revlimid	38015	Treatment of myelodysplastic syndromes	Designated/Approved	Approved for Orphan Indication	Treatment of patients with transfusion dependant anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5 q cytogenetic abnormality with or without additional cytogenetic abnormalities	Ê12/27/2005Ê	Ê12/27/2012	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA	180303
4796	Myelodysplastic syndromes	7132			4344	of myelodysplastic syndromes.	C3463824	MYELODYSPLASTIC SYNDROME	neop	Treatment of myelodysplastic syndromes.	Myelodysplastic syndromes|GARD:0007132|RII RETINAMIDE|GARD:0007132	Myelodysplastic syndromes|GARD:0007132|IDARUBICIN|IDAMYCIN|GARD:0007132	Myelodysplastic syndromes|GARD:0007132|RIGOSERTIB|GARD:0007132	decitabine	Dacogen	36227	Treatment of myelodysplastic syndromes.	Designated/Approved	Approved for Orphan Indication	"for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups"	Ê05/02/2006Ê	Ê05/02/2013	Otsuka Pharmaceutical Development	"and Commercialization, Inc."	508 Carnegie Center Drive	Princeton	New Jersey	8540	USA	122298
5582	Myelofibrosis	8618			3184	of secondary	C0027627	Neoplasm Metastasis	neop	Treatment of secondary and primary myelofibrosis	Myelofibrosis|GARD:0008618|FEDRATINIB DIHYDROCHLORIDE MONOHYDRATE|N-TERT-BUTYL-3-[5-METHYL-2-{[4-(2-PRYYOLIDIN-1-YLETHOXY)PHENYL]AMINO}PYRIMIDIN-4-YL-AMINO] BENZENESULFONAMIDE DIHYDROCHLORIDE MONOHYDRATE|GARD:0008618	PRIMARY MYELOFIBROSIS|AGNOGENIC MYELOID METAPLASIA (AMM)|CHRONIC IDIOPATHIC MYELOFIBROSIS (CIMF)|IDIOPATHIC MYELOFIBROSIS|IM|MYELOFIBROSIS WITH MYELOID METAPLASIA|PMF	POLYCYTHEMIA VERA|ERYTHREMIA|OSLER-VAQUEZ DISEASE|POLYCYTHEMIA RUBRA VERA|PRIMARY POLYCYTHEMIA|SPLENOMEGALIC POLYCYTHEMIA|VAQUEZ-OSLER DISEASE	Fedratinib	Inrebic	39951	Treatment of secondary and primary myelofibrosis	Designated/Approved	Approved for Orphan Indication	INREBIC is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).	Ê08/16/2019Ê	Ê08/16/2026	"Impact Biomedicines, Inc. a wholly-owned subsidiary of Celgene Corporation"	86 Morris Avenue		Summit	New Jersey	7901	USA	279409
5575	Myelofibrosis	8618			3301	of myelofibrosis	C0001815	Primary Myelofibrosis	neop	Treatment of myelofibrosis	Myelofibrosis|GARD:0008618|RUXOLITINIB PHOSPHATE|JAKAFI|GARD:0008618	Myelofibrosis|GARD:0008618|OBATOCLAX MESYLATE|GARD:0008618	Myelofibrosis|GARD:0008618|PRM-151|RECOMBINANT HUMAN PENTRAXIN-2|GARD:0008618	ruxolitinib phosphate	Jakafi	39696	Treatment of myelofibrosis	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis"	Ê11/16/2011Ê	Ê11/16/2018	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA	265308
5400	Myeloid leukemia	8226			935	of acute myeloid leukemia	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myeloid leukemia (AML)	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	ACUTE MYELOID LEUKEMIA|DOID:9119|MESH:D015470	gilteritinib	Xospata	42929	Treatment of acute myeloid leukemia (AML)	Designated/Approved	Approved for Orphan Indication	XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.	Ê11/28/2018Ê	Ê11/28/2025	"Astellas Pharma US, Inc."	1 Astellas Way		Northbrook	Illinois	60062	USA	587217
5425	Myeloid leukemia	8226			963	of acute myeloid leukemia	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myeloid leukemia (AML)	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	ACUTE MYELOID LEUKEMIA|DOID:9119|MESH:D015470	Glasdegib	Daurismo	42914	Treatment of acute myeloid leukemia (AML)	Designated/Approved	Approved for Orphan Indication	"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy."	Ê11/21/2018Ê	Ê11/21/2025	"Pfizer, Inc."	445 Eastern Point Road		Groton	Connecticut	6340	USA	585517
5438	Myeloid leukemia	8226			1703	of acute myeloid leukemia	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myeloid leukemia (AML)	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	ACUTE MYELOID LEUKEMIA|DOID:9119|MESH:D015470	ivosidenib	Tibsovo	42164	Treatment of acute myeloid leukemia (AML)	Designated/Approved	Approved for Orphan Indication	TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.	Ê07/20/2018Ê	Ê07/20/2025	"Agios Pharmaceuticals, Inc."	88 Sidney Street		Cambridge	Massachusetts	2139	USA	481515
5438	Myeloid leukemia	8226			1703	of acute myeloid leukemia	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myeloid leukemia (AML)	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	ACUTE MYELOID LEUKEMIA|DOID:9119|MESH:D015470	ivosidenib	Tibsovo	42164	Treatment of acute myeloid leukemia (AML)	Designated/Approved	Approved for Orphan Indication	TIBSOVO is indicated for the treatment of newly-diagnosed acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test in adult patients who are >= 75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.	Ê05/02/2019Ê	Ê05/02/2026	"Agios Pharmaceuticals, Inc."	88 Sidney Street		Cambridge	Massachusetts	2139	USA	481515
5435	Myeloid leukemia	8226			1508	of acute myeloid leukemia.	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myeloid leukemia.	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	ACUTE MYELOID LEUKEMIA|DOID:9119|MESH:D015470	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	venetoclax	Venclexta	42404	Treatment of acute myeloid leukemia.	Designated/Approved	Approved for Orphan Indication	"VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy."	Ê11/21/2018Ê	Ê11/21/2025	AbbVie Inc.	1 North Waukegan Road	"Dept PA72, Bldg. AP30-4"	North Chicago	Illinois	60064	USA	506815
5424	Myeloid leukemia	8226			3166	of acute myeloid leukemia	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myeloid leukemia	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	ACUTE MYELOID LEUKEMIA|DOID:9119|MESH:D015470	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	midostaurin	Rydapt	40001	Treatment of acute myeloid leukemia	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation."	Ê04/28/2017Ê	Ê04/28/2024	Novartis Pharmaceuticals Corporation	"One Health Plaza, 105/3W038"		East Hanover	New Jersey	7936	USA	285909
5377	Myeloid leukemia	8226			3311	of acute myeloid leukemia	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myeloid leukemia	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	ACUTE MYELOID LEUKEMIA|DOID:9119|MESH:D015470	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	Cytarabine:daunorubicin liposome injection	Vyxeos	39682	Treatment of acute myeloid leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)	Ê08/03/2017Ê	Ê08/03/2024	"Celator Pharmaceuticals, Inc."	200 Princeton South Corporate Center	Suite 180	Ewing	New Jersey	8628	USA	265808
5415	Myeloid leukemia	8226			4285	of acute myeloid leukemia	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myeloid leukemia	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	ACUTE MYELOID LEUKEMIA|DOID:9119|MESH:D015470	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	Gemtuzumab ozogamicin	Mylotarg	36488	Treatment of acute myeloid leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy	Ê05/17/2000Ê	Ê05/17/2007	"Wyeth Pharmaceuticals, Inc., a Pfizer Company"	10646 Science Center Drive		San Diego	California	92121	USA	127899
5415	Myeloid leukemia	8226			4285	of acute myeloid leukemia	C0023467	"Leukemia, Myelocytic, Acute"	neop	Treatment of acute myeloid leukemia	THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT RELATED AML|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|T-AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|NCIT:C8252|NCI:C8252|UMLS:C1336735	ACUTE MYELOID LEUKEMIA|DOID:9119|MESH:D015470	T-AML|THERAPY-RELATED ACUTE MYELOID LEUKEMIA|TREATMENT RELATED AML|TREATMENT RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT RELATED ACUTE MYELOID LEUKEMIA|TREATMENT-RELATED AML|TREATMENT-RELATED ACUTE MYELOCYTIC LEUKEMIA|TREATMENT-RELATED ACUTE MYELOGENOUS LEUKEMIA|TREATMENT-RELATED ACUTE MYELOID LEUKEMIA|NCI:C8252|UMLS:C1336735	Gemtuzumab ozogamicin	Mylotarg	36488	Treatment of acute myeloid leukemia	Designated/Approved	Approved for Orphan Indication	Treatment of newly-diagnosed CD33-positive acute myeloid leukemia in adults and treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and in pediatric patients 2 years and older	Ê09/01/2017Ê	Ê09/01/2024	"Wyeth Pharmaceuticals, Inc., a Pfizer Company"	10646 Science Center Drive		San Diego	California	92121	USA	127899
996	Myxedema coma		MISSING		4893	of myxedema coma/precoma.	C0238298	Myxedema coma	dsyn	Treatment of myxedema coma/precoma.	LIOTHYRONINE SODIUM|LIOTHYRONINE SODIUM INJECTION|TRIOSTAT			Liothyronine sodium injection	Triostat	33084	Treatment of myxedema coma/precoma.	Designated/Approved	Approved for Orphan Indication	Treatment of myxedema coma/precoma.	Ê12/31/1991Ê	Ê12/31/1998	SmithKline Beecham Pharmaceuticals	One Franklin Plaza		Philadelphia	Pennsylvania	19101	USA	46090
2008	N-acetylglutamate synthase deficiency	7158	done		4422	of N-acetylglutamate synthetase deficiency.	C0268543	"Hyperammonemia, type III"	dsyn	Treatment of N-acetylglutamate synthetase deficiency.	N-acetylglutamate synthase deficiency|GARD:0007158|CARGLUMIC ACID|CARBAGLU|GARD:0007158	HYPERAMMONEMIA DUE TO N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY|ACUTE HYPERAMMONEMIA|MESH:C536109	HYPERAMMONEMIA DUE TO N-ACETYLGLUTAMATE SYNTHETASE DEFICIENCY|CHRONIC HYPERAMMONEMIA|MESH:C536109	carglumic acid	Carbaglu	35815	Treatment of N-acetylglutamate synthetase deficiency.	Designated/Approved	Approved for Orphan Indication	As an adjunctive therapy for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS) and as manitenance therapy for chronic hyperammonemia due to NAGS deficiency	Ê03/18/2010Ê	Ê03/18/2017	Orphan Europe SARL	Immeuble Le Wilson	70 avenue du General de Gaulle	92800 Puteaux			France	109997
4816	Narcolepsy	7162			2549	of narcolepsy	C0027404	Narcolepsy	dsyn	Treatment of narcolepsy	"NARCOLEPSY, WITHOUT CATAPLEXY|NARCOLEPSY|NARCOLEPSY WITHOUT CATAPLEXY|DOID:8986|MESH:D009290"	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	Solriamfetol	Sunosi	41141	Treatment of narcolepsy	Designated/Approved	Approved for Orphan Indication	SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy	Ê06/17/2019Ê	Ê06/17/2026	Jazz Pharmaceuticals Ireland Limited	5th Floor Waterloo Exchange	Waterloo Road	Dublin			United Kingdom	375112
4813	Narcolepsy	7162			3002	of narcolepsy	C0027404	Narcolepsy	dsyn	Treatment of narcolepsy	"NARCOLEPSY, WITHOUT CATAPLEXY|NARCOLEPSY|NARCOLEPSY WITHOUT CATAPLEXY|DOID:8986|MESH:D009290"	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	Pitolisant	n/a	40315	Treatment of narcolepsy	Designated/Approved	Approved for Orphan Indication	WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy	Ê08/14/2019Ê	Ê08/14/2026	"Harmony Biosciences, LLC"	630 W Germantown Pike	Suite 215	Plymouth Meeting	Pennsylvania	19462	USA	307210
4811	Narcolepsy	7162			4606	of narcolepsy.	C0027404	Narcolepsy	dsyn	Treatment of narcolepsy.	"NARCOLEPSY, WITHOUT CATAPLEXY|NARCOLEPSY|NARCOLEPSY WITHOUT CATAPLEXY|DOID:8986|MESH:D009290"	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	sodium oxybate	Xyrem	34645	Treatment of narcolepsy.	Designated/Approved	Approved for Orphan Indication	Treatment of cataplexy associated with narcolepsy	Ê07/17/2002Ê	Ê07/17/2009	Jazz Pharmaceuticals	3170 Porter Drive		Palo Alto	California	94304	USA	85894
4811	Narcolepsy	7162			4606	of narcolepsy.	C0027404	Narcolepsy	dsyn	Treatment of narcolepsy.	"NARCOLEPSY, WITHOUT CATAPLEXY|NARCOLEPSY|NARCOLEPSY WITHOUT CATAPLEXY|DOID:8986|MESH:D009290"	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	sodium oxybate	Xyrem	34645	Treatment of narcolepsy.	Designated/Approved	Approved for Orphan Indication	Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.	Ê10/26/2018Ê	Ê10/26/2025	Jazz Pharmaceuticals	3170 Porter Drive		Palo Alto	California	94304	USA	85894
4811	Narcolepsy	7162			4606	of narcolepsy.	C0027404	Narcolepsy	dsyn	Treatment of narcolepsy.	"NARCOLEPSY, WITHOUT CATAPLEXY|NARCOLEPSY|NARCOLEPSY WITHOUT CATAPLEXY|DOID:8986|MESH:D009290"	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	sodium oxybate	Xyrem	34645	Treatment of narcolepsy.	Designated/Approved	Approved for Orphan Indication	Treatment of excessive daytime sleepiness in patients with narcolepsy	Ê11/18/2005Ê	Ê11/18/2012	Jazz Pharmaceuticals	3170 Porter Drive		Palo Alto	California	94304	USA	85894
4819	Narcolepsy	7162			4710	in narcolepsy.	C0027404	Narcolepsy	dsyn	Treatment of excessive daytime sleepiness in narcolepsy.	Narcolepsy|GARD:0007162|OXYBATE|XYREM|GARD:0007162	Narcolepsy|GARD:0007162|MODAFINIL|PROVIGIL|GARD:0007162	NARCOLEPSY	Modafinil	Provigil	34043	Treatment of excessive daytime sleepiness in narcolepsy.	Designated/Approved	Approved for Orphan Indication	Improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.	Ê12/24/1998Ê	Ê12/24/2005	"Cephalon, Inc."	145 Brandywine Parkway		West Chester	Pennsylvania	19380	USA	73793
2036	Neonatal severe hyperparathyroidism	2838	approximate		3006	with primary hyperparathyroidism	C0221002	"Hyperparathyroidism, Primary"	dsyn	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	Primary hyperparathyroidism|GARD:0008612|CINACALCET|SENSIPAR|GARD:0008612	Primary hyperparathyroidism|GARD:0008612|CINACALCET|SENSIPAR|GARD:0008612	Neonatal severe hyperparathyroidism|GARD:0002838|CINACALCET|SENSIPAR|GARD:0002838	cinacalcet	Sensipar	40298	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	Designated/Approved	Approved for Orphan Indication	"Treatment of hypercalcemia in adult patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo parathyroidectomy."	Ê11/21/2014Ê	Ê11/21/2021	"Amgen, Inc."	One Amgen Center Drive	"Bldg 17, 1A-4-4, Mail Stop 17-1-B"	Thousand Oaks	California	91320	USA	165102
2036	Neonatal severe hyperparathyroidism	2838	approximate		3006	with primary hyperparathyroidism	C0221002	"Hyperparathyroidism, Primary"	dsyn	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	Primary hyperparathyroidism|GARD:0008612|CINACALCET|SENSIPAR|GARD:0008612	Primary hyperparathyroidism|GARD:0008612|CINACALCET|SENSIPAR|GARD:0008612	Neonatal severe hyperparathyroidism|GARD:0002838|CINACALCET|SENSIPAR|GARD:0002838	cinacalcet	Sensipar	40298	"Treatment of hypercalcemia in patients with primary hyperparathyroidism for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but who are unable to undergo surgery"	Designated/Approved	Approved for Orphan Indication	Treatment of severe hypercalcemia in patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy	Ê02/25/2011Ê	Ê02/25/2018	"Amgen, Inc."	One Amgen Center Drive	"Bldg 17, 1A-4-4, Mail Stop 17-1-B"	Thousand Oaks	California	91320	USA	165102
4846	Neuroblastoma	7185			3564	of neuroblastomas	C0027819	Neuroblastoma	neop	For the diagnosis of neuroblastomas	Neuroblastoma|GARD:0007185|IOBENGUANE I 123|ADREVIEW|GARD:0007185	Pheochromocytoma|GARD:0007385|IOBENGUANE I 123|ADREVIEW|GARD:0007385	CONGENITAL CENTRAL HYPOVENTILATION SYNDROME	Iobenguane I 123	Adreview	39052	For the diagnosis of neuroblastomas	Designated/Approved	Approved for Orphan Indication	To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests	Ê09/19/2008Ê	Ê09/19/2015	"GE Healthcare, Inc."	101 Carnegie Center		Princeton	New Jersey	8540	USA	226406
4837	Neuroblastoma	7185			2876	of neuroblastoma	C0027819	Neuroblastoma	neop	Treatment of neuroblastoma	REFRACTORY NEUROBLASTOMA|CL521932|NCIT:C134153|NCI:C134153	Neuroblastoma|GARD:0007185|PERIFOSINE|GARD:0007185	Neuroblastoma|GARD:0007185|ANISINA|GARD:0007185	dinutuximab	Unituxin	40532	Treatment of neuroblastoma	Designated/Approved	Approved for Orphan Indication	"For use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy"	Ê03/10/2015Ê	Ê03/10/2022	United Therapeutics Corporation	55 TW Alexander Drive		Research Triangle Park	North Carolina	27709	USA	324210
6067	Neuroendocrine tumor	13445			2241	of neuroendocrine tumors	C0206754	Neuroendocrine Tumors	neop	The management of neuroendocrine tumors	"Gastroenteropancreatic neuroendocrine tumor|GARD:0002437|SATOREOTIDE TRIZOXETAN GALLIUM GA-68|68GA-OPS202, SMALL SOMATOSTATIN ANALOG LABELED WITH 68GALLIUM|GARD:0002437"	"Pancreatic neuroendocrine tumor|GARD:0013034|SATOREOTIDE TRIZOXETAN GALLIUM GA-68|68GA-OPS202, SMALL SOMATOSTATIN ANALOG LABELED WITH 68GALLIUM|GARD:0013034"	Neuroendocrine tumor|GARD:0013445|GALLIUM OXODOTREOTIDE GA-68|RADIOLABELED SOMASTATIN ANALOG|GALIOMEDIX(TM)|GARD:0013445	Gallium-68 (DOTA0-Phel-Tyr3)octreotide	n/a	41572	The management of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.	Ê08/21/2019Ê	ÊN/A	University of Iowa Hospital & Clinics	Department of Radiology/PET Imaging Center	200 Hawkins Drive	Iowa City	Iowa	52242	USA	409513
612	Neuroendocrine tumor	13445	done		2190	of neuroendocrine tumors	C0206754	Neuroendocrine Tumors	neop	Diagnostic for the clinical management of neuroendocrine tumors	Neuroendocrine tumor|GARD:0013445|EDOTREOTIDE GALLIUM GA-68|GALLIUM (68GA) EDOTREOTIDE|SOMAKIT TOC|GARD:0013445	"Neuroendocrine tumor|GARD:0013445|EDOTREOTIDE GALLIUM GA-68|GALLIUM [GA-68]-N-[(4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZACYCLODODEC-1-YL)ACETYL]-D-PHENYLALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHANYL-L-LYSYL-L-THREONINYL-L-CYSTEINYL-L-THREONINE-CYCLIC(2-7)DISULFIDE|NETSPOT|GARD:0013445"	"Neuroendocrine tumor|GARD:0013445|EDOTREOTIDE GALLIUM GA-68|GALLIUM [GA-68]-N-[(4,7,10-TRICARBOXYMETHYL-1,4,7,10-TETRAAZACYCLODODEC-1-YL)ACETYL]-D-PHENYLALANYL-L-CYSTEINYL-L-TYROSYL-D-TRYPTOPHANYL-L-LYSYL-L-THREONINYL-L-CYSTEINYL-L-THREONINE-CYCLIC(2-7)DISULFIDE|NETSPOT|GARD:0013445"	"Gallium [Ga-68]-N-[(4,7,10-Tricarboxymethyl-1,4,7,10-tetraazacyclododec-1-yl)acetyl]-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryptophanyl-L-lysyl-L-threoninyl-L-cysteinyl-L-threonine-cyclic(2-7)disulfide"	Netspot	41639	Diagnostic for the clinical management of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"For use after radiolabeling with Ga 68, with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients."	Ê06/01/2016Ê	Ê06/01/2023	"Advanced Accelerator Applications, USA"	57 East Willow Street		Millburn	New Jersey	7041	USA	413613
6058	Neuroendocrine tumor	13445			2730	of neuroendocrine tumors	C0206754	Neuroendocrine Tumors	neop	Treatment of neuroendocrine tumors	Neuroendocrine tumor|GARD:0013445|OCTREOTIDE|SANDOSTATIN LAR|GARD:0013445	Neuroendocrine tumor|GARD:0013445|IOBENGUANE I 131|GARD:0013445	Neuroendocrine tumor|GARD:0013445|LEAD-212 DOTAMTATE|ALPHAMEDIXâ¢|GARD:0013445	lanreotide acetate	Somatuline Depot	40780	Treatment of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with unresectable,well- or moderately-differentiated locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival"	Ê12/16/2014Ê	Ê12/16/2021	"Ipsen Biopharmaceuticals, Inc."	106 Allen Road		Basking Ridge	New Jersey	7920	USA	347811
6052	Neuroendocrine tumor	13445			3397	of neuroendocrine tumors	C0206754	Neuroendocrine Tumors	neop	Treatment of neuroendocrine tumors	Neuroendocrine tumor|GARD:0013445|OCTREOTIDE|SANDOSTATIN LAR|GARD:0013445	Neuroendocrine tumor|GARD:0013445|IOBENGUANE I 131|GARD:0013445	Neuroendocrine tumor|GARD:0013445|LEAD-212 DOTAMTATE|ALPHAMEDIXâ¢|GARD:0013445	everolimus	Afinitor	39492	Treatment of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"Treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease; and treatment of adult patients with progressive, well-differentiated, non-functional, neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin, with unresectable, locally advanced or metastatic disease."	Ê02/26/2016Ê	Ê02/26/2023	Novartis Pharmaceuticals Corp.	"One Health Plaza, 315/5450A"		East Hanover	New Jersey	7936	USA	254107
6052	Neuroendocrine tumor	13445			3397	of neuroendocrine tumors	C0206754	Neuroendocrine Tumors	neop	Treatment of neuroendocrine tumors	Neuroendocrine tumor|GARD:0013445|OCTREOTIDE|SANDOSTATIN LAR|GARD:0013445	Neuroendocrine tumor|GARD:0013445|IOBENGUANE I 131|GARD:0013445	Neuroendocrine tumor|GARD:0013445|LEAD-212 DOTAMTATE|ALPHAMEDIXâ¢|GARD:0013445	everolimus	Afinitor	39492	Treatment of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"Treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease"	Ê05/05/2011Ê	Ê05/05/2018	Novartis Pharmaceuticals Corp.	"One Health Plaza, 315/5450A"		East Hanover	New Jersey	7936	USA	254107
6062	Neuroendocrine tumor	13445			3476	of neuroendocrine tumors	C0206754	Neuroendocrine Tumors	neop	Treatment of neuroendocrine tumors	Neuroendocrine tumor|GARD:0013445|OCTREOTIDE|SANDOSTATIN LAR|GARD:0013445	Neuroendocrine tumor|GARD:0013445|IOBENGUANE I 131|GARD:0013445	Neuroendocrine tumor|GARD:0013445|LEAD-212 DOTAMTATE|ALPHAMEDIXâ¢|GARD:0013445	Iobenguane I 131	Azedra Ultratrace	38735	Treatment of neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"AZEDRA is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy."	Ê07/30/2018Ê	Ê07/30/2025	"Progenics Pharmaceuticals, Inc."	One World Trade Center.	"47th Floor, Suite J"	New York	New York	10007	USA	216205
4090	Neuromyelitis optica	6267			2356	of neuromyelitis optica	C0027873	Neuromyelitis Optica	dsyn	Treatment of neuromyelitis optica	Neuromyelitis optica|GARD:0006267|CLADRIBINE|GARD:0006267	Neuromyelitis optica spectrum disorder|GARD:0009414|CLADRIBINE|GARD:0009414	"Neuromyelitis optica|GARD:0006267|MEDI-551|HUMANIZED AFFINITY-OPTIMIZED, AFUCOSYLATED IMMUNOGLOBULIN G1 KAPPA MONOCLONAL ANTIBODY AGAINST CD19|GARD:0006267"	eculizumab	Soliris	41449	Treatment of neuromyelitis optica	Designated/Approved	Approved for Orphan Indication	Soliris is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.	Ê06/27/2019Ê	Ê06/27/2026	"Alexion Pharmaceuticals, Inc."	121 Seaport Boulevard		Boston	Massachusetts	2210	USA	398713
5870	Neuronal ceroid lipofuscinosis	10739			2408	of neuronal ceroid lipofuscinosis type 2	C0027877	Neuronal Ceroid-Lipofuscinoses	dsyn	Treatment of neuronal ceroid lipofuscinosis type 2	"CATHEPSIN D DEFICIENCY|CTSD NEURONAL CEROID LIPOFUSCINOSIS|CEROID LIPOFUSCINOSIS, NEURONAL, TYPE 10|NEURONAL CEROID LIPOFUSCINOSIS DUE TO CATHEPSIN D DEFICIENCY|CLN10|NEURONAL CEROID LIPOFUSCINOSIS CAUSED BY MUTATION IN CTSD|NEURONAL CEROID LIPOFUSCINOSIS CATHEPSIN D-DEFICIENT|NEURONAL CEROID LIPOFUSCINOSIS TYPE 10|CEROID LIPOFUSCINOSIS, NEURONAL, 10|CLN10 DISEASE, LATE INFANTILE (SUBTYPE)|CLN10 DISEASE, JUVENILE (SUBTYPE)|CEROID LIPOFUSCINOSIS, NEURONAL, 10; CLN10|CLN10 DISEASE, ADULT (SUBTYPE)|CEROID LIPOFUSCINOSIS, NEURONAL, CATHEPSIN D-DEFICIENT|CEROID LIPOFUSCINOSIS NEURONAL CATHEPSIN D-DEFICIENT|NEURONAL CEROID LIPOFUSCINOSIS, CONGENITAL|CLN10 DISEASE, CONGENITAL (SUBTYPE)|CLN10 DISEASE|NEURONAL CEROID LIPOFUSCINOSIS 10|DOID:0110725|ORPHANET:228337|SCTID:720831008|MESH:C566438|OMIM:610127|GARD:0001218|MONDO:0012414"	Neuronal ceroid lipofuscinosis|GARD:0010739|CERLIPONASE ALFA|GARD:0010739	ceroid lipofuscinosis|GARD:0010973|CERLIPONASE ALFA|GARD:0010973	cerliponase alfa	Brineura	41365	Treatment of neuronal ceroid lipofuscinosis type 2	Designated/Approved	Approved for Orphan Indication	"To slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency."	Ê04/27/2017Ê	Ê04/27/2024	"BioMarin Pharmaceutical, Inc."	105 Digital Drive		Novato	California	94949	USA	391913
695	"Neutropenia, severe chronic"		MISSING		4867	with severe chronic neutropenia	C2931027	"Neutropenia, severe chronic"	dsyn	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	"FILGRASTIM, LICENSE HOLDER UNSPECIFIED|FILGRASTIM|NEUPOGEN"			Filgrastim	Neupogen	33184	Treatment of patients with severe chronic neutropenia (absolute neutrophil count less than 500/mm3).	Designated/Approved	Approved for Orphan Indication	Treatment of patients with severe chronic neutropenia.	Ê12/19/1994Ê	Ê12/19/2001	"Amgen, Inc."	1840 Dehavilland Drive		Thousand Oaks	California	91320	USA	49390
2977	Non 24 hour sleep wake disorder	10949	done		3069	Non-24-hour sleepwake disorder	C0012634	Disease	dsyn	Non-24-hour sleepwake disorder in blind individuals without light perception	Non 24 hour sleep wake disorder|GARD:0010949|TASIMELTEON|HETLIOZ|GARD:0010949			tasimelteon	Hetlioz	40197	Non-24-hour sleepwake disorder in blind individuals without light perception	Designated/Approved	Approved for Orphan Indication	Treatment of non-24-hour sleep-wake disorder	Ê01/31/2014Ê	Ê01/31/2021	"Vanda Pharmaceuticals, Inc."	"2200 Penn. Ave., NW"	Suite 300 E	Washington	District of Columbia	20037	USA	297409
2557	"Non-small cell lung cancer, childhood"	9343	approximate		1566	of squamous non-small cell lung cancer	C0007131	Non-Small Cell Lung Carcinoma	neop	Treatment of squamous non-small cell lung cancer	ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CARCINOMA|ADVANCED LUNG NON-SQUAMOUS NON-SMALL CELL CARCINOMA|ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER|NCIT:C147924|NCI:C147924	"Non-small cell lung cancer, childhood|GARD:0009343|NECITUMUMAB|GARD:0009343"	ADVANCED NON-SMALL CELL SQUAMOUS LUNG CARCINOMA|ADVANCED LUNG NON-SMALL CELL SQUAMOUS CARCINOMA|ADVANCED NON-SMALL CELL SQUAMOUS LUNG CANCER|NCIT:C153201|NCI:C153201	necitumumab	n/a	42328	Treatment of squamous non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	"Use in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic, squamous, non-small cell lung cancer. Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer."	Ê11/24/2015Ê	Ê11/24/2022	Eli Lilly and Company	33 ImClone Drive		Branchburg	New Jersey	8876	USA	418213
1802	"Non-small cell lung cancer, childhood"	9343	approximate		1857	of ALK-positive non-small cell lung cancer	C1663627	"ALK protein, human"	aapp	Treatment of ALK-positive non-small cell lung cancer	NON-SMALL CELL LUNG CANCER (DISORDER)|NON-SMALL CELL LUNG CANCER|ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	"NON SMALL CELL LUNG CANCER RECURRENT|CARCINOMA, NON-SMALL-CELL LUNG|METASTATIC NON-SMALL CELL LUNG CANCER|DOID:4832|MESH:D002289"	alectinib	Alecensa	42031	Treatment of ALK-positive non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib."	Ê12/11/2015Ê	Ê12/11/2022	"Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)"	"1 DNA Way, MS #355E"		South San Francisco	California	94080	USA	462814
1802	"Non-small cell lung cancer, childhood"	9343	approximate		1857	of ALK-positive non-small cell lung cancer	C1663627	"ALK protein, human"	aapp	Treatment of ALK-positive non-small cell lung cancer	NON-SMALL CELL LUNG CANCER (DISORDER)|NON-SMALL CELL LUNG CANCER|ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE, METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	"NON SMALL CELL LUNG CANCER RECURRENT|CARCINOMA, NON-SMALL-CELL LUNG|METASTATIC NON-SMALL CELL LUNG CANCER|DOID:4832|MESH:D002289"	alectinib	Alecensa	42031	Treatment of ALK-positive non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test."	Ê11/06/2017Ê	Ê11/06/2024	"Hoffmann-La Roche, Inc. (c/o Genentech, Inc.)"	"1 DNA Way, MS #355E"		South San Francisco	California	94080	USA	462814
1796	"Non-small cell lung cancer, childhood"	9343	approximate		1656	of non-small cell lung cancer	C0007131	Non-Small Cell Lung Carcinoma	neop	Treatment of non-small cell lung cancer with squamous histology.	"Non-small cell lung cancer, childhood|GARD:0009343|AFATINIB|GILOTRIF(R)|GARD:0009343"	SINONASAL UNDIFFERENTIATED CARCINOMA		afatinib	Gilotrif	42219	Treatment of non-small cell lung cancer with squamous histology.	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with metastatic, squamous, non-small cell lung cancer progressing after platinum-based chemotherapy"	Ê04/15/2016Ê	Ê04/15/2023	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	P. O. Box 368	Ridgefield	Connecticut	6877	USA	484115
1956	"Non-small cell lung cancer, childhood"	9343	approximate		1426	non-small cell lung cancer (NSCLC).	C0007131	Non-Small Cell Lung Carcinoma	neop	"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC)."	"Non-small cell lung cancer, childhood|GARD:0009343|BRIGATINIB|GARD:0009343"			brigatinib	Alunbrig	42488	"Treatment of anaplastic lymphoma kinase-positive (ALK+), c-ros 1 oncogene positive (ROS1+), or epidermal growth factor receptor positive (EGFR+) non-small cell lung cancer (NSCLC)."	Designated/Approved	Approved for Orphan Indication	Treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib	Ê04/28/2017Ê	Ê04/28/2024	"ARIAD Pharmaceuticals, Inc."	26 Landsdowne Street		Cambridge	Massachusetts	2139	USA	505415
2065	"Non-small cell lung cancer, childhood"	9343	approximate		2954	ROS-positive non-small cell lung cancer	C0007131	Non-Small Cell Lung Carcinoma	neop	"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer"	"Non-small cell lung cancer, childhood|GARD:0009343|CRIZOTINIB|XALKORI|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|BRIGATINIB|GARD:0009343"	NON-SMALL CELL LUNG CANCER (DISORDER)|NON-SMALL CELL LUNG CANCER|ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289	crizotinib	Xalkori	40434	"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer"	Designated/Approved	Approved for Orphan Indication	Treatment of patients with metastatic NSCLC whose tumors are ROS1-positive	Ê03/11/2016Ê	Ê03/11/2023	"Pfizer, Inc."	10646 Science Center Drive		San Diego	California	92121	USA	310610
2065	"Non-small cell lung cancer, childhood"	9343	approximate		2954	ROS-positive non-small cell lung cancer	C0007131	Non-Small Cell Lung Carcinoma	neop	"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer"	"Non-small cell lung cancer, childhood|GARD:0009343|CRIZOTINIB|XALKORI|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|BRIGATINIB|GARD:0009343"	NON-SMALL CELL LUNG CANCER (DISORDER)|NON-SMALL CELL LUNG CANCER|ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289	crizotinib	Xalkori	40434	"Treatment of ALK-positive, MET-positive, or ROS-positive non-small cell lung cancer"	Designated/Approved	Approved for Orphan Indication	Treatment of patients with locally advanced or metastatic non-small cell lungcancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDAapprovedtest	Ê08/26/2011Ê	Ê08/26/2018	"Pfizer, Inc."	10646 Science Center Drive		San Diego	California	92121	USA	310610
2090	"Non-small cell lung cancer, childhood"	9343	approximate		1591	with BRAF mutation positive non-small cell lung cancer.	C0104940	Proto-Oncogene Proteins B-raf	aapp	Treatment of patients with BRAF mutation positive non-small cell lung cancer.	"Non-small cell lung cancer, childhood|GARD:0009343|DABRAFENIB|TAFINLER|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|TRAMETINIB|DABRAFENIB AND TRAMETINIB|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|DABRAFENIB|DABRAFENIB AND TRAMETINIB|GARD:0009343"	dabrafenib and trametinib	Mekinist	42306	Treatment of patients with BRAF mutation positive non-small cell lung cancer.	Designated/Approved	Approved for Orphan Indication	"Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test."	Ê06/22/2017Ê	Ê06/22/2024	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	495915
1115	"Non-small cell lung cancer, childhood"	9343	approximate		1850	with non-small cell lung cancer	C0007131	Non-Small Cell Lung Carcinoma	neop	"Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer"	"Non-small cell lung cancer, childhood|GARD:0009343|ENTRECTINIB|N-[5-(3,5-DIFLUOROBENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYLPIPERAZIN-1YL)-2-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)BENZAMIDE|N-(5-(3,5-DIFLUOROBENZYL)-1H-INDAZOL-3-YL)-4-(4-METHYLPIPERAZIN-1YL)-2-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)BENZAMIDE|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|ENTRECTINIB|N-[5-(3,5-DIFLUOROBENZYL)-1H-INDAZOL-3-YL]-4-(4-METHYLPIPERAZIN-1YL)-2-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)BENZAMIDE|N-(5-(3,5-DIFLUOROBENZYL)-1H-INDAZOL-3-YL)-4-(4-METHYLPIPERAZIN-1YL)-2-(TETRAHYDRO-2H-PYRAN-4-YLAMINO)BENZAMIDE|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|BRIGATINIB|GARD:0009343"	entrectinib	n/a	42038	"Treatment of TrkA-positive, TrkB-positive, TrkC-positive ROS1-positive or ALK-positive non-small cell lung cancer"	Designated/Approved	Approved for Orphan Indication	ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.	Ê08/15/2019Ê	Ê08/15/2026	"Genentech, Inc."	1 DNA Way	MS#241A	South San Francisco	California	94080	USA	462914
2623	"Non-small cell lung cancer, childhood"	9343	approximate		1998	of epidermal growth factor receptor mutation-positive non-small cell lung cancer	C1960925	Epidermal growth factor receptor positive non-small cell lung cancer	neop	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|METASTATIC EGFR T790M MUTATION POSITIVE NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	"Non-small cell lung cancer, childhood|GARD:0009343|OSIMERTINIB|TAGRISSO|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|GEFITINIB|IRESSA|GARD:0009343"	osimertinib	Tagrisso	41886	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	"For treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR TKI therapy"	Ê11/13/2015Ê	Ê11/13/2022	AstraZeneca Pharmaceuticals LP	P. O. Box 8355	1800 Concord Pike	Wilmington	Delaware	19803	USA	445214
2623	"Non-small cell lung cancer, childhood"	9343	approximate		1998	of epidermal growth factor receptor mutation-positive non-small cell lung cancer	C1960925	Epidermal growth factor receptor positive non-small cell lung cancer	neop	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|METASTATIC EGFR T790M MUTATION POSITIVE NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	"Non-small cell lung cancer, childhood|GARD:0009343|OSIMERTINIB|TAGRISSO|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|GEFITINIB|IRESSA|GARD:0009343"	osimertinib	Tagrisso	41886	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	"TAGRISSO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test"	Ê04/18/2018Ê	Ê04/18/2025	AstraZeneca Pharmaceuticals LP	P. O. Box 8355	1800 Concord Pike	Wilmington	Delaware	19803	USA	445214
2264	"Non-small cell lung cancer, childhood"	9343	approximate		2006	of epidermal growth factor receptor mutation-positive non-small cell lung cancer	C1960925	Epidermal growth factor receptor positive non-small cell lung cancer	neop	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|METASTATIC EGFR T790M MUTATION POSITIVE NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	"Non-small cell lung cancer, childhood|GARD:0009343|OSIMERTINIB|TAGRISSO|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|GEFITINIB|IRESSA|GARD:0009343"	gefitinib	Iressa	41877	Treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	For the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test	Ê07/13/2015Ê	Ê07/13/2022	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA	443014
1793	"Non-small cell lung cancer, childhood"	9343	approximate		2476	of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	C1960925	Epidermal growth factor receptor positive non-small cell lung cancer	neop	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|METASTATIC EGFR T790M MUTATION POSITIVE NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	"Non-small cell lung cancer, childhood|GARD:0009343|OSIMERTINIB|TAGRISSO|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|GEFITINIB|IRESSA|GARD:0009343"	afatinib	Gilotrif	41246	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Designated/Approved	Approved for Orphan Indication	GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.	Ê01/12/2018Ê	Ê01/12/2025	"Boehringer Ingelheim Pharmaceuticals, Inc."	P. O. Box 368	900 Ridgebury Road	Ridgefield	Connecticut	6877	USA	375712
1793	"Non-small cell lung cancer, childhood"	9343	approximate		2476	of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	C1960925	Epidermal growth factor receptor positive non-small cell lung cancer	neop	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|METASTATIC EGFR T790M MUTATION POSITIVE NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	"Non-small cell lung cancer, childhood|GARD:0009343|OSIMERTINIB|TAGRISSO|GARD:0009343"	"Non-small cell lung cancer, childhood|GARD:0009343|GEFITINIB|IRESSA|GARD:0009343"	afatinib	Gilotrif	41246	Treatment of epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).	Designated/Approved	Approved for Orphan Indication	First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.	Ê07/12/2013Ê	Ê07/12/2020	"Boehringer Ingelheim Pharmaceuticals, Inc."	P. O. Box 368	900 Ridgebury Road	Ridgefield	Connecticut	6877	USA	375712
2018	"Non-small cell lung cancer, childhood"	9343	approximate		2268	with non-small cell lung cancer	C0007131	Non-Small Cell Lung Carcinoma	neop	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	THYROID CANCER			ceritinib	Zykadia	41544	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Designated/Approved	Approved for Orphan Indication	Treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test	Ê05/26/2017Ê	Ê05/26/2024	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA	405213
2018	"Non-small cell lung cancer, childhood"	9343	approximate		2268	with non-small cell lung cancer	C0007131	Non-Small Cell Lung Carcinoma	neop	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	THYROID CANCER			ceritinib	Zykadia	41544	Treatment of patients with non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase(ALK)-positive	Designated/Approved	Approved for Orphan Indication	ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic nonsmall cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.	Ê04/29/2014Ê	Ê04/29/2021	Novartis Pharmaceuticals Corp.	One Health Plaza		East Hanover	New Jersey	7936	USA	405213
2091	"Non-small cell lung cancer, childhood"	9343	approximate		1815	of non-small cell lung cancer	C0007131	Non-Small Cell Lung Carcinoma	neop	"Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations."				dacomitinib	Vizimpro	42066	"Treatment of non-small cell lung cancer with EGFR, HER2, HER4, or DDR2 mutations."	Designated/Approved	Approved for Orphan Indication	For the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R	Ê09/27/2018Ê	Ê09/27/2025	"Pfizer, Inc."	235 East 42nd Street		New York	New York	10017	USA	435114
961	"Non-small cell lung cancer, childhood"	9343	approximate		1686	ROS1-positive non-small cell lung cancer	C0812281	ROS1 gene	gngm	Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer				Lorlatinib	Lorbrena	42178	Treatment of anaplastic lymphoma kinase (ALK)-positive or ROS1-positive non-small cell lung cancer	Designated/Approved	Approved for Orphan Indication	LORBRENA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or alectinib as the first ALK inhibitor therapy for metastatic disease; or ceritinib as the first ALK inhibitor therapy for metastatic disease.	Ê11/02/2018Ê	Ê11/02/2025	"Pfizer, Inc."	235 East 42nd Street (M/S 219/9/30)		New York	New York	10017	USA	481015
Missing	Nontuberculous mycobacterial lung disease	12829			2409	by non-tuberculous mycobacteria	C0041296	Tuberculosis	dsyn	Treatment of infections caused by non-tuberculous mycobacteria	Nontuberculous mycobacterial lung disease|GARD:0012829|AMIKACIN|LIPOSOMAL AMIKACIN|ARIKACE|GARD:0012829	NONTUBERCULOUS MYCOBACTERIAL LUNG DISEASE|MYCOBACTERIA OTHER THAN TUBERCULOSIS (MOTT)|NONTUBERCULOUS MYCOBACTERIAL DISEASE|NONTUBERCULOSIS MYCOBACTERIUM|NTM	TUBERCULOSIS|CONSUMPTION|TB	liposomal amikacin	Arikayce	41358	Treatment of infections caused by non-tuberculous mycobacteria	Designated/Approved	Approved for Orphan Indication	Treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy	Ê09/28/2018Ê	Ê09/28/2025	Insmed Incorporated	10 Finderne Avenue	Building 10	Bridgewater	New Jersey	8807	USA	342011
5902	Noonan syndrome	10955			3604	with Noonan syndrome	C0028326	Noonan Syndrome	dsyn	Treatment of short stature in patients with Noonan syndrome	Noonan syndrome|GARD:0010955|SOMATROPIN|NORDITROPIN|GARD:0010955	NOONAN SYNDROME|FEMALE PSEUDO-TURNER SYNDROME|MALE TURNER SYNDROME|NS|TURNER PHENOTYPE WITH NORMAL CHROMOSOMES (KARYOTYPE)	COSTELLO SYNDROME|FACIOCUTANEOSKELETAL SYNDROME|FCS SYNDROME	Somatropin	Norditropin	38938	Treatment of short stature in patients with Noonan syndrome	Designated/Approved	Approved for Orphan Indication	Treatment of short stature in patients with Noonan syndrome	Ê05/31/2007Ê	Ê05/31/2014	Novo Nordisk Inc.	100 College Road West		Princeton	New Jersey	8540	USA	226606
4864	Onchocerciasis	7252			2940	of onchocerciasis volvulus	C0029001	Onchocerciasis	dsyn	Treatment of onchocerciasis volvulus in children and adults	Onchocerciasis|GARD:0007252|MOXIDECTIN|GARD:0007252			moxidectin	n/a	40450	Treatment of onchocerciasis volvulus in children and adults	Designated/Approved	Approved for Orphan Indication	Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older	Ê06/13/2018Ê	Ê06/13/2025	Medicines Development Limited	"Level 1, 18 Kevanagh Street"	Southbank VIC 3006	Melbourne			Australia	316510
3071	Orotic aciduria type 1	5429	done		2326	of hereditary orotic aciduria	C0220987	Hereditary orotic aciduria	dsyn	Treatment of hereditary orotic aciduria	"OROTIC ACIDURIA|UREA CYCLE DISORDERS, INBORN|HEREDITARY OROTIC ACIDURIA|DOID:50833|MESH:D056806"	Orotic aciduria type 1|GARD:0005429|URIDINE TRIACETATE|GARD:0005429	OROTIC ACIDURIA TYPE 1|OROTIDYLIC PYROPHOSPHORYLASE AND OROTIDYLIC DECARBOXYLASE DEFICIENCY|UMPS DEFICIENCY|URIDINE MONOPHOSPHATE SYNTHASE DEFICIENCY|UMP SYNTHTASE DEFICIENCY|OROTATE PHOSPHORIBOSYLTRANSFERASE AND OMP DECARBOXYLASE DEFICIENCY|UMPS|URIDINE MONOPHOSPHATE SYNTHETASE DEFICIENCY|HEREDITARY OROTIC ACIDURIA|OROTIC ACIDURIA II (FORMERLY)|OROTICACIDURIA 1|GARD:0005429|OMIM:258900|ORPHA:30|ORPHANET:30|UMLS:C0268130	uridine triacetate	n/a	41495	Treatment of hereditary orotic aciduria	Designated/Approved	Approved for Orphan Indication	Treatment of hereditary orotic aciduria	Ê09/04/2015Ê	Ê09/04/2022	"Wellstat Therapeutics, Inc."	14200 Shady Grove Road	Suite 600	Rockville	Maryland	20850	USA	401013
4879	Osteogenic sarcoma	7284			5189	of osteogenic sarcoma.	C0029463	Osteosarcoma	neop	Treatment of osteogenic sarcoma.	Osteogenic sarcoma|GARD:0007284|TRIMETREXATE|NEUTREXIN|GARD:0007284	Osteogenic sarcoma|GARD:0007284|CTCE-9908|SDF-1 (108) LYSINE DLMER|GARD:0007284	Osteogenic sarcoma|GARD:0007284|METHOTREXATE SODIUM|METHOTREXATE|GARD:0007284	Methotrexate sodium	Methotrexate	31341	Treatment of osteogenic sarcoma.	Designated/Approved	Approved for Orphan Indication	For the use of high dose methotrexate with leucovorin rescue in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor.	Ê04/07/1988Ê	Ê04/07/1995	Lederle Laboratories	Division of American Cyanamid Company	401 N. Middletown Road	Pearl River	New York	10965	USA	9985
886	Osteopetrosis	4155	done		4499	"with severe, malignant osteopetrosis."	C1318518	Infantile malignant osteopetrosis	dsyn	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	Osteopetrosis|GARD:0004155|INTERFERON GAMMA-1B|ACTIMMUNE|GARD:0004155	Osteopetrosis|GARD:0004155|INTERFERON GAMMA-1B|ACTIMMUNE|GARD:0004155	"OSTEOPETROSIS|OSTEOPETROSIS, INFANTILE MALIGNANT 1|SEVERE, MALIGNANT OSTEOPETROSIS|DOID:13533|MESH:C564915"	Interferon gamma-1b	Actimmune	35338	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	Designated/Approved	Approved for Orphan Indication	"Delaying time to disease progression in patients with severe, malignant osteopetrosis."	Ê02/10/2000Ê	Ê02/10/2007	Horizon Therapeutic Ireland DAC	"Connaught House, 1st Floor"	1 Burlington Road	Dublin 4			Ireland	98796
4873	Osteosarcoma	7284			5057	of osteosarcoma.	C0029463	Osteosarcoma	neop	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Osteosarcoma|GARD:0007284|LEUCOVORIN|LEUCOVORIN CALCIUM|GARD:0007284	Osteosarcoma|GARD:0007284|LEVOLEUCOVORIN|FUSILEV|GARD:0007284	COLORECTAL CANCER|METASTATIC COLORECTAL CANCER|DOID:9256|MESH:D015179	Leucovorin	Leucovorin Calcium	32372	For rescue use after high dose methotrexate therapy in the treatment of osteosarcoma.	Designated/Approved	Approved for Orphan Indication		Ê08/31/1988Ê	Ê08/31/1995	Immunex Corporation	51 University Street		Seattle	Washington	98101	USA	30588
4869	Osteosarcoma	7284			4811	of osteosarcoma.	C0029463	Osteosarcoma	neop	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Osteosarcoma|GARD:0007284|LEVOLEUCOVORIN|FUSILEV|GARD:0007284			Levoleucovorin	Fusilev	33451	For use in conjunction with high-dose methotrexate in the treatment of osteosarcoma.	Designated/Approved	Approved for Orphan Indication	Levoleucovorin rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists	Ê03/07/2008Ê	Ê03/07/2015	Acrotech Biopharma LLC	279 Princeton Hightstown Road		East Windsor	New Jersey	8520	USA	48490
4894	Ovarian cancer	7295			3676	with ovarian cancer	C0029925	Ovarian Carcinoma	neop	Therapeutic treatment of patients with ovarian cancer	Ovarian cancer|GARD:0007295|BEVACIZUMAB|AVASTIN|GARD:0007295	OVARIAN CANCER	HEREDITARY BREAST AND OVARIAN CANCER SYNDROME|HBOC|HBOC SYNDROME	bevacizumab	Avastin	38757	Therapeutic treatment of patients with ovarian cancer	Designated/Approved	Approved for Orphan Indication	"Avastin, in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, is indicated for the treatment of patients with stage III or IV epithelial ovarian, fallopian tube, orprimary peritoneal cancer following initial surgical resection. Avastin, in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, in combination with carboplatin and paclitaxel, or with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitiverecurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer."	Ê06/13/2018Ê	Ê06/13/2025	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	216405
4894	Ovarian cancer	7295			3676	with ovarian cancer	C0029925	Ovarian Carcinoma	neop	Therapeutic treatment of patients with ovarian cancer	Ovarian cancer|GARD:0007295|BEVACIZUMAB|AVASTIN|GARD:0007295	OVARIAN CANCER	HEREDITARY BREAST AND OVARIAN CANCER SYNDROME|HBOC|HBOC SYNDROME	bevacizumab	Avastin	38757	Therapeutic treatment of patients with ovarian cancer	Designated/Approved	Approved for Orphan Indication	"Avastin in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan is indicated for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens. Avastin, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine, followed by Avastin as a single agent, is indicated for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer."	Ê12/06/2016Ê	Ê12/06/2023	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	216405
4894	Ovarian cancer	7295			3676	with ovarian cancer	C0029925	Ovarian Carcinoma	neop	Therapeutic treatment of patients with ovarian cancer	Ovarian cancer|GARD:0007295|BEVACIZUMAB|AVASTIN|GARD:0007295	OVARIAN CANCER	HEREDITARY BREAST AND OVARIAN CANCER SYNDROME|HBOC|HBOC SYNDROME	bevacizumab	Avastin	38757	Therapeutic treatment of patients with ovarian cancer	Designated/Approved	Approved for Orphan Indication	"In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for treatment of patients with platinum-resistant, recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than 2 prior chemotherapy regimens"	Ê11/14/2014Ê	Ê11/14/2021	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	216405
4920	Ovarian cancer	7295			1684	of ovarian cancer	C0029925	Ovarian Carcinoma	neop	Treatment of ovarian cancer	Ovarian cancer|GARD:0007295|DCVAC OVCA|GARD:0007295	Ovarian cancer|GARD:0007295|DPX-SURVIVAC|GARD:0007295	"Ovarian cancer|GARD:0007295|PACLITAXEL|PACLITAXEL, MICELLAR|PACLICAL|GARD:0007295"	gemcitabine ready-to-use	Infugem	42179	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	INFUGEM in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.	Ê07/16/2018Ê	ÊTBD	Sun Pharmaceutical Industries Ltd.	Acme Plaza	"Andheri (East), Mumbai 400059"				India	477015
4945	Ovarian cancer	7295			2258	of ovarian cancer	C0029925	Ovarian Carcinoma	neop	Treatment of ovarian cancer	Ovarian cancer|GARD:0007295|DCVAC OVCA|GARD:0007295	Ovarian cancer|GARD:0007295|DPX-SURVIVAC|GARD:0007295	"Ovarian cancer|GARD:0007295|PACLITAXEL|PACLITAXEL, MICELLAR|PACLICAL|GARD:0007295"	olaparib	Lynparza	41563	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	Indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy	Ê12/19/2014Ê	Ê12/19/2021	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA	409213
4945	Ovarian cancer	7295			2258	of ovarian cancer	C0029925	Ovarian Carcinoma	neop	Treatment of ovarian cancer	Ovarian cancer|GARD:0007295|DCVAC OVCA|GARD:0007295	Ovarian cancer|GARD:0007295|DPX-SURVIVAC|GARD:0007295	"Ovarian cancer|GARD:0007295|PACLITAXEL|PACLITAXEL, MICELLAR|PACLICAL|GARD:0007295"	olaparib	Lynparza	41563	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy."	Ê08/17/2017Ê	Ê08/17/2024	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA	409213
4945	Ovarian cancer	7295			2258	of ovarian cancer	C0029925	Ovarian Carcinoma	neop	Treatment of ovarian cancer	Ovarian cancer|GARD:0007295|DCVAC OVCA|GARD:0007295	Ovarian cancer|GARD:0007295|DPX-SURVIVAC|GARD:0007295	"Ovarian cancer|GARD:0007295|PACLITAXEL|PACLITAXEL, MICELLAR|PACLICAL|GARD:0007295"	olaparib	Lynparza	41563	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	"Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza."	Ê12/19/2018Ê	Ê12/19/2025	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA	409213
4915	Ovarian cancer	7295			2559	of ovarian cancer	C0029925	Ovarian Carcinoma	neop	Treatment of ovarian cancer	Ovarian cancer|GARD:0007295|DCVAC OVCA|GARD:0007295	Ovarian cancer|GARD:0007295|DPX-SURVIVAC|GARD:0007295	"Ovarian cancer|GARD:0007295|PACLITAXEL|PACLITAXEL, MICELLAR|PACLICAL|GARD:0007295"	rucaparib	Rubraca	41121	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	"For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy."	Ê04/06/2018Ê	Ê04/06/2025	"Clovis Oncology, Inc."	5500 Flatiron Parkway	Suite 100	Boulder	Colorado	80301	USA	374712
4915	Ovarian cancer	7295			2559	of ovarian cancer	C0029925	Ovarian Carcinoma	neop	Treatment of ovarian cancer	Ovarian cancer|GARD:0007295|DCVAC OVCA|GARD:0007295	Ovarian cancer|GARD:0007295|DPX-SURVIVAC|GARD:0007295	"Ovarian cancer|GARD:0007295|PACLITAXEL|PACLITAXEL, MICELLAR|PACLICAL|GARD:0007295"	rucaparib	Rubraca	41121	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	As monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies	Ê12/19/2016Ê	Ê12/19/2023	"Clovis Oncology, Inc."	5500 Flatiron Parkway	Suite 100	Boulder	Colorado	80301	USA	374712
4928	Ovarian cancer	7295			3024	of ovarian cancer	C0029925	Ovarian Carcinoma	neop	Treatment of ovarian cancer	Ovarian cancer|GARD:0007295|DCVAC OVCA|GARD:0007295	Ovarian cancer|GARD:0007295|DPX-SURVIVAC|GARD:0007295	"Ovarian cancer|GARD:0007295|PACLITAXEL|PACLITAXEL, MICELLAR|PACLICAL|GARD:0007295"	niraparib	Zejula	40298	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	"ZEJULA is indicated for the treatment of adult patients with advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either, (1) a deleterious or suspected deleterious BRCA mutation, or (2) genomic instability and who have progressed more than six months after response to the last platinum-based chemotherapy"	Ê10/23/2019Ê	Ê10/23/2026	"TESARO, Inc."	1000 Winter St.	Suite 3300	Waltham	Massachusetts	2451	USA	306510
4928	Ovarian cancer	7295			3024	of ovarian cancer	C0029925	Ovarian Carcinoma	neop	Treatment of ovarian cancer	Ovarian cancer|GARD:0007295|DCVAC OVCA|GARD:0007295	Ovarian cancer|GARD:0007295|DPX-SURVIVAC|GARD:0007295	"Ovarian cancer|GARD:0007295|PACLITAXEL|PACLITAXEL, MICELLAR|PACLICAL|GARD:0007295"	niraparib	Zejula	40298	Treatment of ovarian cancer	Designated/Approved	Approved for Orphan Indication	"Indicated for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy"	Ê03/27/2017Ê	Ê03/27/2024	"TESARO, Inc."	1000 Winter St.	Suite 3300	Waltham	Massachusetts	2451	USA	306510
4914	Ovarian cancer	7295			4367	of ovarian cancer.	C0029925	Ovarian Carcinoma	neop	Treatment of ovarian cancer.	Ovarian cancer|GARD:0007295|DCVAC OVCA|GARD:0007295	Ovarian cancer|GARD:0007295|DPX-SURVIVAC|GARD:0007295	"Ovarian cancer|GARD:0007295|PACLITAXEL|PACLITAXEL, MICELLAR|PACLICAL|GARD:0007295"	Doxorubicin liposome	Doxil	36103	Treatment of ovarian cancer.	Designated/Approved	Approved for Orphan Indication	"Treatment of metastatic carcinoma of the ovary in patients with disease that is refractory to both paclitaxel- and platinium-based chemotherapy regimens. Refractory disease is defined as disease that has progressed while on treatment, or within 6 months of completing treatment."	Ê06/28/1999Ê	Ê06/28/2006	Alza Corporation	1550 Plymouth St.	PO Box 7210	Mountain View	California	94039	USA	117398
Missing	Ovarian cancer	7295			5261	of advanced adenocarcinoma	C0001418	Adenocarcinoma	neop	Treatment of advanced adenocarcinoma of the ovary.				Altretamine	Hexalen	30721	Treatment of advanced adenocarcinoma of the ovary.	Designated/Approved	Approved for Orphan Indication	Single agent palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent based combination.	Ê12/26/1990Ê	Ê12/26/1997	"Medimmune Oncology, Inc."	One Tower Bridge	"100 Front St., Suite 400"	West Conshohocken	Pennsylvania	19428	USA	983
Missing	Ovarian cancer	7295			4908	of advanced ovarian carcinoma.	C0029925	Ovarian Carcinoma	neop	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.				Amifostine	Ethyol	33023	For use as a chemoprotective agent for cisplatin in the treatment of advanced ovarian carcinoma.	Designated/Approved	Approved for Orphan Indication	To reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer.	Ê12/08/1995Ê	Ê12/08/2002	"Medimmune Oncology, Inc."	One Tower Bridge	"100 Front St., Suite 400"	West Conshohocken	Pennsylvania	19428	USA	42789
441	Paget disease of bone 	8615	done	Not a rare disease	5143	of symptomatic Paget's disease	C0029401	Osteitis Deformans	dsyn	Treatment of symptomatic Paget's disease (osteitis deformans).	" Paget disease of bone, familial|GARD:0004191|CALCITONIN HUMAN|CALCITONIN-HUMAN FOR INJECTION|CIBACALCIN|GARD:0004191"	Paget disease of bone |GARD:0008615|CALCITONIN HUMAN|CALCITONIN-HUMAN FOR INJECTION|CIBACALCIN|GARD:0008615	" Paget disease of bone, familial|GARD:0004191|CALCITONIN SALMON|CALCITONIN SALMON NASAL SPRAY|MIACALCIN NASAL SPRAY|GARD:0004191"	Calcitonin-human for injection	Cibacalcin	31797	Treatment of symptomatic Paget's disease (osteitis deformans).	Designated/Approved	Approved for Orphan Indication		Ê10/31/1986Ê	Ê10/31/1993	Novartis Pharmaceutical Corporation	59 Route 10		East Hanover	New Jersey	7936	USA	13186
2598	Pancreatic cancer	9364	done	Not a rare disease	453	of pancreatic cancer	C0235974	Pancreatic carcinoma	neop	Treatment of pancreatic cancer	Pancreatic cancer|GARD:0009364|BLEOMYCIN|GARD:0009364	Pancreatic cancer|GARD:0009364|BARDOXOLONE|GARD:0009364	Pancreatic cancer|GARD:0009364|PAMREVLUMAB|GARD:0009364	olaparib	Lynparza	43384	Treatment of pancreatic cancer	Designated/Approved	Approved for Orphan Indication	Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.	Ê12/27/2019Ê	Ê12/27/2026	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P.O. Box 8355	Wilmington	Delaware	19803	USA	655318
2267	Pancreatic cancer	9364	done	Not a rare disease	1683	of pancreatic cancer	C0235974	Pancreatic carcinoma	neop	Treatment of pancreatic cancer	Pancreatic cancer|GARD:0009364|BLEOMYCIN|GARD:0009364	Pancreatic cancer|GARD:0009364|BARDOXOLONE|GARD:0009364	Pancreatic cancer|GARD:0009364|PAMREVLUMAB|GARD:0009364	gemcitabine ready-to-use	Infugem	42179	Treatment of pancreatic cancer	Designated/Approved	Approved for Orphan Indication	INFUGEM is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. INFUGEM is indicated for patients previously treated with fluorouracil.	Ê07/16/2018Ê	ÊTBD	Sun Pharmaceutical Industries Ltd.	Acme Plaza	"Andheri (East), Mumbai 400059"				India	476915
2386	Pancreatic cancer	9364	done	Not a rare disease	2743	of pancreatic cancer	C0235974	Pancreatic carcinoma	neop	Treatment of pancreatic cancer	Pancreatic cancer|GARD:0009364|BLEOMYCIN|GARD:0009364	Pancreatic cancer|GARD:0009364|BARDOXOLONE|GARD:0009364	Pancreatic cancer|GARD:0009364|PAMREVLUMAB|GARD:0009364	irinotecan liposome injection	n/a	40745	Treatment of pancreatic cancer	Designated/Approved	Approved for Orphan Indication	"For use in combination with fluorouracil and leucovorin, for the treatment of patients with metastatic adenocarcinoma of the pancreas that has progressed following gemcitabine-based therapy"	Ê10/22/2015Ê	Ê10/22/2022	"Ipsen Bioscience,Inc."	650 East Kendall Street		Cambridge	Massachusetts	2142	USA	344311
2635	Pancreatic cancer	9364	done	Not a rare disease	3143	of pancreatic cancer.	C0235974	Pancreatic carcinoma	neop	Treatment of pancreatic cancer.	Pancreatic cancer|GARD:0009364|BLEOMYCIN|GARD:0009364	Pancreatic cancer|GARD:0009364|BARDOXOLONE|GARD:0009364	Pancreatic cancer|GARD:0009364|PAMREVLUMAB|GARD:0009364	paclitaxel protein-bound particles	Abraxane	40059	Treatment of pancreatic cancer.	Designated/Approved	Approved for Orphan Indication	"Treatment of metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine."	Ê09/06/2013Ê	Ê09/06/2020	"Abraxis BioScience, LLC"	"9225 Indian Creek Parkway, Suite 900"		Overland Park	Kansas	66210	USA	291009
5980	Pancreatic neuroendocrine tumor	13034			3245	of gastro-entero-pancreatic neuroendocrine tumors	C0242363	Islet Cell Tumor	neop	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Pancreatic neuroendocrine tumor|GARD:0013034|EDOTREOTIDE LUTETIUM LU-177|LUTETIUM (177LU)-EDOTREOTIDE|GARD:0013034	Pancreatic neuroendocrine tumor|GARD:0013034|DOTATATE LUTENIUM LU-177|[LU-177]-DOTA-TYR3-OCTREOTATE|GARD:0013034	Neuroendocrine tumor|GARD:0013445|DOTATATE LUTENIUM LU-177|[LU-177]-DOTA-TYR3-OCTREOTATE|GARD:0013445	lutetium Lu 177 dotatate	n/a	39825	Treatment of gastro-entero-pancreatic neuroendocrine tumors	Designated/Approved	Approved for Orphan Indication	"Treatment of somatostatin receptor positive GEP-NETs including foregut, midgut, and hindgut neuroendocrine tumors in adults"	Ê01/26/2018Ê	Ê01/26/2025	Advanced Accelerator Applications	57 East Willow Street		Millburn	New Jersey	7041	USA	271008
1770	Panuveitis	8577	approximate		2099	"panuveitis,"	C0030343	Panuveitis	dsyn	"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis"	  Panuveitis|GARD:0008577|SIROLIMUS|GARD:0008577	Panuveitis|GARD:0008577|SIROLIMUS|GARD:0008577	Posterior uveitis |GARD:0004457|SIROLIMUS|GARD:0004457	adalimumab	Humira	41772	"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis"	Designated/Approved	Approved for Orphan Indication	"Treatment of non-infectious intermediate, posterior, and panuveitis in adults and pediatric patients 2 years of age and older"	Ê09/28/2018Ê	Ê09/28/2025	"AbbVie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA	318510
1770	Panuveitis	8577	approximate		2099	"panuveitis,"	C0030343	Panuveitis	dsyn	"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis"	  Panuveitis|GARD:0008577|SIROLIMUS|GARD:0008577	Panuveitis|GARD:0008577|SIROLIMUS|GARD:0008577	Posterior uveitis |GARD:0004457|SIROLIMUS|GARD:0004457	adalimumab	Humira	41772	"Treatment of non-infectious intermediate, posterior, or panuveitis, or chronic non-infectious anterior uveitis"	Designated/Approved	Approved for Orphan Indication	"Indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients"	Ê06/30/2016Ê	Ê06/30/2023	"AbbVie, Inc."	1 North Waukegan Road		North Chicago	Illinois	60064	USA	318510
2120	Panuveitis	8577	approximate		4380	panuveitis	C0030343	Panuveitis	dsyn	"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis"	Panuveitis |GARD:0008577|DEXAMETHASONE|DEXAMETHASONE INTRAVITREAL IMPLANT|OZURDEX|GARD:0008577	Panuveitis|GARD:0008577|DEXAMETHASONE INTRAVITREAL IMPLANT|OZURDEX|GARD:0008577	 Posterior uveitis|GARD:0004457|DEXAMETHASONE|DEXAMETHASONE INTRAVITREAL IMPLANT|OZURDEX|GARD:0004457	dexamethasone intravitreal implant	Ozurdex	36049	"Treatment of non-infectious ocular inflammation of the posterior segment in patients with intermediate, posterior, and panuveitis"	Designated/Approved	Approved for Orphan Indication	For treatment of non-infectious uveitis affecting the posterior segment of the eye	Ê09/24/2010Ê	Ê09/24/2017	Allergan	2525 Dupont Drive		Irvine	California	92623	USA	115298
5508	Panuveitis	8577			3288	traumatic anterior uveitis	C0042165	Anterior uveitis	dsyn	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Panuveitis|GARD:0008577|DIFLUPREDNATE|DUREZOL|GARD:0008577	Anterior uveitis|GARD:0010941|DIFLUPREDNATE|DUREZOL|GARD:0010941		difluprednate	Durezol	39721	Treatment of endogenous and traumatic anterior uveitis and panuveitis.	Designated/Approved	Approved for Orphan Indication	Treatment of endogenous anterior uveitis	Ê06/13/2012Ê	Ê06/13/2019	Alcon Pharmaceuticals. Ltd.	Route Des Arsenaux 41	1701 Fribourg (P.O. Box 61)				Switzerland	265608
1630	Papillary thyroid carcinoma 	12027	approximate		4771	of thyroid cancer.	C0007115	Malignant neoplasm of thyroid	neop	As an adjunct in the diagnosis of thyroid cancer.	" Thyroid cancer, follicular |GARD:0005206|THYROTROPIN|THYROTROPIN ALPHA|THYROGEN|GARD:0005206"	" Thyroid cancer, medullary |GARD:0007004|THYROTROPIN|THYROTROPIN ALPHA|THYROGEN|GARD:0007004"	  Anaplastic thyroid cancer|GARD:0000664|THYROTROPIN|THYROTROPIN ALPHA|THYROGEN|GARD:0000664	Thyrotropin alpha	Thyrogen	33658	As an adjunct in the diagnosis of thyroid cancer.	Designated/Approved	Approved for Orphan Indication	As an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with thyroid cancer.	Ê11/30/1998Ê	Ê11/30/2005	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA	63191
1628	Papillary thyroid carcinoma 	12027	done		4163	combined papillary/follicular carcinomas	C0007133	"Carcinoma, Papillary"	neop	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid"	" Thyroid cancer, follicular|GARD:0005206|TIRATRICOL|3,5,3'-TRIIODOTHYROACETATE|GARD:0005206"	"Papillary thyroid carcinoma |GARD:0012027|TIRATRICOL|3,5,3'-TRIIODOTHYROACETATE|GARD:0012027"	" Thyroid cancer, follicular|GARD:0005206|THYROTROPIN ALFA|THYROGEN|GARD:0005206"	Thyrotropin alfa	Thyrogen	37106	"Treatment of well-differentiated papillary, follicular or combined papillary/follicular carcinomas of the thyroid"	Designated/Approved	Approved for Orphan Indication	For use as an adjunctive treatment for radioiodine ablation of thyroid tissue remnants in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of metastatic thyroid cancer	Ê12/14/2007Ê	Ê12/14/2014	Genzyme Corporation	One Kendall Square		Cambridge	Massachusetts	2139	USA	142301
4981	Parathyroid carcinoma	7329			4021	with parathyroid carcinoma	C0687150	Parathyroid Gland Adenocarcinoma	neop	Treatment of hypercalcemia in patients with parathyroid carcinoma	Parathyroid carcinoma|GARD:0007329|CINACALCET|SENSIPAR|GARD:0007329	PRIMARY HYPERPARATHYROIDISM|PHPT	MULTIPLE ENDOCRINE NEOPLASIA TYPE 2|MEN-2|MEN2 SYNDROME	cinacalcet	Sensipar	37753	Treatment of hypercalcemia in patients with parathyroid carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of hypercalcemia in patients with parathyroid carcinoma	Ê03/08/2004Ê	Ê03/08/2011	"Amgen, Inc."		One Amgen Center Drive	Thousand Oaks	California	91320	USA	163402
991	Parkinson disease	10251	done	Not a rare disease	4273	of late stage Parkinson's disease	C0030567	Parkinson Disease	dsyn	Treatment of late stage Parkinson's disease	Parkinson disease|GARD:0010251|APOMORPHINE|GARD:0010251	Parkinson disease|GARD:0010251|APOMORPHINE|GARD:0010251	Parkinson disease|GARD:0010251|CARBIDOPA|LEVODOPA AND CARBIDOPA|DUODOPA|GARD:0010251	levodopa and carbidopa	Duopa	36543	Treatment of late stage Parkinson's disease	Designated/Approved	Approved for Orphan Indication	Treatment of motor flucuations in patients with advanced Parkinson's disease	Ê01/09/2015Ê	Ê01/09/2022	"AbbVie, Inc."	1 N. Waukegan Road	Building AP30-1	North Chicago	Illinois	60064	USA	129499
269	Parkinson disease	10251	done	Not a rare disease	4702	with late-stage Parkinson's disease.	C0030567	Parkinson Disease	dsyn	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Parkinson disease|GARD:0010251|APOMORPHINE|GARD:0010251	Parkinson disease|GARD:0010251|APOMORPHINE HYDROCHLORIDE|APOMORPHINE HCL|APOKYN|GARD:0010251		Apomorphine HCl	Apokyn	34081	Treatment of the on-off fluctuations associated with late-stage Parkinson's disease.	Designated/Approved	Approved for Orphan Indication	"For the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose-wearing-off"" and unpredictable :on/off"" episodes) associated with advanced Parkinson's disease"	Ê04/20/2004Ê	Ê04/20/2011	"US WorldMeds, LLC"	4010 Dupont Circle	Suite L-07	Louisville	Kentucky	40207	USA	57591
1469	Parkinson disease	10251	done		5232	symptomatic Parkinsonism.	C0030569	Secondary Parkinson Disease	dsyn	"As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism."	Parkinson disease|GARD:0010251|SELEGILINE HYDROCHLORIDE|SELEGILINE HCL|ELDEPRYL|GARD:0010251			Selegiline HCl	Eldepryl	30993	"As an adjuvant to levodopa and carbidopa treatment of idiopathic Parkinson's disease (paralysis agitans), postencephalitic Parkinsonism, and symptomatic Parkinsonism."	Designated/Approved	Approved for Orphan Indication		Ê06/05/1989Ê	Ê06/05/1996	"Somerset Pharmaceuticals, Inc."	"400 Morris Ave., Suite 7s"		Denville	New Jersey	7834	USA	583
4985	Paroxysmal nocturnal hemoglobinuria	7337			1189	of paroxysmal nocturnal hemoglobinuria	C0024790	Paroxysmal nocturnal hemoglobinuria	dsyn	Treatment of paroxysmal nocturnal hemoglobinuria	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA|DOID:60284|MESH:D006457	Paroxysmal nocturnal hemoglobinuria (PNH)|GARD:0007337|RA-101495|SYNTHETIC 15-AMINO-ACID MACROCYCLIC PEPTIDE ACYLATED WITH A ETHYLENEGLYCOL PALMITOYLATED LINKER|GARD:0007337	Paroxysmal nocturnal hemoglobinuria|GARD:0007337|RA-101495|SYNTHETIC 15-AMINO-ACID MACROCYCLIC PEPTIDE ACYLATED WITH A ETHYLENEGLYCOL PALMITOYLATED LINKER|GARD:0007337	Ravulizumab-cwvz	Ultomiris	42739	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved	Approved for Orphan Indication	ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).	Ê12/21/2018Ê	ÊTBD	"Alexion Pharmaceuticals, Inc."	100 College Street		New Haven	Connecticut	6510	USA	513015
4984	Paroxysmal nocturnal hemoglobinuria	7337			3988	of paroxysmal nocturnal hemoglobinuria	C0024790	Paroxysmal nocturnal hemoglobinuria	dsyn	Treatment of paroxysmal nocturnal hemoglobinuria	PAROXYSMAL NOCTURNAL HEMOGLOBINURIA|DOID:60284|MESH:D006457	Paroxysmal nocturnal hemoglobinuria (PNH)|GARD:0007337|RA-101495|SYNTHETIC 15-AMINO-ACID MACROCYCLIC PEPTIDE ACYLATED WITH A ETHYLENEGLYCOL PALMITOYLATED LINKER|GARD:0007337	Paroxysmal nocturnal hemoglobinuria|GARD:0007337|RA-101495|SYNTHETIC 15-AMINO-ACID MACROCYCLIC PEPTIDE ACYLATED WITH A ETHYLENEGLYCOL PALMITOYLATED LINKER|GARD:0007337	eculizumab	Soliris	37853	Treatment of paroxysmal nocturnal hemoglobinuria	Designated/Approved	Approved for Orphan Indication	Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis	Ê03/16/2007Ê	Ê03/16/2014	"Alexion Pharmaceuticals, Inc."	121 Seaport Boulevard		Boston	Massachusetts	2210	USA	173203
4993	Patent ductus arteriosus	7342			4496	of patent ductus arteriosus	C3495549	Patent ductus arteriosus - persisting type	dsyn	Treatment of patent ductus arteriosus	PATENT DUCTUS ARTERIOSUS|DOID:13832|MESH:D004374	Patent ductus arteriosus|GARD:0007342|IBUPROFEN LYSINE|NEOPROFEN|GARD:0007342	"ALPROSTADIL|PROSTAGLANDIN E1|(11ALPHA,13E,15S)-11,15-DIHYDROXY-9-OXOPROST-13-EN-1-OIC ACID|MUSE (INTRAURETHRAL ALPROSTADIL SUPPOSITORY)|PGE1|CAVERJECT|MUSE|CHEBI:15544|NCIT:C28816|NCI:C28816|NSC:165559|UMLS:C0002335"	Ibuprofen lysine	Neoprofen	35367	Treatment of patent ductus arteriosus	Designated/Approved	Approved for Orphan Indication	"For closure of a clinically significant patent ductus arteriosus in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective"	Ê04/13/2006Ê	Ê04/13/2013	"Lundbeck, Inc."	Four Parkway North		Deerfield	Illinois	60015	USA	101496
5702	Pediatric Crohn's disease	9856			3579	of pediatric Crohn's disease	C2931133	Pediatric Crohn's disease	dsyn	Treatment of pediatric Crohn's disease	"Pediatric Crohn's disease|GARD:0009856|BECLOMETHASONE DIPROPIONATE|BECLOMETHASONE 17,21-DIPROPRIONATE|GARD:0009856"	"Pediatric Crohn's disease|GARD:0009856|CLARITHROMYCIN|CLARITHROMYCIN, RIFABUTIN, CLOFAZIMINE|GARD:0009856"	"Pediatric Crohn's disease|GARD:0009856|CLOFAZIMINE|CLARITHROMYCIN, RIFABUTIN, CLOFAZIMINE|GARD:0009856"	adalimumab	Humira	39009	Treatment of pediatric Crohn's disease	Designated/Approved	Approved for Orphan Indication	"Reducing signs and symptoms and inducing and maintaining clinical remission in patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate."	Ê09/23/2014Ê	Ê09/23/2021	"AbbVie, Inc."	1 N. Waukegan Road	"Bldg AP30, Dept. PA77"	North Chicago	Illinois	60064	USA	230306
872	Pediatric Crohn's disease	9856	done		3975	Crohn's Disease	C0010346	Crohn Disease	dsyn	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Pediatric Crohn's disease|GARD:0009856|USTEKINUMAB|STELARA|GARD:0009856	"Pediatric Crohn's disease|GARD:0009856|INFLIXIMAB, LICENSE HOLDER UNSPECIFIED|INFLIXIMAB|REMICADE|GARD:0009856"	Pediatric Crohn's disease|GARD:0009856|ADALIMUMAB|HUMIRA|GARD:0009856	Infliximab	Remicade	37937	Treatment of pediatric (0 to 16 years of age) Crohn's Disease	Designated/Approved	Approved for Orphan Indication	For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventional therapy	Ê05/19/2006Ê	Ê05/19/2013	"Centocor, Inc."	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA	175803
328	Pediatric ulcerative colitis	9857	done		3747	with ulcerative colitis	C0009324	Ulcerative Colitis	dsyn	Treatment of pediatric patients with ulcerative colitis	Pediatric ulcerative colitis|GARD:0009857|COBITOLIMOD|GARD:0009857	Pediatric ulcerative colitis|GARD:0009857|MESALAMINE|MESALAMINE; 5-AMINOSALICYLIC ACID|5-AMINOSALICYLIC ACID|LIALDA|GARD:0009857	Pediatric ulcerative colitis|GARD:0009857|ACETYLCYSTEINE|MESALAMINE AND N-ACETYCYSTEINE|N-ACETYLCYSTEINE|GARD:0009857	Balsalazide disodium	Colazal	38576	Treatment of pediatric patients with ulcerative colitis	Designated/Approved	Approved for Orphan Indication	Treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older. Safety and Effectiveness of Colazal beyond 8 weeks in children (ages 5-17) and 12 weeks in adults have not been established.	Ê12/20/2006Ê	Ê12/20/2013	"Salix Pharmaceuticals, Inc."	400 Somerset Corporate Blvd		Bridgewater	New Jersey	8807	USA	208205
2372	Pediatric ulcerative colitis	9857	done	Not a rare disease	3976	ulcerative colitis	C0009324	Ulcerative Colitis	dsyn	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Pediatric ulcerative colitis|GARD:0009857|ROSEBURIA HOMINIS|ROSBURIX|GARD:0009857	Pediatric ulcerative colitis|GARD:0009857|OZANIMOD|GARD:0009857	Pediatric ulcerative colitis|GARD:0009857|ACETYLCYSTEINE|MESALAMINE AND N-ACETYCYSTEINE|N-ACETYLCYSTEINE|GARD:0009857	infliximab	Remicade	37937	Treatment of pediatric (0 to 16 years of age) ulcerative colitis	Designated/Approved	Approved for Orphan Indication	For reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy	Ê09/23/2011Ê	Ê09/23/2018	Janssen Biotech Inc.	200 Great Valley Parkway		Malvern	Pennsylvania	19355	USA	175903
4996	Pemphigus	7352			1827	of pemphigus vulgaris.	C0030809	Pemphigus Vulgaris	dsyn	Treatment of pemphigus vulgaris.	Pemphigus vulgaris|GARD:0007355|MYCOPHENOLATE MOFETIL|CELLCEPT|GARD:0007355	Pemphigus vulgaris|GARD:0007355|PRN-1008|SMALL MOLECULE BRUTON'S AGAMMAGLOBULINEMIA TYROSINE KINASE (BKT) INHIBITOR|GARD:0007355	Pemphigus vulgaris|GARD:0007355|RITUXIMAB|RITUXAN(R); MABTHERA(R)|GARD:0007355	rituximab	Rituxan(R); Mabthera(R)	42058	Treatment of pemphigus vulgaris.	Designated/Approved	Approved for Orphan Indication	RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.	Ê06/07/2018Ê	Ê06/07/2025	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	465014
5017	Peripheral T-cell lymphoma	7368			3135	of peripheral T-cell lymphoma (PTCL).	C0079774	Peripheral T-Cell Lymphoma	neop	Treatment of peripheral T-cell lymphoma (PTCL).	Peripheral T-cell lymphoma|GARD:0007368|DENILEUKIN DIFTITOX|GARD:0007368	Peripheral T-cell lymphoma|GARD:0007368|CERDULATINIB|GARD:0007368	"PERIPHERAL T-CELL LYMPHOMA|LYMPHOMA, T-CELL, PERIPHERAL|DOID:50749|MESH:D016411"	Belinostat	Beleodaq	40059	Treatment of peripheral T-cell lymphoma (PTCL).	Designated/Approved	Approved for Orphan Indication	Treatment of patients with relapsed or refractory peripheral T-cell lymphoma	Ê07/03/2014Ê	Ê07/03/2021	Acrotech Biopharma LLC	279 Princeton Hightstown Road		East Windsor	New Jersey	8520	USA	289309
2055	Peyronie disease	7379	done		4529	of Peyronie's disease.	C0030848	Peyronie Disease	dsyn	Treatment of Peyronie's disease.	Peyronie disease|GARD:0007379|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|XIAFLEX|GARD:0007379	PLANTAR FIBROMATOSIS|LEDERHOSE DISEASE|LEDDERHOSE DISEASE|GARD:0006873|MESH:C537000|MEDDRA:10035154|ORPHANET:199251|MONDO:0016036	"DUPUYTRENâS CONTRACTURE|PALMAR FIBROMAS|PALMAR FIBROMATOSIS, FAMILIAL|PLANTAR FIBROMAS|PLANTAR FIBROMATOSIS, FAMILIAL"	collagenase clostridium histolyticum	Xiaflex	35136	Treatment of Peyronie's disease.	Designated/Approved	Approved for Orphan Indication	Treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.	Ê12/06/2013Ê	Ê12/06/2020	"Auxilium Pharmaceuticals, Inc."	640 Lee Road		Chesterbrook	Pennsylvania	19087	USA	95496
5028	Pheochromocytoma	7385			3565	of pheochromocytomas	C0031511	Pheochromocytoma	neop	For the diagnosis of pheochromocytomas	Pheochromocytoma|GARD:0007385|IOBENGUANE I 123|ADREVIEW|GARD:0007385	Neuroblastoma|GARD:0007185|IOBENGUANE I 123|ADREVIEW|GARD:0007185	PHEOCHROMOCYTOMA|ADRENAL PARAGANGLIOMA|CHROMAFFIN CELL TUMOR|PARAGANGLIOMA	Iobenguane I 123	Adreview	39052	For the diagnosis of pheochromocytomas	Designated/Approved	Approved for Orphan Indication	To be used in the detection of primary or metastatic pheochromocytomas or neuroblastomas as an adjunct to other diagnostic tests	Ê09/19/2008Ê	Ê09/19/2015	"GE Healthcare, Inc."	101 Carnegie Center		Princeton	New Jersey	8540	USA	226506
1217	Pigmented villonodular synovitis	7396	done		2160	of pigmented villonodular synovitis/giant cell tumor	C0039106	Pigmented villonodular synovitis	neop	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Pigmented villonodular synovitis|GARD:0007396|OTILIMAB|RECOMBINANT HUMAN MONOCLONAL ANTIBODY OF THE IGG1 KAPPA CLASS AGAINST HUMAN MACROPHAGE COLONY-STIMULATING FACTOR|GARD:0007396	"Pigmented villonodular synovitis|GARD:0007396|PEXIDARTINIB HYDROCHLORIDE|[5-(5-CHLORO-1H-PYRROLO[2,3-B]PYRIDIN-3-YLMETHYL)-PYRIDIN-2-YL]-(6-TRIFLUOROMETHYL-PYRIDIN-3-YLMETHYL)-AMINE HYDROCHLORIDE SALT|GARD:0007396"	Pigmented villonodular synovitis|GARD:0007396|OTILIMAB|RECOMBINANT HUMAN MONOCLONAL ANTIBODY OF THE IGG1 KAPPA CLASS AGAINST HUMAN MACROPHAGE COLONY-STIMULATING FACTOR|GARD:0007396	pexidartinib	Turalio	41684	Treatment of pigmented villonodular synovitis/giant cell tumor of the tendon sheath	Designated/Approved	Approved for Orphan Indication	TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.	Ê08/02/2019Ê	Ê08/02/2026	"Daiichi Sankyo, Inc."	211 Mount Airy Road		Basking Ridge	New Jersey	7920	USA	419913
1531	"Pleural Effusion, Malignant"		MISSING		4430	of malignant pleural effusion	C0080032	"Pleural Effusion, Malignant"	dsyn	Treatment of malignant pleural effusion	TALC|STERILE TALC|STERITALC	BLEOMYCIN SULFATE|BLENOXANE	MINOCYCLINE HYDROCHLORIDE|MINOCYCLINE HCL|MINOCIN INTRAVENOUS	Sterile talc	Steritalc	35772	Treatment of malignant pleural effusion	Designated/Approved	Approved for Orphan Indication	To decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion.	Ê05/01/2017Ê	Ê05/01/2024	Novatech SA	Z.I. Athelia III	13705 La Ciotat Cedex				France	106797
1533	"Pleural Effusion, Malignant"		MISSING		4555	of malignant pleural effusion.	C0080032	"Pleural Effusion, Malignant"	dsyn	Treatment of malignant pleural effusion.	TALC|STERILE TALC|STERITALC	BLEOMYCIN SULFATE|BLENOXANE	MINOCYCLINE HYDROCHLORIDE|MINOCYCLINE HCL|MINOCIN INTRAVENOUS	Sterile talc powder	Sclerosol Intrapleural Aerosol	34960	Treatment of malignant pleural effusion.	Designated/Approved	Approved for Orphan Indication	Prevention of recurrence of malignant pleural effusions in symptomatic patients.	Ê12/24/1997Ê	Ê12/24/2004	Lymol Medical Corporation	4 Plympton Street		Woburn	Massachusetts	1801	USA	91595
353	"Pleural Effusion, Malignant"		MISSING		4681	of malignant pleural effusion.	C0080032	"Pleural Effusion, Malignant"	dsyn	Treatment of malignant pleural effusion.	TALC|STERILE TALC|STERITALC	BLEOMYCIN SULFATE|BLENOXANE	MINOCYCLINE HYDROCHLORIDE|MINOCYCLINE HCL|MINOCIN INTRAVENOUS	Bleomycin sulfate	Blenoxane	34229	Treatment of malignant pleural effusion.	Designated/Approved	Approved for Orphan Indication	Treatment of malignant pleural effusion.	Ê02/20/1996Ê	Ê02/20/2003	Bristol-Myers Squibb Pharmaceutical Research Institute	P.O. Box 4000		Princeton	New Jersey	8543	USA	76193
284	Pneumocystic carinii pneumonia	7409	done		4886	Pneumocystis Carinii Pneumonia.	C1535939	Pneumocystis jiroveci pneumonia	dsyn	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Pneumocystic carinii pneumonia|GARD:0007409|CLINDAMYCIN|CLEOCIN|GARD:0007409	Pneumocystic carinii pneumonia|GARD:0007409|PRIMAQUINE PHOSPHATE|GARD:0007409	Pneumocystic carinii pneumonia|GARD:0007409|ATOVAQUONE|MEPRON|GARD:0007409	Atovaquone	Mepron	33126	Treatment of AIDS associated Pneumocystis Carinii Pneumonia.	Designated/Approved	Approved for Orphan Indication	For the acute oral treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole.	Ê11/25/1992Ê	Ê11/25/1999	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA	48890
1664	Pneumocystic carinii pneumonia	7409	done		5160	of Pneumocystis carinii pneumonia	C1535939	Pneumocystis jiroveci pneumonia	dsyn	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Pneumocystic carinii pneumonia|GARD:0007409|CLINDAMYCIN|CLEOCIN|GARD:0007409	Pneumocystic carinii pneumonia|GARD:0007409|EFLORNITHINE HYDROCHLORIDE|EFLORNITHINE HCL|ORNIDYL|GARD:0007409	PNEUMOCYSTIS CARINII PNEUMONIA|DOID:11339|MESH:D011020	Trimetrexate glucuronate	Neutrexin	31547	Treatment of Pneumocystis carinii pneumonia in AIDS patients.	Designated/Approved	Approved for Orphan Indication	"Concurrent leucovorin administration as an alternative therapy for the treatment of moderate to severe PCP in immunocompromised patients who are intolerant of, or are refractory to, trimethoprim sulfamethoxazole."	Ê12/17/1993Ê	Ê12/17/2000	"Medimmune Oncology, Inc."	One Tower Bridge	"100 Front St., Suite 400"	West Conshohocken	Pennsylvania	19428	USA	14286
1269	Pneumocystic carinii pneumonia	7409	done		5091	of Pneumocystis carinii pneumonia	C1535939	Pneumocystis jiroveci pneumonia	dsyn	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Pneumocystic carinii pneumonia|GARD:0007409|PENTAMIDINE ISETHIONATE|PENTAMIDINE ISETHIONATE (INHALATION)|PNEUMOPENT|GARD:0007409	Pneumocystic carinii pneumonia|GARD:0007409|PENTAMIDINE ISETHIONATE|NEBUPENT|GARD:0007409		Pentamidine isethionate	Nebupent	32154	Prevention of Pneumocystis carinii pneumonia in patients at high risk of developing this disease.	Designated/Approved	Approved for Orphan Indication		Ê06/15/1989Ê	Ê06/15/1996	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA	25887
1270	Pneumocystic carinii pneumonia	7409	done		5240	of Pneumocystis carinii pneumonia.	C1535939	Pneumocystis jiroveci pneumonia	dsyn	Treatment of Pneumocystis carinii pneumonia.	PNEUMOCYSTIS CARINII PNEUMONIA|DOID:11339|MESH:D011020	Pneumocystic carinii pneumonia|GARD:0007409|ATOVAQUONE|MEPRON|GARD:0007409	Pneumocystic carinii pneumonia|GARD:0007409|CLINDAMYCIN|CLEOCIN|GARD:0007409	Pentamidine isethionate	Pentam 300	30740	Treatment of Pneumocystis carinii pneumonia.	Designated/Approved	Approved for Orphan Indication		Ê10/16/1984Ê	Ê10/16/1991	"Fujisawa USA, Inc."	3 Parkway North Center		Deerfield	Illinois	60015	USA	1083
281	Pneumocystic carinii pneumonia	7409	done		4808	of Pneumocystis carinii pneumonia	C1535939	Pneumocystis jiroveci pneumonia	dsyn	"Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3."				Atovaquone	Mepron	33464	"Prevention of Pneumocystis carinii pneumonia (PCP) in high-risk, HIV-infected patients defined by a history of one or more episodes of PCP and/or a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3."	Designated/Approved	Approved for Orphan Indication	Prevention of PCP in patients who are intolerant to trimethoprim-sulfamethoxazole.	Ê01/05/1999Ê	Ê01/05/2006	Glaxo Wellcome Research and Development	5 Moore Drive	PO Box 13398	Research Triangle Park	North Carolina	27709	USA	48990
1531	Pneumothorax		MISSING	Not a disease	4431	of pneumothorax	C0032326	Pneumothorax	dsyn	Treatment of pneumothorax	Primary spontaneous pneumothorax|GARD:0004997|TALC|STERILE TALC|STERITALC|GARD:0004997	CATAMENIAL PNEUMOTHORAX|GARD:0009858|OMIM:131200|UMLS:C0340007	CATAMENIAL PNEUMOTHORAX	Sterile talc	Steritalc	35772	Treatment of pneumothorax	Designated/Approved	Approved for Orphan Indication	Steritalc is indicated in adults to decrease the recurrence of pneumothorax.	Ê05/01/2017Ê	Ê05/01/2024	Novatech SA	Z.I. Athelia III	13705 La Ciotat Cedex				France	109297
2207	Polyarticular onset juvenile idiopathic arthritis	10967	done		4368	of moderately to severely active polyarticular-course juvenile rheumatoid arthritis	C0311221	Polyarticular juvenile rheumatoid arthritis	dsyn	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	"Polyarticular onset juvenile idiopathic arthritis|GARD:0010967|ETANERCEPT, LICENSE HOLDER UNSPECIFIED|ETANERCEPT|ENBREL|GARD:0010967"			etanercept	Enbrel	36095	Reduction in signs and symptoms of moderately to severely active polyarticular-course juvenile rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.	Designated/Approved	Approved for Orphan Indication	Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older	Ê05/27/1999Ê	Ê05/27/2006	Immunex Corporation	One Amgen Center Drive		Thousand Oaks	California	91320	USA	116198
2505	Polyarticular onset juvenile idiopathic arthritis	10967	done		1644	with active polyarticular juvenile idiopathic arthritis	C0311221	Polyarticular juvenile rheumatoid arthritis	dsyn	Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant of or had an inadequate response to first-line therapy.				methotrexate oral solution	Xatmep	42243	Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who are intolerant of or had an inadequate response to first-line therapy.	Designated/Approved	Approved for Orphan Indication	"Management of pediatric patients with active polyarticular juvenile idiopathic arthritis (pJIA) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs)."	Ê04/25/2017Ê	Ê04/25/2024	"Silvergate Pharmaeuticals, Inc."	6251 Greenwood Plaza Blvd	Suite 101	Greenwood Village	Colorado	80111	USA	479515
1685	Polycystic ovarian syndrome	7421	done		5096	with polycystic ovarian disease	C0032460	Polycystic Ovary Syndrome	dsyn	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	Polycystic ovarian syndrome|GARD:0007421|UROFOLLITROPIN|METRODIN|GARD:0007421			Urofollitropin	Metrodin	32106	For induction of ovulation in patients with polycystic ovarian disease who have an elevated LH/FSH ratio and who have failed to respond to adequate clomiphene citrate therapy.	Designated/Approved	Approved for Orphan Indication		Ê09/18/1986Ê	Ê09/18/1993	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA	14086
5035	Polycythemia vera	7422			3035	of polycythemia vera	C0032463	Polycythemia Vera	neop	Treatment of polycythemia vera	Polycythemia vera|GARD:0007422|GIVINOSTAT|GARD:0007422	Polycythemia vera|GARD:0007422|ANAGRELIDE|AGRYLIN|GARD:0007422	Polycythemia vera|GARD:0007422|MGN-4893|INHIBITOR OF MICRORNA-451|GARD:0007422	ruxolitinib	Jakafi	40263	Treatment of polycythemia vera	Designated/Approved	Approved for Orphan Indication	Treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.	Ê12/04/2014Ê	Ê12/04/2021	Incyte Corporation	1801 Augustine Cut-Off		Wilmington	Delaware	19803	USA	302310
5774	Porphyria	10353			3328	of erythropoietic porphyrias	C0162530	"Porphyria, Erythropoietic"	dsyn	Treatment of erythropoietic porphyrias	Porphyria|GARD:0010353|AFAMELANOTIDE|GARD:0010353	CONGENITAL ERYTHROPOIETIC PORPHYRIA|CEP|GUNTHER DISEASE|UROPORPHYRINOGEN III SYNTHASE DEFICIENCY|UROS DEFICIENCY	X-LINKED PROTOPORPHYRIA|XLDPP|X-LINKED DOMINANT PROTOPORPHYRIA|XLP	afamelanotide	Scenesse	39646	Treatment of erythropoietic porphyrias	Designated/Approved	Approved for Orphan Indication	SCENESSE is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP)	Ê10/08/2019Ê	Ê10/08/2026	Clinuvel Inc.	P. O. Box 94026		Menlo Park	California	94026	USA	263208
5779	Porphyria	10353			1310	of acute hepatic porphyria	C0268328	Porphobilinogen synthase deficiency	dsyn	Treatment of acute hepatic porphyria	Porphyria|GARD:0010353|SYNTHETIC DOUBLE-STRANDED SMALL INTERFERING RNA (SIRNA) OLIGONUCLEOTIDE TARGETING DELTA-AMINOEVULINIC ACID SYNTHASE 1|GARD:0010353	VARIEGATE PORPHYRIA|PORPHYRIA VARIEGATA|VP	HEREDITARY COPROPORPHYRIA|HCP	givosiran	Givlaari	42611	Treatment of acute hepatic porphyria	Designated/Approved	Approved for Orphan Indication	GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).	Ê11/20/2019Ê	Ê11/20/2026	"Alnylam Pharmaceuticals, Inc."	101 Main Street		Cambridge	Massachusetts	2142	USA	535516
702	Posterior uveitis	4457	done		4232	Treatment uveitis	C0042164	Uveitis	dsyn	Treatment uveitis involving the posterior segment of the eye.	Posterior uveitis|GARD:0004457|FLUOCINOLONE|RETISERT|GARD:0004457	"CONTACT DERMATITIS|DERMATITIS, CONTACT|DOID:2773|MESH:D003877"		Fluocinolone	Retisert	36738	Treatment uveitis involving the posterior segment of the eye.	Designated/Approved	Approved for Orphan Indication	Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye	Ê04/08/2005Ê	Ê04/08/2012	"Bausch & Lomb Pharmaceuticals, Inc."	8500 Hidden River Parkway		Tampa	Florida	33637	USA	132800
2259	Postherpetic neuralgia		MISSING	Not a rare disease	2765	of postherpetic neuralgia	C0032768	Postherpetic neuralgia	dsyn	Treatment of postherpetic neuralgia	CAPSAICIN	ZUCAPSAICIN|CIVAMIDE	CLONIDINE|NALTREXONE/CLONIDINE COMBINATION	gabapentin enacarbil	Horizant	40701	Treatment of postherpetic neuralgia	Designated/Approved	Approved for Orphan Indication	Management of postherpetic neuralgia in adults.	Ê06/06/2012Ê	Ê06/06/2019	"Arbor Pharmaceuticals, LLC"	6 Concourse Parkway	Suite 1800	Atlanta	Georgia	30328	USA	330710
1992	Postherpetic neuralgia		MISSING		3181	with postherpetic neuralgia	C0032768	Postherpetic neuralgia	dsyn	Management of neuropathic pain in patients with postherpetic neuralgia	Herpes zoster oticus|GARD:0007525|CAPSAICIN|QUTENZA|GARD:0007525	SEIZURES|PARTIAL ONSET SEIZURES|MESH:D012640	PERIPHERAL NEUROPATHY|DIABETIC NEUROPATHIES|DIABETIC PERIPHERAL NEUROPATHY|DOID:60053|MESH:D003929	capsaicin	Qutenza	39955	Management of neuropathic pain in patients with postherpetic neuralgia	Designated/Approved	Approved for Orphan Indication	Management of neuropathic pain associated with postherpetic neuralgia	Ê11/16/2009Ê	Ê11/16/2016	"Averitas Pharma, Inc."	360 Mount Kemble Avenue		Morristown	New Jersey	7960	USA	269508
994	Postherpetic neuralgia		MISSING		4548	in postherpetic neuralgia.	C0032768	Postherpetic neuralgia	dsyn	"For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia."	LIDOCAINE|LIDOCAINE PATCH 5%|LIDODERM PATCH			Lidocaine patch 5%	Lidoderm Patch	34996	"For relief of allodynia (painful hypersensitivity), and chronic pain in postherpetic neuralgia."	Designated/Approved	Approved for Orphan Indication		Ê03/19/1999Ê	Ê03/19/2006	"Teikoku Pharma USA, Inc."	745-D Camden Ave.		Campbell	California	95008	USA	92395
2258	Postherpetic neuralgia		MISSING		2913	of postherpetic neuralgia	C0032768	Postherpetic neuralgia	dsyn	Management of postherpetic neuralgia	"PAIN DISORDER|NEURALGIA, POSTHERPETIC|NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA|DOID:60164|MESH:D051474"	Herpes zoster oticus|GARD:0007525|CAPSAICIN|QUTENZA|GARD:0007525	Herpes zoster oticus|GARD:0007525|GABAPENTIN|GRALISE|GARD:0007525	gabapentin	Gralise	40490	Management of postherpetic neuralgia	Designated/Approved	Approved for Orphan Indication	For the management of postherpetic neuralgia	Ê01/28/2011Ê	Ê01/28/2018	"Depomed, Inc."	1360 O'Brien Drive		Menlo Park	California	94025	USA	236506
3544	Prader-Willi syndrome	5575			4309	of short stature	C0013336	Dwarfism	dsyn	Treatment of short stature in patients with Prader-Willi syndrome.	Prader-Willi syndrome|GARD:0005575|SOMATROPIN (RDNA)|SOMATROPIN [RDNA]|GENOTROPIN|GARD:0005575	FROELICH SYNDROME|ADIPOSOGENITAL DYSTROPHY|BABINSKI-FROELICH SYNDROME|DYSTROPHIA ADIPOSOGENITALIS|FROLICH'S SYNDROME|HYPOTHALAMIC INFANTILISM-OBESITY|LAUNOIS-CLERET SYNDROME	PRADER-WILLI SYNDROME|PWS|WILLI-PRADER SYNDROME|PRADER-LABHART-WILLI SYNDROME|GARD:0005575|OMIM:176270|ORPHA:739|ORPHANET:739|UMLS:C0032897	Somatropin [rDNA]	Genotropin	36347	Treatment of short stature in patients with Prader-Willi syndrome.	Designated/Approved	Approved for Orphan Indication	Long-term treatment of pediatric patients who have growth failure due to Prader-Willi syndrome (PWS).	Ê06/20/2000Ê	Ê06/20/2007	Pharmacia & Upjohn	7000 Portage Rd.	0633-298-113	Kalamazoo	Michigan	49001	USA	124799
5051	Precocious puberty	7446			2550	of central precocious puberty	C0342543	"Precocious Puberty, Central"	dsyn	Treatment of central precocious puberty	Precocious puberty|GARD:0007446|TRIPTORELIN PAMOATE|GARD:0007446	Precocious puberty|GARD:0007446|DESLORELIN|SOMAGARD|GARD:0007446	Precocious puberty|GARD:0007446|NAFARELIN ACETATE|SYNAREL NASAL SOLUTION|GARD:0007446	triptorelin pamoate	Triptodur	41141	Treatment of central precocious puberty	Designated/Approved	Approved for Orphan Indication	Treatment of pediatric patients 2 years of age and older with central precocious puberty	Ê06/29/2017Ê	Ê06/29/2024	"Arbor Pharmaceuticals, LLC"	6 Concourse Parkway	Suite 1800	Atlanta	Georgia	30328	USA	376012
5054	Precocious puberty	7446			3711	of central precocious puberty	C0342543	"Precocious Puberty, Central"	dsyn	Treatment of central precocious puberty	Precocious puberty|GARD:0007446|TRIPTORELIN PAMOATE|GARD:0007446	Precocious puberty|GARD:0007446|DESLORELIN|SOMAGARD|GARD:0007446	Precocious puberty|GARD:0007446|NAFARELIN ACETATE|SYNAREL NASAL SOLUTION|GARD:0007446	Histrelin	Supprelin La	38674	Treatment of central precocious puberty	Designated/Approved	Approved for Orphan Indication	Treatment of central precocious puberty	Ê05/03/2007Ê	Ê05/03/2014	"Endo Pharmaceuticals Solutions, Inc."	100 Endo Blvd		Chadds Ford	Pennsylvania	19317	USA	212605
5055	Precocious puberty	7446			5058	of central precocious puberty.	C0342543	"Precocious Puberty, Central"	dsyn	Treatment of central precocious puberty.	Precocious puberty|GARD:0007446|TRIPTORELIN PAMOATE|GARD:0007446	Precocious puberty|GARD:0007446|DESLORELIN|SOMAGARD|GARD:0007446	Precocious puberty|GARD:0007446|NAFARELIN ACETATE|SYNAREL NASAL SOLUTION|GARD:0007446	Histrelin acetate	Supprelin Injection	32365	Treatment of central precocious puberty.	Designated/Approved	Approved for Orphan Indication	Treatment of central precocious puberty.	Ê12/24/1991Ê	Ê12/24/1998	Roberts Pharmaceutical Corp.	Meridian Center III	6 Industrial Way West	Eatontown	New Jersey	7724	USA	16986
5052	Precocious puberty	7446			5061	of central precocious puberty	C0342543	"Precocious Puberty, Central"	dsyn	Treatment of central precocious puberty	Precocious puberty|GARD:0007446|TRIPTORELIN PAMOATE|GARD:0007446	Precocious puberty|GARD:0007446|DESLORELIN|SOMAGARD|GARD:0007446	Precocious puberty|GARD:0007446|NAFARELIN ACETATE|SYNAREL NASAL SOLUTION|GARD:0007446	Leuprolide acetate	Lupron Injection	32349	Treatment of central precocious puberty	Designated/Approved	Approved for Orphan Indication	Treatment of children with central precocious puberty	Ê04/16/1993Ê	Ê04/16/2000	"Tap Pharmaceuticals, Inc."	2355 Waukegan Road		Deerfield	Illinois	60015	USA	28688
5053	Precocious puberty	7446			5064	of central precocious puberty.	C0342543	"Precocious Puberty, Central"	dsyn	Treatment of central precocious puberty.	Precocious puberty|GARD:0007446|TRIPTORELIN PAMOATE|GARD:0007446	Precocious puberty|GARD:0007446|DESLORELIN|SOMAGARD|GARD:0007446	Precocious puberty|GARD:0007446|NAFARELIN ACETATE|SYNAREL NASAL SOLUTION|GARD:0007446	Nafarelin acetate	Synarel Nasal Solution	32344	Treatment of central precocious puberty.	Designated/Approved	Approved for Orphan Indication	Treatment of central precocious puberty (gonadotropin-dependent precocious puberty) in children of both sexes.	Ê02/26/1992Ê	Ê02/26/1999	"Syntex (USA), Inc."	3401 Hillview Avenue		Palo Alto	California	94303	USA	29888
1762	Preventing hepatic injury from acetaminophin overdose		MISSING		1821	from acetaminophin overdose	C4018909	Overdose	fndg	Preventing hepatic injury from acetaminophin overdose	ACETYLCYSTEINE|ACETYLCYSTEINE EFFERVESCENT TABLETS FOR ORAL SOLUTION|CETYLEV			acetylcysteine effervescent tablets for oral solution	Cetylev	42059	Preventing hepatic injury from acetaminophin overdose	Designated/Approved	Approved for Orphan Indication	Indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion	Ê01/29/2016Ê	ÊN/A	"Arbor Pharmaceuticals, Inc."	6 Concourse Parkway	Suite 1800	Atlanta	Georgia	30328	USA	401713
2346	Prevention of preterm birth in singleton pregnancies		MISSING		3524	of preterm birth	C0151526	Premature Birth	fndg	Prevention of preterm birth in singleton pregnancies	HYDROXYPROGESTERONE CAPROATE|MAKENA			hydroxyprogesterone caproate	Makena	39107	Prevention of preterm birth in singleton pregnancies	Designated/Approved	Approved for Orphan Indication	Makena auto-injector for subcutaneous injection is indicated to reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth.	Ê02/14/2018Ê	ÊN/A	"AMAG Pharma USA, Inc."	1100 Winter Street		Waltham	Massachusetts	2154	USA	218706
2346	Prevention of preterm birth in singleton pregnancies		MISSING		3524	of preterm birth	C0151526	Premature Birth	fndg	Prevention of preterm birth in singleton pregnancies	HYDROXYPROGESTERONE CAPROATE|MAKENA			hydroxyprogesterone caproate	Makena	39107	Prevention of preterm birth in singleton pregnancies	Designated/Approved	Approved for Orphan Indication	To reduce the risk of preterm birth in women with singleton pregnancy who have a history of singleton spontaneous preterm birth	Ê02/03/2011Ê	Ê02/03/2018	"AMAG Pharma USA, Inc."	1100 Winter Street		Waltham	Massachusetts	2154	USA	218706
1692	Primary biliary cholangitis	7459	done		4818	with primary biliary cirrhosis	C0008312	Primary biliary cirrhosis	dsyn	Treatment of patients with primary biliary cirrhosis	Primary biliary cholangitis|GARD:0007459|URSODIOL|URSO 250|GARD:0007459	BANTIâS SYNDROME|BANTI'S DISEASE|HYPERSPLENISM|IDIOPATHIC CONGESTIVE SPLENOMEGALY|IDIOPATHIC PORTAL HYPERTENSION	CHOLANGIOCARCINOMA|BILE DUCT ADENOCARCINOMA|BILIARY TRACT CANCER	Ursodiol	Urso 250	33409	Treatment of patients with primary biliary cirrhosis	Designated/Approved	Approved for Orphan Indication		Ê12/10/1997Ê	Ê12/10/2004	"Aptalis Pharma US, Inc."	100 Somerset corporate Blvd		Bridgewater	New Jersey	8807	USA	22187
2594	Primary biliary cholangitis	7459	done		3371	of primary biliary cirrhosis	C0008312	Primary biliary cirrhosis	dsyn	Treatment of primary biliary cirrhosis	PRIMARY BILIARY CIRRHOSIS|PRIMARY BILIARY CHOLANGITIS|DOID:12236|MESH:D008105	Primary biliary cholangitis|GARD:0007459|NGM-282|ENGINEERED VARIANT OF RECOMBINANT HUMAN FIBROBLAST GROWTH FACTOR 19|GARD:0007459	Primary biliary cholangitis|GARD:0007459|USTEKINUMAB|USTEKINUMAB; HUMAN MONOCLONCAL ANTIBODY TO INTERKEUKIN 12P40|STELARA|GARD:0007459	obeticholic acid	Ocaliva	39547	Treatment of primary biliary cirrhosis	Designated/Approved	Approved for Orphan Indication	"Treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA"	Ê05/27/2016Ê	Ê05/27/2023	"Intercept Pharmaceuticals, Inc."	4760 Eastgate Mall		San Diego	California	92122	USA	253207
985	Primary carnitine deficiency	5104	done	Not a rare disease	5260	of genetic carnitine deficiency.	C0342788	Renal carnitine transport defect	dsyn	Treatment of genetic carnitine deficiency.	Primary carnitine deficiency|GARD:0005104|LEVOCARNITINE|CARNITOR|GARD:0005104	Primary carnitine deficiency|GARD:0005104|LEVOCARNITINE|CARNITOR|GARD:0005104	CARNITINE PALMITOYL TRANSFERASE 1A DEFICIENCY|CARNITINE PALMITOYLTRANSFERASE 1A DEFICIENCY|CPT1A DEFICIENCY|HEPATIC CPT1|HEPATIC CARNITINE PALMITOYLTRANSFERASE 1 DEFICIENCY|L-CPT 1 DEFICIENCY|CARNITINE PALMITOYL TRANSFERASE IA DEFICIENCY|HEPATIC CARNITINE PALMITOYL TRANSFERASE 1 DEFICIENCY|HEPATIC CARNITINE PALMITOYL TRANSFERASE I DEFICIENCY|L-CPT1 DEFICIENCY|L-CPTI DEFICIENCY|GARD:0001120|ORPHA:156|ORPHANET:156|UMLS:C1829703|OMIM:255120	Levocarnitine	Carnitor	30740	Treatment of genetic carnitine deficiency.	Designated/Approved	Approved for Orphan Indication		Ê04/10/1986Ê	Ê04/10/1993	"Leadiant Biosciences, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA	1384
987	Primary carnitine deficiency	5104	approximate		5054	of carnitine deficiency	C0342788	Renal carnitine transport defect	dsyn	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Primary carnitine deficiency|GARD:0005104|LEVOCARNITINE|CARNITOR|GARD:0005104	Primary carnitine deficiency|GARD:0005104|LEVOCARNITINE|CARNITOR|GARD:0005104		Levocarnitine	Carnitor	32392	Treatment of manifestations of carnitine deficiency in patients with end stage renal disease who require dialysis.	Designated/Approved	Approved for Orphan Indication	Prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis.	Ê12/15/1999Ê	Ê12/15/2006	"Leadiant Biosciences, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA	27888
989	Primary carnitine deficiency	5104	done		5246	secondary carnitine deficiency	C2025219	Secondary carnitine deficiency	patf	Treatment of primary and secondary carnitine deficiency of genetic origin.	Primary carnitine deficiency|GARD:0005104|LEVOCARNITINE|CARNITOR|GARD:0005104			Levocarnitine	Carnitor	30889	Treatment of primary and secondary carnitine deficiency of genetic origin.	Designated/Approved	Approved for Orphan Indication	Treatment of primary systemic carnitine deficiency. (approved 12/27/85) Treatment of secondary carnitine deficiency. (approved 12/16/92)	Ê12/16/1992Ê	Ê12/16/1999	"Leadiant Biosciences, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA	1584
Missing	Primary liver cancer	6608			2275	with known hepatocellular carcinoma	C2239176	Liver carcinoma	neop	Management of patients with known hepatocellular carcinoma (HCC)	ACUTE INTERMITTENT PORPHYRIA|AIP|SWEDISH PORPHYRIA	"GLYCOGEN STORAGE DISEASE TYPE III|AMYLO-1,6-GLUCOSIDASE DEFICIENCY|CORI DISEASE|AGL DEFICIENCY|GLYCOGENOSIS TYPE III|FORBES DISEASE|LIMITED DEXTRINOSIS|GDE DEFICIENCY|GLYCOGEN DEBRANCHER DEFICIENCY|GSD-III"	TYROSINEMIA TYPE 1|FAH DEFICIENCY|FUMARYLACETOACETASE DEFICIENCY|FUMARYLACETOACETATE HYDROLASE DEFICIENCY|HEPATORENAL TYROSINEMIA|HEREDITARY TYROSINEMIA TYPE 1	ethiodized oil injection	Lipiodol	41543	Management of patients with known hepatocellular carcinoma (HCC)	Designated/Approved	Approved for Orphan Indication	Selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC)	Ê04/04/2014Ê	Ê04/04/2021	Guerbet LLC	"120 West 7th St., Suite 108"		Bloomington	Indiana	47404	USA	400113
Missing	Primary liver cancer	6608			1109	of hepatocellular carcinoma.	C2239176	Liver carcinoma	neop	Treatment of hepatocellular carcinoma.	ADVANCED ADULT HEPATOCELLULAR CARCINOMA|ADVANCED ADULT HEPATOMA|ADVANCED HEPATOCELLULAR CANCER|NCIT:C28302|NCI:C28302|UMLS:C1706732	"HEPATOCELLULAR CARCINOMA|HCC|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CELL CARCINOMA|CARCINOMA, HEPATOCELLULAR, MALIGNANT|PRIMARY CARCINOMA OF THE LIVER CELLS|HEPATOMA|HEPATOCELLULAR CANCER|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|CARCINOMA OF LIVER CELLS|CARCINOMA OF THE LIVER CELLS|NCIT:C3099|NCI:C3099|UMLS:C0019204"	"CARCINOMA, HEPATOCELLULAR, MALIGNANT|HEPATOCELLULAR CARCINOMA|HEPATOCELLULAR ADENOCARCINOMA|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CARCINOMA|HEPATOMA|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|PRIMARY CARCINOMA OF THE LIVER CELLS|CARCINOMA OF THE LIVER CELLS|LIVER CELL CARCINOMA|HEPATOCELLULAR CANCER|CANCER, HEPATOCELLULAR|LIVER AND INTRAHEPATIC BILE DUCT CARCINOMA|HCC|CARCINOMA OF LIVER CELLS|CARCINOMA OF LIVER|HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION|HEPATOBLASTOMA|LIVER CANCER|NCIT:C3099|ORPHANET:88673|MESH:D006528|COHD:4001171|DOID:684|OMIM:114550|ONCOTREE:HCC|EFO:0000182|DOID:686|MEDDRA:10049010|NCIT:C7956|NCIT:C7927|MONDO:0007256"	cabozantinib	Cabometyx	42796	Treatment of hepatocellular carcinoma.	Designated/Approved	Approved for Orphan Indication	CABOMETYX is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.	Ê01/14/2019Ê	Ê01/14/2026	"Exelixis, Inc."	1851 Harbor Bay Parkway		Alameda	California	94502	USA	552916
Missing	Primary liver cancer	6608			1636	of hepatocellular carcinoma	C2239176	Liver carcinoma	neop	Treatment of hepatocellular carcinoma	ADVANCED ADULT HEPATOCELLULAR CARCINOMA|ADVANCED ADULT HEPATOMA|ADVANCED HEPATOCELLULAR CANCER|NCIT:C28302|NCI:C28302|UMLS:C1706732	"HEPATOCELLULAR CARCINOMA|HCC|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CELL CARCINOMA|CARCINOMA, HEPATOCELLULAR, MALIGNANT|PRIMARY CARCINOMA OF THE LIVER CELLS|HEPATOMA|HEPATOCELLULAR CANCER|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|CARCINOMA OF LIVER CELLS|CARCINOMA OF THE LIVER CELLS|NCIT:C3099|NCI:C3099|UMLS:C0019204"	"CARCINOMA, HEPATOCELLULAR, MALIGNANT|HEPATOCELLULAR CARCINOMA|HEPATOCELLULAR ADENOCARCINOMA|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CARCINOMA|HEPATOMA|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|PRIMARY CARCINOMA OF THE LIVER CELLS|CARCINOMA OF THE LIVER CELLS|LIVER CELL CARCINOMA|HEPATOCELLULAR CANCER|CANCER, HEPATOCELLULAR|LIVER AND INTRAHEPATIC BILE DUCT CARCINOMA|HCC|CARCINOMA OF LIVER CELLS|CARCINOMA OF LIVER|HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION|HEPATOBLASTOMA|LIVER CANCER|NCIT:C3099|ORPHANET:88673|MESH:D006528|COHD:4001171|DOID:684|OMIM:114550|ONCOTREE:HCC|EFO:0000182|DOID:686|MEDDRA:10049010|NCIT:C7956|NCIT:C7927|MONDO:0007256"	nivolumab	Opdivo	42249	Treatment of hepatocellular carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib	Ê09/22/2017Ê	Ê09/22/2024	Bristol-Myers Squibb Company	P. O. Box 5326		Princeton	New Jersey	8543	USA	489915
Missing	Primary liver cancer	6608			1707	of hepatocellular carcinoma	C2239176	Liver carcinoma	neop	Treatment of hepatocellular carcinoma	ADVANCED ADULT HEPATOCELLULAR CARCINOMA|ADVANCED ADULT HEPATOMA|ADVANCED HEPATOCELLULAR CANCER|NCIT:C28302|NCI:C28302|UMLS:C1706732	"HEPATOCELLULAR CARCINOMA|HCC|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CELL CARCINOMA|CARCINOMA, HEPATOCELLULAR, MALIGNANT|PRIMARY CARCINOMA OF THE LIVER CELLS|HEPATOMA|HEPATOCELLULAR CANCER|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|CARCINOMA OF LIVER CELLS|CARCINOMA OF THE LIVER CELLS|NCIT:C3099|NCI:C3099|UMLS:C0019204"	"CARCINOMA, HEPATOCELLULAR, MALIGNANT|HEPATOCELLULAR CARCINOMA|HEPATOCELLULAR ADENOCARCINOMA|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CARCINOMA|HEPATOMA|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|PRIMARY CARCINOMA OF THE LIVER CELLS|CARCINOMA OF THE LIVER CELLS|LIVER CELL CARCINOMA|HEPATOCELLULAR CANCER|CANCER, HEPATOCELLULAR|LIVER AND INTRAHEPATIC BILE DUCT CARCINOMA|HCC|CARCINOMA OF LIVER CELLS|CARCINOMA OF LIVER|HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION|HEPATOBLASTOMA|LIVER CANCER|NCIT:C3099|ORPHANET:88673|MESH:D006528|COHD:4001171|DOID:684|OMIM:114550|ONCOTREE:HCC|EFO:0000182|DOID:686|MEDDRA:10049010|NCIT:C7956|NCIT:C7927|MONDO:0007256"	regorafenib	Stivarga	42159	Treatment of hepatocellular carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with sorafenib.	Ê04/27/2017Ê	Ê04/27/2024	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd	P. O. Box 915	Whippany	New Jersey	7981	USA	478015
Missing	Primary liver cancer	6608			2138	of hepatocellular carcinoma	C2239176	Liver carcinoma	neop	Treatment of hepatocellular carcinoma	ADVANCED ADULT HEPATOCELLULAR CARCINOMA|ADVANCED ADULT HEPATOMA|ADVANCED HEPATOCELLULAR CANCER|NCIT:C28302|NCI:C28302|UMLS:C1706732	"HEPATOCELLULAR CARCINOMA|HCC|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CELL CARCINOMA|CARCINOMA, HEPATOCELLULAR, MALIGNANT|PRIMARY CARCINOMA OF THE LIVER CELLS|HEPATOMA|HEPATOCELLULAR CANCER|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|CARCINOMA OF LIVER CELLS|CARCINOMA OF THE LIVER CELLS|NCIT:C3099|NCI:C3099|UMLS:C0019204"	"CARCINOMA, HEPATOCELLULAR, MALIGNANT|HEPATOCELLULAR CARCINOMA|HEPATOCELLULAR ADENOCARCINOMA|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CARCINOMA|HEPATOMA|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|PRIMARY CARCINOMA OF THE LIVER CELLS|CARCINOMA OF THE LIVER CELLS|LIVER CELL CARCINOMA|HEPATOCELLULAR CANCER|CANCER, HEPATOCELLULAR|LIVER AND INTRAHEPATIC BILE DUCT CARCINOMA|HCC|CARCINOMA OF LIVER CELLS|CARCINOMA OF LIVER|HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION|HEPATOBLASTOMA|LIVER CANCER|NCIT:C3099|ORPHANET:88673|MESH:D006528|COHD:4001171|DOID:684|OMIM:114550|ONCOTREE:HCC|EFO:0000182|DOID:686|MEDDRA:10049010|NCIT:C7956|NCIT:C7927|MONDO:0007256"	lenvatinib	Lenvima	41725	Treatment of hepatocellular carcinoma	Designated/Approved	Approved for Orphan Indication	LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)	Ê08/15/2018Ê	Ê08/15/2025	Eisai Inc.	155 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA	423714
Missing	Primary liver cancer	6608			2691	of hepatocellular carcinoma	C2239176	Liver carcinoma	neop	Treatment of hepatocellular carcinoma	ADVANCED ADULT HEPATOCELLULAR CARCINOMA|ADVANCED ADULT HEPATOMA|ADVANCED HEPATOCELLULAR CANCER|NCIT:C28302|NCI:C28302|UMLS:C1706732	"HEPATOCELLULAR CARCINOMA|HCC|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CELL CARCINOMA|CARCINOMA, HEPATOCELLULAR, MALIGNANT|PRIMARY CARCINOMA OF THE LIVER CELLS|HEPATOMA|HEPATOCELLULAR CANCER|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|CARCINOMA OF LIVER CELLS|CARCINOMA OF THE LIVER CELLS|NCIT:C3099|NCI:C3099|UMLS:C0019204"	"CARCINOMA, HEPATOCELLULAR, MALIGNANT|HEPATOCELLULAR CARCINOMA|HEPATOCELLULAR ADENOCARCINOMA|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CARCINOMA|HEPATOMA|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|PRIMARY CARCINOMA OF THE LIVER CELLS|CARCINOMA OF THE LIVER CELLS|LIVER CELL CARCINOMA|HEPATOCELLULAR CANCER|CANCER, HEPATOCELLULAR|LIVER AND INTRAHEPATIC BILE DUCT CARCINOMA|HCC|CARCINOMA OF LIVER CELLS|CARCINOMA OF LIVER|HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION|HEPATOBLASTOMA|LIVER CANCER|NCIT:C3099|ORPHANET:88673|MESH:D006528|COHD:4001171|DOID:684|OMIM:114550|ONCOTREE:HCC|EFO:0000182|DOID:686|MEDDRA:10049010|NCIT:C7956|NCIT:C7927|MONDO:0007256"	ramucirumab	n/a	40851	Treatment of hepatocellular carcinoma	Designated/Approved	Approved for Orphan Indication	"CYRAMZA, as a single agent, is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of >=400 ng/mL and have been treated with sorafenib."	Ê05/10/2019Ê	Ê05/10/2026	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA	353911
Missing	Primary liver cancer	6608			3651	of hepatocellular carcinoma	C2239176	Liver carcinoma	neop	Treatment of hepatocellular carcinoma	ADVANCED ADULT HEPATOCELLULAR CARCINOMA|ADVANCED ADULT HEPATOMA|ADVANCED HEPATOCELLULAR CANCER|NCIT:C28302|NCI:C28302|UMLS:C1706732	"HEPATOCELLULAR CARCINOMA|HCC|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CELL CARCINOMA|CARCINOMA, HEPATOCELLULAR, MALIGNANT|PRIMARY CARCINOMA OF THE LIVER CELLS|HEPATOMA|HEPATOCELLULAR CANCER|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|CARCINOMA OF LIVER CELLS|CARCINOMA OF THE LIVER CELLS|NCIT:C3099|NCI:C3099|UMLS:C0019204"	"CARCINOMA, HEPATOCELLULAR, MALIGNANT|HEPATOCELLULAR CARCINOMA|HEPATOCELLULAR ADENOCARCINOMA|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CARCINOMA|HEPATOMA|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|PRIMARY CARCINOMA OF THE LIVER CELLS|CARCINOMA OF THE LIVER CELLS|LIVER CELL CARCINOMA|HEPATOCELLULAR CANCER|CANCER, HEPATOCELLULAR|LIVER AND INTRAHEPATIC BILE DUCT CARCINOMA|HCC|CARCINOMA OF LIVER CELLS|CARCINOMA OF LIVER|HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION|HEPATOBLASTOMA|LIVER CANCER|NCIT:C3099|ORPHANET:88673|MESH:D006528|COHD:4001171|DOID:684|OMIM:114550|ONCOTREE:HCC|EFO:0000182|DOID:686|MEDDRA:10049010|NCIT:C7956|NCIT:C7927|MONDO:0007256"	Sorafenib	Nexavar	38827	Treatment of hepatocellular carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of unresectable hepatocellular carcinoma	Ê11/16/2007Ê	Ê11/16/2014	Bayer Pharmaceuticals Corporation	400 Morgan Lane		West Haven	Connecticut	6516	USA	220206
Missing	Primary liver cancer	6608			1017	of hepatocellular carcinoma	C2239176	Liver carcinoma	neop	Treatment of hepatocellular carcinoma (HCC)	Childhood hepatocellular carcinoma|GARD:0009331|BLU-9931|SMALL MOLECULE FGFR4 INHIBITOR|GARD:0009331	"CARCINOMA, HEPATOCELLULAR, MALIGNANT|HEPATOCELLULAR CARCINOMA|HEPATOCELLULAR ADENOCARCINOMA|PRIMARY CARCINOMA OF LIVER CELLS|LIVER CARCINOMA|HEPATOMA|LIVER CELL CANCER (HEPATOCELLULAR CARCINOMA)|PRIMARY CARCINOMA OF THE LIVER CELLS|CARCINOMA OF THE LIVER CELLS|LIVER CELL CARCINOMA|HEPATOCELLULAR CANCER|CANCER, HEPATOCELLULAR|LIVER AND INTRAHEPATIC BILE DUCT CARCINOMA|HCC|CARCINOMA OF LIVER CELLS|CARCINOMA OF LIVER|HEPATOBLASTOMA CAUSED BY SOMATIC MUTATION|HEPATOBLASTOMA|LIVER CANCER|NCIT:C3099|ORPHANET:88673|MESH:D006528|COHD:4001171|DOID:684|OMIM:114550|ONCOTREE:HCC|EFO:0000182|DOID:686|MEDDRA:10049010|NCIT:C7956|NCIT:C7927|MONDO:0007256"	"Childhood hepatocellular carcinoma|GARD:0009331|H3B-6527|(N-{2-[(6-{[(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)CARBAMOYL](METHYL)AMINO}PYRIMIDIN-4- YL)AMINO]-5-(4-ETHYLPIPERAZIN-1-YL)PHENYL}PROP-2-ENAMIDE)|GARD:0009331"	pembrolizumab	Keytruda	42898	Treatment of hepatocellular carcinoma (HCC)	Designated/Approved	Approved for Orphan Indication	KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib	Ê11/09/2018Ê	Ê11/09/2025	"Merck, Sharp & Dohme Corp"	1 Merck Drive		Whitehouse Station	New Jersey	8889	USA	576917
2599	Primary malignant neoplasm of the peritoneum		MISSING		572	of primary peritoneal cancer	C1299307	Primary malignant neoplasm of the peritoneum	neop	Treatment of primary peritoneal cancer	REFRACTORY PRIMARY PERITONEAL CARCINOMA|REFRACTORY PRIMARY PERITONEAL CANCER|NCIT:C152046|NCI:C152046	PELAREOREP|REOLYSIN(R)	OLAPARIB	olaparib	Lynparza	43235	Treatment of primary peritoneal cancer	Designated/Approved	Approved for Orphan Indication	"Maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy; and treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy."	Ê08/17/2017Ê	Ê08/17/2024	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA	419013
2599	Primary malignant neoplasm of the peritoneum		MISSING		572	of primary peritoneal cancer	C1299307	Primary malignant neoplasm of the peritoneum	neop	Treatment of primary peritoneal cancer	REFRACTORY PRIMARY PERITONEAL CARCINOMA|REFRACTORY PRIMARY PERITONEAL CANCER|NCIT:C152046|NCI:C152046	PELAREOREP|REOLYSIN(R)	OLAPARIB	olaparib	Lynparza	43235	Treatment of primary peritoneal cancer	Designated/Approved	Approved for Orphan Indication	"Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum based chemotherapy. Select patients with gBRCAm advanced epithelial ovarian, fallopian tube or primary peritoneal cancer for therapy based on FDA-approved companion diagnostic for Lynparza."	Ê12/19/2018Ê	Ê12/19/2025	AstraZeneca Pharmaceuticals LP	1800 Concord Pike	P. O. Box 8355	Wilmington	Delaware	19803	USA	419013
1077	Primary orthostatic hypotension	12959	approximate		5202	with symptomatic orthostatic hypotension.	C0020651	"Hypotension, Orthostatic"	fndg	Treatment of patients with symptomatic orthostatic hypotension.	"INTRACRANIAL HYPOTENSION|HYPOTENSION, ORTHOSTATIC|NEUROGENIC ORTHOSTATIC HYPOTENSION|DOID:4723|MESH:D007024"	Primary orthostatic hypotension|GARD:0012959|MIDODRINE HYDROCHLORIDE|MIDODRINE HCL|AMATINE|GARD:0012959	Autonomic failure|GARD:0010428|DROXIDOPA|NORTHERA|GARD:0010428	Midodrine HCl	Amatine	31219	Treatment of patients with symptomatic orthostatic hypotension.	Designated/Approved	Approved for Orphan Indication	Treatment of symptomatic orthostatic hypotension.	Ê09/06/1996Ê	Ê09/06/2003	Shire	725 Chesterbrook Blvd		Wayne	Pennsylvania	19087	USA	7585
655	Pulmonary arterial hypertension	7501	done		5191	of primary pulmonary hypertension.	C0152171	Idiopathic pulmonary hypertension	dsyn	Treatment of primary pulmonary hypertension.	"PRIMARY PULMONARY HYPERTENSION|PULMONARY HYPERTENSION, PRIMARY|DOID:14557|MESH:D065627"	Pulmonary arterial hypertension|GARD:0007501|EPOPROSTENOL|FLOLAN|GARD:0007501	PULMONARY ARTERIAL HYPERTENSION|PRIMARY PULMONARY HYPERTENSION|PPH|PAH|IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION|IDIOPATHIC PULMONARY HYPERTENSION|HERITABLE PULMONARY ARTERIAL HYPERTENSION|HEREDITARY PULMONARY ARTERIAL HYPERTENSION|FAMILIAL PULMONARY ARTERIAL HYPERTENSION|FPAH|GARD:0007501|OMIM:178600	Epoprostenol	Flolan	31315	Treatment of primary pulmonary hypertension.	Designated/Approved	Approved for Orphan Indication	Long-term intravenous treatment of primary pulmonary hypertension in NYHA Class III and Class IV patients.	Ê09/20/1995Ê	Ê09/20/2002	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA	8785
1164	Pulmonary arterial hypertension	7501	approximate		4694	of persistent pulmonary hypertension	C1135361	Persistent pulmonary hypertension	dsyn	Treatment of persistent pulmonary hypertension in the newborn.	Pulmonary arterial hypertension|GARD:0007501|NITRIC OXIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|NITRIC OXIDE|INOMAX|GARD:0007501	 Alveolar capillary dysplasia|GARD:0008644|BERACTANT|SURVANTA INTRATRACHEAL SUSPENSION|GARD:0008644	Nitric oxide	Inomax	34142	Treatment of persistent pulmonary hypertension in the newborn.	Designated/Approved	Approved for Orphan Indication	"In conjunction with ventilatory support and other appropriate agents, in the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation."	Ê12/23/1999Ê	Ê12/23/2006	Mallinckrodt Hospital Products	1425 U.S. 206		Bedminster Township	New Jersey	7921	USA	74493
2578	Pulmonary arterial hypertension	7501	approximate		2589	of persistent pulmonary hypertension	C1135361	Persistent pulmonary hypertension	dsyn	Treatment of persistent pulmonary hypertension in newborns	Pulmonary arterial hypertension|GARD:0007501|NITRIC OXIDE|GARD:0007501	PULMONARY ARTERIAL HYPERTENSION|FPAH|HPAH|IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION|IPAH|PAH|PRECAPILLARY PULMONARY HYPERTENSION|PRIMARY OBLITERATIVE PULMONARY VASCULAR DISEASE|PRIMARY PULMONARY HYPERTENSION|ASSOCIATED PULMONARY ARTERIAL HYPERTENSION|APAH	VENTRICULAR SEPTAL DEFECTS|CONGENITAL VENTRICULAR DEFECTS|HOLE IN THE HEART|VSD	nitric oxide	n/a	41078	Treatment of persistent pulmonary hypertension in newborns	Designated/Approved	Approved for Orphan Indication	GENOSYL is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.	Ê12/20/2019Ê	ÊTBD	VERO BIOTECH	"387 Technology Circle, Suite 125"		Atlanta	Georgia	30313	USA	368512
5110	Pulmonary arterial hypertension	7501			2283	of pulmonary arterial hypertension.	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension.	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	riociguat	Adempas	41536	Treatment of pulmonary arterial hypertension.	Designated/Approved	Approved for Orphan Indication	"Treatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay clinical worsening."	Ê10/08/2013Ê	Ê10/08/2020	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd.		Whippany	New Jersey	7981	USA	392113
5112	Pulmonary arterial hypertension	7501			2986	of pulmonary arterial hypertension	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	treprostinil (inhalational)	Tyvaso	40346	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	"Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distance"	Ê07/30/2009Ê	Ê07/30/2016	"LungRx, Inc."	A Subsidary of United Therapeutics Corp.	1077 Highway A1A	Satellite Beach	Florida	32937	USA	189104
5084	Pulmonary arterial hypertension	7501			3019	of pulmonary arterial hypertension	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	selexipag	Uptravi	40298	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	"For treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH"	Ê12/21/2015Ê	Ê12/21/2022	"Actelion Pharmaceuticals, Ltd."	Gewerbestrasse 16		Allschwil CH-4123			Switzerland	304810
5117	Pulmonary arterial hypertension	7501			3129	of pulmonary arterial hypertension	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	macitentan	Opsumit	40059	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	"Treatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Opsumit also reduced hospitalization for PAH."	Ê10/18/2013Ê	Ê10/18/2020	Actelion Pharmaceuticals Ltd	Gewerbestrasse 16		Allschwil			Switzerland	282209
5088	Pulmonary arterial hypertension	7501			3558	of pulmonary arterial hypertension	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	tadalafil	Adcirca	39069	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension (WHO Group I) to improve exercise ability	Ê05/22/2009Ê	Ê05/22/2016	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA	228206
5104	Pulmonary arterial hypertension	7501			3875	of pulmonary arterial hypertension	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	Iloprost inhalation solution	Ventavis	38216	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms	Ê12/29/2004Ê	Ê12/29/2011	"CoTherix, Inc."	5000 Shoreline Court		South San Francisco	California	94080	USA	186904
5099	Pulmonary arterial hypertension	7501			3891	of pulmonary arterial hypertension	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	ambrisentan	Letairis	38184	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension (WHO group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening	Ê06/15/2007Ê	Ê06/15/2014	Gilead Colorado	7575 West 103rd Avenue	Suite 102	Westminister	Colorado	80021	USA	183604
Missing	Pulmonary arterial hypertension	7501			4215	of pulmonary arterial hypertension	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	bosentan	Tracleer	36805	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	"Treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability"	Ê09/05/2017Ê	Ê09/05/2024	"Actelion Pharmaceuticals, Ltd."	1840 Gateway Drive	Suite 300	Cherry Hill	New Jersey	8002	USA	134200
Missing	Pulmonary arterial hypertension	7501			4215	of pulmonary arterial hypertension	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	bosentan	Tracleer	36805	Treatment of pulmonary arterial hypertension	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension.	Ê11/20/2001Ê	Ê11/20/2008	"Actelion Pharmaceuticals, Ltd."	1840 Gateway Drive	Suite 300	Cherry Hill	New Jersey	8002	USA	134200
5111	Pulmonary arterial hypertension	7501			4458	of pulmonary arterial hypertension.	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension.	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	treprostinil	Remodulin;Orenitram	35585	Treatment of pulmonary arterial hypertension.	Designated/Approved	Approved for Orphan Indication	Treatment of pulmonary arterial hypertension.	Ê05/21/2002Ê	Ê05/21/2009	United Therapeutics Corp.	55 T.W. Alexander Dr.		Research Triangle Park	North Carolina	27709	USA	105197
5111	Pulmonary arterial hypertension	7501			4458	of pulmonary arterial hypertension.	C2973725	Pulmonary arterial hypertension	dsyn	Treatment of pulmonary arterial hypertension.	Pulmonary arterial hypertension|GARD:0007501|TERGURIDE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|BARDOXOLONE|GARD:0007501	Pulmonary arterial hypertension|GARD:0007501|IMATINIB|GARD:0007501	treprostinil	Remodulin;Orenitram	35585	Treatment of pulmonary arterial hypertension.	Designated/Approved	Approved for Orphan Indication	Orenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve exercise capacity.	Ê10/18/2019Ê	Ê10/18/2026	United Therapeutics Corp.	55 T.W. Alexander Dr.		Research Triangle Park	North Carolina	27709	USA	105197
2163	Pure autonomic failure 	10428	approximate		3531	nondiabetic autonomic neuropathy.	C0259749	Autonomic neuropathy	dsyn	"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy."	Autonomic failure|GARD:0010428|DROXIDOPA|NORTHERA|GARD:0010428	 Dopamine beta hydroxylase deficiency |GARD:0001903|DROXIDOPA|NORTHERA|GARD:0001903	 Hereditary sensory and autonomic neuropathy|GARD:0012688|DROXIDOPA|NORTHERA|GARD:0012688	droxidopa	Northera	39099	"Treatment of neurogenic symptomatic orthostatic hypotension in patients with primary autonomic failure, dopamine-beta-hydroxylase deficiency, and nondiabetic autonomic neuropathy."	Designated/Approved	Approved for Orphan Indication	"Treatment of orthostatic dizziness, lightheadedness, or the ""feeling that you are about to black out"" in adult patients with symptomatic neurogenic orthostatic hypotension caused by primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy."	Ê02/18/2014Ê	Ê02/18/2021	Lundbeck LLC	Four Parkway North		Deerfield	Illinois	60015	USA	229506
6015	Renal cell carcinoma	13215			5051	of metastatic renal cell carcinoma.	C0278678	Metastatic Renal Cell Cancer	neop	Treatment of metastatic renal cell carcinoma.	METASTATIC RENAL CELL CARCINOMA|RENAL CELL CARCINOMA|DOID:7486|MESH:D002292	Renal cell carcinoma|GARD:0013215|ALDESLEUKIN|PROLEUKIN|GARD:0013215	Renal cell carcinoma|GARD:0013215|INTERFERON ALFA-2B (RECOMBINANT)|INTRON A|GARD:0013215	Aldesleukin	Proleukin	32400	Treatment of metastatic renal cell carcinoma.	Designated/Approved	Approved for Orphan Indication	Treatment of adults (>18 years old) with metastatic renal cell carcinoma.	Ê05/05/1992Ê	Ê05/05/1999	Chiron Corporation	4560 Horton St.		Emeryville	California	94608	USA	29088
6005	Renal cell carcinoma	13215			3827	of renal cell carcinoma	C0007134	Renal Cell Carcinoma	neop	Treatment of renal cell carcinoma	"RENAL CELL CARCINOMA|CARCINOMA, RENAL CELL|ADVANCED RENAL CELL CARCINOMA|DOID:4450|MESH:D002292"	METASTATIC RENAL CELL CARCINOMA|RENAL CELL CARCINOMA|DOID:7486|MESH:D002292	Renal cell carcinoma|GARD:0013215|IROFULVEN|GARD:0013215	Temsirolimus	Torisel	38337	Treatment of renal cell carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of advanced renal cell carcinoma	Ê05/30/2007Ê	Ê05/30/2014	"Wyeth Pharmaceuticals, Inc."	P. O. Box 8299		Philadelphia	Pennsylvania	19101	USA	196404
6010	Renal cell carcinoma	13215			3847	of renal cell carcinoma.	C0007134	Renal Cell Carcinoma	neop	Treatment of renal cell carcinoma.	"RENAL CELL CARCINOMA|CARCINOMA, RENAL CELL|ADVANCED RENAL CELL CARCINOMA|DOID:4450|MESH:D002292"	METASTATIC RENAL CELL CARCINOMA|RENAL CELL CARCINOMA|DOID:7486|MESH:D002292	Renal cell carcinoma|GARD:0013215|IROFULVEN|GARD:0013215	Sorafenib	Nexavar	38268	Treatment of renal cell carcinoma.	Designated/Approved	Approved for Orphan Indication	Treatment of patients with advanced renal cell carcinoma	Ê12/20/2005Ê	Ê12/20/2012	Bayer Pharmaceutical Corporation	400 Morgan Lane		West Haven	Connecticut	6516	USA	185204
5997	Renal cell carcinoma	13215			3977	of renal cell carcinoma	C0007134	Renal Cell Carcinoma	neop	Treatment of renal cell carcinoma	"RENAL CELL CARCINOMA|CARCINOMA, RENAL CELL|ADVANCED RENAL CELL CARCINOMA|DOID:4450|MESH:D002292"	METASTATIC RENAL CELL CARCINOMA|RENAL CELL CARCINOMA|DOID:7486|MESH:D002292	Renal cell carcinoma|GARD:0013215|IROFULVEN|GARD:0013215	bevacizumab	Avastin	37931	Treatment of renal cell carcinoma	Designated/Approved	Approved for Orphan Indication	Treatment of renal cell carcinoma in combination with interferon alfa	Ê07/31/2009Ê	Ê07/31/2016	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	172903
1314	Renal hypouricemia	9496	approximate		5236	of uric acid nephrolithiasis.	C0403719	Uric acid urolithiasis	dsyn	Prevention of uric acid nephrolithiasis.	Renal hypouricemia|GARD:0009496|POTASSIUM CITRATE|UROCIT-K|GARD:0009496			Potassium citrate	Urocit-K	30987	Prevention of uric acid nephrolithiasis.	Designated/Approved	Approved for Orphan Indication		Ê08/30/1985Ê	Ê08/30/1992	University of Texas Health Science Center at Dallas	5323 Harry Hines Blvd		Dallas	Texas	75235	USA	2784
1338	"Respiratory distress syndrome, infant"	112	done		4687	in premature infants.	C0021294	"Infant, Premature"	dsyn	For the treatment and prevention of respiratory distress syndrome in premature infants.	"NEWBORN RESPIRATORY DISTRESS SYNDROME|RESPIRATORY DISTRESS SYNDROME, INFANT|RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS|DOID:12716|MESH:D012127"	"Respiratory distress syndrome, infant|GARD:0000112|PULMONARY SURFACTANT REPLACEMENT, PORCINE|PORACTANT ALFA|CUROSURF|GARD:0000112"	"Respiratory distress syndrome, infant|GARD:0000112|BERACTANT|SURVANTA INTRATRACHEAL SUSPENSION|GARD:0000112"	"Pulmonary surfactant replacement, porcine"	Curosurf	34183	For the treatment and prevention of respiratory distress syndrome in premature infants.	Designated/Approved	Approved for Orphan Indication	Treatment (rescue) of respiratory distress syndrome in premature infants.	Ê11/18/1999Ê	ÊN/A	"Chiesi USA, Inc."	175 Regency Woods Place	Suite 600	Cary	North Carolina	27518	USA	71192
344	"Respiratory distress syndrome, infant"	112	done		5170	of neonatal respiratory distress syndrome	C0035220	"Respiratory Distress Syndrome, Newborn"	dsyn	Treatment of neonatal respiratory distress syndrome	"NEWBORN RESPIRATORY DISTRESS SYNDROME|RESPIRATORY DISTRESS SYNDROME, NEWBORN|RESPIRATORY DISTRESS SYNDROME, NEONATAL|DOID:12716|MESH:D012127"	"Respiratory distress syndrome, infant|GARD:0000112|DIPALMITOYLPHOSPHATIDYLGLYCEROL, DL-|DIPALMITOYLPHOSPHATIDYLCHOLINE /PHOSPHATIDYLGLYCEROL|DIPALMITOYLPHOSPHATIDYLGLYCEROL|ALEC|GARD:0000112"	"Respiratory distress syndrome, infant|GARD:0000112|COLFOSCERIL PALMITATE|DIPALMITOYLPHOSPHATIDYLCHOLINE /PHOSPHATIDYLGLYCEROL|DIPALMITOYLPHOSPHATIDYLCHOLINE|ALEC|GARD:0000112"	Beractant	Survanta Intratracheal Suspension	31448	Treatment of neonatal respiratory distress syndrome	Designated/Approved	Approved for Orphan Indication	"Treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation"	Ê07/01/1991Ê	Ê07/01/1998	Ross Laboratories	625 Cleveland Avenue		Columbus	Ohio	43215	USA	10885
344	"Respiratory distress syndrome, infant"	112	done		5170	of neonatal respiratory distress syndrome	C0035220	"Respiratory Distress Syndrome, Newborn"	dsyn	Treatment of neonatal respiratory distress syndrome	"NEWBORN RESPIRATORY DISTRESS SYNDROME|RESPIRATORY DISTRESS SYNDROME, NEWBORN|RESPIRATORY DISTRESS SYNDROME, NEONATAL|DOID:12716|MESH:D012127"	"Respiratory distress syndrome, infant|GARD:0000112|DIPALMITOYLPHOSPHATIDYLGLYCEROL, DL-|DIPALMITOYLPHOSPHATIDYLCHOLINE /PHOSPHATIDYLGLYCEROL|DIPALMITOYLPHOSPHATIDYLGLYCEROL|ALEC|GARD:0000112"	"Respiratory distress syndrome, infant|GARD:0000112|COLFOSCERIL PALMITATE|DIPALMITOYLPHOSPHATIDYLCHOLINE /PHOSPHATIDYLGLYCEROL|DIPALMITOYLPHOSPHATIDYLCHOLINE|ALEC|GARD:0000112"	Beractant	Survanta Intratracheal Suspension	31448	Treatment of neonatal respiratory distress syndrome	Designated/Approved	Approved for Orphan Indication	Prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency	Ê07/02/1991Ê	Ê07/02/1998	Ross Laboratories	625 Cleveland Avenue		Columbus	Ohio	43215	USA	10885
1977	"Respiratory distress syndrome, infant"	112	approximate		5206	of respiratory failure	C1145670	Respiratory Failure	dsyn	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	"Respiratory distress syndrome, infant|GARD:0000112|CALFACTANT|INFASURF|GARD:0000112"			calfactant	Infasurf	31205	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	Designated/Approved	Approved for Orphan Indication	Treatment and prevention of respiratory failure due to pulmonary surfactant deficiency in preterm infants.	Ê07/01/1998Ê	ÊN/A	ONY Biotech Inc.	1576 Sweet Home Road		Amherst	New York	14228	USA	6285
512	"Respiratory distress syndrome, infant"	112	done		4969	"of hyaline membrane disease (HMD),"	C0020192	Hyaline Membrane Disease	dsyn	"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages."				"Colfosceril palmitate, cetyl alcohol, tyloxapol"	Exosurf Neonatal For Intratracheal Suspension	32801	"1. Prevention of hyaline membrane disease, also known as respiratory distress syndrome, in infants born at 32 weeks gestation or less 2. prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages."	Designated/Approved	Approved for Orphan Indication	"Prevention of hyaline membrane disease (HMD), also known as respiratory distress syndrome (RDS), in infants born at 32 weeks gestation or less and in the treatment of established HMO at all gestational ages"	Ê08/02/1990Ê	Ê08/02/1997	Glaxo Wellcome Inc.	5 Moore Drive		Research Triangle Park	North Carolina	27709	USA	14886
1408	respiratory syncytial virus		MISSING		4879	of RSV disease.	C0012634	Disease	dsyn	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN INTRAVENOUS (HUMAN)|RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN (HUMAN)|RESPIGAM			Respiratory syncytial virus immune globulin (Human)	Respigam	33143	Prophylaxis of respiratory syncytial virus lower respiratory tract infections in infants and young children at high risk of RSV disease.	Designated/Approved	Approved for Orphan Indication	For the prevention of serious lower respiratory tract infections caused by RSV in children less than 24 months of age with bronchopulmonary dysplasia or a history of prematurity (less than or equal to 35 weeks gestation).	Ê01/18/1996Ê	Ê01/18/2003	MedImmune & Massachussetts Public Health Biologics Labs.	35 West Watkins Mill Road		Gaithersburg	Maryland	20878	USA	51190
3573	Retinitis pigmentosa	5694			1796	of inherited retinal dystrophy	C0154860	Hereditary retinal dystrophy	dsyn	Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations				voretigene neparvovec-rzyl	Luxturna	42081	Treatment of inherited retinal dystrophy due to biallelic RPE65 gene mutations	Designated/Approved	Approved for Orphan Indication	an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells determined by a treating physician	Ê12/19/2017Ê	Ê12/19/2024	"Spark Therapeutics, Inc."	3737 Market Street	Suite 1300	Philadelphia	Pennsylvania	19104	USA	466414
3604	Rickets	5700			3078	of X-linked hypophosphatemia	C0733682	"Hypophosphatemic Rickets, X-Linked Dominant"	dsyn	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	X-linked hypophosphatemia|GARD:0012943|KRN-23|RECOMBINANT HUMAN IGG1 MONOCLONAL ANTIBODY|GARD:0012943	Rickets|GARD:0005700|KRN-23|RECOMBINANT HUMAN IGG1 MONOCLONAL ANTIBODY|GARD:0005700	"X-LINKED HYPOPHOSPHATEMIA|X-LINKED HYPOPHOSPHATEMIC RICKETS|XLH|HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT|HYPOPHOPHATEMIA, X-LINKED|VITAMIN D-RESISTANT RICKETS, X-LINKED|HYPOPHOPHATEMIC VITAMIN D-RESISTANT RICKETS|HPDR|GARD:0012943|ORPHA:89936|ORPHANET:89936|OMIM:307800"	burosumab-twza	Crysvita	40161	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Designated/Approved	Approved for Orphan Indication	CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older.	Ê09/27/2019Ê	Ê09/27/2026	"Kyowa Kirin, Inc."	135 US Highway 202/206	Suite 6	Bedminster	New Jersey	7921	USA	296109
3604	Rickets	5700			3078	of X-linked hypophosphatemia	C0733682	"Hypophosphatemic Rickets, X-Linked Dominant"	dsyn	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	X-linked hypophosphatemia|GARD:0012943|KRN-23|RECOMBINANT HUMAN IGG1 MONOCLONAL ANTIBODY|GARD:0012943	Rickets|GARD:0005700|KRN-23|RECOMBINANT HUMAN IGG1 MONOCLONAL ANTIBODY|GARD:0005700	"X-LINKED HYPOPHOSPHATEMIA|X-LINKED HYPOPHOSPHATEMIC RICKETS|XLH|HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT|HYPOPHOPHATEMIA, X-LINKED|VITAMIN D-RESISTANT RICKETS, X-LINKED|HYPOPHOPHATEMIC VITAMIN D-RESISTANT RICKETS|HPDR|GARD:0012943|ORPHA:89936|ORPHANET:89936|OMIM:307800"	burosumab-twza	Crysvita	40161	Treatment of X-linked hypophosphatemia (formerly known as vitamin D-resistant rickets)	Designated/Approved	Approved for Orphan Indication	CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older	Ê04/17/2018Ê	Ê04/17/2025	"Kyowa Kirin, Inc."	135 US Highway 202/206	Suite 6	Bedminster	New Jersey	7921	USA	296109
1071	Rosacea		MISSING	Not a rare disease	5108	of acne rosacea.	C0035854	Rosacea	dsyn	Treatment of acne rosacea.	METRONIDAZOLE|METRONIDAZOLE (TOPICAL)|METROGEL	ROSACEA CONJUNCTIVITIS|ROSACEA|ACNE ROSACEA|DOID:9709|MESH:D012393	"KERATITIS|KERATITIS, HERPETIC|HERPES ZOSTER KERATITIS|DOID:4677|MESH:D016849"	Metronidazole (topical)	Metrogel	32072	Treatment of acne rosacea.	Designated/Approved	Approved for Orphan Indication		Ê11/22/1988Ê	Ê11/22/1995	"Galderma Laboratories, Inc."	P.O. Box 331329		Fort Worth	Texas	76163	USA	21687
5780	Scurvy	10406			3462	of scurvy	C0036474	Scurvy	dsyn	Treatment of scurvy	Scurvy|GARD:0010406|ASCORBIC ACID|ASCOR L 500|GARD:0010406	SCURVY|DOID:13724|MESH:D012614	ASCORBIC ACID DEFICIENCY|VITAMIN C DEFICIENCY|DOID:13577|MESH:D001206	ascorbic acid	Ascor	39325	Treatment of scurvy	Designated/Approved	Approved for Orphan Indication	"for the treatment of scurvy in adult and pediatric patients age 5 months and older for whom oral administrtaion is not possible, insufficient or contraindicated"	Ê10/02/2017Ê	Ê10/02/2024	McGuff Pharmaceuticals Inc.	2921 W. MacArthur Blvd.	Suite 141	Santa Ana	California	92704	USA	243707
2203	Secondary pulmonary hypertension		MISSING	Not a rare disease	4342	of secondary pulmonary hypertension	C0264936	Secondary pulmonary hypertension	dsyn	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	EPOPROSTENOL|FLOLAN			epoprostenol	Flolan	36241	Treatment of secondary pulmonary hypertension due to intrinsic precapillary pulmonary vascular disease.	Designated/Approved	Approved for Orphan Indication	treatment of pulmonary arterial hypertension (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.	Ê04/14/2000Ê	Ê04/14/2007	GlaxoSmithKline	2301 Renaissance Blvd	P. O. Box 61540	King of Prussia	Pennsylvania	19406	USA	121698
Missing	Severe combined immunodeficiency	7628			1792	of adenosine deaminase deficiency	C0268124	Adenosine deaminase deficiency	dsyn	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency.	Severe combined immunodeficiency|GARD:0007628|EZN-2279 |(MONOMETHOXYPOLYETHYLENE GLYCOL) RECOMBINANT ADENOSINE DEAMINASE|GARD:0007628	Adenosine deaminase deficiency|GARD:0005748|EZN-2279 |(MONOMETHOXYPOLYETHYLENE GLYCOL) RECOMBINANT ADENOSINE DEAMINASE|GARD:0005748	"ADENOSINE DEAMINASE DEFICIENCY|ADA DEFICIENCY|SEVERE COMBINED IMMUNODEFICIENCY DUE TO ADENOSINE DEAMINASE DEFICIENCY|SEVERE COMBINED IMMUNODEFICIENCY DUE TO ADA DEFICIENCY|SCID DUE TO ADA DEFICIENCY|SEVERE COMBINED IMMUNODEFICIENCY, AUTOSOMAL RECESSIVE, T CELL-NEGATIVE, B CELL-NEGATIVE, NK CELL-NEGATIVE, DUE TO ADENOSINE DEAMINASE DEFICIENCY|ADA-SCID|ADENOSINE DEAMINASE DEFICIENT SEVERE COMBINED IMMUNODEFICIENCY|GARD:0005748|OMIM:102700|ORPHA:277|ORPHANET:277"	elapegademase-lvlr	Revcovi	42082	Treatment of adenosine deaminase deficiency in patients with severe combined immunodeficiency.	Designated/Approved	Approved for Orphan Indication	Treatment of Adenosine Deaminase-Severe Combined Immunodeficiency (ADA-SCID).	Ê10/05/2018Ê	ÊTBD	"Leadiant Biosciences, Inc."	9841 Washingtonian Blvd	Suite 500	Gaithersburg	Maryland	20878	USA	467514
3252	Short bowel syndrome	1502			4590	of short bowel syndrome	C0036992	Short Bowel Syndrome	dsyn	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Short bowel syndrome|GARD:0001502|GLUTAMINE|NUTRESTORE|GARD:0001502			Glutamine	Nutrestore	34764	For use with human growth hormone in the treatment of short bowel syndrome (nutrient malabsorption from the gastrointestinal tract resulting from an inadequate absorptive surface).	Designated/Approved	Approved for Orphan Indication	Treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth hormone that is approved for this indication.	Ê06/10/2004Ê	Ê06/10/2011	"Emmaus Medical, Inc."	20725 S. Western Avenue	Suite 136	Torrence	California	90501	USA	85794
3256	Short bowel syndrome	1502			4239	of short bowel syndrome.	C0036992	Short Bowel Syndrome	dsyn	Treatment of short bowel syndrome.	Short bowel syndrome|GARD:0001502|HUMAN INSULIN (RDNA)|GARD:0001502	Short bowel syndrome|GARD:0001502|CROFELEMER|MYTESI|GARD:0001502	Short bowel syndrome|GARD:0001502|GLEPAGLUTIDE|GARD:0001502	teduglutide [rDNA origin]	Gattex	36706	Treatment of short bowel syndrome.	Designated/Approved	Approved for Orphan Indication	GATTEX is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support.	Ê05/16/2019Ê	Ê05/16/2026	"Shire-NPS Pharmaceuticals, Inc."	650 E. Kendall Street		Cambridge	Massachusetts	2142	USA	126999
3256	Short bowel syndrome	1502			4239	of short bowel syndrome.	C0036992	Short Bowel Syndrome	dsyn	Treatment of short bowel syndrome.	Short bowel syndrome|GARD:0001502|HUMAN INSULIN (RDNA)|GARD:0001502	Short bowel syndrome|GARD:0001502|CROFELEMER|MYTESI|GARD:0001502	Short bowel syndrome|GARD:0001502|GLEPAGLUTIDE|GARD:0001502	teduglutide [rDNA origin]	Gattex	36706	Treatment of short bowel syndrome.	Designated/Approved	Approved for Orphan Indication	Treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support	Ê12/21/2012Ê	Ê12/21/2019	"Shire-NPS Pharmaceuticals, Inc."	650 E. Kendall Street		Cambridge	Massachusetts	2142	USA	126999
3258	Short bowel syndrome	1502			4587	alone	C0439044	Living Alone	fndg	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	Short bowel syndrome|GARD:0001502|SOMATROPIN (R-DNA)|ZORBTIVE|GARD:0001502			Somatropin (r-DNA)	Zorbtive	34764	For use alone or in combination with glutamine in the treatment of short bowel syndrome.	Designated/Approved	Approved for Orphan Indication	Treatment of short bowel syndrome in patients receiving specialized nutritional support	Ê12/01/2003Ê	Ê12/01/2010	"EMD Serono, Inc."	One Technology Place		Roackland	Massachusetts	2370	USA	80394
Missing	Sickle cell anemia	8614			3326	of sickle cell disease	C0002895	"Anemia, Sickle Cell"	dsyn	Treatment of sickle cell disease	 Sickle cell - hemoglobin D disease |GARD:0012458|CETIEDIL CITRATE|CETIEDIL CITRATE INJECTION|GARD:0012458	 Sickle cell - hemoglobin D disease |GARD:0012458|CLOTRIMAZOLE|GARD:0012458	 Sickle cell - hemoglobin D disease |GARD:0012458|SENICAPOC|BIS(4-FLUOROPHENYL)PHENYLACETAMIDE|ICA-17043|GARD:0012458	crizanlizumab	Adakveo	39651	Treatment of sickle cell disease	Designated/Approved	Approved for Orphan Indication	ADAKVEO is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.	Ê11/15/2019Ê	Ê11/15/2026	Novartis Pharmaceuticals Corporation	One Health Plaza	Building 337 B11.3D	East Hanover	New Jersey	07936-	USA	259708
938	Sickle cell anemia	8614	done		4167	of sickle cell disease	C0002895	"Anemia, Sickle Cell"	dsyn	Treatment of sickle cell disease	 Sickle cell - hemoglobin D disease |GARD:0012458|CETIEDIL CITRATE|CETIEDIL CITRATE INJECTION|GARD:0012458	 Sickle cell - hemoglobin D disease |GARD:0012458|CLOTRIMAZOLE|GARD:0012458	 Sickle cell - hemoglobin D disease |GARD:0012458|SENICAPOC|BIS(4-FLUOROPHENYL)PHENYLACETAMIDE|ICA-17043|GARD:0012458	L-glutamine	Endari	37104	Treatment of sickle cell disease	Designated/Approved	Approved for Orphan Indication	To reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older.	Ê07/07/2017Ê	Ê07/07/2024	"Emmaus Medical, Inc."	"21250 Hawthorne Blvd., Suite 800"		Torrance	California	90503	USA	145901
719	Sickle cell anemia	8614	done		1544	of sickle cell disease (SCD).	C0002895	"Anemia, Sickle Cell"	dsyn	Treatment of sickle cell disease (SCD).	 Sickle cell - hemoglobin D disease |GARD:0012458|GBT-440|2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL) METHOXY)BENZALDEHYDE|GARD:0012458	" Sickle cell - hemoglobin D disease |GARD:0012458|IMR-687|6-[(3S,4S-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMADAZO[1,5-A]PYRAZIN-8-ONE|GARD:0012458"	Sickle cell anemia |GARD:0008614|GBT-440|2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL) METHOXY)BENZALDEHYDE|GARD:0008614	Voxelotor	Oxbryta	42367	Treatment of sickle cell disease (SCD).	Designated/Approved	Approved for Orphan Indication	OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.	Ê11/25/2019Ê	Ê11/25/2026	"Global Blood Therapeutics, Inc."	171 Oyster Point Blvd	Suite 300	South San Francisco	California	94080	USA	499715
2340	Sickle cell anemia	8614	done		2340	of sickle cell disease	C0002895	"Anemia, Sickle Cell"	dsyn	Treatment of sickle cell disease in patients under 18 years of age	 Sickle cell - hemoglobin D disease |GARD:0012458|HYDROXYUREA|HYDROXYCARBAMIDE (HYDROXYUREA)|SIKLOS|GARD:0012458	Sickle cell anemia |GARD:0008614|HYDROXYUREA|HYDROXYCARBAMIDE (HYDROXYUREA)|SIKLOS|GARD:0008614	 Sickle delta beta thalassemia |GARD:0010819|HYDROXYUREA|HYDROXYCARBAMIDE (HYDROXYUREA)|SIKLOS|GARD:0010819	hydroxycarbamide (hydroxyurea)	Siklos	41479	Treatment of sickle cell disease in patients under 18 years of age	Designated/Approved	Approved for Orphan Indication	"To reduce the frequency of painful crises and to reduce the need for blood transfusions in pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crisis"	Ê12/21/2017Ê	Ê12/21/2024	Addmedica Laboratories	37 rue de Caumartin		Paris			France	400413
5564	Sickle cell anemia	8614			4877	with sickle cell anemia	C0002895	"Anemia, Sickle Cell"	dsyn	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Sickle cell anemia|GARD:0008614|HYDROXYUREA|DROXIA|GARD:0008614			Hydroxyurea	Droxia	33147	Treatment of patients with sickle cell anemia as shown by the presence of hemoglobin S.	Designated/Approved	Approved for Orphan Indication	To reduce the frequency of painful crises and to reduce the need for blood transfusions in adult patients with sickle cell anemia with recurrent moderate to severe painful crises (generally at least 3 during the preceding 12 months).	Ê02/25/1998Ê	Ê02/25/2005	Bristol-Myers Squibb Pharmaceutical Research Institute	P.O. Box 4000		Princeton	New Jersey	8543	USA	49590
1293	Sjogren syndrome	10252	done		4767	keratoconjunctivitis sicca	C0013238	Dry Eye Syndromes	dsyn	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	Sjogren syndrome|GARD:0010252|PILOCARPINE HYDROCHLORIDE|PILOCARPINE HCL|SALAGEN|GARD:0010252			Pilocarpine HCl	Salagen	33662	Treatment of xerostomia and keratoconjunctivitis sicca in Sjogren's syndrome patients.	Designated/Approved	Approved for Orphan Indication	Treatment of dry mouth in patients with Sjogren's syndrome.	Ê02/11/1998Ê	Ê02/11/2005	"MGI Pharma, Inc."	5775 West Old Shakopee Rd.	Suite 100	Bloomington	Minnesota	55437	USA	62091
1268	Small cell lung cancer	9344	done		808	of Small Cell Lung Cancer	C0149925	Small cell carcinoma of lung	neop	Treatment of Small Cell Lung Cancer	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|NONSQUAMOUS NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	NON-SMALL CELL LUNG CANCER (DISORDER)|NON-SMALL CELL LUNG CANCER|ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289	pembrolizumab	Keytruda	43011	Treatment of Small Cell Lung Cancer	Designated/Approved	Approved for Orphan Indication	KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.	Ê06/17/2019Ê	Ê06/17/2026	"Merck, Sharp, & Dohme, a subsidiary of Merck & Co., Inc."	1 Merck Drive		Whitehouse Station	New Jersey	8889	USA	605417
2583	Small cell lung cancer	9344	done		1625	of small cell lung cancer.	C0149925	Small cell carcinoma of lung	neop	Treatment of small cell lung cancer.	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	"NON-SMALL CELL LUNG CARCINOMA|CARCINOMA, NON-SMALL-CELL LUNG|NONSQUAMOUS NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289"	NON-SMALL CELL LUNG CANCER (DISORDER)|NON-SMALL CELL LUNG CANCER|ALK-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER|DOID:3908|MESH:D002289	nivolumab	Opdivo	42262	Treatment of small cell lung cancer.	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.	Ê08/16/2018Ê	Ê08/16/2025	Bristol-Myers Squibb Company	5 Research Parkway		Wallingford	Connecticut	6492	USA	491415
276	Small cell lung cancer	9344	done		1257	of small cell lung cancer	C0149925	Small cell carcinoma of lung	neop	Treatment of small cell lung cancer (SCLC)	Small cell lung cancer|GARD:0009344|ATEZOLIZUMAB|GARD:0009344	Small cell lung cancer|GARD:0009344|LURBINECTEDIN|ZEPSYRE|GARD:0009344	Small cell lung cancer|GARD:0009344|DOCETAXEL|DOCETAXEL ENCAPSULATED IN AN ALBUMIN-STABILIZED LIPOSOME|GARD:0009344	atezolizumab	Tecentriq	42656	Treatment of small cell lung cancer (SCLC)	Designated/Approved	Approved for Orphan Indication	"TECENTRIQ, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)"	Ê03/18/2019Ê	Ê03/18/2026	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	541216
5048	Smallpox	7444			3542	of smallpox	C0037354	Smallpox	dsyn	Treatment of smallpox	Smallpox|GARD:0007444|BRINCIDOFOVIR|GARD:0007444	Smallpox|GARD:0007444|TECOVIRIMAT|GARD:0007444	Smallpox|GARD:0007444|HILTONOL|POLYINOSINIC-POLYCYTIDILIC ACID (POLY-ICLC)|GARD:0007444	tecovirimat	Tpoxx	39078	Treatment of smallpox	Designated/Approved	Approved for Orphan Indication	TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.	Ê07/13/2018Ê	Ê07/13/2025	"SIGA Technologies, Inc."	4575 SW Research Way	Suite 230	Corvallis	Oregon	97333	USA	229806
3511	Soft tissue sarcoma	4898			999	of soft tissue sarcoma	C1261473	Sarcoma	neop	Treatment of soft tissue sarcoma	RELAPSED ADULT SARCOMA OF THE SOFT TISSUE|RECURRENT ADULT SOFT TISSUE SARCOMA|NCI2004_11_17:C7822|DOID:7712	PEDIATRIC SARCOMA OF THE SOFT TISSUE|CHILDHOOD SOFT TISSUE SARCOMA|NCI2004_11_17:C7715|DOID:3521	REFRACTORY SOFT TISSUE SARCOMA|NCIT:C139001|NCI:C139001	tazemetostat	n/a	42901	Treatment of soft tissue sarcoma	Designated/Approved	Approved for Orphan Indication	TAZVERIK is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.	Ê01/23/2020Ê	ÊTBD	"Epizyme, Inc."	400 Technology Square	4th Floor	Cambridge	Massachusetts	2139	USA	578417
3514	Soft tissue sarcoma	4898			1966	of soft tissue sarcoma	C1261473	Sarcoma	neop	Treatment of soft tissue sarcoma	RELAPSED ADULT SARCOMA OF THE SOFT TISSUE|RECURRENT ADULT SOFT TISSUE SARCOMA|NCI2004_11_17:C7822|DOID:7712	PEDIATRIC SARCOMA OF THE SOFT TISSUE|CHILDHOOD SOFT TISSUE SARCOMA|NCI2004_11_17:C7715|DOID:3521	REFRACTORY SOFT TISSUE SARCOMA|NCIT:C139001|NCI:C139001	olaratumab	Lartruvo	41921	Treatment of soft tissue sarcoma	Designated/Approved	Approved for Orphan Indication	"In combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery."	Ê10/19/2016Ê	Ê10/19/2023	Eli Lilly and Company	"Lilly Corporate Center, Drop Code 2543"		Indianapolis	Indiana	46285	USA	448414
3505	Soft tissue sarcoma	4898			2606	of soft tissue sarcoma	C1261473	Sarcoma	neop	Treatment of soft tissue sarcoma	RELAPSED ADULT SARCOMA OF THE SOFT TISSUE|RECURRENT ADULT SOFT TISSUE SARCOMA|NCI2004_11_17:C7822|DOID:7712	PEDIATRIC SARCOMA OF THE SOFT TISSUE|CHILDHOOD SOFT TISSUE SARCOMA|NCI2004_11_17:C7715|DOID:3521	REFRACTORY SOFT TISSUE SARCOMA|NCIT:C139001|NCI:C139001	eribulin mesylate	Halaven	41043	Treatment of soft tissue sarcoma	Designated/Approved	Approved for Orphan Indication	Treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracyclne-containing regimen	Ê01/28/2016Ê	Ê01/28/2023	Eisai Inc.	155 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA	367112
3509	Soft tissue sarcoma	4898			3854	of soft tissue sarcoma	C1261473	Sarcoma	neop	Treatment of soft tissue sarcoma	RELAPSED ADULT SARCOMA OF THE SOFT TISSUE|RECURRENT ADULT SOFT TISSUE SARCOMA|NCI2004_11_17:C7822|DOID:7712	PEDIATRIC SARCOMA OF THE SOFT TISSUE|CHILDHOOD SOFT TISSUE SARCOMA|NCI2004_11_17:C7715|DOID:3521	REFRACTORY SOFT TISSUE SARCOMA|NCIT:C139001|NCI:C139001	trabectedin	Yondelis	38260	Treatment of soft tissue sarcoma	Designated/Approved	Approved for Orphan Indication	For the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen	Ê10/23/2015Ê	Ê10/23/2022	"Janssen Research & Development, LLC"	920 US Highway 202	P. O. Box 300	Raritan	New Jersey	8869	USA	193604
3500	Soft tissue sarcoma	4898			3113	of soft tissue sarcomas	C1261473	Sarcoma	neop	Treatment of soft tissue sarcomas	Soft tissue sarcoma|GARD:0004898|PALIFOSFAMIDE|GARD:0004898	Soft tissue sarcoma|GARD:0004898|DIGITOXIN|GARD:0004898	Soft tissue sarcoma|GARD:0004898|IDOXURIDINE|GARD:0004898	pazopanib	Votrient	40106	Treatment of soft tissue sarcomas	Designated/Approved	Approved for Orphan Indication	Advanced soft tissue sarcoma (STS) who have received prior chemotherapy	Ê04/26/2012Ê	Ê04/26/2019	Novartis Pharmaceuticals Corp	1 Health Plaza		East Hanover	New Jersey	7936	USA	293809
5155	Spinal muscular atrophy	7674			1973	of spinal muscular atrophy	C0026847	Spinal Muscular Atrophy	dsyn	Treatment of spinal muscular atrophy	Spinal muscular atrophy|GARD:0007674|ATALUREN|GARD:0007674	Spinal muscular atrophy|GARD:0007674|NUSINERSEN|GARD:0007674	Spinal muscular atrophy|GARD:0007674|SODIUM PHENYLBUTYRATE|BUPHENYL|GARD:0007674	onasemnogene abeparvovec	Zolgensma	41912	Treatment of spinal muscular atrophy	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene.	Ê05/24/2019Ê	Ê05/24/2026	"AveXis, Inc."	2275 Half Day Road	Suite 200	Bannockburn	Illinois	60015	USA	444714
5142	Spinal muscular atrophy	7674			2799	of spinal muscular atrophy	C0026847	Spinal Muscular Atrophy	dsyn	Treatment of spinal muscular atrophy	Spinal muscular atrophy|GARD:0007674|ATALUREN|GARD:0007674	Spinal muscular atrophy|GARD:0007674|NUSINERSEN|GARD:0007674	Spinal muscular atrophy|GARD:0007674|SODIUM PHENYLBUTYRATE|BUPHENYL|GARD:0007674	nusinersen	Spinraza	40651	Treatment of spinal muscular atrophy	Designated/Approved	Approved for Orphan Indication	Treatment of spinal muscular atrophy in pediatric and adult patients	Ê12/23/2016Ê	Ê12/23/2023	"Biogen, Inc"	225 Binney Street		Cambridge	Massachusetts	2142	USA	336711
2022	Squamous cell carcinoma of the head and neck	8503	done		4237	of squamous cell cancer	C0007137	Squamous cell carcinoma	neop	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	Squamous cell carcinoma of the head and neck|GARD:0008503|CETUXIMAB|ERBITUX|GARD:0008503			cetuximab	Erbitux	36710	Treatment of squamous cell cancer of the head and neck in patients who express epidermal growth factor receptor	Designated/Approved	Approved for Orphan Indication	"For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed"	Ê03/01/2006Ê	Ê03/01/2013	ImClone Systems Incorporated	33 ImClone Drive		Branchburg	New Jersey	8876	USA	132700
5741	Status epilepticus	10191			688	of status epilepticus	C0038220	Status Epilepticus	dsyn	Treatment of status epilepticus	Status epilepticus|GARD:0010191|ALLOPREGNANOLONE|GARD:0010191	Status epilepticus|GARD:0010191|MIDAZOLAM|ZENEOÂ®-MIDAZOLAM|GARD:0010191	Status epilepticus|GARD:0010191|MIDAZOLAM|GARD:0010191	midazolam	Seizalam	42404	Treatment of status epilepticus	Designated/Approved	Approved for Orphan Indication	SEIZALAM is indicated for the treatment of status epilepticus in adults.	Ê09/14/2018Ê	Ê09/14/2025	Meridian Medical Technologies	6350 Stevens Forest Road	Suite 301	Columbia	Maryland	21046	USA	508215
2379	Status epilepticus	10191	done		2349	of epilepsy patients	C0014544	Epilepsy	dsyn	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Status epilepticus|GARD:0010191|CARBAMAZEPINE|INTRAVENOUS CARBAMAZEPINE|CARNEXIV|GARD:0010191			intravenous carbamazepine	Carnexiv	41452	Treatment of epilepsy patients who cannot take anything by mouth (NPO)	Designated/Approved	Approved for Orphan Indication	"Replacement therapy for oral carbamazepine formulations, when oral administration is temporarily not feasible, in adults with the following seizure types: (1) Partial seizures with complex symptomology; (2)Generalized tonic-clonic seizures; and (3) Mixed seizure patterns which include the above or other partial or generalized seizures"	Ê10/07/2016Ê	Ê10/07/2023	Lundbeck LLC	Four Parkway North		Deerfield	Illinois	60015	USA	265508
5740	Status epilepticus	10191			4825	with status epilepticus	C0038220	Status Epilepticus	dsyn	For the acute treatment of patients with status epilepticus of the grand mal type.	Status epilepticus|GARD:0010191|FOSPHENYTOIN|CEREBYX|GARD:0010191			Fosphenytoin	Cerebyx	33393	For the acute treatment of patients with status epilepticus of the grand mal type.	Designated/Approved	Approved for Orphan Indication	For the control of generalized convulsive status epilepticus.	Ê08/05/1996Ê	Ê08/05/2003	Warner-Lambert Company	2800 Plymouth Road		Ann Arbor	Michigan	48106	USA	55790
2517	Status epilepticus	10191	approximate		3110	seizure clusters	C1959629	Seizure Adverse Event	fndg	"Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)"	Status epilepticus|GARD:0010191|MIDAZOLAM|GARD:0010191			midazolam	Nayzilam	40106	"Rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity (e.g. acute repetitive seizures, seizure clusters)"	Designated/Approved	Approved for Orphan Indication	"NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patients usual seizure pattern in patients with epilepsy 12 years of age and older."	Ê05/17/2019Ê	Ê05/17/2026	"UCB, Inc."	1950 Lake Park Drive	Building 2100	Smyrna	Georgia	30080	USA	277809
3013	Stomach cancer	7704	done		1075	of gastric cancer	C0024623	Malignant neoplasm of stomach	neop	Treatment of gastric cancer including cancer of the gastroesophageal junction	Stomach cancer|GARD:0007704|AVELUMAB|BAVENCIO|GARD:0007704	Stomach cancer|GARD:0007704|MASITINIB MESYLATE|GARD:0007704	Stomach cancer|GARD:0007704|NAPABUCASIN|GARD:0007704	trifluridine/tipiracil	Lonsurf	42842	Treatment of gastric cancer including cancer of the gastroesophageal junction	Designated/Approved	Approved for Orphan Indication	"LONSURF is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy."	Ê02/22/2019Ê	Ê02/22/2026	"Taiho Oncology, Inc."	101 Carnegie Center	Suite 101	Princeton	New Jersey	8540	USA	564116
2739	Stomach cancer	7704	done		2656	of gastric cancer	C0024623	Malignant neoplasm of stomach	neop	Treatment of gastric cancer	Stomach cancer|GARD:0007704|IPILIMUMAB|NIVOLUMAB AND IPILIMUMAB|GARD:0007704	REFRACTORY GASTRIC CARCINOMA|REFRACTORY GASTRIC (STOMACH) CANCER|NCIT:C147996|NCI:C147996	Stomach cancer|GARD:0007704|MINNELIDE|C21H27O10P|GARD:0007704	ramucirumab	Cyramza	40955	Treatment of gastric cancer	Designated/Approved	Approved for Orphan Indication	"CYRAMZA as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy."	Ê04/21/2014Ê	Ê04/21/2021	Eli Lilly and Company	33 ImClone Drive		Branchburg	New Jersey	8876	USA	359711
2739	Stomach cancer	7704	done		2656	of gastric cancer	C0024623	Malignant neoplasm of stomach	neop	Treatment of gastric cancer	Stomach cancer|GARD:0007704|IPILIMUMAB|NIVOLUMAB AND IPILIMUMAB|GARD:0007704	REFRACTORY GASTRIC CARCINOMA|REFRACTORY GASTRIC (STOMACH) CANCER|NCIT:C147996|NCI:C147996	Stomach cancer|GARD:0007704|MINNELIDE|C21H27O10P|GARD:0007704	ramucirumab	Cyramza	40955	Treatment of gastric cancer	Designated/Approved	Approved for Orphan Indication	"Treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, as a single agent or in combination with paclitaxel, after prior fluoropyrimidine- or platinium-containing chemotherapy."	Ê11/05/2014Ê	ÊN/A	Eli Lilly and Company	33 ImClone Drive		Branchburg	New Jersey	8876	USA	359711
2659	Stomach cancer	7704	done		1690	"of gastric cancer,"	C0024623	Malignant neoplasm of stomach	neop	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	Stomach cancer|GARD:0007704|TRASTUZUMAB|HERCEPTIN|GARD:0007704	Stomach cancer|GARD:0007704|IBRUTINIB|IMBRUVICA|GARD:0007704	Stomach cancer|GARD:0007704|PEMBROLIZUMAB|KEYTRUDA|GARD:0007704	pembrolizumab	Keytruda	42171	"Treatment of gastric cancer, including gastroesophageal junction adenocarcinoma"	Designated/Approved	Approved for Orphan Indication	"KEYTRUDA is indicated for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) =1] as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy."	Ê09/22/2017Ê	Ê09/22/2024	Merck Research Laboratories	351 North Sumneytown Pike	UG2C-50	North Wales	Pennsylvania	19454	USA	481715
3030	Stomach cancer	7704	approximate		3116	advanced adenocarcinoma	C0001418	Adenocarcinoma	neop	"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction"				trastuzumab	Herceptin	40099	"Treatment of HER2-overexpressing advanced adenocarcinoma of the stomach, including gastroesophageal junction"	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, who have not received prior treatment for metastatic disease"	Ê10/20/2010Ê	Ê10/20/2017	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	292409
2728	Strawberry nevus of skin		MISSING		3305	of proliferating infantile hemangiomas	C0206733	Strawberry nevus of skin	neop	Treatment of proliferating infantile hemangiomas requiring systemic therapy	PROPRANOLOL|HEMANGEOL			propranolol	Hemangeol	39696	Treatment of proliferating infantile hemangiomas requiring systemic therapy	Designated/Approved	Approved for Orphan Indication	Treatment of proliferating infantile hemangioma requiring systemic therapy.	Ê03/14/2014Ê	Ê03/14/2021	Pierre Fabre Dermatologie	"8 Campus Drive, 2nd Floor"		Parsippany	New Jersey	7054	USA	266708
2567	Subarachnoid Hemorrhage		MISSING		2711	of subarachnoid hemorrhage.	C0038525	Subarachnoid Hemorrhage	dsyn	Treatment of subarachnoid hemorrhage.	CLAZOSENTAN|ERAJET	GLYBURIDE	NIMODIPINE|INTRAVENTRICULAR NIMODIPINE	nimodipine	Nymalize	40802	Treatment of subarachnoid hemorrhage.	Designated/Approved	Approved for Orphan Indication	"Improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V)."	Ê05/10/2013Ê	Ê05/10/2020	"Arbor Pharmaceuticals, Inc."	6 Concourse Parkway	Suite 1800	Atlanta	Georgia	30328	USA	338611
5929	Systemic sclerosis 	12427			1356	the associated interstitial lung disease	C0206062	"Lung Diseases, Interstitial"	dsyn	Treatment of systemic sclerosis (including the associated interstitial lung disease).	Systemic sclerosis |GARD:0012427|NINTEDANIB|GARD:0012427	Systemic sclerosis |GARD:0012427|PIRFENIDONE|GARD:0012427	"SCLERODERMA|PROGRESSIVE SYSTEMIC SCLEROSIS|PSS|SCLEROSIS, FAMILIAL PROGRESSIVE SYSTEMIC|SYSTEMIC SCLEROSIS"	nintedanib	Ofev	42557	Treatment of systemic sclerosis (including the associated interstitial lung disease).	Designated/Approved	Approved for Orphan Indication	OFEV is indicated to slow the rate of decline in pulmonary function in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD).	Ê09/06/2019Ê	Ê09/06/2026	"Boehringer Ingelheim Pharmaceuticals, Inc."	900 Ridgebury Road	Box 368	Ridgefield	Connecticut	6877	USA	528516
2931	"Tachycardia, Ventricular"		MISSING	Not a disease	3323	"For ventricular tachycardia,"	C0042514	"Tachycardia, Ventricular"	dsyn	"For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible."	SOTALOL|SOTALOL (IV)|SO-AQUEOUS			sotalol (IV)	So-Aqueous	39654	"For ventricular tachycardia, ventricular fibrillation, or the maintenance of sinus rhythm in patients converted from atrial fibrillation or atrial flutter when oral administration is not possible."	Designated/Approved	Approved for Orphan Indication	"For use as a substitute for oral sotalol in patients who are unable to take sotalol orally [oral sotalol is indicated for maintenance of normal sinus rhythm in patients with history of highly symptomatic atrial fibrillation /flutter, and for treatment of documented life-threatening ventricular arrhythmias]"	Ê07/02/2009Ê	Ê07/02/2016	AltaThera Pharmaceuticals LLC	311 South Wacker Drive	Suite 2275A	Chicago	Illinois	60606	USA	247707
5172	Testicular cancer	7746			5144	of testicular cancer.	C0153594	Malignant neoplasm of testis	neop	Treatment of testicular cancer.	REFRACTORY MALIGNANT TESTICULAR GERM CELL TUMOR|REFRACTORY TESTICULAR CANCER|REFRACTORY CANCER OF TESTIS|REFRACTORY CANCER OF THE TESTIS|NCI:C9077|UMLS:C1377904	TESTICULAR CANCER|TESTICULAR NEOPLASMS|REFRACTORY TESTICULAR TUMORS|DOID:2998|MESH:D013736	REFRACTORY TESTICULAR CANCER|REFRACTORY CANCER OF TESTIS|REFRACTORY CANCER OF THE TESTIS|REFRACTORY MALIGNANT TESTICULAR GERM CELL TUMOR|REFRACTORY TESTICULAR CARCINOMA|TESTIS REFRACTORY CANCER|UMLS:C1377904|NCIT:C9077|DOID:7928|MONDO:0004401	Ifosfamide	Ifex	31797	Treatment of testicular cancer.	Designated/Approved	Approved for Orphan Indication	"In combination with certain other approved antineoplastic agents, for third line chemotherapy in the treatment of germ cell testicular cancer."	Ê12/30/1988Ê	Ê12/30/1995	Bristol-Myers Squibb Pharmaceutical Research Institute	"5 Research Parkway, P.O. Box 5100"		Wallingford	Connecticut	6492	USA	17786
5175	Thalassemia	7756			2427	of B-thalassemia	C0039730	Thalassemia	dsyn	Treatment of B-thalassemia	Thalassemia|GARD:0007756|SOTATERCEPT|RECOMBINANT FUSION PROTEIN CONSISTING OF A MODIFIED FORM OF THE EXTRACELLULAR DOMAIN OF HUMAN ACTIVIN RECEPTOR IIB (ACTRIIB) LINKED TO A HUMAN IGG1 FC DOMAIN|GARD:0007756	Thalassemia|GARD:0007756|AUTOLOGOUS CD34+ HEMATOPOIETIC STEM CELLS TRANSDUCED WITH LENTIGLOBIN BB305 LENTIVIRAL VECTOR ENCODING THE HUMAN BA-T87Q-GLOBIN GENE|GARD:0007756	BETA THALASSEMIA|MEDITERRANEAN ANEMIA	Luspatercept-aamt	Reblozyl	41344	Treatment of B-thalassemia	Designated/Approved	Approved for Orphan Indication	REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.	Ê11/08/2019Ê	Ê11/08/2026	Celgene Corporation	86 Morris Avenue		Summit	New Jersey	7901	USA	389813
5191	Thrombasthenia	7760			3905	in Glanzmann's thrombasthenia	C0040015	Thrombasthenia	dsyn	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Thrombasthenia|GARD:0007760|COAGULATION FACTOR VIIA (RECOMBINANT)|NOVOSEVEN RT|GARD:0007760	"GLANZMANN THROMBASTHENIA|GLANZMANN DISEASE|GLANZMANN-NAEGELI SYNDROME|GLANZMANN THROMBASTHENIA, TYPE A|GLYCOPROTEIN COMPLEX IIB/IIIA, DEFICIENCY OF|GP IIB-IIIA COMPLEX, DEFICIENCY OF|GTA|PLATELET FIBRINOGEN RECEPTOR DEFICIENCY|THROMBASTHENIA|THROMBASTHENIA OF GLANZMANN AND NAEGELI|INTEGRIN AIIBB3 DEFICIENCY OF"	MAY HEGGLIN ANOMALY|DOHLE LEUKOCYTE INCLUSIONS WITH GIANT PLATELETS|DOHLE'S BODIES-MYELOPATHY|HEGGLIN'S DISEASE|LEUKOCYTIC INCLUSIONS WITH PLATELET ABNORMALITY|MACROTHROMBOCYTOPENIA WITH LEUKOCYTE INCLUSIONS|MHA	coagulation factor VIIa (recombinant)	Novoseven Rt	38156	Treatment of bleeding episodes in Glanzmann's thrombasthenia	Designated/Approved	Approved for Orphan Indication	"Treatment of bleeding episodes and peri-operative management in adults and children with Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets."	Ê07/02/2014Ê	Ê07/02/2021	Novo Nordisk Inc.	800 Scudders Mill Rd.		Plainsboro	New Jersey	8536	USA	186004
449	"Thrombotic thrombocytopenic purpura, acquired "	4607	approximate		3207	of thrombotic thrombocytopenic purpura	C0034155	"Purpura, Thrombotic Thrombocytopenic"	dsyn	Treatment of thrombotic thrombocytopenic purpura	Congenital thrombotic thrombocytopenic purpura|GARD:0009430|ANFIBATIDE|GARD:0009430	"Thrombotic thrombocytopenic purpura, acquired|GARD:0004607|ANFIBATIDE|GARD:0004607"	 Congenital thrombotic thrombocytopenic purpura|GARD:0009430|CAPLACIZUMAB|GARD:0009430	Caplacizumab	Cablivi	39917	Treatment of thrombotic thrombocytopenic purpura	Designated/Approved	Approved for Orphan Indication	"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy."	Ê02/06/2019Ê	Ê02/06/2026	"Ablynx, a wholly owned subsidiary of Sanofi Group"	55 Corporate Drive		Bridgewater	New Jersey	8807	USA	277909
1969	"Thyroid cancer, follicular "	5206	done		2896	anaplastic thyroid carcinoma	C0238461	Anaplastic thyroid carcinoma	neop	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	 Anaplastic thyroid cancer |GARD:0000664|VANDETANIB|CAPRELSA(R)|GARD:0000664	"Thyroid cancer, follicular |GARD:0005206|VANDETANIB|CAPRELSA(R)|GARD:0005206"	" Thyroid cancer, medullary |GARD:0007004|VANDETANIB|CAPRELSA(R)|GARD:0007004"	cabozantinib	Cometriq	40511	"Treatment of follicular, medullary and anaplastic thyroid carcinoma and metastatic or locally advanced papillary thyroid cancer."	Designated/Approved	Approved for Orphan Indication	"Treatment of progressive, metastatic medullary thyroid cancer (MTC)."	Ê11/29/2012Ê	Ê11/29/2019	"Exelixis, Inc."	1851 Harbor Bay Parkway		Alameda	California	94502	USA	297109
3082	"Thyroid cancer, follicular "	5206	done		3721	"with follicular thyroid carcinoma,"	C0206682	Follicular thyroid carcinoma	neop	"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma"	 Papillary thyroid carcinoma|GARD:0012027|VANDETANIB|CAPRELSA(R)|GARD:0012027	Papillary thyroid carcinoma|GARD:0012027|VANDETANIB|CAPRELSA(R)|GARD:0012027	 Anaplastic thyroid cancer |GARD:0000664|VANDETANIB|CAPRELSA(R)|GARD:0000664	vandetanib	Caprelsa(R)	38646	"Treatment of patients with follicular thyroid carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma, and locally advanced and metastatic papillary thyroid carcinoma"	Designated/Approved	Approved for Orphan Indication	Treatment of asymptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease	Ê04/06/2011Ê	Ê04/06/2018	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA	211005
2415	"Thyroid cancer, follicular "	5206	done		2469	papillary thyroid cancer	C0238463	Papillary thyroid carcinoma	neop	"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer"	" Thyroid cancer, medullary |GARD:0007004|LENVATINIB|LENVIMA|GARD:0007004"	 Anaplastic thyroid cancer |GARD:0000664|LENVATINIB|LENVIMA|GARD:0000664	 Papillary thyroid carcinoma|GARD:0012027|LENVATINIB|LENVIMA|GARD:0012027	lenvatinib	Lenvima	41270	"Treatment of follicullar, medullary, anaplastic, and metastatic or locally advanced papillary thyroid cancer"	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine refractory differentiated thyroid cancer"	Ê02/13/2015Ê	Ê02/13/2022	"Eisai, Inc."	155 Tice Blvd		Woodcliff Lake	New Jersey	7677	USA	378412
2926	"Thyroid cancer, medullary "	7004	done		2676	papillary thyroid cancer	C0238463	Papillary thyroid carcinoma	neop	"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	"Thyroid cancer, medullary |GARD:0007004|SORAFENIB|NEXAVAR|GARD:0007004"	 Anaplastic thyroid cancer |GARD:0000664|SORAFENIB|NEXAVAR|GARD:0000664	Anaplastic thyroid cancer|GARD:0000664|SORAFENIB|NEXAVAR|GARD:0000664	sorafenib	Nexavar	40889	"Treatment of medullary thyroid cancer, anaplastic thyroid cancer, and recurrent or metastatic follicular or papillary thyroid cancer"	Designated/Approved	Approved for Orphan Indication	"Treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DCT) that is refractory to radioactive iodine treatment."	Ê11/22/2013Ê	Ê11/22/2020	"Bayer HealthCare Pharmaceuticals, Inc."	100 Bayer Blvd.	PO Box 915	Whippany	New Jersey	7981	USA	320310
1874	Tourette syndrome	7783	done		3685	of Tourette's syndrome	C0040517	Gilles de la Tourette syndrome	dsyn	Treatment of Tourette's syndrome	Tourette syndrome|GARD:0007783|NBI-98782|(+)-A-DIHYDROTETRABENAZINE|(+)-DIHYDROTETRABENAZINE|GARD:0007783	Tourette syndrome|GARD:0007783|MECAMYLAMINE|INVERSINE|GARD:0007783	Tourette syndrome|GARD:0007783|TIAPRIDE|GARD:0007783	aripiprazole	Abilify	38742	Treatment of Tourette's syndrome	Designated/Approved	Approved for Orphan Indication	Treatment of pediatric patients with Tourette's	Ê12/12/2014Ê	Ê12/12/2021	Otsuka Pharmaceutical Development	and Commercialization	1st Floor	Princeton	New Jersey	8540	USA	207905
1538	Toxoplasma gondii encephalitis	MESH:D016781	MISSING		4648	of Toxoplasma gondii encephalitis	C0085315	"Toxoplasmosis, Cerebral"	dsyn	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	SULFADIAZINE			Sulfadiazine	n/a	34407	For use in combination with pyrimethamine for the treatment of Toxoplasma gondii encephalitis in patients with and without AIDS.	Designated/Approved	Approved for Orphan Indication	"Toxoplasmosis, as adjunctive with pyrimethamine"	Ê07/29/1994Ê	Ê07/29/2001	"Eon Labs Manufacturing, Inc."	227-15 North Conduit Avenue		Laurelton	New York	11413	USA	78093
1908	Transverse myelitis	7796	approximate		5101	"multiple sclerosis,"	C0026769	Multiple Sclerosis	dsyn	"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy)."	Transverse myelitis|GARD:0007796|BACLOFEN|LIORESAL INTRATHECAL|GARD:0007796	Transverse myelitis|GARD:0007796|BACLOFEN|LIORESAL INTRATHECAL|GARD:0007796	Myelitis|GARD:0007130|BACLOFEN|LIORESAL INTRATHECAL|GARD:0007130	baclofen	Lioresal Intrathecal	32091	"Treatment of intractable spasticity caused by spinal cord injury, multiple sclerosis, and other spinal diseases (including spinal ischemia, spinal tumor, transverse myelitis, cervical spondylosis, and degenerative myelopathy)."	Designated/Approved	Approved for Orphan Indication	Management of severe spasticity of spinal cord origin in patients who are unresponsive to oral baclofen therapy or experience intolerable CNS side effects at effective doses.	Ê06/25/1992Ê	Ê06/25/1999	"Medtronic, Inc."	800 53rd Avenue N.E.		Minneapolis	Minnesota	55432	USA	23987
808	Treatment of acute cyanide poisoning		MISSING		3968					Treatment of acute cyanide poisoning	HYDROXOCOBALAMIN|CYANOKIT	HYDROXOCOBALAMIN	HYDROXOCOBALAMIN|HYDROXYCOBALAMIN/SODIUM THIOSULFATE|HYDROXYCOBALAMIN	Hydroxocobalamin	Cyanokit	37950	Treatment of acute cyanide poisoning	Designated/Approved	Approved for Orphan Indication	Treatment on known or suspected cyanide poisoning	Ê12/15/2006Ê	Ê12/15/2013	"SERB, S.A."	480 Avenue Louise		Brussels			Belgium	177403
3016	Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome		MISSING		906	of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome	C4039583	Chimeric antigen receptor	aapp	Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome	TOCILIZUMAB|ACTEMRA			tocilizumab	Actemra	42948	Treatment of chimeric antigen receptor (CAR) T cell-induced cytokine release syndrome	Designated/Approved	Approved for Orphan Indication	Treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and pediatric patients 2 years of age and older	Ê08/30/2017Ê	Ê08/30/2024	"Genentech Inc., a member of the Roche Group"	1 DNA Way	MS #355e	South San Francisco	California	94080	USA	589317
1711	Treatment of complications of vaccinia vaccination		MISSING		3901	of complications	C0009566	Complication	patf	Treatment of complications of vaccinia vaccination	HUMAN VACCINIA VIRUS IMMUNE GLOBULIN|VACCINIA IMMUNE GLOBULIN (HUMAN) INTRAVENOUS|CNJ-016			Vaccinia Immune Globulin (Human) Intravenous	Cnj-016	38156	Treatment of complications of vaccinia vaccination	Designated/Approved	Approved for Orphan Indication	"treatment and/or modification of the following conditions, which are complications resulting from smallpox vaccination: Eczema vaccinatum Progressive vaccinia Severe generalized vaccinia Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard."	Ê05/02/2005Ê	ÊN/A	Cangene Corporation	104 Chancellor Matheson Road		"Winnipeg, ManitobaR3T 5Y3"			Canada	179303
993	Treatment of heroin addicts suitable for maintenance on opiate agonists.		MISSING	Not a disease	5217					Treatment of heroin addicts suitable for maintenance on opiate agonists.	LEVOMETHADYL ACETATE HYDROCHLORIDE|ORLAAM			Levomethadyl acetate hydrochloride	Orlaam	31071	Treatment of heroin addicts suitable for maintenance on opiate agonists.	Designated/Approved	Approved for Orphan Indication	For the management of opiate dependence.	Ê07/09/1993Ê	Ê07/09/2000	Biodevelopment Corporation	"8180 Greensboro Drive, Suite 1000"		McLean	Virginia	22102	USA	4784
494	treatment of intractable chronic pain.		MISSING		5020	of pain	C1962977	Pain NOS Adverse Event	fndg	"For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates."	CLONIDINE|DURACLON			Clonidine	Duraclon	32532	"For continous epidural administration as adjunctive therapy with intraspinal opiates for the treatment of pain in cancer patients tolerant to, or unresponsive to, intraspinal opiates."	Designated/Approved	Approved for Orphan Indication	In combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone.	Ê10/02/1996Ê	Ê10/02/2003	"Roxane Laboratories, Inc."	PO Box 16532		Columbus	Ohio	43216	USA	34388
1096	treatment of intractable chronic pain.		MISSING	Not a disease	4900					For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	MORPHINE SULFATE|MORPHINE SULFATE CONCENTRATE (PRESERVATIVE FREE)|INFUMORPH			Morphine sulfate concentrate (preservative free)	Infumorph	33066	For use in microinfusion devices for intraspinal administration in the treatment of intractable chronic pain.	Designated/Approved	Approved for Orphan Indication	For intrathecal or epidural infusion in the treatment of tractable chronic pain. It was developed for use in continuous microinfusion devices and may require dilution before use as directed.	Ê07/19/1991Ê	Ê07/19/1998	"Elkins-Sinn, Inc."	2 Esterbrook Lane		Cherry Hill	New Jersey	8003	USA	18587
2110	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy		MISSING		4124	with hematologic disorders	C0018939	Hematological Disease	dsyn	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	DEFERIPRONE|FERRIPROX			deferiprone	Ferriprox	37237	Treatment of iron overload in patients with hematologic disorders requiring chronic transfusion therapy	Designated/Approved	Approved for Orphan Indication	Treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate	Ê10/14/2011Ê	Ê10/14/2018	"ApoPharma, Inc. A Division of"	Apotex Research Inc.	"Toronto, Canada M9L 1T9"				Canada	150701
2899	Treatment of known or suspected cyanide poisoning		MISSING	Not a disease	3369					Treatment of known or suspected cyanide poisoning	HYDROXOCOBALAMIN|CYANOKIT	SODIUM THIOSULFATE|SODIUM NITRITE AND SODIUM THIOSULFATE|NITHIODOTE	SODIUM NITRITE|SODIUM NITRITE AND SODIUM THIOSULFATE|NITHIODOTE	sodium nitrite and sodium thiosulfate	Nithiodote	39547	Treatment of known or suspected cyanide poisoning	Designated/Approved	Approved for Orphan Indication	For sequential use for the treatment of cyanide poisoning that is judged to be life-threatening	Ê01/14/2011Ê	Ê01/14/2018	Hope Pharmaceuticals	16416 N. 92nd Street		Scottsdale	Arizona	85260	USA	244207
1534	Treatment of lead poisoning in children.		MISSING	Not a disease	5251					Treatment of lead poisoning in children.	LEAD POISONING|LEAD POISONING IN CHILDREN|MESH:D007855	SUCCIMER|CHEMET CAPSULES	TOXIC EFFECT OF HEAVY METAL|HEAVY METAL POISONING|HEAVY METAL TOXICITY|HEAVY METAL TOXICOSIS|CHRONIC HEAVY METAL POISONING|SCTID:85866007|MESH:C535854|EFO:1001518|GARD:0006577|MONDO:0023305	Succimer	Chemet Capsules	30811	Treatment of lead poisoning in children.	Designated/Approved	Approved for Orphan Indication		Ê01/30/1991Ê	Ê01/30/1998	Bock Pharmacal Company	P.O. Box 419056		Saint Louis	Missouri	63141	USA	1984
709	Treatment of methanol or ethylene glycol poisoning.		MISSING	Not a disease	5026					Treatment of methanol or ethylene glycol poisoning.	FOMEPIZOLE|ANTIZOLE	FOMEPIZOLE|ANTIZOLE	"FOMEPIZOLE|4-METHYLPYRAZOLE|4 METHYLPYRAZOLE|1H-PYRAZOLE, 4-METHYL-|4-METHYLPYRAZOL|PRODUCT CONTAINING FOMEPIZOLE|FOMEPIZOLE PRODUCT|MESH:D000077604|UMLS:C0048504|NCI:C47538|SNOMEDCT_US:109100006|SNOMEDCT_US:386970006"	Fomepizole	Antizole	32499	Treatment of methanol or ethylene glycol poisoning.	Designated/Approved	Approved for Orphan Indication	"Use for suspected or confirmed methanol poisoning, either alone or in combination with hemodialysis"	Ê12/08/2000Ê	Ê12/08/2007	"Rare Disease Therapeutics, Inc."	12975 Brookprinter Pl	Suite 170	Poway	California	92064	USA	33388
709	Treatment of methanol or ethylene glycol poisoning.		MISSING	Not a disease	5026					Treatment of methanol or ethylene glycol poisoning.	FOMEPIZOLE|ANTIZOLE	FOMEPIZOLE|ANTIZOLE	"FOMEPIZOLE|4-METHYLPYRAZOLE|4 METHYLPYRAZOLE|1H-PYRAZOLE, 4-METHYL-|4-METHYLPYRAZOL|PRODUCT CONTAINING FOMEPIZOLE|FOMEPIZOLE PRODUCT|MESH:D000077604|UMLS:C0048504|NCI:C47538|SNOMEDCT_US:109100006|SNOMEDCT_US:386970006"	Fomepizole	Antizole	32499	Treatment of methanol or ethylene glycol poisoning.	Designated/Approved	Approved for Orphan Indication	"As an antidote to ethylene glycol (antifreeze) poisoning, or for use in suspected ethylene glycol ingestion."	Ê12/04/1997Ê	Ê12/04/2004	"Rare Disease Therapeutics, Inc."	12975 Brookprinter Pl	Suite 170	Poway	California	92064	USA	33388
2201	Treatment of NTRK fusion-positive solid tumors		MISSING		946	of NTRK fusion-positive solid tumors	C0280100	solid tumor	neop	Treatment of NTRK fusion-positive solid tumors	ENTRECTINIB	LAROTRECTINIB	"LOXO-195|(13E,14E,22R,6R)-35-FLUORO-6-METHYL-7-AZA-1(5,3)-PYRAZOLO[1,5-A]PYRIMIDINA-3(3,2)-PYRIDINA-2(1,2)-PYRROLIDINACYCLOOCTAPHAN-8-ONE"	entrectinib	n/a	42921	Treatment of NTRK fusion-positive solid tumors	Designated/Approved	Approved for Orphan Indication	"ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have either progressed following treatment or have no satisfactory alternative therapy"	Ê08/15/2019Ê	Ê08/15/2026	"Genentech, Inc."	1 DNA Way	MS#241A	South San Francisco	California	94080	USA	587117
2412	Treatment of NTRK fusion-positive solid tumors		MISSING		1060	of solid tumors	C0280100	solid tumor	neop	Treatment of solid tumors with NTRK-fusion proteins	LAROTRECTINIB	"LOXO-195|(13E,14E,22R,6R)-35-FLUORO-6-METHYL-7-AZA-1(5,3)-PYRAZOLO[1,5-A]PYRIMIDINA-3(3,2)-PYRIDINA-2(1,2)-PYRROLIDINACYCLOOCTAPHAN-8-ONE"		larotrectinib	Vitrakvi	42864	Treatment of solid tumors with NTRK-fusion proteins	Designated/Approved	Approved for Orphan Indication	VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity; and have no satisfactory alternative treatments or that have progressed following treatment.	Ê11/26/2018Ê	Ê11/26/2025	Bayer HealthCare Pharmaceuticals Inc.	100 Bayer Boulevard		Whippany	New Jersey	7981	USA	578317
1966	Treatment of opiate addiction in opiate users		MISSING		4609					Treatment of opiate addiction in opiate users	BUPRENORPHINE HYDROCHLORIDE|SUBUTEX	BUPRENORPHINE|BUPRENORPHINE IN COMBINATION WITH NALOXONE|SUBOXONE	NALOXONE|BUPRENORPHINE IN COMBINATION WITH NALOXONE|SUBOXONE	buprenorphine in combination with naloxone	Suboxone	34634	Treatment of opiate addiction in opiate users	Designated/Approved	Approved for Orphan Indication	Treatment of opioid dependence in patients 16 years of age or older	Ê10/08/2002Ê	Ê10/08/2009	"Indivior, Inc."	10710 Midlothian Turnpike	Suite 430	Richmond	Virginia	23235	USA	79093
1192	Treatment of parenteral nutrition-associated liver disease		MISSING		3388	of parenteral nutrition-associated liver disease	C0243083	associated disease	patf	Treatment of parenteral nutrition-associated liver disease	FISH OIL|OMEGAVEN EMULSION|OMEGAVEN	TRICHOHEPATOENTERIC SYNDROME|PHENOTYPIC DIARRHEA|SD/THE|SYNDROMATIC DIARRHEA|SYNDROMIC DIARRHEA|SYNDROMIC DIARRHEA/TRICHO-HEPATO-ENTERIC SYNDROME|TRICHO-HEPATO-ENTERIC SYNDROME|GARD:0005258|ORPHA:84064|ORPHANET:84064	"MICROVILLUS INCLUSION DISEASE|CONGENITAL FAMILIAL PROTRACTED DIARRHEA|CONGENITAL MICROVILLUS ATROPHY|DAVIDSON'S DISEASE|FAMILIAL ENTEROPATHY, MICROVILLUS"	fish oil triglycerides	Omegaven	39505	Treatment of parenteral nutrition-associated liver disease	Designated/Approved	Approved for Orphan Indication	Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC)	Ê07/27/2018Ê	Ê07/27/2025	"Fresenius Kabi USA, LLC"	3 Corporate Drive		Lake Zurich	Illinois	60047	USA	251507
2291	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients		MISSING	Not a disease	3623					Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	GLYCOPYRROLATE|CUVPOSA			glycopyrrolate	Cuvposa	38877	Treatment of pathologic (chronic moderate to severe) drooling in pediatric patients	Designated/Approved	Approved for Orphan Indication	To reduce chronic drooling in patients aged 3 - 16 with neurologic conditions associated with problem drooling (e.g. cerebral palsy)	Ê07/28/2010Ê	Ê07/28/2017	"Shionogi, Inc."	300 Campus Drive		Florham	New Jersey	7932	USA	204105
2283	Treatment of patients at risk of methotrexate toxicity		MISSING	Not a disease	3990					Treatment of patients at risk of methotrexate toxicity	GLUCARPIDASE|VORAXAZE	LANGERHANS CELL HISTIOCYTOSIS|LCH|HISTIOCYTOSIS X|EOSINOPHILIC GRANULOMA (FORMERLY)|LETTERER-SIWE DISEASE (FORMERLY)|HAND-SCHÃLLER-CHRISTIAN SYNDROME (FORMERLY)	GRANULOMATOSIS WITH POLYANGIITIS|GPA|MIDLINE GRANULOMATOSIS|NECROTIZING RESPIRATORY GRANULOMATOSIS|PATHERGIC GRANULOMATOSIS|WEGENERâS DISEASE|WEGENER GRANULOMATOSIS|WEGENERâS GRANULOMATOSIS	glucarpidase	Voraxaze	37852	Treatment of patients at risk of methotrexate toxicity	Designated/Approved	Approved for Orphan Indication	Treatment of toxic (>1 micromole/liter) plasma methotrexate concentrations in patients with delayed methotrexate clearance due to impaired renal function.	Ê01/17/2012Ê	Ê01/17/2019	BTG International Inc.	5214 Maryland Way	Suite 405	Brentwood	Tennessee	37027	USA	163702
420	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures		MISSING	Not a disease	2465	of major bleeding	C0019080	Hemorrhage	patf	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	COAGULATION FACTOR VII HUMAN|PROTHROMBIN COMPLEX CONCENTRATE (HUMAN)|KCENTRA	COAGULATION FACTOR IX HUMAN|PROTHROMBIN COMPLEX CONCENTRATE (HUMAN)|KCENTRA	COAGULATION FACTOR X HUMAN|PROTHROMBIN COMPLEX CONCENTRATE (HUMAN)|KCENTRA	prothrombin complex concentrate (human)	Kcentra	41270	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or need for an urgent surgery/invasive procedure."	Ê12/13/2013Ê	Ê12/13/2020	CSL Behring	1020 First Avenue	PO Box 61501	King of Prussia	Pennsylvania	19406	USA	305310
420	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures		MISSING	Not a disease	2465	of major bleeding	C0019080	Hemorrhage	patf	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	COAGULATION FACTOR VII HUMAN|PROTHROMBIN COMPLEX CONCENTRATE (HUMAN)|KCENTRA	COAGULATION FACTOR IX HUMAN|PROTHROMBIN COMPLEX CONCENTRATE (HUMAN)|KCENTRA	COAGULATION FACTOR X HUMAN|PROTHROMBIN COMPLEX CONCENTRATE (HUMAN)|KCENTRA	prothrombin complex concentrate (human)	Kcentra	41270	Treatment of patients needing urgent reversal of Vitamin K antagonist therapy for treatment of major bleeding and/or surgical procedures	Designated/Approved	Approved for Orphan Indication	"Urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding."	Ê04/29/2013Ê	Ê04/29/2020	CSL Behring	1020 First Avenue	PO Box 61501	King of Prussia	Pennsylvania	19406	USA	305310
596	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination."		MISSING	Not a disease	3918	to	C0041260	Tryptophanase	aapp	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination."	PENTETIC ACID|DIETHYLENETRIAMINEPENTAACETIC ACID (DTPA)	PENTETIC ACID|DIETHYLENETRIAMINEPENTAACETATE (DPTA)		Diethylenetriaminepentaacetic acid (DTPA)	n/a	38105	"Treatment of patients with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination."	Designated/Approved	Approved for Orphan Indication	"Treatment of internal contamination with plutonium, americium or curium"	Ê08/11/2004Ê	Ê08/11/2011	Hameln Pharmaceuticals gmbh	Langes Feld 13		Hameln			Germany	186804
1336	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium		MISSING	Not a disease	4026					Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	HEAVY METAL POISONING|RADIOACTIVE CESIUM AND/OR RADIOACTIVE OR NON-RADIOACTIVE THALLIUM INTERNAL CONTAMINATION|MESH:C535854	FERRIC FERROCYANIDE|IRON(III)-HEXACYANOFERRATE(II)|PRUSSIAN BLUE|RADIOGARDASE	FERRIC FERROCYANIDE|FERRIC HEXACYANOFERRATE (II) PRUSSIAN BLUE	iron(III)-hexacyanoferrate(II)	Radiogardase	37742	Treatment of patients with known or suspected internal contamination with radioactive or non-radioactive cesium or thallium	Designated/Approved	Approved for Orphan Indication	Treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination	Ê10/02/2003Ê	Ê10/02/2010	"Heyl Chemisch-Pharmzeutische Fabrik GMBH & Co, KG"	Goerzallee 253	"D-14167 Berlin, Federal Republic of Germany"				Germany	169203
5050	Treatment of severe complications from the smallpox vaccine		MISSING		3903	of severe complications	C0009566	Complication	patf	Treatment of severe complications from the smallpox vaccine	Smallpox|GARD:0007444|VACCINIA IMMUNE GLOBULIN (HUMAN) INTRAVENOUS|GARD:0007444	SMALLPOX		Vaccinia Immune Globulin (Human) Intravenous	n/a	38156	Treatment of severe complications from the smallpox vaccine	Designated/Approved	Approved for Orphan Indication	"Treatment and modification of aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard; eczema vaccinatum; progressive vaccinia; severe generalized vaccinia, and vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions"	Ê02/18/2005Ê	Ê02/18/2012	DynPort Vaccine Company LLC	64 Thomas Johnson Drive		Frederick	Maryland	21702	USA	184204
226	Treatment of xerostomia induced by radiation therapy for head and neck cancer.		MISSING	Not a rare disease	4401	for head and neck cancer.	C0278996	Cancer of Head and Neck	neop	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	AMIFOSTINE|ETHYOL			Amifostine	Ethyol	35927	Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer.	Designated/Approved	Approved for Orphan Indication	"Reduction of the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands."	Ê06/24/1999Ê	Ê06/24/2006	"Medimmune Oncology, Inc."	One Tower Bridge	"100 Front St., Suite 400"	West Conshohocken	Pennsylvania	19428	USA	111698
1292	Treatment of xerostomia induced by radiation therapy for head and neck cancer.		MISSING	Not a disease	4881	for head and neck cancer.	C0278996	Cancer of Head and Neck	neop	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	PILOCARPINE|SALAGEN			Pilocarpine	Salagen	33140	Treatment of xerostomia induced by radiation therapy for head and neck cancer.	Designated/Approved	Approved for Orphan Indication	Treatment of symptoms of xerostomia from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck.	Ê03/22/1994Ê	Ê03/22/2001	"MGI Pharma, Inc."	5775 West Old Shakopee Rd.	Suite 100	Bloomington	Minnesota	55437	USA	45990
2475	Trichuriasis 	10720	done		2000	(hookworm	C0019911	Hookworm Infections	dsyn	"Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm)."	 Ancylostomiasis|GARD:0009742|MEBENDAZOLE|VERMOX 500 MG CHEWABLE TABLETS|GARD:0009742	Trichuriasis |GARD:0010720|MEBENDAZOLE|VERMOX 500 MG CHEWABLE TABLETS|GARD:0010720		mebendazole	Vermox 500 Mg Chewable Tablets	41885	"Treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm), Ascaris lumbricoides (large roundworm), and Ancylostoma duodenale and Nectar americanus (hookworm)."	Designated/Approved	Approved for Orphan Indication	treatment of patients one year of age and older withgastrointestinal infections caused by Ascaris lumbricoides (roundworm) and Trichuris trichiura (whipworm)	Ê10/19/2016Ê	ÊN/A	"Janssen Pharmaceutical Research & Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA	397013
639	"Trypanosomiasis, Human East-African"	7826	done		5163	of Trypanosoma brucei gambiense infection	C0009450	Communicable Diseases	dsyn	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	"Trypanosomiasis, Human East-African|GARD:0007826|EFLORNITHINE HYDROCHLORIDE|EFLORNITHINE HCL|ORNIDYL|GARD:0007826"			Eflornithine HCl	Ornidyl	31525	Treatment of Trypanosoma brucei gambiense infection (sleeping sickness).	Designated/Approved	Approved for Orphan Indication		Ê11/28/1990Ê	Ê11/28/1997	Hoechst Marion Roussel	P.O. Box 9627		Kansas City	Missouri	64134	USA	13586
5213	Tuberculosis	7827			4772	of tuberculosis infections	C0041296	Tuberculosis	dsyn	Treatment of tuberculosis infections	Tuberculosis|GARD:0007827|NITRIC OXIDE|GARD:0007827	Tuberculosis|GARD:0007827|AMINOSALICYLIC ACID|PASER GRANULES|GARD:0007827	TULAREMIA|DOID:2123|MESH:D014406	Aminosalicylic acid	Paser Granules	33653	Treatment of tuberculosis infections	Designated/Approved	Approved for Orphan Indication	Treatment of tuberculosis	Ê06/30/1994Ê	Ê06/30/2001	Jacobus Pharmaceutical Company	37 Cleveland Avenue	P.O. Box 5290	Princeton	New Jersey	8540	USA	65792
1422	Tuberculosis	7827	done		5192	of tuberculosis.	C0041296	Tuberculosis	dsyn	For the short-course treatment of tuberculosis.	"Tuberculosis|GARD:0007827|PYRAZINAMIDE|RIFAMPIN, ISONIAZID, PYRAZINAMIDE|RIFAMPIN , ISONIAZID, PYRAZINAMIDE|RIFATER|GARD:0007827"	"Tuberculosis|GARD:0007827|RIFAMPIN|RIFAMPIN, ISONIAZID, PYRAZINAMIDE|RIFATER|GARD:0007827"	"Tuberculosis|GARD:0007827|ISONIAZID|RIFAMPIN, ISONIAZID, PYRAZINAMIDE|RIFATER|GARD:0007827"	"Rifampin, isoniazid, pyrazinamide"	Rifater	31302	For the short-course treatment of tuberculosis.	Designated/Approved	Approved for Orphan Indication	Short-course treatment of tuberculosis.	Ê05/31/1994Ê	Ê05/31/2001	Hoechst Marion Roussel	P.O. Box 9627		Kansas City	Missouri	64134	USA	6585
5228	Tuberculosis	7827			4571	of pulmonary tuberculosis.	C0041327	"Tuberculosis, Pulmonary"	dsyn	Treatment of pulmonary tuberculosis.	Tuberculosis|GARD:0007827|RIFALAZIL|GARD:0007827	"MULTIDRUG-RESISTANT TUBERCULOSIS|TUBERCULOSIS, MULTIDRUG-RESISTANT|DOID:401|MESH:D018088"	Tuberculosis|GARD:0007827|RIFAPENTINE|PRIFTIN|GARD:0007827	Rifapentine	Priftin	34859	Treatment of pulmonary tuberculosis.	Designated/Approved	Approved for Orphan Indication		Ê06/22/1998Ê	Ê06/22/2005	Hoechst Marion Roussel	P.O. Box 9627	Mail Station: H3-M2516	Kansas City	Missouri	64134	USA	89495
5227	Tuberculosis	7827			5180					For antituberculosis treatment where use of the oral form of the drug is not feasible.	Tuberculosis|GARD:0007827|RIFAMPIN|RIFADIN I.V.|GARD:0007827			Rifampin	Rifadin I.V.	31390	For antituberculosis treatment where use of the oral form of the drug is not feasible.	Designated/Approved	Approved for Orphan Indication		Ê05/25/1989Ê	Ê05/25/1996	Hoechst Marion Roussel	P.O. Box 9627		Kansas City	Missouri	64134	USA	7685
4	Tuberculosis	7827	done		3478	of tuberculosis	C0041296	Tuberculosis	dsyn	Treatment of tuberculosis	Tuberculosis|GARD:0007827|TUBIMOD|GARD:0007827	Tuberculosis|GARD:0007827|AMINOSIDINE|GABBROMICINA|GARD:0007827	Tuberculosis|GARD:0007827|Q-203|SUBSTITUTED IMIDAZOPYRIDINE AMIDE|GARD:0007827	Pretomanid	Pretomanid	39268	Treatment of tuberculosis	Designated/Approved	Approved for Orphan Indication	"Pretomanid tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB)."	Ê08/14/2019Ê	Ê08/14/2026	Global Alliance for TB Drug Development	40 Wall Street	24th Floor	New York	New York	10005	USA	243107
5214	Tuberculosis	7827			3820	of active tuberculosis	C0151332	Active tuberculosis	dsyn	Treatment of active tuberculosis	Tuberculosis|GARD:0007827|TUBIMOD|GARD:0007827	Tuberculosis|GARD:0007827|Q-203|SUBSTITUTED IMIDAZOPYRIDINE AMIDE|GARD:0007827	Tuberculosis|GARD:0007827|CLOFAZIMINE|LAMPRENE|GARD:0007827	bedaquiline	Sirturo	38362	Treatment of active tuberculosis	Designated/Approved	Approved for Orphan Indication	SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (12 to less than 18 years of age and weighing at least 30 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB). Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.	Ê08/09/2019Ê	Ê08/09/2026	"Janssen Research & Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA	199304
5214	Tuberculosis	7827			3820	of active tuberculosis	C0151332	Active tuberculosis	dsyn	Treatment of active tuberculosis	Tuberculosis|GARD:0007827|TUBIMOD|GARD:0007827	Tuberculosis|GARD:0007827|Q-203|SUBSTITUTED IMIDAZOPYRIDINE AMIDE|GARD:0007827	Tuberculosis|GARD:0007827|CLOFAZIMINE|LAMPRENE|GARD:0007827	bedaquiline	Sirturo	38362	Treatment of active tuberculosis	Designated/Approved	Approved for Orphan Indication	Part of combination therapy in adults (greater than or equal to 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).	Ê12/28/2012Ê	Ê12/28/2019	"Janssen Research & Development, LLC"	920 Route 202 South		Raritan	New Jersey	8869	USA	199304
2213	Tuberous sclerosis 	7830	done		3170	"TSC-associated subependymal giant cell astrocytoma (SEGA),"	C0205768	Subependymal Giant Cell Astrocytoma	neop	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Lymphangioleiomyomatosis|GARD:0003319|EVEROLIMUS|AFINITOR|GARD:0003319	Tuberous sclerosis|GARD:0007830|EVEROLIMUS|AFINITOR|GARD:0007830	Astrocytoma|GARD:0012928|EVEROLIMUS|AFINITOR|GARD:0012928	everolimus	Afinitor	39972	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Designated/Approved	Approved for Orphan Indication	Treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical resection	Ê10/29/2010Ê	Ê10/29/2017	Novartis Pharmaceuticals Corp.	"One Health Plaza, 315/5450A"		East Hanover	New Jersey	7936	USA	283609
2213	Tuberous sclerosis 	7830	done		3170	"TSC-associated subependymal giant cell astrocytoma (SEGA),"	C0205768	Subependymal Giant Cell Astrocytoma	neop	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Lymphangioleiomyomatosis|GARD:0003319|EVEROLIMUS|AFINITOR|GARD:0003319	Tuberous sclerosis|GARD:0007830|EVEROLIMUS|AFINITOR|GARD:0007830	Astrocytoma|GARD:0012928|EVEROLIMUS|AFINITOR|GARD:0012928	everolimus	Afinitor	39972	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Designated/Approved	Approved for Orphan Indication	Treatment of adults with renal angiomyolipoma and tuberous sclerosis complex (TSC) not requiring immediate surgery.	Ê04/26/2012Ê	Ê04/26/2019	Novartis Pharmaceuticals Corp.	"One Health Plaza, 315/5450A"		East Hanover	New Jersey	7936	USA	283609
2213	Tuberous sclerosis 	7830	done		3170	"TSC-associated subependymal giant cell astrocytoma (SEGA),"	C0205768	Subependymal Giant Cell Astrocytoma	neop	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Lymphangioleiomyomatosis|GARD:0003319|EVEROLIMUS|AFINITOR|GARD:0003319	Tuberous sclerosis|GARD:0007830|EVEROLIMUS|AFINITOR|GARD:0007830	Astrocytoma|GARD:0012928|EVEROLIMUS|AFINITOR|GARD:0012928	everolimus	Afinitor	39972	"Treatment of tuberous sclerosis complex including TSC-associated subependymal giant cell astrocytoma (SEGA), TSC-associated angiomyolipoma and TSC-associated lymphangioleiomyomatosis (LAM)"	Designated/Approved	Approved for Orphan Indication	For the adjunctive treatment of adult and pediatric patients age 2 years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures.	Ê04/10/2018Ê	Ê04/10/2025	Novartis Pharmaceuticals Corp.	"One Health Plaza, 315/5450A"		East Hanover	New Jersey	7936	USA	283609
Missing	Tumor necrosis factor receptor-associated periodic syndrome	8457			2544					Treatment of TNF-receptor associated periodic syndrome (TRAPS)	"TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME|FPF|FAMILIAL HIBERNIAN FEVER|FHF|TRAPS|HIBERNIAN FEVER, FAMILIAL|TNF RECEPTOR-ASSOCIATED PERIODIC SYNDROME|PERIODIC FEVER, FAMILIAL, AUTOSOMAL DOMINANT|TNF RECEPTOR-ASSOCIATED PERIODIC FEVER SYNDROME|GARD:0008457|OMIM:142680|ORPHA:32960|ORPHANET:32960|UMLS:C1275126"	TUMOR NECROSIS FACTOR RECEPTOR-ASSOCIATED PERIODIC SYNDROME|AUTOSOMAL DOMINANT PERIODIC FEVER WITH AMYLOIDOSIS|BENIGN AUTOSOMAL DOMINANT FAMILIAL PERIODIC FEVER|FAMILIAL HIBERNIAN FEVER|TNF RECEPTOR-ASSOCIATED PERIODIC SYNDROME|TRAPS	SCHNITZLER SYNDROME|SCHNITZLER'S SYNDROME	canakinumab	Ilaris	41156	Treatment of TNF-receptor associated periodic syndrome (TRAPS)	Designated/Approved	Approved for Orphan Indication	Indicated for the treatment of Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients	Ê09/23/2016Ê	Ê09/23/2023	Novartis Pharmaceuticals Corporation	One Health Plaza		East Hanover	New Jersey	7936	USA	376912
1509	Turner syndrome	7831	done		5181	of short stature	C0013336	Dwarfism	dsyn	"1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000)."	Turner syndrome |GARD:0007831|SOMATREM|SOMATREM FOR INJECTION|PROTROPIN|GARD:0007831	 Growth hormone deficiency|GARD:0006552|SOMATREM|SOMATREM FOR INJECTION|PROTROPIN|GARD:0006552		Somatrem for injection	Protropin	31390	"1. Long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion (prevalence 15,000) 2. Treatment of short stature associated with Turner's syndrome (prevalence 8000)."	Designated/Approved	Approved for Orphan Indication		Ê10/17/1985Ê	Ê10/17/1992	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	10785
1517	Turner syndrome	7831	done		5129	with Turner's syndrome	C0041408	Turner Syndrome	dsyn	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Turner syndrome |GARD:0007831|SOMATROPIN|SOMATROPIN (RDNA ORIGIN) INJECTION|NORDITROPIN|GARD:0007831	 Growth hormone deficiency|GARD:0006552|SOMATROPIN|SOMATROPIN (RDNA ORIGIN) INJECTION|NORDITROPIN|GARD:0006552		Somatropin (rDNA origin) injection	Norditropin	31968	1. Treatment of growth failure in children due to inadequate growth hormone secretion 2. Treatment of short stature associated with Turner's syndrome	Designated/Approved	Approved for Orphan Indication	Long-term treatment of children who have growth failure due to inadequate secretion of endogenous growth hormone.	Ê06/20/2000Ê	ÊN/A	Novo Nordisk Pharmaceuticals	100 Overlook Center	Suite 200	Princeton	New Jersey	8540	USA	13386
1523	Turner syndrome	7831	done		5007	with Turner's syndrome.	C0041408	Turner Syndrome	dsyn	Treatment of short stature associated with Turner's syndrome.	Turner syndrome|GARD:0007831|OXANDROLONE|OXANDRIN|GARD:0007831	Turner syndrome|GARD:0007831|SOMATROPIN|SOMATROPIN FOR INJECTION|NUTROPIN|GARD:0007831	Turner syndrome |GARD:0007831|SOMATREM|SOMATREM FOR INJECTION|PROTROPIN|GARD:0007831	Somatropin for injection	Nutropin	32590	Treatment of short stature associated with Turner's syndrome.	Designated/Approved	Approved for Orphan Indication	Treatment of growth failure associated with Turner syndrome.	Ê12/30/1996Ê	Ê12/30/2003	"Genentech, Inc."	1 DNA Way		South San Francisco	California	94080	USA	12686
5242	Turner syndrome	7831			4920	with Turner syndrome.	C0041408	Turner Syndrome	dsyn	Treatment of short stature associated with Turner syndrome.	Turner syndrome|GARD:0007831|SOMATROPIN|HUMATROPE|GARD:0007831	Turner syndrome|GARD:0007831|SOMATROPIN|SOMATROPIN FOR INJECTION|NUTROPIN|GARD:0007831	Turner syndrome|GARD:0007831|OXANDROLONE|OXANDRIN|GARD:0007831	Somatropin	Humatrope	33001	Treatment of short stature associated with Turner syndrome.	Designated/Approved	Approved for Orphan Indication	Treatment of short stature associated with Turner syndrome in patients whose epiphyses are not closed.	Ê12/30/1996Ê	Ê12/30/2003	Eli Lilly and Company	Lilly Corporate Center		Indianapolis	Indiana	46285	USA	45090
3380	Tyrosinemia type 1	2658			4577	of tyrosinemia type 1.	C0268490	"Tyrosinemia, Type I"	dsyn	Treatment of tyrosinemia type 1.	"FUMARYLACETOACETASE DEFICIENCY|FUMARYLACETOACETATE HYDROLASE DEFICIENCY|TYPE I TYROSINEMIA|HEPATORENAL TYROSINEMIA|TYROSINEMIA TYPE I|FAH DEFICIENCY|TYROSINEMIA, TYPE 1|TYROSINEMIA, TYPE I|TYROSINEMIA TYPE 1|TYRSN1|TYROSINEMIA, TYPE I; TYRSN1|SCTID:410056006|NCIT:C98641|DOID:0050726|MEDDRA:10069462|UMLS:C0268490|ORPHANET:882|OMIM:276700|GARD:0002658|MONDO:0010161"	TYROSINEMIA TYPE I|TYROSINEMIAS|HEREDITARY TYROSINEMIA TYPE 1|DOID:50726|MESH:D020176	Tyrosinemia type 1|GARD:0002658|NITISINONE|ORFADIN|GARD:0002658	Nitisinone	Orfadin	34835	Treatment of tyrosinemia type 1.	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1	Ê01/18/2002Ê	Ê01/18/2009	Swedish Orphan Biovitrum AB	"890 Winter Street, Suite 115"		Waltham	Massachusetts	2451	USA	89095
3380	Tyrosinemia type 1	2658			4577	of tyrosinemia type 1.	C0268490	"Tyrosinemia, Type I"	dsyn	Treatment of tyrosinemia type 1.	"FUMARYLACETOACETASE DEFICIENCY|FUMARYLACETOACETATE HYDROLASE DEFICIENCY|TYPE I TYROSINEMIA|HEPATORENAL TYROSINEMIA|TYROSINEMIA TYPE I|FAH DEFICIENCY|TYROSINEMIA, TYPE 1|TYROSINEMIA, TYPE I|TYROSINEMIA TYPE 1|TYRSN1|TYROSINEMIA, TYPE I; TYRSN1|SCTID:410056006|NCIT:C98641|DOID:0050726|MEDDRA:10069462|UMLS:C0268490|ORPHANET:882|OMIM:276700|GARD:0002658|MONDO:0010161"	TYROSINEMIA TYPE I|TYROSINEMIAS|HEREDITARY TYROSINEMIA TYPE 1|DOID:50726|MESH:D020176	Tyrosinemia type 1|GARD:0002658|NITISINONE|ORFADIN|GARD:0002658	Nitisinone	Orfadin	34835	Treatment of tyrosinemia type 1.	Designated/Approved	Approved for Orphan Indication	Treatment of hereditary tyrosinemia type 1 in combination with dietary restriction of tyrosine and phenylalanine.	Ê04/22/2016Ê	ÊN/A	Swedish Orphan Biovitrum AB	"890 Winter Street, Suite 115"		Waltham	Massachusetts	2451	USA	89095
2290	Urea cycle disorders	7837	approximate		3199	with deficiencies	C0162429	Malnutrition	dsyn	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	GLYCEROL PHENYLBUTYRATE|RAVICTI			glycerol phenylbutyrate	Ravicti	39930	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Designated/Approved	Approved for Orphan Indication	"Use as a nitrogen-binding agent for chronic management of adult and pediatric patients > or =2 years of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (eg, essential amino acids, arginine, citrulline, protein-free calorie supplements)."	Ê02/01/2013Ê	Ê02/01/2020	"Horizon Pharma USA, INc."	150 South Saunders Road	Suite 400	Lake Forest	Illinois	60045	USA	203505
2290	Urea cycle disorders	7837	approximate		3199	with deficiencies	C0162429	Malnutrition	dsyn	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	GLYCEROL PHENYLBUTYRATE|RAVICTI			glycerol phenylbutyrate	Ravicti	39930	Maintenance treatment of patients with deficiencies in enzymes of the urea cycle	Designated/Approved	Approved for Orphan Indication	For use as a nitrogen-binding agent for chronic management of patients 2 months of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.	Ê04/28/2017Ê	Ê04/28/2024	"Horizon Pharma USA, INc."	150 South Saunders Road	Suite 400	Lake Forest	Illinois	60045	USA	203505
1931	Urea cycle disorders	7837	approximate		4669	with deficiencies	C0162429	Malnutrition	dsyn	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Urea cycle disorders|GARD:0007837|BENZOIC ACID|BENZOATE/PHENYLACETATE|BENZOATE /PHENYLACETATE|AMMONUL|GARD:0007837	Urea cycle disorders|GARD:0007837|PHENYL ACETATE|BENZOATE/PHENYLACETATE|BENZOATE/ PHENYLACETATE|AMMONUL|GARD:0007837	ORNITHINE TRANSCARBAMYLASE DEFICIENCY|HYPERAMMONEMIA DUE TO ORNITHINE TRANSCARBAMYLASE DEFICIENCY|ORNITHINE CARBAMYLTRANSFERASE DEFICIENCY|OTC DEFICIENCY	benzoate/phenylacetate	Ammonul	34295	Treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Designated/Approved	Approved for Orphan Indication	Adjunctive therapy in the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle.	Ê02/17/2005Ê	Ê02/17/2012	Medicis Pharmaceutical Corp.	8125 N. Hayden Road		Scottsdale	Arizona	85258	USA	77993
2905	Urea cycle disorders	7837	done		4668	of urea cycle disorders	C0154246	"Urea Cycle Disorders, Inborn"	dsyn	"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency."				sodium phenylbutyrate	Buphenyl	34295	"Treatment of urea cycle disorders: carbamylphosphate synthetase deficiency, ornithine transcarbamylase deficiency, and arginiosuccinic acid synthetase deficiency."	Designated/Approved	Approved for Orphan Indication	"Adjunctive therapy in the chronic managment of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase."	Ê04/30/1996Ê	Ê04/30/2003	Medicis Pharmaceutical Corp.	8125 N. Hayden Road		Scottsdale	Arizona	85258	USA	77893
480	Urinary Bladder Calculi (disorder)		MISSING		4980	bladder calculi	C0005683	Urinary Bladder Calculi (disorder)	dsyn	Treatment of renal and bladder calculi of the apatite or struvite variety.	"MAGNESIUM CARBONATE|CITRIC ACID, GLUCONO-DELTA-LACTONE AND MAGNESIUM CARBONATE|RENACIDIN IRRIGATION"	"MAGNESIUM CARBONATE|CITRIC ACID, GLUCONO-DELTA-LACTONE AND MAGNESIUM CARBONATE|CITRIC ACID|RENACIDIN IRRIGATION"	"GLUCONOLACTONE|CITRIC ACID, GLUCONO-DELTA-LACTONE AND MAGNESIUM CARBONATE|GLUCONO-DELTA-LACTONE|RENACIDIN IRRIGATION"	"Citric acid, glucono-delta-lactone and magnesium carbonate"	Renacidin Irrigation	32748	Treatment of renal and bladder calculi of the apatite or struvite variety.	Designated/Approved	Approved for Orphan Indication		Ê10/02/1990Ê	Ê10/02/1997	"United-Guardian, Inc."	P.O. Box 2500		Smithtown	New York	11787	USA	40189
2262	Vernal keratitis	10531	approximate		3504	of acute herpetic keratitis	C0019357	"Keratitis, Herpetic"	dsyn	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Vernal keratitis|GARD:0010531|GANCICLOVIR|ZIRGAN|GARD:0010531			ganciclovir	Zirgan	39163	Treatment of acute herpetic keratitis (dendritic and geographic ulcers)	Designated/Approved	Approved for Orphan Indication	Treatment of acute herpetic keratitis (dendritic ulcers)	Ê09/15/2009Ê	Ê09/15/2016	"Sirion Therapeutics, Inc."	9314 East Broadway Avenue		Tampa	Florida	33619	USA	237607
1763	Vernal keratitis	10531	approximate		2888	of acute herpetic keratitis	C0019357	"Keratitis, Herpetic"	dsyn	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2				acyclovir	n/a	40525	Treatment of acute herpetic keratitis caused by Herpes Simplex Virus type 1 and 2	Designated/Approved	Approved for Orphan Indication	AVACLYR is a sterile topical antiviral indicated for the treatment of acute herpetic keratitis (dendritic ulcers) in patients with herpes simplex (HSV-1 and HSV-2) virus.	Ê03/29/2019Ê	Ê03/29/2026	Fera Pharmaceuticals	134 Birch Hill Road		Locust Valley	New York	11560	USA	325010
5252	Vernal keratoconjunctivitis	7854			4801	of vernal keratoconjunctivitis.	C0022577	"Keratoconjunctivitis, Vernal"	dsyn	Treatment of vernal keratoconjunctivitis.	Vernal keratoconjunctivitis|GARD:0007854|CYCLOSPORINE A|GARD:0007854	KERATOCONJUNCTIVITIS|VERNAL KERATOCONJUNCTIVITIS|DOID:9368|MESH:D007637	Vernal keratoconjunctivitis|GARD:0007854|LODOXAMIDE TROMETHAMINE|ALOMIDE OPHTHALMIC SOLUTION|GARD:0007854	Lodoxamide tromethamine	Alomide Ophthalmic Solution	33527	Treatment of vernal keratoconjunctivitis.	Designated/Approved	Approved for Orphan Indication	"Treatment of ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, vernal keratitis."	Ê09/23/1993Ê	Ê09/23/2000	"Alcon Laboratories, Inc."	6201 South Freeway		Fort Worth	Texas	76134	USA	59791
5254	Vernal keratoconjunctivitis	7854			5197	of vernal keratoconjunctivitis.	C0022577	"Keratoconjunctivitis, Vernal"	dsyn	Treatment of vernal keratoconjunctivitis.	Vernal keratoconjunctivitis|GARD:0007854|CYCLOSPORINE A|GARD:0007854	KERATOCONJUNCTIVITIS|VERNAL KERATOCONJUNCTIVITIS|DOID:9368|MESH:D007637	Vernal keratoconjunctivitis|GARD:0007854|LODOXAMIDE TROMETHAMINE|ALOMIDE OPHTHALMIC SOLUTION|GARD:0007854	Cromolyn sodium 4% ophthalmic solution	Opticrom 4% Ophthalmic Solution	31252	Treatment of vernal keratoconjunctivitis.	Designated/Approved	Approved for Orphan Indication		Ê10/03/1984Ê	Ê10/03/1991	Fisons Corporation	755 Jefferson Rd.	P.O. Box 1710	Rochester	New York	14603	USA	8285
3534	VIPoma	5493			4384	(VIPoma	C0011993	Vipoma	neop	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	VIPOMA|VASOACTIVE INTESTINAL PEPTIDE TUMORS (VIPOMAS)|DOID:5574|MESH:D003969	VIPoma|GARD:0005493|OCTREOTIDE|SANDOSTATIN LAR|GARD:0005493	CARCINOID SYNDROME|CARCINOID APUDOMA|CARCINOID CANCER|CARCINOID DISEASE|FUNCTIONING ARGENTAFFINOMA|FUNCTIONING CARCINOID|MALIGNANT CARCINOID SYNDROME|NEUROENDOCRINE TUMOR CARCINOID TYPE	Octreotide	Sandostatin Lar	36031	Treatment of diarrhea associated with vasoactive intestinal peptide tumors (VIPoma).	Designated/Approved	Approved for Orphan Indication	Treatment of profuse watery diarrhea associated with VIPoma.	Ê11/25/1998Ê	Ê11/25/2005	Novartis Pharmaceuticals Corporation	59 Route 10		East Hanover	New Jersey	7936	USA	116898
1704	Von Willebrand disease	7867	done		2910	of von Willebrand disease.	C0042974	von Willebrand Disease	dsyn	Treatment of von Willebrand disease.	VON WILLEBRAND DISEASE|DOID:12531|MESH:D014842	Von Willebrand disease|GARD:0007867|VON WILLEBRAND FACTOR HUMAN|VON WILLEBRAND FACTOR HUMAN CONCENTRATE|WILFACTIN|GARD:0007867	"Von Willebrand disease|GARD:0007867|ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN), DRIED, PASTEURIZED|HUMATE-P|GARD:0007867"	recombinant von Willebrand factor (rhVWF)	n/a	40505	Treatment of von Willebrand disease.	Designated/Approved	Approved for Orphan Indication	Indicated for on-demand treatment and control of bleeding episodes in adults (age 18 and older) diagnosed with von Willebrand disease (VWD)	Ê12/08/2015Ê	Ê12/08/2022	"Baxalta US, Inc."	650 E. Kendall Street		Cambridge	Massachusetts	2142	USA	322210
1704	Von Willebrand disease	7867	done		2910	of von Willebrand disease.	C0042974	von Willebrand Disease	dsyn	Treatment of von Willebrand disease.	VON WILLEBRAND DISEASE|DOID:12531|MESH:D014842	Von Willebrand disease|GARD:0007867|VON WILLEBRAND FACTOR HUMAN|VON WILLEBRAND FACTOR HUMAN CONCENTRATE|WILFACTIN|GARD:0007867	"Von Willebrand disease|GARD:0007867|ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN), DRIED, PASTEURIZED|HUMATE-P|GARD:0007867"	recombinant von Willebrand factor (rhVWF)	n/a	40505	Treatment of von Willebrand disease.	Designated/Approved	Approved for Orphan Indication	Indicated for use in adults (age 18 and older) diagnosed with von Willebrand disease (VWD) for perioperative management of bleeding	Ê04/13/2018Ê	Ê04/13/2025	"Baxalta US, Inc."	650 E. Kendall Street		Cambridge	Massachusetts	2142	USA	322210
258	Von Willebrand disease	7867	done		4538	of von Willebrand's disease	C0042974	von Willebrand Disease	dsyn	Treatment of von Willebrand's disease	"Von Willebrand disease|GARD:0007867|ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN), DRIED, PASTEURIZED|HUMATE-P|GARD:0007867"	VON WILLEBRAND DISEASE|DOID:12531|MESH:D014842	Von Willebrand disease|GARD:0007867|ANTIHEMOPHILIC FACTOR (HUMAN)|ALPHANATE|GARD:0007867	Antihemophilic factor (human)	Alphanate	35069	Treatment of von Willebrand's disease	Designated/Approved	Approved for Orphan Indication	For surgical and/or invasive procedures in patients with von Willebrand Disease (VWD) in whom desmopressin is either ineffective or contraindicated. It is not indicated for patients with severe VWD (Type 3) undergoing major surgery	Ê01/31/2007Ê	Ê01/31/2014	Grifols Biologicals Inc.	5555 Valley Boulevard		Los Angeles	California	90032	USA	93895
260	Von Willebrand disease	7867	done		4735	with von Willebrand's disease	C0042974	von Willebrand Disease	dsyn	Treatment of patients with von Willebrand's disease	"Von Willebrand disease|GARD:0007867|ANTIHEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX (HUMAN), DRIED, PASTEURIZED|HUMATE-P|GARD:0007867"	Von Willebrand disease|GARD:0007867|ANTIHEMOPHILIC FACTOR (HUMAN)|ALPHANATE|GARD:0007867	Von Willebrand disease|GARD:0007867|VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)|HUMAN PLASMA COAGULATION FACTOR VIII AND HUMAN PLASMA VON WILLEBRAND FACTOR|WILATE|GARD:0007867	"Antihemophilic factor/von Willebrand factor complex (human), dried, pasteurized"	Humate-P	33893	Treatment of patients with von Willebrand's disease	Designated/Approved	Approved for Orphan Indication	"(1) In adult patients for treatment and prevention of bleeding in hemophilia A (classic hemophilia) and (2) in adult and pediatric patients for treatment of spontaneous and trauma-induced bleeding episodes in severe von Willebrand disease, and in mild and moderate von Willebrand disease where use of desmopressin is known or suspected to be inadequate."	Ê04/01/1999Ê	Ê04/01/2006	CSL Behring	1020 First Avenue	PO Box 61501	King Of Prussia	Pennsylvania	19406	USA	67992
1737	Von Willebrand disease	7867	done		3499	of von Willebrand disease	C0042974	von Willebrand Disease	dsyn	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Von Willebrand disease|GARD:0007867|VON WILLEBRAND FACTOR/COAGULATION FACTOR VIII COMPLEX (HUMAN)|HUMAN PLASMA COAGULATION FACTOR VIII AND HUMAN PLASMA VON WILLEBRAND FACTOR|WILATE|GARD:0007867			Human plasma coagulation Factor VIII and human plasma von Willebrand Factor	Wilate	39190	Treatment of von Willebrand disease except for surgical and/or invasive procedures in patients with von Willebrand disease in whom desmopressin is either ineffective or contraindicated	Designated/Approved	Approved for Orphan Indication	Treatment of spontaneous or trauma-induced bleeding episodes in patients with severe von Willebrand disease (VWD) as well as patients with mild or moderate VWD in whom the use of desmopressin is known or suspected to be ineffective or contraindicated	Ê12/04/2009Ê	ÊN/A	"Octapharma USA, Inc."	121 River Street	12th Floor	Hoboken	New Jersey	7030	USA	234106
1921	Waldenstrom macroglobulinemia	7872	done		2044	Nodal Marginal Zone Lymphoma	C0242647	Mucosa-Associated Lymphoid Tissue Lymphoma	neop	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	 Marginal zone lymphoma |GARD:0013237|BENDAMUSTINE|BENDAMUSTINE FOR 50ML ADMIXTURE|BENDEKA|GARD:0013237	Marginal zone lymphoma|GARD:0013237|BENDAMUSTINE FOR 50ML ADMIXTURE|BENDEKA|GARD:0013237	 Follicular lymphoma|GARD:0002356|BENDAMUSTINE|BENDAMUSTINE FOR 50ML ADMIXTURE|BENDEKA|GARD:0002356	bendamustine for 50ml admixture	Bendeka	41822	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	Designated/Approved	Approved for Orphan Indication	Treatment of patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	Ê12/07/2015Ê	Ê12/07/2022	"Eagle Pharmaceuticals, Inc."	50 Tice Blvd	Suite 315	Woodcliff Lake	New Jersey	7677	USA	430314
1925	Waldenstrom macroglobulinemia	7872	done		2212	Nodal Marginal Zone Lymphoma	C0242647	Mucosa-Associated Lymphoid Tissue Lymphoma	neop	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	 Marginal zone lymphoma |GARD:0013237|BENDAMUSTINE|BENDAMUSTINE FOR 50ML ADMIXTURE|BENDEKA|GARD:0013237	Marginal zone lymphoma|GARD:0013237|BENDAMUSTINE FOR 50ML ADMIXTURE|BENDEKA|GARD:0013237	 Follicular lymphoma|GARD:0002356|BENDAMUSTINE|BENDAMUSTINE FOR 50ML ADMIXTURE|BENDEKA|GARD:0002356	bendamustine hydrochloride	Treanda	41604	"Treatment of Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-Associated Lymphoma Tissue (MALT), and Nodal Marginal Zone Lymphoma (Collectively Indolent B-cell Non-Hodgkin's Lymphoma)"	Designated/Approved	Approved for Orphan Indication	Treatment of Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.	Ê10/31/2008Ê	Ê10/31/2015	"Cephalon, Inc."	A wholly owned subsidiary of Teva Pharmaceuticals	PO Box 4011	Frazer	Pennsylvania	19355	USA	253107
5260	Waldenstrom macroglobulinemia	7872			2263	of Waldenstrom's macroglobulinemia	C0024419	Waldenstrom Macroglobulinemia	neop	Treatment of Waldenstrom's macroglobulinemia	Waldenstrom macroglobulinemia|GARD:0007872|IBRUTINIB|IMBRUVICA|GARD:0007872	WALDENSTROM MACROGLOBULINEMIA|WALDENSTROM'S MACROGLOBULINAEMIA|LYMPHOPLASMACYTIC LYMPHOMA|WALDENSTROM'S SYNDROME|MACROGLOBULINEMIA OF WALDENSTROM|GARD:0007872|OMIM:153600	Waldenstrom macroglobulinemia|GARD:0007872|OPROZOMIB|GARD:0007872	ibrutinib	Imbruvica	41562	Treatment of Waldenstrom's macroglobulinemia	Designated/Approved	Approved for Orphan Indication	Treatment of patients with Waldenstrom's macroglobulinemia	Ê01/29/2015Ê	Ê01/29/2022	"Pharmacyclics, LLC"	995 E. Arques Avenue		Sunnyvale	California	94085	USA	407413
1750	Wilson disease	7893	done		5186	of Wilson's disease.	C0019202	Hepatolenticular Degeneration	dsyn	Treatment of Wilson's disease.	Wilson disease|GARD:0007893|BIS(CHOLINE)TETRATHIOMOLYBDATE|CHOLINE TETRATHIOMOLYBDATE|GARD:0007893	Wilson disease|GARD:0007893|ZINC ACETATE|GALZIN|GARD:0007893	Wilson disease|GARD:0007893|TIOMOLIBDATE DIAMMONIUM|AMMONIUM TETRATHIOMOLYBDATE|COPREXA|GARD:0007893	Zinc acetate	Galzin	31357	Treatment of Wilson's disease.	Designated/Approved	Approved for Orphan Indication	For maintenance treatment of patients with Wilson's disease who have been initially treated with a chelating agent.	Ê01/28/1997Ê	Ê01/28/2004	Lemmon Company	1510 Delp Drive		Kulpsville	Pennsylvania	19443	USA	11185
1660	Wilson disease	7893	done		5224	with Wilson's disease	C0019202	Hepatolenticular Degeneration	dsyn	"Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine."	Wilson disease|GARD:0007893|TRIENTINE HYDROCHLORIDE|TRIENTINE HCL|SYPRINE|GARD:0007893			Trientine HCl	Syprine	31040	"Treatment of patients with Wilson's disease who are intolerant, or inadequately responsive to penicillamine."	Designated/Approved	Approved for Orphan Indication		Ê11/08/1985Ê	Ê11/08/1992	Merck Sharp & Dohme Research	Division Of Merck And Company		West Point	Pennsylvania	19486	USA	4884
5292	Zollinger-Ellison syndrome	7918			4313	of gastrinoma	C0017150	Gastrinoma	neop	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Zollinger-Ellison syndrome|GARD:0007918|SYNTHETIC PORCINE SECRETIN|SECREFLO|GARD:0007918	Zollinger-Ellison syndrome|GARD:0007918|SYNTHETIC HUMAN SECRETIN|CHIROSTIM|GARD:0007918	ZOLLINGER-ELLISON SYNDROME|GASTRINOMA|PANCREATIC ULCEROGENIC TUMOR SYNDROME|ZES|Z-E SYNDROME	Synthetic porcine secretin	Secreflo	36329	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Designated/Approved	Approved for Orphan Indication	Use in secretin stimulation testing for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma	Ê04/04/2002Ê	Ê04/04/2009	"ChiRhoClin, Inc."	1550 Gallaudet Ave.		Silver Spring	Maryland	20905	USA	120498
5291	Zollinger-Ellison syndrome	7918			4318	of gastrinoma	C0017150	Gastrinoma	neop	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Zollinger-Ellison syndrome|GARD:0007918|SYNTHETIC PORCINE SECRETIN|SECREFLO|GARD:0007918	Zollinger-Ellison syndrome|GARD:0007918|SYNTHETIC HUMAN SECRETIN|CHIROSTIM|GARD:0007918	ZOLLINGER-ELLISON SYNDROME|GASTRINOMA|PANCREATIC ULCEROGENIC TUMOR SYNDROME|ZES|Z-E SYNDROME	Synthetic human secretin	Chirostim	36327	For use in the diagnosis of gastrinoma associated with Zollinger-Ellison syndrome.	Designated/Approved	Approved for Orphan Indication	"Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography"	Ê04/09/2004Ê	ÊN/A	"ChiRhoClin, Inc."	1550 Gallaudet Ave.		Silver Spring	Maryland	20905	USA	120798
5747	Zygomycosis	10224			2238	of zygomycosis	C0043541	Zygomycosis	dsyn	Treatment of zygomycosis	Zygomycosis|GARD:0010224|POSACONAZOLE|POSORIL|GARD:0010224	Zygomycosis|GARD:0010224|AMPHOTERICIN B LIPID COMPLEX|ABELCET|GARD:0010224	BASIDIOBOLOMYCOSIS|ZYGOMYCOSIS|DOID:50278|MESH:D020096	isavuconazonium sulfate	Cresemba	41572	Treatment of zygomycosis	Designated/Approved	Approved for Orphan Indication	Treatment of invasive mucormycosis in patients 18 years of age and older	Ê03/06/2015Ê	Ê03/06/2022	Astellas Pharma Global Development Inc.	1 Astellas Way		Northbrook	Illinois	60062	USA	395013
1940			MISSING	"not a disease, a procedure"	3748					Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	BIOCARBONATE INFUSATE|BICARBONATE INFUSATE|NORMOCARB HF			biocarbonate infusate	Normocarb Hf	38573	Use in the management of patients undergoing continuous renal replacement therapy with hemofiltration	Designated/Approved	Approved for Orphan Indication	Use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace water and to correct electrolytes and acid-base imbalances in adults and children	Ê07/26/2006Ê	Ê07/26/2013	"Dialysis Solutions, Inc."	14 Emmett Place	"Whitby, Ontario L1R 2B4"				Canada	198904
Missing			MISSING	"not a disease, a procedure"	4974	of ovarian carcinoma.	C0029925	Ovarian Carcinoma	neop	Detection of ovarian carcinoma.	"MINRETUMOMAB|MONOCLONAL ANTIBODY CC49|MOAB CC-49/TAG72 (DW)|MOAB CC49|ANTIBODY CC49, MONOCLONAL|MONOCLONAL ANTIBODY CC-49|CC-49|MAB CC49|CC-49 MONOCLONAL ANTIBODY|NCIT:C2567|NCI:C2567|NSC:620537|UMLS:C0281345"	"FAMILIAL BREAST CANCER|BREAST CANCER, FAMILIAL|HERITABLE BREAST CANCER|GENETIC BREAST CANCER|HEREDITARY BREAST CANCER|HEREDITARY BREAST CARCINOMA|FAMILIAL BREAST CARCINOMA|GARD:0010415|OMIM:114480|ORPHA:227535|ORPHANET:227535"	LI-FRAUMENI SYNDROME|LFS	Satumomab pendetide	Oncoscint Cr/Ov	32776	Detection of ovarian carcinoma.	Designated/Approved	Approved for Orphan Indication	For determining the extent and location of extraphepatic malignant disease in patients with known colorectal and ovarian cancer.	Ê12/29/1992Ê	Ê12/29/1999	Cytogen Corporation	600 College Road East		Princeton	New Jersey	8540	USA	36789
1273			MISSING	"not a disease, a process"	5193	to	C0041260	Tryptophanase	aapp	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	PENTASTARCH|PENTASPAN			Pentastarch	Pentaspan	31287	As an adjunct in leukapheresis to improve the harvesting and increase the yield of leukocytes by centrifugal means.	Designated/Approved	Approved for Orphan Indication		Ê05/19/1987Ê	Ê05/19/1994	DuPont Pharmaceuticals	E.I. Du Pont De Nemours & Co.		Wilmington	Delaware	19898	USA	8085
2696			MISSING	"not a disease, a procedure"	4004	to	C0041260	Tryptophanase	aapp	For use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy	PLERIXAFOR|MOZOBIL (R)			plerixafor	Mozobil (R)	37812	For use to improve the yield of progentor cells in the apheresis product for subsequest stem cell transplantation following myelosuppressive or myeloablative chemotherapy	Designated/Approved	Approved for Orphan Indication	To enhance mobilization of hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma	Ê12/15/2008Ê	Ê12/15/2015	Genzyme Corporation	500 Kendall Street		Cambridge	Massachusetts	2142	USA	167903
1548			MISSING	"not a disease, a procedure"	4311	of exocrine pancreas function.	C0678872	exocrine pancreas function	ortf	For use in the evaluation of exocrine pancreas function.	SECRETIN HUMAN|SYNTHETIC HUMAN SECRETIN	SECRETIN PORCINE|SYNTHETIC PORCINE SECRETIN|SECREFLO	JOHANSON-BLIZZARD SYNDROME|JBS	Synthetic porcine secretin	Secreflo	36329	For use in the evaluation of exocrine pancreas function.	Designated/Approved	Approved for Orphan Indication	For use in secretin stimulation testing for: Stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangio-pancreatography (ERCP)	Ê11/01/2002Ê	Ê11/01/2009	"ChiRhoClin, Inc."	1550 Gallaudet Ave.		Silver Spring	Maryland	20905	USA	120298
1547			MISSING	"not a disease, a procedure"	4257	pancreatic fluid secretion.	C1160607	pancreatic juice secretion	ortf	"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion."	SECRETIN HUMAN|SYNTHETIC HUMAN SECRETIN	SECRETIN PORCINE|SYNTHETIC PORCINE SECRETIN|SECREFLO		Synthetic porcine secretin	Secreflo	36592	"For use in conjunction with diagnostic, therapeutic, or combined diagnostic/therapeutic procedures for pancreatic disorders to increase pancreatic fluid secretion."	Designated/Approved	Approved for Orphan Indication	"Use in secretin stimulation testing for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction"	Ê04/04/2002Ê	Ê04/04/2009	"ChiRhoClin, Inc."	15500 Gallaudet Ave.		Silver Spring	Maryland	20905	USA	130299
1555			MISSING	"not a disease, a procedure"	3221	with melanoma	C0025202	melanoma	neop	For localization of sentinel lymph nodes in patients with melanoma	"TECHNETIUM TC-99M SULFUR COLLOID|TECHNETIUM TC99M SULFUR COLLOID INJECTION, LYOPHILIZED|TECHNETIUM TC99M SULFUR COLLOI"			"Technetium Tc99m sulfur colloid injection, lyophilized"	Technetium Tc99m Sulfur Colloi	39889	For localization of sentinel lymph nodes in patients with melanoma	Designated/Approved	Approved for Orphan Indication	Localization of lymph nodes draining a primary tumor in patients with melanoma when used with a hand-held gamma counter	Ê08/13/2012Ê	Ê08/13/2019	"Pharmalucence, Inc."	10 DeAngelo Drive		Bedford	Massachusetts	1730	USA	271608
1672			MISSING	"not a disease, a procedure"	3607	staining	C1704680	Staining (finding)	fndg	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	TRYPAN BLUE|MEMBRANEBLUE			Trypan blue	Membraneblue	38931	Selectively staining epiretinal membranes during ophthalmic surgical vitrectomy procedures	Designated/Approved	Approved for Orphan Indication	"For use as an aid in ophthalmic surgery by staining the epiretinal membranes during ophthalmic surgical vitrectomy procedures, facilitating removal of the tissue"	Ê02/20/2009Ê	Ê02/20/2016	Dutch Ophthalmic Research Center Int'l BV	Scheijdelveweg 2	P.O. Box 43 3214ZG Zuidland				Netherlands	207505
Missing			MISSING	"not a disease, a procedure"	2555	staining	C1704680	Staining (finding)	fndg	For use as an aid in ophthalmic surgery by selectively staining the internal limiting membrane				Brilliant Blue G Ophthalmic Solution 0.025%	Dorc Ilm-Blue	41121	For use as an aid in ophthalmic surgery by selectively staining the internal limiting membrane	Designated/Approved	Approved for Orphan Indication	TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is indicated to selectively stain the internal limiting membrane (ILM).	Ê12/20/2019Ê	Ê12/20/2026	Dutch Opthalmic Research Center International BV	"Scheijdelveweg 2, 3214 VN"		Zuidland			Netherlands	341811